



US012384789B2

(12) **United States Patent**
Woll et al.(10) **Patent No.:** US 12,384,789 B2
(45) **Date of Patent:** *Aug. 12, 2025(54) **COMPOUNDS FOR TREATING
HUNTINGTON'S DISEASE**(71) Applicant: **PTC Therapeutics, Inc.**, South Plainfield, NJ (US)(72) Inventors: **Matthew G. Woll**, Dunellen, NJ (US); **Lukiana Amedzo**, Somerset, NJ (US); **Suresh Babu**, Pennington, NJ (US); **Scott J. Barraza**, Piscataway, NJ (US); **Anuradha Bhattacharyya**, Edison, NJ (US); **Gary Mitchell Karp**, Princeton Junction, NJ (US); **Anthony R. Mazzotti**, Rahway, NJ (US); **Jana Narasimhan**, Scotch Plains, NJ (US); **Jigar Patel**, Edison, NJ (US); **Anthony Turpoff**, Hillsborough, NJ (US); **Zhenrong Xu**, Chalfont, PA (US)(73) Assignee: **PTC Therapeutics, Inc.**, South Plainfield, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 40 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **17/723,163**(22) Filed: **Apr. 18, 2022**(65) **Prior Publication Data**

US 2022/0251098 A1 Aug. 11, 2022

Related U.S. Application Data

(63) Continuation of application No. 16/617,450, filed as application No. PCT/US2018/035954 on Jun. 5, 2018, now Pat. No. 11,407,753.

(60) Provisional application No. 62/514,999, filed on Jun. 5, 2017.

(51) **Int. Cl.**

C07D 487/04 (2006.01)
C07D 401/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)
C07D 471/04 (2006.01)
C07D 491/048 (2006.01)
C07D 498/04 (2006.01)
C07D 513/04 (2006.01)
C07D 519/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07D 487/04** (2013.01); **C07D 401/14** (2013.01); **C07D 413/14** (2013.01); **C07D 417/14** (2013.01); **C07D 471/04** (2013.01);
C07D 491/048 (2013.01); **C07D 498/04** (2013.01); **C07D 513/04** (2013.01); **C07D 519/00** (2013.01)

(58) **Field of Classification Search**CPC .. C07D 487/04; C07D 401/14; C07D 413/14;
C07D 417/14; C07D 471/04; C07D
491/048; C07D 498/04; C07D 513/04;
C07D 519/00

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,558,618 A	1/1971	Trepanier
4,122,274 A	10/1978	Juby
4,342,870 A	8/1982	Kennis et al.
4,613,603 A	9/1986	Sanofi
4,902,695 A	2/1990	Ornstein
5,089,633 A	2/1992	Powers et al.
5,599,816 A	2/1997	Chu et al.
5,627,274 A	5/1997	Kole et al.
5,665,593 A	9/1997	Kole et al.
5,916,808 A	6/1999	Kole et al.
5,916,916 A	6/1999	Hauser et al.
5,976,879 A	11/1999	Kole et al.
6,172,216 B1	1/2001	Bennett et al.
6,210,892 B1	4/2001	Bennett et al.
6,214,986 B1	4/2001	Bennett et al.
6,468,607 B1	10/2002	Takehara et al.
6,630,488 B1	10/2003	Lamothe et al.
6,977,255 B2	12/2005	Robertson et al.
7,326,711 B2	2/2008	Wang et al.
7,399,767 B2	7/2008	Zhang et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101360738 A	2/2009
CN	102971311 A	3/2013

(Continued)

OTHER PUBLICATIONS

Berge et al. "Pharmaceutical Salts". Journal of Pharmaceutical Sciences. 66(1):1-19. (Year: 1977).*

(Continued)

Primary Examiner — Jeffrey S Lundgren*Assistant Examiner* — Ibrahim D Bori(74) *Attorney, Agent, or Firm* — McCarter & English, LLP; Michael J. DeGrazia(57) **ABSTRACT**

The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,473,784 B2	1/2009	Liu et al.	EP	2560008 A2	2/2013
7,569,337 B2	8/2009	Auberson	EP	2841428 B1	8/2018
7,576,110 B2	8/2009	Cowart et al.	FR	2914188 A1	10/2008
7,655,657 B2	2/2010	Stoner et al.	GB	1047935 A	11/1966
7,897,792 B2	3/2011	Iikuea et al.	GB	1383409	2/1975
7,910,578 B2	3/2011	Peters et al.	JP	S58-52307 A	3/1983
8,143,274 B2	3/2012	Hattori et al.	JP	S61-36282	2/1986
8,314,119 B2	11/2012	Schrimpf et al.	JP	2006219453 A *	8/2006
8,337,941 B2	12/2012	Gubernator et al.	JP	2009-508957 A	3/2009
8,563,550 B2	10/2013	Peverello et al.	JP	2009-545540	12/2009
8,633,019 B2	1/2014	Paushkin et al.	JP	2012-530071 A	11/2012
8,765,747 B2	7/2014	Choi et al.	JP	2013-40945	2/2013
8,846,661 B2	9/2014	Schrimpf et al.	JP	2017-512834	5/2017
8,921,361 B2	12/2014	Cmiljanovic et al.	JP	2017-533237 A	11/2017
8,940,716 B2	1/2015	Ye et al.	WO	1993/023398 A1	11/1993
9,340,537 B2	5/2016	Furet et al.	WO	1994/026877 A1	11/1994
9,371,336 B2	6/2016	Lee et al.	WO	1996/039407 A1	12/1996
9,399,649 B2	7/2016	Chen et al.	WO	1998/025930 A1	6/1998
9,617,268 B2	4/2017	Woll et al.	WO	2001/053266 A1	7/2001
9,969,754 B2	5/2018	Ratni et al.	WO	2002/062290 A2	8/2002
2002/0099208 A1	7/2002	Yu et al.	WO	2002/087589 A1	11/2002
2003/0004164 A1	1/2003	Bebbington et al.	WO	2005/0113335 A2	12/2004
2003/0199526 A1	10/2003	Choquette et al.	WO	2005/012288 A1	2/2005
2004/0224952 A1	11/2004	Cowart et al.	WO	2005/019215 A1	3/2005
2005/0054836 A1	3/2005	Krainer et al.	WO	2005/061513 A1	7/2005
2005/0074801 A1	4/2005	Monia et al.	WO	2005/066166 A2	7/2005
2005/0159597 A1	7/2005	Ji et al.	WO	2005/072720 A1	8/2005
2006/0172962 A1	8/2006	Vickers et al.	WO	2005/105801 A1	11/2005
2006/0205741 A1	9/2006	Zhang et al.	WO	2006/131835 A2	12/2006
2007/0078144 A1	4/2007	Stockwell et al.	WO	2006/138418 A2	12/2006
2007/0105807 A1	5/2007	Sazani et al.	WO	2007/003604 A2	1/2007
2007/0191374 A1	8/2007	Hodgetts	WO	2007/016392 A2	2/2007
2008/0171792 A1	7/2008	Jobdevairakkam et al.	WO	2007/018738 A1	2/2007
2008/0255162 A1	10/2008	Bruendl et al.	WO	2007/047913 A2	4/2007
2009/0163464 A1	6/2009	Black et al.	WO	2007/056580 A2	5/2007
2009/0163515 A1	6/2009	Birault et al.	WO	2007/065892 A1	6/2007
2009/0170793 A1	7/2009	Gaur	WO	2007/071055 A1	6/2007
2009/0264433 A1	10/2009	Russell et al.	WO	2007/089584 A2	8/2007
2010/0004233 A1	1/2010	Iikura et al.	WO	2007/089611 A2	8/2007
2010/0035279 A1	2/2010	Gubernator et al.	WO	2007/090073 A2	8/2007
2010/0267721 A1	10/2010	Hohlweg et al.	WO	2007/109211 A2	9/2007
2011/0086833 A1	4/2011	Paushkin et al.	WO	2007/110364 A1	10/2007
2011/0118289 A1	5/2011	Giordani et al.	WO	2007/130383 A2	11/2007
2012/0083495 A1	4/2012	Heemskerk et al.	WO	2007/133561 A2	11/2007
2013/0046093 A1	2/2013	Lee et al.	WO	2007/133756 A2	11/2007
2014/0051672 A1	2/2014	Cheung et al.	WO	2007/135121 A1	11/2007
2014/0121197 A1	5/2014	Burli et al.	WO	2008/011109 A2	1/2008
2014/0206661 A1	7/2014	Axford et al.	WO	2008/014822 A1	2/2008
2014/0329825 A1	11/2014	Heback et al.	WO	2008/020302 A2	2/2008
2015/0005289 A1	1/2015	Qi et al.	WO	2008/049864 A1	5/2008
2015/0018301 A1	1/2015	Lee et al.	WO	2008/077188 A1	7/2008
2015/0057218 A1	2/2015	Zhong et al.	WO	2009/042907 A1	4/2009
2015/0080383 A1	3/2015	Yang et al.	WO	2009/085945 A1	7/2009
2015/0119380 A1	4/2015	Woll et al.	WO	2009/114874 A2	9/2009
2016/0244762 A1	8/2016	Vorechovsky et al.	WO	2009/126635 A1	10/2009
2017/0000794 A1	1/2017	Naryshkin	WO	2009/151546 A2	12/2009
2017/0001995 A1	1/2017	Metzger et al.	WO	2009/156861 A2	12/2009
2017/0002016 A1	1/2017	Shishido et al.	WO	2010/000032 A1	1/2010
2017/0096411 A1	4/2017	Vechorkin et al.	WO	2010/019236 A1	2/2010
2017/0151225 A1	6/2017	Dahl	WO	2010/024903 A1	3/2010
2017/0355989 A1	12/2017	Konstantinova et al.	WO	2010/045303 A2	4/2010
2018/0118748 A1	5/2018	Slaugenhaupt et al.	WO	2010/071819 A1	6/2010
2018/0161456 A1	6/2018	Naryshkin et al.	WO	2010/093425 A1	8/2010
2018/0282347 A1	10/2018	Arlt et al.	WO	2010/130934 A2	11/2010
2019/0264267 A1	8/2019	Yang et al.	WO	2010/145208 A1	12/2010
2020/0056173 A1	2/2020	Vargeese et al.	WO	2011/032045 A1	3/2011
2020/0080083 A1	3/2020	Vargeese et al.	WO	2011/050245 A1	4/2011
			WO	2011/057204 A2	5/2011
			WO	2011/062853 A1	5/2011
			WO	2011/085990 A1	7/2011
			WO	2011/097641 A1	8/2011
CN	103533835 A	1/2014	WO	2011/097643 A1	8/2011
CN	101426772 A	5/2014	WO	2011/097644 A2	8/2011
CN	104768960 B	3/2017	WO	2012/012467 A2	1/2012
DE	2345064 A1	4/1974	WO	2012/019106 A2	2/2012
EP	1227084 A1	7/2002			

FOREIGN PATENT DOCUMENTS

CN	103533835 A	1/2014	WO	2011/097641 A1	8/2011
CN	101426772 A	5/2014	WO	2011/097643 A1	8/2011
CN	104768960 B	3/2017	WO	2011/097644 A2	8/2011
DE	2345064 A1	4/1974	WO	2012/012467 A2	1/2012
EP	1227084 A1	7/2002	WO	2012/019106 A2	2/2012

(56)	References Cited		WO	2021/084495 A1	5/2021
FOREIGN PATENT DOCUMENTS					
WO	2012/075393 A2	6/2012	WO	2021/174163 A1	9/2021
WO	2012/103806 A1	8/2012	WO	2021/207453 A1	10/2021
WO	2012/104823 A2	8/2012	WO	2022/103980 A1	5/2022
WO	2012/109395 A1	8/2012	WO	2023/009816 A1	2/2023
WO	2012/116965 A1	9/2012	WO	2023/244996 A2	12/2023
OTHER PUBLICATIONS					
Brunhilde Wirth et al., "Moving towards treatments for spinal muscular atrophy: hopes and limits", Expert Opinion on Emerging drugs, 20(3):353-356, Apr. 28, 2015.					
Cheung et al., "Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)", J. Med. Chem. vol. 61(24):11021-11036, Nov. 8, 2018 (published), pp. A-P.					
Chiara Zanetta et al., "Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials", Clinical Therapeutics, 36(1):128-140, Dec. 17, 2013.					
Coady et al., 2010, "Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy", J. Neurosci., vol. 30(1), pp. 126-130, 2010.					
Combrink et al., "Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation for the benzimidazol-2-one heterocycle moiety", Bioorganic & Medicinal Chemistry Letters, 17(17):4784-4790, Aug. 4, 2007.					
European Patent Office, Communication pursuant to Article 94(3) EPC, European Application No. 14877918.4, date of mailing Mar. 23, 2018.					
Greene, Protective Groups in Organic Syntehsis, 1991, Wiley, New York, pp. v-xxi and 1-17.					
H. Kubinyi, "3D QSAR in Drug Design—Theory Methods and Applications", pp. vii-ix and pp. 243-244, 1998.					
Higuchi and V. Stella, "Pro-drugs as novel delivery systems", vol. 14 of the A.C.S. Symposium Series and in Bioreversible Carriers in Drug Design, ed., Edward B. Roche, American Pharmaceutical Association and Pergamon Press (1975).					
Hua et al., "Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model", Nature, vol. 478(7367), pp. 123-126, 2012.					
Jarecki et al., "Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy", Human molecular genetics, 14(14):2003-2018, 2005.					
Knight et al., "Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold", Bioorganic & Medicinal Chemistry, vol. 12(17):4749-4759, 2004.					
Kocar, Transformations of 3-aminopyridazines. Synthesis of 4-oxo-4H-pyrimido [1,2-b]pyridazine and 1-(substituted pyridazin-3-yl)-1H-1,2,3-triazole derivatives, Arkivoc, vol. 8, 2002, 143-156.					
Lazarev et al., "Factors Affecting Aggregate Formation in Cell Models of Huntington's Disease and Amyotrophic Lateral Sclerosis", Acta Naturae, vol. 5(2):81-89, Apr. 2013.					
Le et al., "SMND7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN", Human Molecular Genetics, vol. 14(5), pp. 845-857, 2005.					
Liu et al., "A novel nuclear structure containing the survival of motor neurons protein", EMBO J. vol. 15(14), pp. 3555-3565 (1996).					
MacDonald et al., "Quantification Assays for Total and Polyglutamine-Expanded Huntington Proteins", PLOS One, 2014, vol. 9(5), published May 9, 2014, pp. 1-17.					
Makhortova et al., "A screen for regulators of survival of motor neuron proteins levels", Nature chemical biology, vol. 7(8):544-552, 2011.					
Markus Riessland et al., "The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells", Hum Genet 120:101-110, May 26, 2006.					
WO	WO-2016170163 A1 *	10/2016 C07D 487/04		
WO	2016/184832 A1	11/2016			
WO	2017/023987 A1	2/2017			
WO	2017/081111 A1	5/2017			
WO	2017/097728 A1	6/2017			
WO	2017/100726 A1	6/2017			
WO	2017/153601 A1	9/2017			
WO	2017/175068 A1	10/2017			
WO	2017/189829 A1	11/2017			
WO	2017/210134 A1	12/2017			
WO	2018/013770 A1	1/2018			
WO	2018/081091 A1	5/2018			
WO	2018/187209 A1	10/2018			
WO	2018/218133 A1	11/2018			
WO	2018/226622 A1	12/2018			
WO	2019/005980 A1	1/2019			
WO	2019/005993 A1	1/2019			
WO	2019/028440 A1	2/2019			
WO	2019/165073 A1	8/2019			
WO	2019/183364 A1	9/2019			
WO	2019/183367 A1	9/2019			
WO	2019/191092 A1	10/2019			
WO	2019/191229 A1	10/2019			
WO	2020/005873 A1	1/2020			
WO	2020/005877 A1	1/2020			
WO	2020/005882 A1	1/2020			
WO	2020/190793 A1	9/2020			
WO	2020/231977 A1	11/2020			
WO	2021/007378 A1	1/2021			

(56)

References Cited**OTHER PUBLICATIONS**

- Naryshkin et al., "SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy", *Science*, vol. 345(6197):688-693, 2014 (including supplementary materials).
- Palacino et al., "SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice", *Nature: Chemical Biology*, pp. 511-517 and 5 Supplemental pp. +S1-S20, vol. 11, Jun. 1, 2015.
- Passini et al., "Antisense Oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy", *Sci Transl. Med.*, vol. 3(72), 2001.
- Peng, Lijie et al., "Identification of pyrido[1,2-alpha]pyrimidine-4-ones as new molecules improving the transcriptional functions of estrogen-related receptor alpha", *Journal of medicinal chemistry*, vol. 54(21):7729-7733, 2011.
- Potkin et al., "New directions in therapeutics for Huntington disease", *Future Neurology*, vol. 13(2):101-121, May 2018.
- Pryor et al., "Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease", *Sci. Signal.*, dated Oct. 28, 2014, 2014, vol. 7, Issue 349, ra103, pp. 1-12.
- PubChem/NCBI Database accession No. CID 377422 [online], 2005, retrieved on Jul. 4, 2016, URL <http://pubchem.ncbi.nlm.nih.gov/compound/377422>.
- Seisuke Mimori et al., "Protective Effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress," *Biological & Pharmaceutical Bulletin of Japan*, 35(1):84-90, Jan. 1, 2012.
- Shao, Ning et al., "Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists", *Biorganic & Medicinal chemistry letters*, vol. 22(5):2075-2078, 2012.
- Sin et al., "Respiratory syncytial virus fusion inhibitors. Part 7: Structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo", *Biorganic & Medicinal Chemistry Letters*, 19(16):4857-4862, Aug. 15, 2009.
- Yuo et al., 2008, "5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells", *Annals of neurology*, vol. 63(1):26-34, 2008.
- Wermuth, "The Practice of Medicinal Chemistry", 2nd ed., 2003, Chapters 9-10.
- Pubchem, Substance Record for SID 249779947, Mar. 31, 2015, "4H-Quinolizin-4one 1; Hydrobromide".
- International Search Report for PCT/EP2012/065499, mailed Sep. 28, 2012.
- Written Opinion of the International Searching Authority in PCT/EP2012/065499, mailed Sep. 28, 2012.
- International Search Report for PCT/EP2014/059699, mailed Aug. 25, 2014.
- Written Opinion of the International Searching Authority in PCT/EP2014/059699, mailed Aug. 25, 2014.
- International Search Report for PCT/EP2015/051066, mailed Feb. 19, 2015.
- Written Opinion of the International Searching Authority in PCT/EP2015/051066, mailed Feb. 19, 2015.
- International Search Report for PCT/EP2015/060343, mailed Jul. 13, 2015.
- Written Opinion of the International Searching Authority in PCT/EP2015/060343, mailed Jul. 13, 2015.
- International Search Report for PCT/EP2016/060952, mailed Jun. 29, 2016.
- Written Opinion of the International Searching Authority in PCT/EP2016/060952, mailed Jun. 29, 2016.
- International Search Report for PCT/EP2016/076905, mailed Feb. 9, 2017.
- Written Opinion of the International Searching Authority in PCT/EP2016/076905, Feb. 9, 2017.
- Written Opinion of the International Searching Authority in PCT/EP2016/077190, mailed Mar. 1, 2017.
- International Search Report for PCT/EP2016/077190, mailed Mar. 1, 2017.
- International Search Report for PCT/EP2016/079816, mailed Jan. 19, 2017.
- Written Opinion of the International Searching Authority in PCT/EP2016/079816, mailed Jan. 19, 2017.
- International Search Report for PCT/US2013/025292, mailed Aug. 30, 2013.
- Written Opinion of the International Searching Authority in PCT/US2013/025292, mailed Aug. 30, 2013.
- International Search Report for PCT/US2016/066042, mailed Mar. 16, 2017.
- Written Opinion of the International Searching Authority in PCT/US2016/066042, mailed Mar. 16, 2017.
- International Search Report for PCT/US2018/035954, mailed Oct. 1, 2018.
- Written Opinion of the International Searching Authority in PCT/US2018/035954, mailed Oct. 1, 2018.
- International Search Report for PCT/US2018/039775, mailed Oct. 29, 2018.
- Written Opinion of the International Searching Authority in PCT/US2018/039775, mailed Oct. 29, 2018.
- International Search Report for PCT/US2018/039794, mailed Oct. 25, 2018.
- Written Opinion of the International Searching Authority in PCT/US2018/039794, mailed Oct. 25, 2018.
- International Search Report for PCT/US2019/024068, mailed Jul. 10, 2019.
- Written Opinion of the International Searching Authority in PCT/US2019/024068, mailed Jul. 10, 2019.
- International Search Report for PCT/US2019/024278, mailed May 28, 2019.
- Written Opinion of the International Searching Authority in PCT/US2019/024278, mailed May 28, 2019.
- Andreassi, C. et al. 2001. *Human Molecular Genetics* 10, 2841-2849. "Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients."
- Artursson P. et al. 1991. *Biochem Biophys Res Comm* 175, 880-5. "Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells."
- Baldo, B. et al. 2012. *J. Biol. Chem.* 287, 1406-1414. "A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein."
- Barbaro, B.A. et al. 2015. *Human Molecular Genetics* 24, 913-925 (published online Oct. 9, 2014). "Comparative study of naturally occurring huntingtin fragments in *Drosophila* points to exon 1 as the most pathogenic species in Huntington's disease."
- Bates, G.P. et al. 2015. *Nature Reviews, Disease Primers* 1, 15005 (published online Apr. 23, 2015). "Huntington disease."
- Bengart, P. et al. 2004. *Nucleic Acids Res.* 32, W154-W159. "Riboswitch finder—a tool for identification of riboswitch RNAs."
- Bhattacharyya, A. et al. 2007 *Drug Discovery Today* 12, 553-560. "Mining the GEMS—a novel platform technology targeting post-transcriptional control mechanisms."
- Bibillo, A and Eickbush, T.H. 2002. *J. Biol. Chem.* 277, 34836-34845. "High Processivity of the Reverse Transcriptase from a Non-long Terminal Repeat Retrotransposon."
- Carroll, J.B. et al. 2015. *Lancet Neurol* 14, 1135-1142 (No. 11—Nov. 2015). "Treating the whole body in Huntington's disease."
- Cartegni, L. et al. 2003. *Nucleic Acids Res.* 31, 3568-3571. "ESEfinder: a web resource to identify exonic splicing enhancers."
- Crooks, G. E., et al. 2004. *Genome Research* 14, 1188-1190. "WebLogo: a sequence logo generator."
- Daguet et al. 2015. *EMBO reports* 16, 1640-1655 (published online Nov. 13, 2015). "The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches."
- DiFiglia, et al 1997. *Science* 277, 1990-1993. "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain".
- Dobin, A. et al. 2013. *Bioinformatics* 29, 15-21. "STAR: ultrafast universal RNA-seq aligner."

(56)

References Cited**OTHER PUBLICATIONS**

- Evers, M.M. et al. 2015. Molecular Neurodegeneration 10, Article No. 21 (published online Apr. 28, 2015). "Making (anti-) sense out of huntingtin levels in Huntington disease."
- Fardaei, M. et al. 2002. Human Molecular Genetics 11, 805-814. "Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells."
- Fernandez-Nogales, M. et al. 2014. Nature Medicine 20, 881-885. "Huntington's disease is a four-repeat tauopathy with tau nuclear rods."
- Gipson, T. A. et al. 2013. RNA Biology 10, 1647-1652. "Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis."
- Gray, M. et al. 2008. J. Neurosci. 28, 6182-6195. "Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neurodegeneration in BACHD mice."
- Griffiths-Jones, S. et al. 2005. Nucleic Acids Res. 33, D121-D124. "Rfam: annotating non-coding RNAs in complete genomes."
- Griffiths-Jones, S. et al. 2006. Nucleic Acids Res. 34, D140-D144. "miRBase: microRNA sequences, targets and gene nomenclature."
- Grillo, G. et al. 2003. Nucleic Acids Res. 31, 3608-3612. "PatSearch: a program for the detection of patterns and structural motifs in nucleotide sequences."
- Grimson, A. et al. 2007. Molecular Cell 27, 91-105. "MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing."
- Heemskerk, J. et al. 2002. Nature Neuroscience Supplement 5, 1027-1029. "From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials."
- Heemskerk, J. et al. 2002. Trends Neurosci. 25, 494-496. "Teaching old drugs new tricks."
- Heemskerk, J. et al. 2005. Chapter 16—"Therapeutics Development for Hereditary Disorders" in ed. Waxman, S. From Neuroscience to Neurology: Neuroscience, Molecular Medicine, and the Therapeutic Transformation of Neurology, pp. 285-291.
- Hernandez-Imas, E. et al. 2015. PLoS One 10, e141735 (published online Oct. 28, 2015). "Functional Analysis of Mutations in Exon 9 of NF1 Reveals the Presence of Several Elements Regulating Splicing."
- Hodges, A. et al. 2006. Human Molecular Genetics 15, 965-977. "Regional and cellular gene expression changes in human Huntington's disease brain."
- Hua et al. 2007. PLoS Biol 5, e73. Enhancement of SMN2 Exon 7 "Inclusion by Antisense Oligonucleotides Targeting the Exon."
- Hua et al. 2008. American J. of Human Genetics 82, 834-848. "Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice."
- The Huntington's Disease Collaborative Research Group, 1993, Cell, 72, pp. 971-983 (1993). "A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease chromosomes."
- Janas, A. M. 2015. "A Stem Cell Model of the Motor Circuit Reveals Distinct Requirements for SMN in Motor Neuron Survival and Function."
- Jacobs, G.H. et al. 2006. Nucleic Acids Res. 34, suppl_1, D37-D40. "Transterm—extended search facilities and improved integration with other databases."
- Kanadia, R.N. et al. 2003. Science 302, 1978-1980. "A Muscleblind Knockout Model for Myotonic Dystrophy."
- Kaplan, A. et al. 2012. Prog. Neurobiol. 99(3), 262-280. "Therapeutic approaches to preventing cell death in Huntington disease."
- Kim, D. et al. 2013. Genome Biology 14, Article No. R36. "TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions."
- Kordasiewicz, H.B. et al. 2012. Neuron, 74, 1031-1044. "Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis."
- Kuhn, A. et al. 2007. Human Molecular Genetics 16, 1845-1861. "Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage."
- Labadoff, A.T. et al. 2015. Plos One 10(10): e0141298 (published online Oct. 23, 2015). "Evidence of Extensive Alternative Splicing in Post Mortem Human Brain HTT Transcription by mRNA Sequencing." (including supplemental information).
- Labadoff, A. et al. 2015. PLoS One 10(12): e0143563 (published online Dec. 4, 2015). "RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expression."
- Labbadia, J. et al. 2013. Trends Biochem. Sci. 38, 378-385. "Huntington's disease: underlying molecular mechanisms and emerging concepts."
- Landles, C. et al. 2010. J. Bio. Chem. 285, 8808-8823. "Proteolysis of Mutant Huntington Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease."
- Lei, et al. 2005. Nucleic Acids Res 33, 3897-3909. "Exonization of AluYa5 in the human ACE gene requires mutations in both 3' and 5' splice sites and is facilitated by a conserved splicing enhancer."
- Liang, Y. et al. 2009. Brain Res. 2009 1286, 221-229. "ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line."
- Love, M. I. et al. 2014. Genome Biology 15, 550. "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2."
- Lunkes, A. et al. 2002. Molecular Cell 10, 259-269. "Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions."
- Macke, T.J. 2001. Nucleic Acids Res. 29, 4724-4735. "RNAMotif, an RNA secondary structure definition and search algorithm."
- Mahmood, I. et al. 1996. Xenobiotica 26, 887-895. "Interspecies scaling: predicting clearance of drugs in humans. Three different approaches."
- Mahmood, I. 2006. Pharm. Sci. 95, 1810-1821. "Prediction of human drug clearance from animal data: Application of the rule of exponents and 'fu corrected intercept method' (FCIM)."
- Mahmoudi, S et al. 2010. PLoS Biology 8(11), e10000521. "WRAP53 is Essential for Cajal Body and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies."
- Mangiarini, L. 1996. Cell 87, 493-506. "Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice."
- Mantione, K.J. et al. 2014. Med. Sci. Monit. Basic Res. 20, 138-141. "Comparing Bioinformation Gene Expression Profiling Methods: Microarray and RNA-Seq."
- Mendoza, L.G. et al. 1999. BioTechniques 27, 778-788. "High-Throughput Microarray-Based Enzyme-Linked Immunosorbent Assay (ELISA)."
- Mielcarek, M. et al. 2014. PLOS Genetics 10: 8 e1004550. "Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease."
- Mignone, F. et al. 2005. Nucleic Acids Res. 33, D141-D146. "UTRdb and UTRsite: a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs."
- Mort, M. et al. 2015. J. of Huntington's Disease 4(2 of 4), 161-171. "Huntingtin Exists as Multiple Splice Forms in Human Brain."
- Neuder, A. et al. 2014. BMC Medical Genomics 7:60. "A common gene expression signature in Huntington's disease patient brain regions."
- Paganetti, P. et al. 2009. ChemBioChem 10, 1678-1688. "Development of Method for the High-Throughput Quantification of Cellular Proteins."
- Pouladi, M. et al. 2013. Nature Review Neuroscience 14, 709-721. "Choosing an animal model for the study of Huntington's disease."
- Ratovitski, T. et al. 2012. Cell Cycle 11, 2006-2021. "Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis."
- Reiner, A. et al. 2011. International Review of Neurobiology 98, 325-372. "Genetics and neuropathology of Huntington's disease."

(56)

References Cited**OTHER PUBLICATIONS**

- Ruzo, A. et al. 2015. PLoS One 10, e0127678 (published online May 26, 2015). "Discovery of Novel Isoforms of Huntington Reveals a New Hominid-Specific Exon."
- Sadeghian, H. et al. 2011. Arch. Neurol. 68, 650-652. "Huntington Chorea Presenting with Motor Neuron Disease."
- Sathasivam, K. et al. 2013. Proc. Natl. Acad. Sci. 110, 2366-2370. "Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease."
- Schilling, G. et al. 2007. J Neuropathol. Exp. Neurol. 66, 313-320. "Characterization of Huntington Pathologic Fragments in Human Huntington Disease, Transgenic Mice, and Cell Models."
- Schwab, C. et al. 2008. J. Neuropathol Exp Neurol 67, 1159-1165. "Colocalization of Transactivation-Responsive DNA-Binding Protein 43 and Huntingtin in Inclusions of Huntington Disease."
- Shlyakhtenko, L.S. et al. 2007. Nanomedicine: Nanotech., Bio., and Med. 3, 192-197. "Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy."
- Southwell, A.L. et al. 2013. Hum. Mol. Genet. 22, 18-34. "A fully humanized transgenic mouse model of Huntington disease."
- Stanek, L.M. et al. 2014. Human Gene Therapy 25, 461-474. "Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Disease."
- Stoilov, P. et al. 2008. Proc. Natl. Acad. Sci. 105, 11218-11223. "A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators."
- Taylor et al. 1999. Nat. Biotechnol. 17, 1097-1100 "Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides."
- Van der Burg, J.M.M. et al. 2009. The Lancet (Neurology) 8, 765-774. "Beyond the brain: widespread pathology in Huntington's disease."
- Varma, H. et al. 2008. Comb Chem High Throughput Screen 11, 238-248. "High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes."
- Vickers et al., 2006. J. Immunol. 176, 3652-3661 "Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2'-O-methoxyethyl-modified oligonucleotide."
- Wachter, A. 2014. Trends in Genetics 30, 172-181. "Gene regulation by structured mRNA elements."
- Weiland, M. et al. 2012. Methods 56, 351-357. "Engineering of ribozyme-based riboswitches for mammalian cells."
- Wild, E.J. et al. 2014. Movement Disorders 29, 1434-1445. "Targets for Future Clinical Trials in Huntington's Disease: What's in the Pipeline?"
- Wilton et al. 1999. Neuromuscul. Disord. 9, 330-338. "Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides."
- Xiong, H.Y. et al. 2015. Science 347, 1254806 (published online Dec. 18, 2014.) "The human splicing code reveals new insights into the genetic determinants of disease."
- Yeo, G. et al. 2004. J. Comput. Biol. 11, 377-394. "Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals."
- Younis et al. 2010. Molecular and Cellular Biology 30, 1718-1728. "Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative Splicing."
- Yu, S. et al. 2014. Trends in Pharmacological Sci. 35, 53-62. "Drugging unconventional targets: insights from Huntington's disease."
- Zona, S. et al. 2014. Biochimica et Biophysica Acta 1839, 1316-1322. "FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance."
- Nair, A.B. et al. 2016. J. Basic and Clinical Pharmacy 7, 27-31. "A simple and practical guide for dose conversion between animals and human."
- Neuder, A. et al. 2017. Scientific Reports 7, 1307 (published online May 2, 2017). "The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients."
- Nopoulos, P. C. 2016. Dialogues Clin Neurosci 18, 91-98. "Huntington disease: a single-gene degenerative disorder of the striatum."
- Ratni, H. et al. 2016. J. Med. Chem. 59, 6086-6100. "Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy."
- Rüb, U. et al. 2016. Brain Pathol. 26, 726-740. "Huntington's disease (HD): the neuropathology of a multisystem neurodegenerative disorder of the human brain."
- Saudou, F. et al. 2016. Neuron 89, 910-926. "The Biology of Huntingtin."
- Wang, G. et al. 2016. Proc. Natl. Acad. Sci. 113, 3359-3364. "Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis."
- Woll, M.G. et al. 2016. J. Med. Chem. 59, 6070-6085. "Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy." International Search Report for PCT/EP2015/063894, mailed Aug. 6, 2015.
- Written Opinion of the International Searching Authority in PCT/EP2015/063894, mailed Aug. 6, 2015.
- Nair et al., "Synthesis and fluorescence properties of 3-benzoxa- and thiazol-2-ylquinoline-5 or 7-maleimides." Indian Journal of Chemistry, Sep. 2004, vol. 43B, pp. 1944-1949.
- Naik et al., "Studies in the Vilsmeier-Haack Reaction: Part XVI—Synthesis of 7-Amino-3-hetarylquinoline Fluorophore & Derivatives," Indian Journal of Chemistry, Jun. 1977, pp. 506-508.
- International Search Report for PCT/US19/38889, mailed Aug. 8, 2019.
- Written Opinion of the International Searching Authority in PCT/US19/38889, mailed Aug. 8, 2019.
- International Search Report for PCT/US19/38895, mailed Aug. 14, 2019.
- Written Opinion of the International Searching Authority in PCT/US19/38895, mailed Aug. 14, 2019.
- Written Opinion of the International Searching Authority in PCT/US19/38900, mailed Aug. 20, 2019.
- International Search Report for PCT/US20/32446, mailed Jul. 7, 2020.
- Written Opinion of the International Searching Authority in PCT/US20/32446, mailed Jul. 7, 2020.
- International Search Report for PCT/US20/41300, mailed Oct. 16, 2020.
- Written Opinion of the International Searching Authority in PCT/US20/41300, mailed Oct. 16, 2020.
- Abdul Khader K K et al., "Regioselective synthesis of C-2 substituted imidazo[4,5-b]pyridines utilizing palladium catalysed C—N bond forming reactions with enolizable heterocycles", Tetrahedron Letters, Elsevier, Amsterdam, NL, vol. 55, No. 10, Feb. 1, 2014, p. 1778-1783.
- Mariusz Mojzych et al., "Synthesis of pyrazolo[4,3-e][1,2,4]triazine sulfonamides, novel Sildenafil analogs with tyrosinase inhibitory activity", Bioorganic & Medicinal Chemistry, vol. 22, No. 23, Oct. 18, 2014, p. 6616-6624.
- Ingo Knepper et al., "3-Acylindoles as versatile starting materials for pyridine ring annulation: synthesis of 1-deazapurine isosteres", Tetrahedron, vol. 67, No. 29, May 14, 2011, p. 5293-5303.
- Chloé Copin et al., "S N Ar versus Buchwald-Hartwig Amination/ Amidation in the Imidazo[2,1-b][1,3,4]thiadiazole Series : S N Ar versus Buchwald-Hartwig Amination/Amidation", European Journal of Organic Chemistry, vol. 2015, No. 31, Sep. 29, 2015, p. 6932-6942.
- Patel Harun M et al, "2,5,6-Trisubstituted imidazo[2,1-b][1,3,4]thiadiazoles: Search for antihyperlipidemic agents", European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR, vol. 65, Apr. 18, 2013, p. 119-133.
- Mazzone G et al, "Sintesi e valutazione biologica preliminare di imidazo[2,1-b]-1,3,4-thiadiazoli-2,6-diaril sostituiti", Farmaco, Edizione Scientifica, Società Chimica Italiana, Pavia, IT, vol. 39, No. 7, Jan. 1, 1984, p. 585-598. English abstract only.

(56)

References Cited**OTHER PUBLICATIONS**

- Fascio Mirta L et al, "Synthesis and antiviral activity of some imidazo[1,2-b][1,3,4]thiadiazole carbohydrate derivatives", Carbohydrate Research, vol. 480, May 21, 2019, p. 61-66.
- Database Registry [Online], Chemical Abstracts Service, Columbus, Ohio, US; Feb. 22, 2018, Database accession No. 2178867-25-7.
- Database Registry [Online], Chemical Abstracts Service, Columbus, Ohio, US; Sep. 25, 2017, Database accession No. 2130694-60-7.
- Database Registry [Online], Chemical Abstracts Service, Columbus, Ohio, US; Sep. 24, 2017, Database accession No. 2130300-22-8.
- Database Registry [Online], Chemical Abstracts Service, Columbus, Ohio, US; Sep. 18, 2017, Database accession No. 2128311-64-6.
- Chemical Abstracts Registry No. 2107242-04-04, indexed in the Registry file on STN CAS Online Aug. 2, 2017. (Year: 2017). USPTO, Office Action dated Feb. 4, 2021 in U.S. Appl. No. 16/617,450; see whole document in general and compounds on pp. 10-14 and 15-18 in particular.
- Daldin et al., "Polyglutamine expansion affects huntingtin conformation in multiple Huntington's disease models", *Scientific Reports*, vol. 7, 15 pages, 2017.
- Gleave et al., "Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB2 agonists for the treatment of inflammatory pain", *Bioorganic & Medicinal Chemistry Letters*, vol. 20, pp. 465-468, 2010.
- Kaida et al., "U1 snRNP protects pre-mRNAs from premature cleavage and polyadenylation"; *Nature*, vol. 468, pp. 664-669; Dec. 2, 2010.
- Ross & Tabrizi, "Huntington's disease: from molecular pathogenesis to clinical treatment"; *The Lancet Neurology*, vol. 10, pp. 83-98, Jan. 2011.
- Wang et al., "Mechanism of alternative splicing and its regulation (Review)", *Biomedical Reports*, vol. 3, pp. 152-158, 2015.
- Berg, J.M., Tymoczko, J.L., & Stryer, L., *Biochemistry* (5th ed.), p. 798, 2002.
- Opposition in European Patent No. 3,386,511, Feb. 25, 2022, 29 pages.
- Bhattacharyya et al., Small molecule splicing modifiers with systemic HTT-lowering activity *Nature Communications* 12(7299), 2021.
- Boudreau et al., 2009. "Nonallele-Specific Silencing of Mutant and Wild-Type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice." *Molecular Therapy: The Journal of the American Society of Gene Therapy* 17 (6): 1053-63.
- Campagne et al., 2019. "Structural Basis of a Small Molecule Targeting RNA for a Specific Splicing Correction." *Nature Chemical Biology* 15 (12): 1191-98, 2019.
- Connelly et al., 2016. "The Emerging Role of RNA as a Therapeutic Target for Small Molecules." *Cell Chemical Biology* 23 (9): 1077-90.
- Effenberger et al., 2016. "Modulating Splicing with Small Molecular Inhibitors of the Spliceosome." *Wiley Interdisciplinary Reviews. RNA* 8 (2).
- Marxreiter et al., 2020. "Huntington Lowering Strategies." *International Journal of Molecular Sciences* 21 (6).
- Mount et al., A catalogue of splice junction sequences *Nucleic Acids Research* 10(2):459-472 (Jan. 22, 1982).
- Nishigaki et al., Syntheses of 9-Deazatheophyllines and 6-Deoxy-9-deazatheophyllines *Chemical and Pharmaceutical Bulletin* 28(5):1636-1641 (1980).
- Ratni et al., Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier . . . , *Journal of Medicinal Chemistry*, 61(15), 6501-6517 (2018).
- Ritz et al., Dose-Response Analysis Using R *PLOS ONE* 10(12) (Dec. 30, 2015).
- Romo et al., 2018. "A Fresh Look at Huntington mRNA Processing in Huntington's Disease." *Journal of Huntington's Disease* 7 (2): 101-8.
- Schilling Judith, Meike Broemer, Ilian Atanassov, Yvonne Duernberger, Ina Vorberg, Christoph Dieterich, Alina Dagane, et al. 2019. "Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease." *Journal of Molecular Biology* 431 (9): 1869-77.
- Sibley et al., 2016. "Lessons from Non-Canonical Splicing." *Nature Reviews. Genetics* 17 (7): 407-21.
- Sivaramakrishnan et al., Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers *Nature Communications* 8(1) (Nov. 2017).
- Southwell et al. 2018. "Huntingtin Suppression Restores Cognitive Function in a Mouse Model of Huntington's Disease." *Science Translational Medicine* (10) 1-12.
- Southwell et al. 2017. "A Novel Humanized Mouse Model of Huntington Disease for Preclinical Development of Therapeutics Targeting Mutant Huntingtin Alleles." *Human Molecular Genetics* 26 (6): 1115-32.
- Tabrizi et al., Huntington Lowering Strategies for Disease Modification in Huntington's Disease *J. Neuron* 101(5):801-819 (Mar. 6, 2019).
- Wild et al., 2017. "Therapies Targeting DNA and RNA in Huntington's Disease." *Lancet Neurology* 16 (10): 837-47.
- International Search Report in PCT/US2021/059010, dated Apr. 26, 2022.
- Written Opinion of the International Searching Authority in PCT/US2021/059010, dated Apr. 26, 2022.
- Reply to Opposition in European Patent No. 3,386,511, Jul. 7, 2022, 427 pages.
- EPO Board Communication in Opposition in European Patent No. 3,386,511, Oct. 18, 2022, 12 pages.
- International Search Report in PCT/US2021/026316, dated Aug. 5, 2021.
- Written Opinion of the International Searching Authority in PCT/US2021/026316, dated Aug. 5, 2021.
- Burli et al., "Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease", *Journal of Medicinal Chemistry*, vol. 56, pp. 9934-9954, 2013.
- Chemical Abstracts Registry No. 1381103-87-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381109-95-0, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381103-06-5, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381085-12-6, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381084-38-3, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381084-19-0, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381069-02-8, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381060-23-6, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381036-73-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381033-11-9, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381016-89-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381016-41-6, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381013-97-3, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380991-96-7, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380991-09-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380955-66-7, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).

(56)

References Cited**OTHER PUBLICATIONS**

- Chemical Abstracts Registry No. 1380889-28-0, indexed in the Registry file on STN CAS Online Jul. 3, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380857-75-9, indexed in the Registry file on STN CAS Online Jul. 3, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1350420-68-6, indexed in the Registry file on STN CAS Online Dec. 7, 2011. (Year: 2011).
- Chemical Abstracts Registry No. 1350191-80-8, indexed in the Registry file on STN CAS Online Dec. 7, 2011. (Year: 2011).
- Chemical Abstracts Registry No. 919610-78-9, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919610-77-8, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919610-71-2, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919610-70-1, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919610-69-8, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919494-40-9, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919494-38-5, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 919494-22-7, indexed in the Registry file on STN CAS Online Feb. 6, 2007. (Year: 2007).
- Chemical Abstracts Registry No. 1348577-48-9, indexed in the Registry file on STN CAS Online Dec. 4, 2011. (Year: 2011).
- Chemical Abstracts Registry No. 1380990-95-3, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380944-26-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380879-49-1, indexed in the Registry file on STN CAS Online Jul. 3, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380858-18-3, indexed in the Registry file on STN CAS Online Jul. 3, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381109-36-9, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381106-70-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380864-49-2, indexed in the Registry file on STN CAS Online Jul. 3, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1380859-62-0, indexed in the Registry file on STN CAS Online Jul. 3, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 1381035-24-0, indexed in the Registry file on STN CAS Online Jul. 4, 2012. (Year: 2012).
- Chemical Abstracts Registry No. 2059673-20-8, indexed in the Registry file on STN CAS Online Jan. 26, 2017. (Year: 2017).
- Chemical Abstracts Registry No. 2224380-48-5, indexed in the Registry file on STN CAS Online May 20, 2018.
- Chemical Abstracts Registry No. 2055492-51-6, indexed in the Registry file on STN CAS Online Jan. 5, 2017.
- Chemical Abstracts Registry No. 1608159-30-3, indexed in the Registry file on STN CAS Online May 22, 2014.
- Chemical Abstracts Registry No. 1349790-59-5, indexed in the Registry file on STN CAS Online Dec. 6, 2011.
- Chemical Abstracts Registry No. 1349075-20-2, indexed in the Registry file on STN CAS Online Dec. 5, 2011.
- Chemical Abstracts Registry No. 1348522-09-7, indexed in the Registry file on STN CAS Online Dec. 4, 2011.
- Chemical Abstracts Registry No. 1348048-78-1, indexed in the Registry file on STN CAS Online Dec. 4, 2011.
- Chemical Abstracts Registry No. 1347905-79-6, indexed in the Registry file on STN CAS Online Dec. 4, 2011.
- Chemical Abstracts Registry No. 1347641-28-4, indexed in the Registry file on STN CAS Online Dec. 2, 2011.
- Chemical Abstracts Registry No. 1347614-67-8, indexed in the Registry file on STN CAS Online Dec. 2, 2011.
- Chemical Abstracts Registry No. 1347467-65-5, indexed in the Registry file on STN CAS Online Dec. 2, 2011.
- Chemical Abstracts Registry No. 2213453-82-6, indexed in the Registry file on STN CAS Online Apr. 16, 2018.
- Chemical Abstracts Registry No. 2170880-44-9, indexed in the Registry file on STN CAS Online Jan. 24, 2018.
- Chemical Abstracts Registry No. 2170880-30-3, indexed in the Registry file on STN CAS Online Jan. 24, 2018.
- Chemical Abstracts Registry No. 2170880-29-0, indexed in the Registry file on STN CAS Online Jan. 24, 2018.
- Chemical Abstracts Registry No. 2170876-00-1, indexed in the Registry file on STN CAS Online Jan. 24, 2018.
- Chemical Abstracts Registry No. 2170875-99-5, indexed in the Registry file on STN CAS Online Jan. 24, 2018.
- Chemical Abstracts Registry No. 2138484-61-2, indexed in the Registry file on STN CAS Online Nov. 3, 2017.
- Chemical Abstracts Registry No. 2117679-02-2, indexed in the Registry file on STN CAS Online Aug. 21, 2017.
- Chemical Abstracts Registry No. 2098833-57-7, indexed in the Registry file on STN CAS Online Jun. 21, 2017.
- Chemical Abstracts Registry No. 2096985-34-9, indexed in the Registry file on STN CAS Online May 23, 2017.
- Chemical Abstracts Registry No. 1957192-78-7, indexed in the Registry file on STN CAS Online Jul. 21, 2016.
- Chemical Abstracts Registry No. 1579964-39-8, indexed in the Registry file on STN CAS Online Apr. 3, 2014.
- Chemical Abstracts Registry No. 1381102-22-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012.
- Chemical Abstracts Registry No. 1381055-52-2, indexed in the Registry file on STN CAS Online Jul. 4, 2012.
- Chemical Abstracts Registry No. 1380859-69-7, indexed in the Registry file on STN CAS Online Jul. 4, 2012.
- Chemical Abstracts Registry No. 1283718-58-0, indexed in the Registry file on STN CAS Online Apr. 21, 2011.
- Chemical Abstracts Registry No. 919610-72-3, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919496-89-2, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919494-45-4, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919494-44-3, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919494-39-6, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919494-26-1, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919494-23-8, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919494-19-2, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919493-72-4, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 919493-71-3, indexed in the Registry file on STN CAS Online Feb. 6, 2007.
- Chemical Abstracts Registry No. 848953-00-4, indexed in the Registry file on STN CAS Online Apr. 21, 2005.
- Chemical Abstracts Registry No. 848952-99-8, indexed in the Registry file on STN CAS Online Apr. 21, 2005.
- Chemical Abstracts Registry No. 120821-79-6, indexed in the Registry file on STN CAS Online May 26, 1989.
- Chemical Abstracts Registry No. 1369171-97-0, indexed in the Registry file on STN CAS Online Apr. 16, 2012.
- Chemical Abstracts Registry No. 1330263-81-4, indexed in the Registry file on STN CAS Online Sep. 9, 2011.
- Alessandro Stella et. al., A short and straightforward approach towards 6-amino and 6-aminoalkyl thiazolo[4,5-c]pyridazines, *Tetrahedron Letters*, 54(8) (2013) pp. 830-833.
- Thuraya Al-Harthi et al., "Design, synthesis and antimicrobial evaluation of novel 2-arylbenzothiazole analogs bearing fluorine and piperazine moieties," *Monatshefte fur Chemie* (2018) 149(3) pp. 645-651.
- Hye Ri Park et al., "Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease," *Bioorganic & Medicinal Chemistry*, 21(17) (2013) pp. 5480-5487.

(56)

References Cited**OTHER PUBLICATIONS**

- Chemical Abstracts Registry No. 1368225-46-0, indexed in the Registry file on STN CAS Online Apr. 15, 2012.
- Chemical Abstracts Registry No. 1330013-08-5, indexed in the Registry file on STN CAS Online Sep. 8, 2011.
- Chemical Abstracts Registry No. 1329755-78-3, indexed in the Registry file on STN CAS Online Sep. 8, 2011.
- Chemical Abstracts Registry No. 1329572-44-2, indexed in the Registry file on STN CAS Online Sep. 7, 2011.
- Chemical Abstracts Registry No. 1329511-91-2, indexed in the Registry file on STN CAS Online Sep. 7, 2011.
- Chemical Abstracts Registry No. 1327110-38-2, indexed in the Registry file on STN CAS Online Sep. 2, 2011.
- Chemical Abstracts Registry No. 1310217-40-3, indexed in the Registry file on STN CAS Online Jun. 23, 2011.
- Chemical Abstracts Registry No. 1310089-22-5, indexed in the Registry file on STN CAS Online Jun. 23, 2011.
- Chemical Abstracts Registry No. 1267789-60-5, indexed in the Registry file on STN CAS Online Mar. 10, 2011.
- Chemical Abstracts Registry No. 1267620-08-5, indexed in the Registry file on STN CAS Online Mar. 9, 2011.
- Chemical Abstracts Registry No. 1267544-92-2, indexed in the Registry file on STN CAS Online Mar. 9, 2011.
- Chemical Abstracts Registry No. 1267173-86-3, indexed in the Registry file on STN CAS Online Mar. 9, 2011.
- Chemical Abstracts Registry No. 1267173-76-1, indexed in the Registry file on STN CAS Online Mar. 9, 2011.
- Chemical Abstracts Registry No. 1266786-33-7, indexed in the Registry file on STN CAS Online Mar. 8, 2011.
- "Chemical Encyclopedia", scientific publishing house "Great Russian Encyclopedia," Moskva, vol. 4, pp. 499-501, 1995.
- V.V. Boltromeyuk, "General Chemistry", Minsk, Graduate School, Grodno State Medical University, Department of General and Bioorganic Chemistry, p. 65, 2012 (textbook).
- Chemical Abstracts Registry No. 1202076-20-7, indexed in the Registry file on STN CAS Online Jan. 13, 2010.
- Chemical Abstracts Registry No. 1202076-21-8, indexed in the Registry file on STN CAS Online Jan. 13, 2010.
- Chemical Abstracts Registry No. 1202076-22-9, indexed in the Registry file on STN CAS Online Jan. 13, 2010.
- Chemical Abstracts Registry No. 889062-91-3, indexed in the Registry file on STN CAS Online Jun. 23, 2006.
- Chemical Abstracts Registry No. 667457-86-5, indexed in the Registry file on STN CAS Online Mar. 25, 2004.
- Chemical Abstracts Registry No. 1691540-69-8, indexed in the Registry file on STN CAS Online Apr. 26, 2015.
- Chemical Abstracts Registry No. 1691540-67-6, indexed in the Registry file on STN CAS Online Apr. 26, 2015.
- Chemical Abstracts Registry No. 1691538-20-1, indexed in the Registry file on STN CAS Online Apr. 26, 2015.
- Chemical Abstracts Registry No. 1691538-17-6, indexed in the Registry file on STN CAS Online Apr. 26, 2015.
- International Search Report in PCT/US2022/038870, dated Nov. 9, 2022.
- Written Opinion of the International Searching Authority in PCT/US2022/038870, dated Nov. 9, 2022.
- Glenn Noronha, et al. Discovery of [7-(2,6-Dichlorophenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine—A Potent, Orally Active Src Kinase Inhibitor with Antitumor Activity in Preclinical Assays. *Bioorg. Med. Chem. Lett.*, vol. 17, No. 3, pp. 602-608, 2007.
- Sara D. Reis et al., "Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders," *Molecular Neurobiology*, vol. 54, pp. 5829-5854, (2016) (Sep. 22, 2016).
- Hideshi Nakamura et al., Synthesis and Chemiluminescence of 5-[(2-Pyridyl)-, (2-Pyrazinyl)-, and (Substituted 2-pyrazinyl)amino]-1,2,4-trioxanes. *The Chemical Society of Japan*, vol. 61, No. 10, (1988) pp. 3776-3778.
- Written Opinion of the International Searching Authority in PCT/US2021/059139, mailed Mar. 14, 2022.
- International Search Report for PCT/US2021/059139, mailed Mar. 14, 2022.
- Hughes, A.C. et al. 2014. *J. Mol. Biol.* 426, 1428-1438. "Identification of Novel Alternative Splicing Events in the Huntington Gene and Assessment of the Functional Consequences Using Structural Protein Homology Modelling."
- Yen, L. et al. 2004. *Nature* 431, 471-6. "Exogenous control of mammalian gene expression through modulation of RNA self-cleavage."
- International Search Report for PCT/US19/38900, mailed Aug. 20, 2019.
- Holste et al., 2008. "Strategies for Identifying RNA Splicing Regulatory Motifs and Predicting Alternative Splicing Events." *PLoS Computational Biology* 4 (1): e21.
- Stephen M. Berge, et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Sciences*, vol. 66, No. 1, pp. 1-19 (1977).
- Chemical Abstracts Registry No. 1207531-45-0, indexed in the Registry file on STN CAS Online Mar. 1, 2010.
- "Drug Structure-Activity Relationship", edited by Li Renli, China Medical Science and Technology Press, 1st edition, Jan. 2004, 1st printing, pp. 182-183).
- Written Opinion of the International Searching Authority in PCT/US23/68335, mailed Dec. 20, 2023.
- International Search Report for PCT/US23/68335, mailed Dec. 20, 2023.

* cited by examiner

1

COMPOUNDS FOR TREATING
HUNTINGTON'S DISEASECROSS-REFERENCE TO RELATED
APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/617,450, filed Nov. 26, 2019, which in turn is a U.S. National Stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2018/035954, filed Jun. 5, 2018, which in turn claims priority to U.S. Provisional Application No. 62/514,999, filed Jun. 5, 2017, the entire contents of which are incorporated by reference herein.

An aspect of the present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof useful for treating or ameliorating Huntington's disease. In particular, another aspect of the present description relates to substituted bicyclic heteroaryl compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.


BACKGROUND

Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent. The disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the "mutant" huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a "CAG repeat" sequence. There are no current small molecule therapies targeting the underlying cause of the disease, leaving a high unmet need for medications that can be used for treating or ameliorating HD. Consequently, there remains a need to identify and provide small molecule compounds for treating or ameliorating HD.

All other documents referred to herein are incorporated by reference into the present application as though fully set forth herein.

SUMMARY

An aspect of the present description includes compounds comprising, a compound of Formula (I):



or a form thereof, wherein R₁, R₂, W₁, W₂, W₃, W₄, W₅ and W₆ are as defined herein.

An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof

2

comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

An aspect of the present description includes a method for use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form or composition thereof.


An aspect of the present description includes a use for a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof in combination with an effective amount of the one or more agents.

DETAILED DESCRIPTION

An aspect of the present description relates to compounds comprising, a compound of Formula (I):



or a form thereof, wherein:

W₁, W₂, W₃, W₄, W₅ and W₆ are independently C—R_a, C—R_b or N,

wherein, when one, two or three of W₁, W₅ and W₆ are N,

then W₂, W₃ and W₄ are C—R_a or C—R_b, and

wherein, when one, two or three of W₂, W₃ and W₄ are N,

then W₁, W₅ and W₆ are C—R_a or C—R_b; R₁ is aryl,

heterocycl, heterocycl-amino, (heterocycl)

(C₁₋₈alkyl)amino or heteroaryl, wherein, each instance of heterocycl is optionally substituted with one, two or three R₃

substituents and optionally, with one additional R₄ substituent, or, wherein, alternatively, each instance of heterocycl is optionally substituted with one, two, three or four R₃ substituents;

R₂ is aryl, heteroaryl, heteroaryl-amino or (heteroaryl)(C₁₋₈alkyl)amino,

wherein, each instance of aryl and heteroaryl is optionally substituted with one, two or three R₆ substituents and optionally, with one additional R₇ substituent;

R_a is, in each instance, independently selected from hydrogen, halogen or C₁₋₈alkyl;

R_b is, in each instance, independently selected from hydrogen, halogen or C₁₋₈alkyl;

R₃ is, in each instance, independently selected from cyano, halogen, hydroxy, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy,

3

C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈ alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈ alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈ alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, [(C₁₋₈ alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈ alkyl)amino, [(C₁₋₈ alkyl)₂-amino-C₁₋₈alkyl]C₁₋₈alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈ alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈ alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈ alkyl)amino;

R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄Cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocycl, heterocycl-C₁₋₈alkyl, heteroaryl or heteroaryl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl, heterocycl and heteroaryl is optionally substituted with one, two or three R₅ substituents;


R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino or C₁₋₈alkyl-thio;

R₆ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, cyano-C₁₋₈alkyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈ alkyl)amino or C₁₋₈alkyl-thio; and,

R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocycl, heteroaryl or heteroaryl-C₁₋₈alkoxy; wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

ASPECTS OF THE DESCRIPTION

Another aspect of the present description includes a compound of Formula (I) comprising, a compound of Formula (I.1):



or a form thereof, wherein:

W_1 , W_2 , W_3 , W_4 , W_5 and W_6 are independently C— R_a , C— R_b or N, wherein, when one, two or three of W_1 , W_5 and W_6 are N, then W_2 , W_3 and W_4 are C— R_a or C— R_b , and

wherein, when one, two or three of W_2 , W_3 and W_4 are N,
then W_1 , W_5 and W_6 are C—R_a or C—R_b;

R_1 is C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl) amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkoxy-

4

R_b is, in each instance, independently selected from hydrogen, or halogen;

R_3 is, in each instance, independently selected from cyano, halogen, hydroxy, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈salkoxy, halo-C₁₋₈salkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl-amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl]₂-amino, (C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino, [(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino, (C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino;

R_4 is C₃₋₁₄cycloalkyl, C₃₋₁₄Cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈salkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocycl, heterocycl-C₁₋₈alkyl, heteroaryl or heteroaryl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl, heterocycl and heteroaryl is optionally substituted with one, two or three R₅ substituents;

R_5 is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈salkoxy, halo-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkyl-thio or heteroaryl-C₁₋₈alkyl;

R_6 is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, cyano-C₁₋₈alkyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl), amino or C₁₋₈alkyl-thio; and,

R_7 is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocycl, heteroaryl or heteroaryl-C₁₋₈alkoxy.

One aspect includes a compound of Formula (I), wherein W₁ is N.

Another aspect includes a compound of Formula (I), wherein W₁ is N, W₄ is C—R_b and W₂, W₃, W₅ and W₆ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₂ is N.

Another aspect includes a compound of Formula (I), wherein W₂ is N, W₄ is C—R_b and W₁, W₃, W₅ and W₆ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₃ is N.

Another aspect includes a compound of Formula (I), wherein W₃ is N, W₄ is C—R_b and W₁, W₂, W₅ and W₆ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₄ is N.

Another aspect includes a compound of Formula (I), wherein W₄ is N and W₁, W₂, W₃, W₅ and W₆ are independently C—R_a.

One aspect includes a compound of Formula (I), wherein W₅ is N.

Another aspect includes a compound of Formula (I), wherein W₅ is N, W₄ is C—R_b and W₁, W₂, W₃ and W₆ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₆ is N.

Another aspect includes a compound of Formula (I), wherein W₆ is N, W₄ is C—R_b and W₁, W₂, W₃ and W₅ are C—R_a.

Another aspect includes a compound of Formula (I), wherein R₁ is aryl, heterocycl, heterocycl-amino, (heterocycl)(C₁₋₈alkyl)amino, or heteroaryl.

Another aspect includes a compound of Formula (I), wherein R₁ is aryl or heteroaryl.

Another aspect includes a compound of Formula (I), wherein R₁ is aryl.

Another aspect includes a compound of Formula (I), wherein R₁ is heteroaryl.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocycl, heterocycl-amino or (heterocycl)(C₁₋₈alkyl)amino.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocycl.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocycl-amino.

Another aspect includes a compound of Formula (I), wherein R₁ is (heterocycl)(C₁₋₈alkyl)amino.

Another aspect includes a compound of Formula (I), wherein R_a is hydrogen or C₁₋₈alkyl.

Another aspect includes a compound of Formula (I), wherein R_b is hydrogen or halogen.

Another aspect includes a compound of Formula (I), wherein R₄ is heterocycl-C₁₋₈alkyl or heteroaryl-C₁₋₈alkyl.

Another aspect includes a compound of Formula (I), wherein R₅ is hydroxy-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, or heteroaryl-C₁₋₈alkyl.

Another aspect includes a compound of Formula (I), wherein R₆ is halogen, hydroxy, cyano, C₁₋₈alkyl, cyano-C₁₋₈alkyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈salkoxy-C₁₋₈alkoxy, or C₁₋₈alkoxy-C₁₋₈alkyl-amino.

Another aspect includes a compound of Formula (I), wherein R₇ is C₃₋₁₄cycloalkyl, heterocycl, or heteroaryl-C₁₋₈alkoxy.

One aspect includes a compound of Formula (I), wherein W₁ and W₅ are N.

Another aspect includes a compound of Formula (I), wherein W₁ and W₆ are N, W₄ is C—R_b and W₂, W₃ and W₆ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₁ and W₆ are N.

Another aspect includes a compound of Formula (I), wherein W₁ and W₆ are N, W₄ is C—R_b and W₂, W₃ and W₅ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₂ and W₃ are N.

Another aspect includes a compound of Formula (I), wherein W₂ and W₃ are N, W₄ is C—R_b and W₁, W₅ and W₆ are C—R_a.

One aspect includes a compound of Formula (I), wherein W₂ and W₄ are N.

Another aspect includes a compound of Formula (I), wherein W₂ and W₄ are N, and W₁, W₃, W₅ and W₆ are independently C—R_a.

One aspect includes a compound of Formula (I), wherein W₃ and W₄ are N.

Another aspect includes a compound of Formula (I), wherein W₃ and W₄ are N, and W₁, W₂, W₅ and W₆ are independently C—R_a.

One aspect includes a compound of Formula (I), wherein W_5 and W_6 are N.

Another aspect includes a compound of Formula (I), wherein W_5 and W_6 are N, W_4 is C— R_b and W_1 , W_2 and W_3 are C— R_a .

Another aspect includes a compound of Formula (I), wherein W_5 and W_6 are N, W_2 is C— R_b and W_1 , W_3 and W_4 are C— R_a .

Another aspect includes a compound of Formula (I), wherein W_5 and W_6 are N, W_3 is C— R_b and W_1 , W_2 and W_4 are C— R_a .

One aspect includes a compound of Formula (I), wherein W_1 , W_5 and W_6 are N.

Another aspect includes a compound of Formula (I), wherein W_1 , W_5 and W_6 are N, W_4 is C— R_b and W_2 and W_3 are C— R_a .

One aspect includes a compound of Formula (I), wherein W_2 , W_3 and W_4 are N.

Another aspect includes a compound of Formula (I), wherein W_2 , W_3 and W_4 are N, and W_1 , W_5 and W_6 are independently C—R _{α} .
 α is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.

One aspect includes a compound of Formula (I), wherein R₁ is heterocyclyl selected from azetidinyl, tetrahydrofuran-yl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-c]pyrazin-(2H)-one, hexahydropyrrolo[1,2-c]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-c]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydro-1H-cyclobuta[1,2-c:1,4-c']dipyrrol-(3H)-yl, (8aS)-octahydro-

pyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo
 [1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]
 pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-
 azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,
 5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-
 enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl,
 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]
 nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diaz-
 abicyclo[2.2.1]heptyl, 1,4-diazabicyclo[3.1.1]heptyl, 3,6-
 diazabicyclo[3.2.0]heptyl, 2,5-diazabicyclo[2.2.2]octyl,
 1,4-diazabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]oct-
 yl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicy-
 clo[3.2.2]nonyl, azaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]
 octanyl, 2,6-diazaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]
 octanyl, 1,7-diazaspiro[4.4]nonyl, 2,6-diazaspiro[3.5]
 nonyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]
 nonyl, 2,7-diazaspiro[4.4]nonyl, 2,7-diazaspiro[4.5]
 decanyl or 6,9-diazaspiro[4.5]decyl; wherein, each
 instance of heterocyclyl is optionally substituted with R₃
 and R₄ substituents.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocyclyl selected from azetidin-1-yl, tetrahydrofuran-3-yl, pyrrolidin-1-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-4-yl, piperazin-1-yl, azepan-4-yl, 1,4-diazepan-1-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, hexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-h]pyrrol-1

(2H)-yl, (3aS,6aS)-hexahdropyrrolo[3,4-h]pyrrol-5
 (1H)-yl, (3aR,6aR)-hexahdropyrrolo[3,4-b]pyrrol-5
 (1H)-yl, hexahdropyrrolo[3,4-c]pyrrol-1(1H)-yl, hexahdropyrrolo[3,4-c]pyrrol-5(1H)-yl, (3aR,6aS)-hexahdropyrrolo[3,4-c]pyrrol-2(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridin-5-yl, octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl,
 hexahdropyrrolo[1,2-a]pyrazin-6(2H)-one, hexahdropyrrolo[1,2-a]pyrazin-2(1H)-yl, (7R,8aS)-hexahdropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-hexahdropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-hexahdropyrrolo[1,2-a]pyrazin-2(1H)-yl, hexahydro-1H-cyclobuta[1,2-c:1,4-c']dipyrrol-2(3H)-yl, (8aS)-octahdropyrrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-octahdropyrrolo[1,2-a]pyrazin-2(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazin-2-yl, 3-azabicyclo[3.1.0]hexan-3-yl, 8-azabicyclo[3.2.1]octan-3-yl, (1R,5S)-8-azabicyclo[3.2.1]octan-3-yl, 8-azabicyclo[3.2.1]oct-2-en-3-yl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-en-3-yl, 9-azabicyclo[3.3.1]nonan-3-yl, (1R,5S)-9-azabicyclo[3.3.1]nonan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl, 1,4-diazabicyclo[3.1.1]heptan-4-yl, 3,6-diazabicyclo[3.2.0]heptan-3-yl, 3,6-diazabicyclo[3.2.0]heptan-6-yl, 2,5-diazabicyclo[2.2.2]octan-2-yl, 1,4-diazabicyclo[3.2.1]octan-4-yl, 3,8-diazabicyclo[3.2.1]octan-3-yl, (1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl, 1,4-diazabicyclo[3.2.2]nonan-4-yl, azaspiro[3.3]heptan-2-yl, 4,7-diazaspiro[2.5]octan-4-yl, 4,7-diazaspiro[2.5]octan-7-yl, 2,6-diazaspiro[3.3]heptan-2-yl, 2,6-diazaspiro[3.4]octan-2-yl, 2,6-diazaspiro[3.4]octan-6-yl, 1,7-diazaspiro[4.4]nonan-1-yl, 1,7-diazaspiro[4.4]nonan-7-yl, 2,6-diazaspiro[3.5]nonan-2-yl, 2,6-diazaspiro[3.5]nonan-6-yl, 2,7-diazaspiro[3.5]nonan-2-yl, 2,7-diazaspiro[3.5]nonan-7-yl, 5,8-diazaspiro[3.5]nonan-8-yl, 2,7-diazaspiro[4.4]nonan-2-yl, 2,7-diazaspiro[4.5]decan-2-yl, 2,7-diazaspiro[4.5]decan-7-yl or 6,9-diazaspiro[4.5]decan-9-yl; wherein, each instance of heterocycl is optionally substituted with R₃ and R₄ substituents.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocyclyl selected from pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.1]heptyl, 2,6-diazaspiro[3.4]octanyl, 2,6-diazaspiro[3.5]nonyl, 2,7-diazaspiro[3.5]honyl.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocyclyl selected from pyrrolidin-3-yl, piperidin-4-yl, piperazin-1-yl, azepan-4-yl, 1,2,5,6-tetrahydropyridin-5-yl, 1,2,3,6-tetrahydropyridin-4-yl, 3-azabicyclo[3.1.0]hexan-3-yl, 8-azabicyclo[3.2.1]octan-3-yl, 2,5-diazabicyclo[2.2.1]heptan-2-yl, 2,6-diazaspiro[3.4]octan-2-yl, 2,6-diazaspiro[3.4]octan-6-yl, 2,6-diazaspiro[3.5]nonan-2-yl, 2,7-diazaspiro[3.5]nonan-2-yl, and 2,7-diazaspiro[3.5]nonan-7-yl.

Another aspect includes a compound of Formula (I), wherein R₁ is substituted heterocycl selected from N,N-dimethylpyrrolidin-3-amine, N,N-dimethylpiperidin-4-amine, N,N-4-trimethylpiperidin-4-amine, 1-methylpiperidin-4-yl, 1-ethylpiperidin-4-yl, 1-(propan-2-yl)piperidin-4-yl, 2-hydroxyethylpiperidin-4-yl, 2-fluoroethylpiperidin-4-yl, 2,2-difluoroethylpiperidin-4-yl, N,N-dimethyl-2-(piperidin-1-yl)ethan-1-amine, N,N-dimethyl-2-(piperidin-1-yl)propan-1-amine, (2S,6S)-2,6-dimethylpiperidin-4-yl, (2R,6S)-2,6-dimethylpiperidin-4-yl, (2S,6S)-2,6-diethylpiperidin-4-yl, (2S,6S)-(2,6-

diethyl-1-methyl)piperidin-4-yl, (2S,6S)-1,2,6-trimethylpiperidin-4-yl, (2R,6S)-1,2,6-trimethylpiperidin-4-yl, (2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl, (2R,6R)-1-ethyl-2,6-dimethylpiperidin-4-yl, (2R,6S)-[1-(2-fluoroethyl)-2,6-dimethyl]piperidin-4-yl, (ethyl-1-ol)piperidin-1-yl, 2,6-dimethylpiperidin-1-yl-ethan-1-ol, 3-(1H-pyrazol-1-yl)propyl)piperidin-4-yl, 3-(1H-benzimidazol-1-yl)propyl)piperidin-4-yl, 2-(1H-benzimidazol-1-yl)ethyl)piperidin-4-yl, 1-ethyl-1,2,3,6-tetrahydropyridin-4-yl, 2,2,6,6-tetramethylpiperidin-4-yl, 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl, (3R,5S)-3,5-dimethylpiperazin-1-yl, 1-methylazepan-4-yl, 1-ethylazepan-4-yl, 2-fluoroethylazepan-4-yl, azepan-1-yl-ethan-1-ol, 4-methyl-1,4-diazepan-1-yl, (3aS,6aS)-1-methylhexahydrotryptrolo[3,4-b]pyrrol-5(1H)-yl, (3aS,6aS)-5-methylhexahydrotryptrolo[3,4-b]pyrrol-1(2H)-yl, (3aR,6aR)-1-methylhexahydrotryptrolo[3,4-b]pyrrol-5(1H)-yl, (3aR,6aS)-5-methylhexahydrotryptrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-(2-hydroxyethyl)hexahydrotryptrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-(propan-2-yl)hexahydrotryptrolo[3,4-c]pyrrol-2(1H)-yl, (3aR,6aS)-5-ethylhexahydrotryptrolo[3,4-c]pyrrol-2(1H)-yl, (4aR,7aR)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-1-ethyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aR,7aR)-1-(2-hydroxyethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (4aS,7aS)-1-(2-hydroxyethyl)octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl, (7R,8aS)-7-hydroxyhexahydrotryptrolo[1,2-a]pyrazin-2(1H)-yl, (8aS)-8a-methyloctahydrotryptrolo[1,2-a]pyrazin-2(1H)-yl, (8aR)-8a-methyloctahydrotryptrolo[1,2-c]pyrazin-2(1H)-yl, (1R,5S,6s)-6-(dimethylamino)-3-azabicyclo[3.1.0]hex-3-yl, N,N-dimethyl-3-azabicyclo[3.1.0]hexan-6-amine, (1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl, 9-methyl-9-azabicyclo[3.3.1]non-3-yl, (3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl, (1R,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl, 5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl, (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl, (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl or (1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl.

another aspect includes a compound of Formula (I), wherein R₁ is substituted heterocyclyl selected from N,N-dimethylpyrrolidin-3-amine, N,N-dimethylpiperidin-4-amine, N,N-4-trimethylpiperidin-4-amine, 1-methylpiperidin-4-yl, 1-ethyl-piperidin-4-yl, 1-(propan-2-yl)piperidin-4-yl, 2-hydroxyethylpiperidin-4-yl, 2-fluoroethylpiperidin-4-yl, 2,2-difluoroethylpiperidin-4-yl, N,N-dimethyl-2-(piperidin-1-yl)ethan-1-amine, N,N-dimethyl-2-(piperidin-1-yl)propan-1-amine, (2S,6S)-2,6-dimethylpiperidin-4-yl, (2R,6S)-2,6-dimethylpiperidin-4-yl, (2S,6S)-2,6-diethylpiperidin-4-yl, (2S,6S)-1,2,6-trimethylpiperidin-4-yl, (2R,6S)-1,2,6-trimethylpiperidin-4-yl, (2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl, (2R,6R)-1-ethyl-2,6-dimethylpiperidin-4-yl, (2R,6S)-1-(2-fluoroethyl)-2,6-dimethylpiperidin-4-yl, piperidin-1-yl-ethan-1-ol, 2,6-dimethylpiperidin-1-yl-ethan-1-ol, 3-(1H-pyrazol-1-yl)propyl)piperidin-4-yl, 3-(1H-benzimidazol-1-yl)propyl)piperidin-4-yl, 2-(1H-benzimidazol-1-yl)ethyl)piperidin-4-yl, 1-ethyl-1,2,3,6-tetrahydropyridin-4-yl, 2,2,6,6-tetramethylpiperidin-4-yl, 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl, (3R,5S)-3,5-dimethylpiperazin-1-yl, 1-methylazepan-4-yl, 1-ethylazepan-4-yl, 2-fluoroethylazepan-4-yl, azepan-1-yl-ethan-1-ol, N,N-

dimethyl-3-azabicyclo[3.1.0]hexan-6-amine, 5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl or (1*S*,4*S*)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl.

One aspect includes a compound of Formula (I), wherein R₁ is heterocycl-l-amino, wherein heterocyclyl is selected from azetidinyl, pyrrolidinyl, piperidinyl, 9-azabicyclo[3.3.1]nonyl or (1R,5S)-9-azabicyclo[3.3.1]nonyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

Another aspect includes a compound of Formula (I), wherein R₁ is heterocycl-yl-amino selected from azetidin-3-yl-amino, pyrrolidin-3-yl-amino, piperidin-4-yl-amino, 9-azabicyclo[3.3.1]non-3-yl-amino, (1R,5S)-9-azabicyclo[3.3.1]non-3-yl-amino, 9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino, (3-exo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino or (1R,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl-amino; wherein, each instance of heterocycl-yl is optionally substituted with R₃ and R₄ substituents.

One aspect includes a compound of Formula (I), wherein R₁ is (heterocyclyl)(C₁₋₈alkyl)amino, wherein heterocyclyl is selected from pyrrolidinyl or piperidinyl; and, wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

Another aspect includes a compound of Formula (I), wherein R₁ is (heterocyclyl)(C₁₋₈alkyl)amino wherein heterocyclyl is piperidinyl.

Another aspect includes a compound of Formula (I), wherein R₁ is (heterocyclyl)(C₁₋₈alkyl)amino selected from (pyrrolidin-3-yl)(methyl)amino or (piperidin-4-yl)(methyl)amino; wherein, each instance of heterocyclyl is optionally substituted with R₃ and R₄ substituents.

One aspect includes a compound of Formula (I), wherein R₃ is selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkyl-carbonyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈ alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, amino-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, C₁₋₈alkyl-carbonyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-

C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino. Another aspect includes a compound of Formula (I), wherein R₃ is selected from cyano, halogen, hydroxy, oxo, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-carbonyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkyl-amino-C₁₋₈alkyl-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, C₁₋₈alkoxy-carbonyl-amino, hydroxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl-amino, (hydroxy-C₁₋₈alkyl)₂-amino or (hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino.

Another aspect includes a compound of Formula (I), wherein R₃ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.

Another aspect includes a compound of Formula (I), R₃ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.

Another aspect includes a compound of Formula (I), wherein R_3 is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

11

Another aspect includes a compound of Formula (I), wherein R₃ is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, trihalo-propyl or dihalo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

Another aspect includes a compound of Formula (I), wherein R₃ is hydroxy-C₁₋₈alkyl selected from hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.

Another aspect includes a compound of Formula (I), wherein R₃ is hydroxy-C₁₋₈alkyl selected from hydroxy-methyl, hydroxy-ethyl, dihydroxy-propyl, hydroxy-butyl or dihydroxy-butyl.

Another aspect includes a compound of Formula (I), wherein R₃ is C₁₋₈alkoxy selected from methoxy, ethoxy, propoxy or isopropoxy.

Another aspect includes a compound of Formula (I), wherein R₃ is halo-C₁₋₈alkoxy selected from trihalo-methoxy, dihalo-methoxy, halo-methoxy, trihalo-ethoxy, dihalo-ethoxy, halo-ethoxy, trihalo-propoxy, dihalo-propoxy or halo-propoxy; wherein, halo is selected from fluoro, chloro, bromo or iodo.

Another aspect includes a compound of Formula (I), wherein R₃ is C₁₋₈alkoxy-carbonyl-amino selected from methoxy-carbonyl-amino, ethoxy-carbonyl-amino, propoxy-carbonyl-amino, isopropoxy-carbonyl-amino, tert-butoxy-carbonyl-amino.

Another aspect includes a compound of Formula (I), wherein R₄ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-C₁₋₈alkyl, C₃₋₁₄cycloalkyl-amino, aryl-C₁₋₈alkyl, aryl-C₁₋₈alkoxy-carbonyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclcyl, heterocyclcyl-C₁₋₈alkyl or heteroaryl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl, heterocyclcyl and heteroaryl is optionally substituted with one, two or three R₅ substituents.

Another aspect includes a compound of Formula (I), wherein R₅ is, in each instance, independently selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkyl-thio or heteroaryl-C₁₋₈alkyl.

One aspect includes a compound of Formula (I), wherein R₂ is aryl, heteroaryl, heteroaryl-amino, (heteroaryl)(C₁₋₈alkyl)amino or (heterocyclcyl)(C₁₋₈alkyl)amino.

Another aspect includes a compound of Formula (I), wherein R₂ is aryl, heteroaryl, heteroaryl-amino or (heteroaryl)(C₁₋₈alkyl)amino.

Another aspect includes a compound of Formula (I), wherein R₂ is aryl.

Another aspect includes a compound of Formula (I), wherein R₂ is heteroaryl.

Another aspect includes a compound of Formula (I), wherein R₂ is heteroaryl-amino.

Another aspect includes a compound of Formula (I), wherein R₂ is (heteroaryl)(C₁₋₈alkyl)amino.

Another aspect includes a compound of Formula (I), wherein R₂ is (heterocyclcyl)(C₁₋₈alkyl)amino.

One aspect includes a compound of Formula (I), wherein R₂ is heteroaryl selected from thieryl, 1H-pyrazolyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzoxazol-2-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 9H-purin-8-yl, furo[3,2-b]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, furo[2,3-d]pyrimidin-6-yl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1H-pyrrolo[2,3-c]pyridin-4-yl, 1H-pyrrolo[1,2-a]pyrimidin-7-yl, 1H-pyrrolo[1,2-a]pyrazin-7-yl, 1H-pyrrolo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-5-yl, 2H-pyrazolo[3,4-c]pyridin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, 2H-pyrazolo[4,3-c]pyridin-5-yl, pyrazolo[1,5-a]pyrazin-2-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-c]pyrimidin-6-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-a]pyrazin-6-yl, 3H-imidazo[4,5-b]pyridin-5-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,3]oxazolo[4,5-b]pyridin-2-yl, [1,3]oxazolo[4,5-c]pyridin-2-yl, [1,3]thiazolo[5,4-b]pyridin-5-yl, [1,3]thiazolo[5,4-c]pyridin-2-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, or quinoxalin-2-yl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

12

pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, 2H-pyrazolo[3,4-c]pyridinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,3]oxazolo[4,5-c]pyridinyl, [1,3]thiazolo[4,5-c]pyridinyl, [1,3]thiazolo[5,4-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl or quinoxalinyl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

Another aspect includes a compound of Formula (I), wherein R₂ is heteroaryl selected from thieryl, thietyl-3-yl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1H-imidazol-1-yl, 1H-imidazol-4-yl, 1,3-thiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-4-yl, 1H-indol-3-yl, 1H-indol-4-yl, 1H-indol-5-yl, 1H-indol-6-yl, 1H-indazol-5-yl, 2H-indazol-5-yl, indolizin-2-yl, benzofuran-2-yl, benzofuran-5-yl, benzothien-2-yl, benzothien-3-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-6-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 9H-purin-8-yl, furo[3,2-b]pyridin-2-yl, furo[3,2-c]pyridin-2-yl, furo[2,3-d]pyrimidin-6-yl, 1H-pyrrolo[2,3-b]pyridin-5-yl, 1H-pyrrolo[2,3-c]pyridin-4-yl, 1H-pyrrolo[1,2-a]pyrimidin-7-yl, 1H-pyrrolo[1,2-a]pyrazin-7-yl, 1H-pyrrolo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyridin-5-yl, 2H-pyrazolo[3,4-c]pyridin-5-yl, 2H-pyrazolo[4,3-b]pyridin-5-yl, 2H-pyrazolo[4,3-c]pyridin-5-yl, pyrazolo[1,5-a]pyrazin-2-yl, imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-6-yl, imidazo[1,2-a]pyrimidin-2-yl, imidazo[1,2-c]pyrimidin-2-yl, imidazo[1,2-b]pyridazin-2-yl, imidazo[1,2-b]pyridazin-6-yl, imidazo[1,2-a]pyrazin-2-yl, imidazo[1,2-a]pyrazin-6-yl, 3H-imidazo[4,5-b]pyridin-5-yl, imidazo[2,1-b][1,3]thiazol-6-yl, imidazo[2,1-b][1,3,4]thiadiazol-6-yl, [1,3]oxazolo[4,5-b]pyridin-2-yl, [1,3]oxazolo[4,5-c]pyridin-2-yl, [1,3]thiazolo[5,4-b]pyridin-5-yl, [1,3]thiazolo[5,4-c]pyridin-2-yl, [1,2,4]triazolo[1,5-a]pyridin-6-yl, or quinoxalin-2-yl; wherein, each instance of heteroaryl is optionally substituted with R₆ and R₇ substituents.

One aspect includes a compound of Formula (I), wherein R₆ is selected from halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, heteroaryl-C₁₋₈alkoxy, aryl-oxy, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, C₁₋₈alkyl-thio, C₃₋₁₄cycloalkyl; wherein, halogen and halo is selected from fluoro, chloro, bromo or iodo.

Another aspect includes a compound of Formula (I), wherein R₆ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.

Another aspect includes a compound of Formula (I), wherein R₆ is C₁₋₈alkyl selected from methyl, ethyl, propyl, isopropyl or tert-butyl.

Another aspect includes a compound of Formula (I), wherein R₆ is halo-C₁₋₈alkyl selected from trihalo-methyl, dihalo-methyl, halo-methyl, trihalo-ethyl, dihalo-ethyl, halo-ethyl, trihalo-propyl, dihalo-propyl or halo-propyl; wherein, halo is selected from fluoro, chloro, bromo or iodo.

13


Another aspect includes a compound of Formula (I), wherein R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, heterocycl or heteroaryl.

One aspect includes a compound of Formula (I), wherein R_a is hydrogen or C₁₋₈alkyl. 5


One aspect includes a compound of Formula (I), wherein R_b is hydrogen or C₁₋₈alkyl.

Another aspect includes a compound of Formula (I), wherein R_j is halo.


One aspect of the compound of Formula (I) includes a 10 compound selected from Formula (Ia), Formula (Ib), Formula (Ic), Formula (Id), Formula (Ie), Formula (If), Formula (Ig), Formula (Ih), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Il), Formula (Im) or Formula (In):




(Ia)




(Ib)




(Ic)




(Id)




(Ie)




(If)




(Ig)



(Ih)



(Ii)




(Ij)


14

-continued


(Ik)




(Il)



(Im)




(In)




or a form thereof.


Another aspect of the compound of Formula (I) includes the compound selected from Formula (Ib), Formula (Ic), Formula (Ie), Formula (If), Formula (Ig), Formula (Ii), Formula (Ij), Formula (Ik), Formula (Il), Formula (Im) or Formula (In):




(Ib)




(Ic)




(Ie)




(If)



(Ig)




(Ih)



(Ii)


15

-continued




(Ik)

5




(II)

10



(Im)

15



(In)

20


or a form thereof.

25

Another aspect of the compound of Formula (I) includes the compound selected from of Formula (Ia1), Formula (Ib1), Formula (Ic1), Formula (Id1), Formula (Ie1), Formula (If1), Formula (Ig1), Formula (Ih1), Formula (Ii1), Formula (Ij1), Formula (Ik1), Formula (II1), Formula (Im1) or Formula (In1), respectively:


(Ia1)

35




(Ib1)

40




(Ic1)

45



(Id1)

50




(Ie1)

55


16

-continued


(Ie1)




(If1)




(Ig1)




(Ih1)




(Ii1)



(Ij1)




(Ik1)

17
-continued


(II1)

5



(Im1)

15




(In1)

20

30


or a form thereof.

Another aspect of the compound of Formula (I) includes the compound selected from Formula (Ib 1), Formula (Ic1),
Formula (Ie1), Formula (If1), Formula (Ig1), Formula
35 (Ii1), Formula (Ij1), Formula (Ik1), Formula (II1), Formula
(Im1) or Formula (In1), respectively:



(Ib1)


40



(Ic1)

45


55




(Ie1)

60


65

**18**
-continued


(If1)




(Ig1)




(Ii1)




(Ik1)



(III1)




(Im1)




19

-continued




or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ia1):




or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ib1):



or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ic1):




or a form thereof.

20

Another aspect of the compound of Formula (I) includes the compound of Formula (Id1):

(In1)

5



(Id1)

10


15

(Ia1)

or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ie1):

25



(Ie1)


30

or a form thereof.

(Ib1)

Another aspect of the compound of Formula (I) includes the compound of Formula (If1):

40



(If1)

50


or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ig1):

55

(Ic1)

60




(Ig1)

65

or a form thereof.

21

Another aspect of the compound of Formula (I) includes the compound of Formula (Ih1):




(Ih1)

5

or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ii1):




(Ii1)

20

or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ij1):




(Ij1)

35

or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Ik1):




(Ik1)

55

or a form thereof.

22

Another aspect of the compound of Formula (I) includes the compound of Formula (III1):




(III1)

10

or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (Im1):




(Im1)

25

or a form thereof.

Another aspect of the compound of Formula (I) includes the compound of Formula (In1):




(In1)

30

or a form thereof.

One aspect of the compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:

45



1


50

55



60

65


23
-continued




2
5
10
15
20
3
25
30
35
40
45
4




24
-continued




5
6




7




25
-continued



9
5
10
15
20




10 25
30
35
40




11 45
50
55
60
65


26
-continued




12
13




14




27
-continued




15




5




10




15




20




25




30




35




40




45




28
-continued



18




19




20


29
-continued




23



5



10



15

20

24

25

30

35

40

45

25


50

55


60

65

30
-continued




26




27


31
-continued




29




5




10




15




20




30




25




30




35




40




45




31




50



55



60






65

32

-continued


32




33

34


33
-continued




35




5




10




15




20




36




25




30




35




40




45




37




50




55




60




65




34
-continued




38




39




40

35
-continued


41



42



45

36
-continued

5

10

15

20



25

30

35

40

45

36
-continued**36**
-continued

43

50

55

60


65

44

45

46

37
-continued



47

5

10

15

20

48

25

30

35

40

49


50

55

60


65

38
-continued




50


51




52




39
-continued



53



54 25




55

55


60

65


40
-continued



56




57




58


41
-continued




59




5




10




15




20




60




25




30




35



40




45




42
-continued


42
-continued



62



63



64

61


50

55


60

65


43
-continued




65




5




10




15




20




66




25




30




35




40




45




67




50



55




60




65


44
-continued




68




69




70

45
-continued


71




5




10




15




20




72




25




30




35




40




45




73




50




55




60




65

46
-continued



5




10




15




25








































































30




35



40



47
-continued



77

5

10

15

20

78

25

30

35

40


79

50


55

60

65




48
-continued




80

81




82



49

-continued



83

5

10

15

20

84

25

30

35

40

85

45

50


55

60

65

50


-continued



86

87

88



30

35

40

85


45

50


55

60



65



51
-continued




89


90
25

91


52
-continued



92




93




94


53
-continued




95




5




10




15




20




96




25




30




35




40




45



54
-continued




98



99

55
-continued



100

5

10

15

20

101


25

30


35

40


102 45




56
-continued



103



104




50

55


60

65




105


57
-continued



106




107




108


58
-continued




5




109



109




110




111

59
-continued



112



5

10

15

20

113


25

30

35

40

114 45




50

55


60

65


60
-continued



115




116



117

61
-continued



118

5

10

15

20

119


25

30


35

40

120 45



62
-continued



121

5

10

15

20

119


25

30

35

40

120 45



122


50

55

60

65

63
-continued



123

5

10

15

20

25

30

35

40


45

50


55

60

65





64
-continued




125

126


127




65
-continued




128




5




10




15




20




129




25




30




35




40




130




50



55




60




65


66
-continued




5




10




15




20




25




30




35




40




45



50




55




60




65



131




132



133

67
-continued



134

5

10

15

20

135

25

30

35

40

136 45


50

55


60

65

68
-continued




137



138

69
-continued



139

5

10

15

20

25

30

35

40

140

45


50

55

60

65


70
-continued



141

142

71
-continued



143

5

10

15

20


25

30


35

40

72
-continued



145



144


45

50

55


60

65



146

73
-continued



147

5

10

15

20

148 25

30

35

40

45


50

55

60

65


74
-continued



150

151

75
-continued



152

5

10

15

20


25

30


35

40


153 45




76
-continued



154




155



156

77
-continued



157

5

10

15


20

25

30

35

78
-continued



159

40
158



45

50

55


60

65





160

79
-continued




161


162
25

163


80
-continued



164




165



166

81
-continued



167

5

10

15

20

168

25

30

35

40

45



169

50


55

60


65




82
-continued



170




171



172

83

-continued



173

5

10

15

20

174

25

30

35

40

45

175

50

55



60

65

84


-continued

176




177

178




US 12,384,789 B2

85
-continued



179

86
-continued



181

5

10

15

20

25

30

35

40

180

45



50

55


60

65

182



87
-continued



183

5

10

15

20

184 25

30

35

40

45

185


50

55

60


65

88
-continued




186


187




188




89
-continued



189




190




191


90
-continued



192




193



194

91
-continued



195

5

10

15

20

196

25

30

35

40


197 45

50


55

60


65




92
-continued



198



93
-continued



200

5

10

15

20


25

30


35

40


201-45




94
-continued



202




203




204

95
-continued




205

5



206 25

30



40


50

55


60

65

96
-continued




208




209


210



97
-continued



211




5

10

15

20

212



25

30

35

40

213 45


50

55


60

65


98
-continued



214




215



216

US 12,384,789 B2

99
-continued



217

5

10

15


20

25

30

35

40



218


50

55


60

65

100
-continued




219



220

101
-continued



221

5

10

15

20


25

30


35

40

222 45



102
-continued



223

5

10

15

20

25

30

35

40

222 45


50

55


60

65

224




225




103

-continued



226



5

10

15

20

227


25

30

40

104

-continued



228

35 wherein the form of the compound is selected from the group consisting of a salt, prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

40 An aspect the compound of Formula (I) or a form thereof (wherein compound number (#1) indicates that the salt form was isolated) includes a compound selected from the group consisting of:

Cpd	Name
1 ¹	2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinoline
2 ¹	6-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)quinoline
3 ¹	6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinolone
4 ¹	3-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
5 ¹	4-methyl-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline
6 ¹	6-(2-methyl-2H-indazol-5-yl)-2-(1-methylpiperidin-4-yl)quinoline
7	2-(2-methyl-2H-indazol-5-yl)-6-(piperazin-1-yl)quinoline
9 ¹	2-(1-ethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)quinoline
10 ¹	2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinazoline
11	6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)quinolin-2-amine
12	N-methyl-6-(2-methyl-2H-indazol-5-yl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)quinolin-2-amine
13	6-(2,7-dimethyl-2H-indazol-5-yl)-2-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)quinoline
14	6-(2,7-dimethyl-2H-indazol-5-yl)-2-(2,2,6,6-tetramethylpiperidin-4-yl)quinoline
15	6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline
16	7-(2,7-dimethyl-2H-indazol-5-yl)-3-(piperidin-4-yl)-1,2,4-benzotriazine
17	3-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
18	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)quinoline
19	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)quinoline
20	6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoro-2-(piperidin-4-yl)quinoline
23	6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinazoline

Cpd	Name
24 ¹	6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-2-(piperidin-4-yl)quinoxaline
25 ¹	3-(7-fluoro-2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
26	2-methyl-5-[7-(piperidin-4-yl)-1,2,4-benzotriazin-3-yl]-2H-indazole-7-carbonitrile
27	3-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
28	3-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
29	3-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperidin-4-yl)quinoline
30	7-(2,7-dimethyl-2H-indazol-5-yl)-3-(piperidin-4-yl)isoquinoline
31 ¹	6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoxaline
32	5-fluoro-7-(7-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)-1,2,4-benzotriazine
33	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
34 ¹	6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoro-2-(piperidin-4-yl)quinazoline
35 ¹	5-[8-fluoro-2-(piperidin-4-yl)quinazolin-6-yl]-2-methyl-2H-indazole-7-carbonitrile
36 ¹	8-fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinazoline
37 ¹	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinazoline
38 ¹	6-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-2-(piperidin-4-yl)quinazoline
39 ¹	6-(2,7-dimethyl-2H-indazol-5-yl)-7-fluoro-2-(piperidin-4-yl)quinazoline
40	3-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-7-(piperidin-4-yl)-1,2,4-benzotriazine
41	5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
42	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-N-methyl-N-(piperidin-4-yl)-1,2,4-benzotriazin-3-amine
43	3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
44	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
45 ¹	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoline
46	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
47 ¹	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(1-methylpiperidin-4-yl)quinoline
48 ¹	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(1-ethylpiperidin-4-yl)-8-fluoroquinoline
49 ¹	8-fluoro-6-(7-methoxy-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline
50 ¹	8-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)quinoline
51 ¹	8-fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)quinoline
52	3-(7-methoxy-2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine
53 ¹	8-fluoro-6-(8-(2-methoxyethoxy)-2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)quinoline
54 ¹	6-[8-fluoro-2-(piperidin-4-yl)quinolin-6-yl]-N-(2-methoxyethyl)-2-methylimidazo[1,2-b]pyridazin-8-amine
55 ¹	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
56 ¹	7-(8-azabicyclo[3.2.1]oct-3-yl)-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,2,4-benzotriazine
57 ¹	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(piperidin-4-yl)-1,2,4-benzotriazine
58 ¹	5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)-1,2,4-benzotriazine
59 ¹	7-(8-ethoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
60 ¹	7-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
61 ¹	5-fluoro-7-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-3-(piperidin-4-yl)-1,2,4-benzotriazine
62 ¹	7-(2,4-dimethyl-1,3-benzoxazol-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
63 ¹	7-(2,4-dimethyl-1H-benzimidazol-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
64 ¹	7-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
65 ¹	7-(2,7-dimethylpyrazolo[1,5-a]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
66 ¹	7-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
67 ¹	7-(2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine
68	5-fluoro-7-(4-fluoro-2-methyl-1,3-benzoxazol-6-yl)-3-(piperidin-4-yl)-1,2,4-benzotriazine
69 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-methylpiperidin-4-yl)-1,2,4-benzotriazine
70	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluoro-1,2,4-benzotriazine
71 ¹	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(piperidin-4-yl)isoquinoline
72 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)isoquinoline
73 ¹	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
74 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
75	2-[4-(7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl)piperidin-1-yl]ethanol
76	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline

Cpd	Name
77	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-propylpiperidin-4-yl)cinnoline
78	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[1-(propan-2-yl)piperidin-4-yl)cinnoline
79	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-methylpiperidin-4-yl)cinnoline
80 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperazin-1-yl)cinnoline
81 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-fluorocinnoline
82	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoxaline
83 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[1-(2-fluoroethyl)piperidin-4-yl)cinnoline
84 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline
85	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)cinnoline
86	1-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]-N,N-dimethylpyrrolidin-3-amine
87 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(2S,6S)-2,6-dimethylpiperidin-4-yl]-5-fluorocinnoline
88	1-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]-N,N-dimethylpiperidin-4-amine
89	(3R)-1-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]-N,N-dimethylpyrrolidin-3-amine
90	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(2R,4R,6S)-2,6-dimethylpiperidin-4-yl]-5-fluorocinnoline
91 ¹	5-fluoro-7-(2-methylimidazo[1,2-a]pyrimidin-6-yl)-3-(piperidin-4-yl)cinnoline
92 ¹	5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline
93 ¹	6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-a]pyridine-8-carbonitrile
94 ¹	5-fluoro-7-(2-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline
95 ¹	5-fluoro-7-(2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline
96 ¹	5-fluoro-7-(7-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline
97 ¹	5-fluoro-7-(6-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline
98 ¹	3-[1-(2,2-difluoroethyl)piperidin-4-yl]-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
99 ¹	5-fluoro-7-(2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline
100 ¹	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(2-methylimidazo[1,2-b]pyridazin-6-yl)cinnoline
101 ¹	7-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
102 ¹	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)cinnoline
103 ¹	7-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
104 ¹	5-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methyl-2H-indazole-7-carbonitrile
105	7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
106	5-fluoro-7-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline
107	{6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}methanol
108	6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile
109 ¹	5-fluoro-7-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline
110	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(1-ethylpiperidin-4-yl)-8-fluoroquinoxaline
111	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)cinnoline
112	7-(8-cyclopropyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
113	{6-[3-(1-ethylpiperidin-4-yl)-5-fluorocinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}methanol
114	6-[3-(1-ethylpiperidin-4-yl)-5-fluorocinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile
115 ¹	7-(8-cyclopropyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
116	7-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
117 ¹	5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
118	7-(2,4-dimethyl-1,3-benzothiazol-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
119	7-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
120 ¹	7-(2,4-dimethyl-1,3-benzothiazol-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
121 ¹	7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
122 ¹	7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-methylpiperidin-4-yl)cinnoline
123 ¹	2-[4-{7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl}piperidin-1-yl]ethan-1-ol
124	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[(25,6S)-1,2,6-trimethylpiperidin-4-yl)cinnoline
125	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(2R,6R)-1-ethyl-2,6-dimethylpiperidin-4-yl]-5-fluorocinnoline

Cpd	Name
126	7-(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
127 ¹	2-[4-(7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl)piperidin-1-yl]-N,N-dimethylethan-1-amine
128 ¹	5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)cinnoline
129	3-(azepan-4-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
130	3-[(2S,6S)-2,6-diethylpiperidin-4-yl]-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
131	3-[(2S,6S)-2,6-diethyl-1-methylpiperidin-4-yl]-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
132	7-(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
133 ¹	7-(2,7-dimethyl[1,3]thiazolo[5,4-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
134 ¹	5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
135 ¹	7-(2,7-dimethyl[1,3]thiazolo[5,4-b]pyridin-5-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
136	7-(4,6-dimethyl[1,3]oxazolo[4,5-c]pyridin-2-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
137	7-(4,6-dimethyl[1,3]oxazolo[4,5-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
138 ¹	2-({6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}oxy)-N,N-dimethylethan-1-amine
139 ¹	3-({6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}oxy)-N,N-dimethylpropan-1-amine
140 ¹	5-fluoro-7-{2-methyl-8-[2-(1H-pyrazol-1-yl)ethoxy]imidazo[1,2-b]pyridazin-6-yl}-3-(piperidin-4-yl)cinnoline
141 ¹	5-fluoro-7-{2-methyl-8-[3-(1H-pyrazol-1-yl)propoxy]imidazo[1,2-b]pyridazin-6-yl}-3-(piperidin-4-yl)cinnoline
142 ¹	5-fluoro-7-{8-[3-(1H-imidazol-1-yl)propoxy]-2-methylimidazo[1,2-b]pyridazin-6-yl}-3-(piperidin-4-yl)cinnoline
143	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(pyrrolidin-3-yl)cinnoline
144	7-(1-ethylpiperidin-4-yl)-5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)cinnoline
145 ¹	3-{1-[3-(1H-benzimidazol-1-yl)propyl]piperidin-4-yl}-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
146 ¹	7-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
147	7-(4,6-dimethyl[1,3]thiazolo[4,5-c]pyridin-2-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
148	7-(2,7-dimethyl[1,3]oxazolo[5,4-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
149	7-(4,6-dimethyl[1,3]thiazolo[4,5-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
150 ¹	7-{8-[3-(1H-benzimidazol-1-yl)propoxy]-2-methylimidazo[1,2-b]pyridazin-6-yl}-5-fluoro-3-(piperidin-4-yl)cinnoline
151 ¹	5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)cinnoline
152	7-(2,7-dimethyl[1,3]oxazolo[5,4-b]pyridin-5-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
153 ¹	7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)cinnoline
154	7-(1-ethylpiperidin-4-yl)-5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)cinnoline
155	2-{(25,65)-4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]-2,6-dimethylpiperidin-1-yl}ethan-1-ol
156 ¹	3-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
157 ¹	3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
158	3-{4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]piperidin-1-yl}-N,N-dimethylpropan-1-amine
159	3-{1-[2-(1H-benzimidazol-1-yl)ethyl]piperidin-4-yl}-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
160	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-{1-[3-(1H-pyrazol-1-yl)propyl]piperidin-4-yl}cinnoline
161	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(2R,6S)-1,2,6-trimethylpiperidin-4-yl)cinnoline
162	7-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
163 ¹	5-fluoro-7-(7-methoxy-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-3-(piperidin-4-yl)cinnoline
164	7-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
165 ¹	8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)quinalizine
166 ¹	8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)quinoline
167 ¹	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
168	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(2R,6S)-1-ethyl-2,6-dimethylpiperidin-4-yl]-5-fluorocinnoline
169	3-[(1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl]-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
170	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[(2R,6S)-1-(2-fluoroethyl)-2,6-dimethylpiperidin-4-yl]cinnoline

Cpd	Name
171 ¹	5-fluoro-3-(7-fluoro-2-methyl-2H-benzotriazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
172	7-(7-ethyl-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
173 ¹	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(7-methoxy-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)cinnoline
174	7-(7-ethyl-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
175 ¹	5-[5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnolin-3-yl]-2-methyl-2H-indazole-7-carbonitrile
176 ¹	6-[5-fluoro-3-(1-methylpiperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile
177 ¹	3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-7-(piperidin-4-yl)cinnoline
178 ¹	6-[5-fluoro-3-[1-(2-hydroxyethyl)piperidin-4-yl]cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile
179 ¹	6-[5-fluoro-3-[1-(2-fluoroethyl)piperidin-4-yl]cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile
180	{6-[5-fluoro-3-(1-methylpiperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}methanol
181 ¹	2-(4-[5-fluoro-7-[8-(hydroxymethyl)-2-methylimidazo[1,2-b]pyridazin-6-yl]cinnolin-3-yl]piperidin-1-yl)ethan-1-ol
182 ¹	(6-[5-fluoro-3-[1-(2-fluoroethyl)piperidin-4-yl]cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol
183	3-(2,7-dimethyl-2H-indazol-5-yl)-7-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
184 ¹	6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinoline
185 ¹	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(piperidin-4-yl)cinnoline
186	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
187	{6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetonitrile
188	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-methylazepan-4-yl)cinnoline
189	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylazepan-4-yl)-5-fluorocinnoline
190	2-[4-(7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl)azepan-1-yl]ethan-1-ol
191 ¹	7-(5,7-dimethyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
192 ¹	8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinaline
193 ¹	6-(1-ethylpiperidin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinaline
194 ¹	5-fluoro-7-[8-(1H-imidazol-1-yl)-2-methylimidazo[1,2-b]pyridazin-6-yl]-3-(piperidin-4-yl)cinnoline
195 ¹	5-fluoro-7-(2-methyl-8-phenoxyimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline
196 ¹	7-(4,6-dimethyl[1,3]thiazolo[5,4-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline
197	7-(4,6-dimethyl[1,3]thiazolo[5,4-c]pyridin-2-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline
198	3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-7-(2,3,6,7-tetrahydro-1H-azepin-4-yl)cinnoline
199	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[1-(2-fluoroethyl)azepan-4-yl)cinnoline
200	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(2-methyl-8-phenoxyimidazo[1,2-b]pyridazin-6-yl)cinnoline
201 ¹	6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinazoline
202 ¹	6-(1-ethylpiperidin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinazoline
203	(3S,4S)-4-[3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluorocinnolin-7-yl]pyridine-3,4-diol
204	5-fluoro-7-(2-methyl-8-propylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline
205 ¹	{6-[3-(1-ethylpiperidin-4-yl)-5-fluorocinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetonitrile
206	2-[6-[3-(1-ethylpiperidin-4-yl)-5-fluorocinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl]ethan-1-ol
207	2-[6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl]ethan-1-ol
208	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)cinnoline
209	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)cinnoline
210 ¹	5-fluoro-7-(2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline
211	5-fluoro-7-[2-methyl-8-(propan-2-yl)imidazo[1,2-b]pyridazin-6-yl]-3-(piperidin-4-yl)cinnoline
212	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(2-methyl-8-propylimidazo[1,2-b]pyridazin-6-yl)cinnoline
213	2-[4-(7-(4,6-dimethyl[1,3]oxazolo[4,5-c]pyridin-2-yl)-5-fluorocinnolin-3-yl)piperidin-1-yl]ethan-1-ol
214	7-(4,6-dimethyl[1,3]oxazolo[4,5-c]pyridin-2-yl)-5-fluoro-3-(1-methylpiperidin-4-yl)cinnoline

Cpd	Name
215	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]cinnoline
216 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-3-yl)cinnoline
217 ¹	3-(2,6-diazaspiro[3.4]octan-2-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
218 ¹	3-(2,6-diazaspiro[3.5]nonan-2-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
219 ¹	3-(2,7-diazaspiro[3.5]nonan-7-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
220 ¹	3-(2,6-diazaspiro[3.4]octan-6-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
221 ¹	3-(2,7-diazaspiro[3.5]nonan-2-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline
222	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-[2-methyl-8-(propan-2-yl)imidazo[1,2-b]pyridazin-6-yl]cinnoline
223	(1R,5S,6s)-3-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]-N,N-dimethyl-3-azabicyclo[3.1.0]hexan-6-amine
224	1-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]-N,N,4-trimethylpiperidin-4-amine
225 ¹	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline
226	5-(5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnolin-7-yl)-2,7-dimethoxyazolo[5,4-b]pyridine
227	7-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnoline and
228	7-(4,6-dimethoxyazolo[4,5-c]pyridin-2-yl)-5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnoline;

wherein the form of the compound is selected from the group consisting of a salt, prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

Another aspect of the compound of Formula (I) or a form thereof is a compound salt selected from the group consisting of:

Cpd	Name
1	2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinoline hydrochloride
2	6-(1-ethylpiperidin-4-yl)-2-(2-methyl-2H-indazol-5-yl)quinoline hydrochloride
3	6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline hydrochloride
4	3-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
5	4-methyl-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline hydrochloride
6	6-(2-methyl-2H-indazol-5-yl)-2-(1-methylpiperidin-4-yl)quinoline hydrochloride
9	2-(1-ethylpiperidin-4-yl)-6-(2-methyl-2H-indazol-5-yl)quinoline hydrochloride
10	2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinazoline hydrochloride
24	6-[2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl]-2-(piperidin-4-yl)quinazoline hydrochloride
25	3-(7-fluoro-2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)-1,2,4-benzotriazine dihydrochloride
31	6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinazoline hydrochloride
34	6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoro-2-(piperidin-4-yl)quinazoline dihydrochloride
35	5-[8-fluoro-2-(piperidin-4-yl)quinazolin-6-yl]-2-methyl-2H-indazole-7-carbonitrile dihydrochloride
36	8-fluoro-6-(7-fluoro-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinazoline dihydrochloride
37	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinazoline dihydrochloride
38	6-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-2-(piperidin-4-yl)quinazoline dihydrochloride
39	6-(2,7-dimethyl-2H-indazol-5-yl)-7-fluoro-2-(piperidin-4-yl)quinazoline dihydrochloride
45	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoline hydrochloride
47	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(1-methylpiperidin-4-yl)quinoline hydrochloride
48	6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-2-(1-ethylpiperidin-4-yl)-8-fluoroquinoline hydrochloride
49	8-fluoro-6-(7-methoxy-2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline hydrochloride

Cpd	Name
50	8-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)quinoline hydrochloride
51	8-fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)quinoline hydrochloride
53	8-fluoro-6-[8-(2-methoxyethoxy)-2-methylimidazo[1,2-b]pyridazin-6-yl]-2-(piperidin-4-yl)quinoline hydrochloride
54	6-[8-fluoro-2-(piperidin-4-yl)quinolin-6-yl]-N-(2-methoxyethyl)-2-methylimidazo[1,2-b]pyridazin-8-amine hydrochloride
55	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
56	7-(8-azabicyclo[3.2.1]oct-3-yl)-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-1,2,4-benzotriazine hydrochloride
57	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
58	5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
59	7-(8-ethoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
60	7-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
61	5-fluoro-7-[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-6-yl]-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
62	7-(2,4-dimethyl-1,3-benzoxazol-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
63	7-(2,4-dimethyl-1H-benzimidazol-6-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
64	7-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
65	7-(2,7-dimethylpyrazolo[1,5-a]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine hydrochloride
66	7-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine dihydrochloride
67	7-(2,7-dimethyl-2H-pyrazolo[3,4-c]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)-1,2,4-benzotriazine dihydrochloride
69	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-methylpiperidin-4-yl)-1,2,4-benzotriazine dihydrochloride
71	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(piperidin-4-yl)isoquinoline hydrochloride
72	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)isoquinoline hydrochloride
73	7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline hydrochloride
74	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride
80	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperazin-1-yl)cinnoline dihydrochloride
81	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-5-fluorocinnoline dihydrochloride
83	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-[1-(2-fluoroethyl)piperidin-4-yl]cinnoline dihydrochloride
84	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride
87	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-[(2S,6S)-2,6-dimethylpiperidin-4-yl]-5-fluorocinnoline hydrochloride
91	5-fluoro-7-(2-methylimidazo[1,2-a]pyrimidin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride
92	5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride
93	6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-a]pyridine-8-carbonitrile dihydrochloride
94	5-fluoro-7-(2-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride
95	5-fluoro-7-(2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline hydrochloride
96	5-fluoro-7-(7-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline hydrochloride
97	5-fluoro-7-(6-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline hydrochloride
98	3-[1-(2,2-difluoroethyl)piperidin-4-yl]-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline dihydrochloride
99	5-fluoro-7-(2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride
100	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(2-methylimidazo[1,2-b]pyridazin-6-yl)cinnoline dihydrochloride
101	7-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride
102	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)cinnoline dihydrochloride
103	7-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride

Cpd	Name
104	5-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methyl-1H-indazole-7-carbonitrile hydrochloride
109	5-fluoro-7-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(piperidin-4-yl)cinnoline hydrochloride
115	7-(8-cyclopropyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline formate
117	5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
120	7-(2,4-dimethyl-1,3-benzothiazol-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline formate
121	7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline dihydrochloride
122	7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-methylpiperidin-4-yl)cinnoline dihydrochloride
123	2-[4-[7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]piperidin-1-yl]ethan-1-ol dihydrochloride
127	2-[4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]piperidin-1-yl]-N,N-dimethylethan-1-amine trihydrochloride
128	5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)cinnoline dihydrochloride
133	7-(2,7-dimethyl[1,3]thiazolo[5,4-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline formate
134	5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
135	7-(2,7-dimethyl[1,3]thiazolo[5,4-b]pyridin-5-yl)-3-(1-ethylpiperidin-4-yl)-5-fluorocinnoline formate
138	2-[6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl]oxy-N,N-dimethylethan-1-amine trihydrochloride
139	3-[6-[5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl]oxy-N,N-dimethylpropan-1-amine trihydrochloride
140	5-fluoro-7-[2-methyl-8-[2-(1H-pyrazol-1-yl)ethoxy]imidazo[1,2-b]pyridazin-6-yl]-3-(piperidin-4-yl)cinnoline dihydrochloride
141	5-fluoro-7-[2-methyl-8-[3-(1H-pyrazol-1-yl)propoxy]imidazo[1,2-b]pyridazin-6-yl]-3-(piperidin-4-yl)cinnoline trihydrochloride
142	5-fluoro-7-[8-[3-(1H-imidazol-1-yl)propoxyl]-2-methylimidazo[1,2-b]pyridazin-6-yl]-3-(piperidin-4-yl)cinnoline trihydrochloride
145	3-[1-[3-(1H-benzimidazol-1-yl)propyl]piperidin-4-yl]-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline trihydrochloride
146	7-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline hydrochloride
150	7-[8-[3-(1H-benzimidazol-1-yl)propoxy]-2-methylimidazo[1,2-b]pyridazin-6-yl]-5-fluoro-3-(piperidin-4-yl)cinnoline trihydrochloride
151	5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)-7-(piperidin-4-yl)cinnoline hydrochloride
153	7-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-5-fluoro-3-(7-fluoro-2-methyl-2H-indazol-5-yl)cinnoline hydrochloride
156	3-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
157	3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
163	5-fluoro-7-(7-methoxy-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-3-(piperidin-4-yl)cinnoline formate
165	8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)quinazoline hydrochloride
166	8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-6-(1,2,3,6-tetrahydropyridin-4-yl)quinoline hydrochloride
167	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
171	5-fluoro-3-(7-fluoro-2-methyl-2H-benzotriazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride
173	3-(1-ethylpiperidin-4-yl)-5-fluoro-7-(7-methoxy-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)cinnoline formate
175	5-[5-fluoro-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnolin-3-yl]-2-methyl-2H-indazole-7-carbonitrile hydrochloride
176	6-[5-fluoro-3-(1-methylpiperidin-4-yl)cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile trihydrochloride
177	3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-7-(piperidin-4-yl)cinnoline hydrochloride
178	6-[5-fluoro-3-[1-(2-hydroxyethyl)piperidin-4-yl]cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile trihydrochloride
179	6-[5-fluoro-3-[1-(2-fluoroethyl)piperidin-4-yl]cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile trihydrochloride
181	2-(4-[5-fluoro-7-[8-(hydroxymethyl)-2-methylimidazo[1,2-b]pyridazin-6-yl]cinnolin-3-yl]piperidin-1-yl)ethan-1-ol trihydrochloride
182	(6-[5-fluoro-3-[1-(2-fluoroethyl)piperidin-4-yl]cinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol trihydrochloride
184	6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinoline hydrochloride

Cpd	Name
185	3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(piperidin-4-yl)cinnoline hydrochloride
191	7-(5,7-dimethyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride
192	8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinoline hydrochloride
193	6-(1-ethylpiperidin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinoline hydrochloride
194	5-fluoro-7-[8-(1H-imidazol-1-yl)-2-methylimidazo[1,2-b]pyridazin-6-yl]-3-(piperidin-4-yl)cinnoline formate
195	5-fluoro-7-(2-methyl-8-phenoxyimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline formate
196	7-(4,6-dimethyl[1,3]thiazolo[5,4-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline formate
201	6-(1-ethyl-1,2,3,6-tetrahydropyridin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinazoline hydrochloride
202	6-(1-ethylpiperidin-4-yl)-8-fluoro-2-(7-fluoro-2-methyl-2H-indazol-5-yl)quinazoline hydrochloride
205	{6-[3-(1-ethylpiperidin-4-yl)-5-fluorocinnolin-7-yl]-2-methylimidazo[1,2-b]pyridazin-8-yl}acetonitrile formate
210	5-fluoro-7-(2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride
216	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-3-yl)cinnoline dihydrochloride
217	3-(2,6-diazaspiro[3.4]octan-2-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline trihydrochloride
218	3-(2,6-diazaspiro[3.5]nonan-2-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline trihydrochloride
219	3-(2,7-diazaspiro[3.5]nonan-7-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline difluoroacetate
220	3-(2,6-diazaspiro[3.4]octan-6-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline difluoroacetate
221	3-(2,7-diazaspiro[3.5]nonan-2-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline difluoroacetate and
225	7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline dihydrochloride;

wherein the form of the compound salt is selected from the group consisting of a prodrug, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or a form thereof.

An aspect of the present description includes a method for use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form or composition thereof.

Another aspect of the present description includes a method for use of a compound salt of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or a form thereof.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising,

35 administering to the subject an effective amount of the compound of Formula (I) or a form thereof.

Another aspect of the present description includes a use for a compound salt of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or a form thereof.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.

Another aspect of the present description includes a use for a compound salt of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof in combination with an effective amount of the one or more agents.

60 Another aspect of the present description includes a use for a compound salt of Formula (I) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or a form thereof in combination with an effective amount of the one or more agents.

Chemical Definitions

The chemical terms used above and throughout the description herein, unless specifically defined otherwise, shall be understood by one of ordinary skill in the art to have the following indicated meanings.

As used herein, the term “C₁₋₈alkyl” generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration, including, but not limited to, methyl, ethyl, n-propyl (also referred to as propyl or propanyl), isopropyl, n-butyl (also referred to as butyl or butynyl), isobutyl, sec-butyl, tert-butyl, n-pentyl (also referred to as pentyl or pentanyl), n-hexyl (also referred to as hexyl or hexanyl), n-heptyl (also referred to as heptyl or heptanyl), n-octyl and the like. In certain aspects, C₁₋₈alkyl includes, but is not limited to, C₁₋₆alkyl, C₁₋₄alkyl and the like. A C₁₋₈alkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₂₋₈alkenyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon double bonds therein, including, but not limited to, ethenyl (also referred to as vinyl), allyl, propenyl and the like. In certain aspects, C₂₋₈alkenyl includes, but is not limited to, C₂₋₆alkenyl, C₂₋₄alkenyl and the like. A C₂₋₈alkenyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₂₋₈alkynyl” generally refers to partially unsaturated hydrocarbon radicals having from two to eight carbon atoms in a straight or branched chain configuration and one or more carbon-carbon triple bonds therein, including, but not limited to, ethynyl, propynyl, butynyl and the like. In certain aspects, C₂₋₈alkynyl includes, but is not limited to, C₂₋₆alkynyl, C₂₋₄alkynyl and the like. A C₂₋₈alkynyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₁₋₈alkoxy” generally refers to saturated hydrocarbon radicals having from one to eight carbon atoms in a straight or branched chain configuration of the formula: —O—C₁₋₈alkyl, including, but not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pent oxy, n-hexoxy and the like. In certain aspects, C₁₋₈alkoxy includes, but is not limited to, C₁₋₆alkoxy, C₁₋₄alkoxy and the like. A C₁₋₈alkoxy radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “C₃₋₁₄cycloalkyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon radical, including, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, 1H-indanyl, indenyl, tetrahydro-naphthalenyl and the like. In certain aspects, C₃₋₁₄cycloalkyl includes, but is not limited to, C₃₋₈cycloalkyl, C₅₋₈cycloalkyl, C₃₋₁₄cycloalkyl and the like. A C₃₋₁₄cycloalkyl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “aryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical, including, but not limited to, phenyl, naphthyl, anthracenyl, fluorenyl, azulenyl, phenanthrenyl and the like. An aryl radical is optionally substituted with substituent species as described herein where allowed by available valences.

As used herein, the term “heteroaryl” generally refers to a monocyclic, bicyclic or polycyclic aromatic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with one or more heteroatoms, such as an O, S or N atom, including, but not limited to, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, 1,3-thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, indolyl, indazolyl, indolizinyl, isoindolyl, benzofuranyl, benzothienyl, benzoimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, purinyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, 1,3-diazinyl, 1,2-diazinyl, 1,2-diazolyl, 1,4-diazanaphthalenyl, acridinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 6H-thieno[2,3-b]pyrrolyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-b]pyridinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-b]pyridinyl, imidazo[1,2-a]pyridinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,2,4]triazolo[1,5-a]pyridinyl, [1,2,4]triazolo[4,3-a]pyridinyl and the like. A heteroaryl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.

In certain aspects, the nomenclature for a heteroaryl radical may differ, such as in non-limiting examples where furanyl may also be referred to as furyl, thienyl may also be referred to as thiophenyl, pyridinyl may also be referred to as pyridyl, benzothienyl may also be referred to as benzothiophenyl and 1,3-benzoxazolyl may also be referred to as 1,3-benzooxazolyl.

In certain other aspects, the term for a heteroaryl radical may also include other regiosomers, such as in non-limiting examples where the term pyrrolyl may also include 2H-pyrrolyl, 3H-pyrrolyl and the like, the term pyrazolyl may also include 1H-pyrazolyl and the like, the term imidazolyl may also include 1H-imidazolyl and the like, the term triazolyl may also include 1H-1,2,3-triazolyl and the like, the term oxadiazolyl may also include 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl and the like, the term tetrazolyl may also include 1H-tetrazolyl, 2H-tetrazolyl and the like, the term indolyl may also include 1H-indolyl and the like, the term indazolyl may also include 1H-indazolyl, 2H-indazolyl and the like, the term benzoimidazolyl may also include 1H-benzoimidazolyl and the term purinyl may also include 9H-purinyl and the like.

As used herein, the term “heterocyclyl” generally refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic carbon atom ring structure radical in which one or more carbon atom ring members have been replaced, where allowed by structural stability, with a heteroatom, such as an O, S or N atom, including, but not limited to, oxiranyl, oxetanyl, azetidinyl, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, isoxazolinyl, isoxazolidinyl, isothiazolinyl, isothiazolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, triazolinyl, triazolidinyl, oxadiazolinyl, oxadiazolidinyl, thiadiazolinyl, thiadiazolidinyl, tetrazolinyl, tetrazolidinyl, pyranyl, dihydro-2H-pyranyl, thiopyranyl, 1,3-dioxanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,4-diazepanyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, 2,3-dihydro-1,4-benzodioxinyl, hexahydro-

pyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 6,9-diazaspiro[4.5]decyl and the like. A heterocycl radical is optionally substituted on a carbon or nitrogen atom ring member with substituent species as described herein where allowed by available valences.

In certain aspects, the nomenclature for a heterocycl radical may differ, such as in non-limiting examples where 1,3-benzodioxolyl may also be referred to as benzo[d][1,3]dioxolyl and 2,3-dihydro-1,4-benzodioxinyl may also be referred to as 2,3-dihydrobenzo[b][1,4]dioxinyl.

As used herein, the term “heteroaryl-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-heteroaryl.

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl-O—C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-NH—C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl-O—C₁₋₈alkyl)₂.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-O—C₁₋₈alkyl).

As used herein, the term “C₁₋₈alkoxy-C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-O—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-O—C₁₋₈alkyl)₂.

As used herein, the term “(C₁₋₈alkoxy-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-O—C₁₋₈alkyl).

As used herein, the term “C₁₋₈alkoxy-carbonyl” refers to a radical of the formula: —C(O)—O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkoxy-carbonyl-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-C(O)—O—C₁₋₈alkyl.

As used herein, the term “C₁₋₈alkoxy-carbonyl-amino” refers to a radical of the formula: —NH—C(O)—O—C₁₋₈alkyl.

As used herein, the term “heteroaryl-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-heteraryl.

As used herein, the term “C₁₋₈alkyl-amino” refers to a radical of the formula: —NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino” refers to a radical of the formula: —N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy” refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl)₂.

As used herein, the term “C₁₋₈alkyl-amino-C₁₋₈alkyl” refers to a radical of the formula: —NH—C₁₋₈alkyl-NH—C₁₋₈alkyl.

As used herein, the term “(C₁₋₈alkyl)₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —NH—C₁₋₈alkyl-N(C₁₋₈alkyl)₂.

As used herein, the term “(C₁₋₈alkyl)-amino-C₁₋₈alkyl” refers to a radical of the formula: —N[C₁₋₈alkyl-N(C₁₋₈alkyl)]₂.

As used herein, the term “[C₁₋₈alkyl]-amino-C₁₋₈alkyl” refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-NH—C₁₋₈alkyl).

As used herein, the term “[C₁₋₈alkyl]₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —N(C₁₋₈alkyl)[C₁₋₈alkyl-N(C₁₋₈alkyl)].

As used herein, the term “[C₁₋₈alkyl]₂-amino-C₂₋₈alkynyl” refers to a radical of the formula: —C₂₋₈alkynyl-NH—C₁₋₈alkyl.

As used herein, the term “[C₁₋₈alkyl]₂-amino-C₂₋₈alkynyl” refers to a radical of the formula: —C₂₋₈alkynyl-N(C₁₋₈alkyl)₂.

As used herein, the term “[C₁₋₈alkyl]-amino-C₂₋₈alkynyl” refers to a radical of the formula: —C₂₋₈alkynyl-N(C₁₋₈alkyl).

As used herein, the term “[C₁₋₈alkyl]₂-amino-C₁₋₈alkyl” refers to a radical of the formula: —NH—C₁₋₈alkyl-C₂₋₈alkynyl.

As used herein, the term “[C₁₋₈alkyl]-thio” refers to a radical of the formula: —S—C₁₋₈alkyl.

As used herein, the term “amino-C₂₋₈alkenyl” refers to a radical of the formula: —C₂₋₈alkenyl-NH₂.

As used herein, the term “amino-C₁₋₈alkyl” refers to a radical of the formula: —C₁₋₈alkyl-NH₂.

As used herein, the term “amino-C₁₋₈alkoxy” refers to a radical of the formula: —C₁₋₈alkyl-OH.

As used herein, the term “amino-C₁₋₈alkyl-NH₂” refers to a radical of the formula: —C₁₋₈alkyl-NH₂.

125

As used herein, the term "amino-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈ alkyl-NH₂.

As used herein, the term "(amino-C₁₋₈alkyl)₂-amino" refers to a radical of the formula: —N(C₁₋₈alkyl)-NH₂.

As used herein, the term "(amino-C₁₋₈alkyl)(C₁₋₈alkyl) amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl)-NH₂.

As used herein, the term "amino-C₂₋₈alkynyl" refers to a radical of the formula: —C₂₋₈alkynyl-NH₂.

As used herein, the term "aryl-C₁₋₈alkoxy-carbonyl" refers to a radical of the formula: —C(O)—O—C₁₋₈ alkyl-aryl.

As used herein, the term "aryl-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-aryl.

As used herein, the term "aryl-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-aryl.

As used herein, the term "(aryl-C₁₋₈alkyl)₂-amino" refers to a radical of the formula: —N(C₁₋₈alkyl-aryl)₂.

As used herein, the term "(aryl-C₁₋₈alkyl)(C₁₋₈alkyl) amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-aryl).

As used herein, the term "aryl-C₁₋₈alkyl-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-NH—C₁₋₈alkyl-aryl.

As used herein, the term "(aryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-aryl)₂.

As used herein, the term "(aryl-C₁₋₈alkyl)(C₁₋₈alkyl) amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-aryl).

As used herein, the term "aryl-amino" refers to a radical of the formula: —NH-aryl.

As used herein, the term "aryl-amino-carbonyl" refers to a radical of the formula: —C(O)—NH-aryl.

As used herein, the term "aryl-sulfonyloxy-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-O—SO₂-aryl.

As used herein, the term "benzoxy-carbonyl" refers to a radical of the formula: —C(O)—O—CH₂-phenyl.

As used herein, the term "C₃₋₁₄cycloalkyl-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-C₃₋₁₄cycloalkyl.

As used herein, the term "C₃₋₁₄cycloalkyl-amino" refers to a radical of the formula: —NH—C₃₋₁₄cycloalkyl.

As used herein, the term "C₃₋₁₄cycloalkyl-oxy" refers to a radical of the formula: —O—C₃₋₁₄cycloalkyl.

As used herein, the term "aryl-oxy" refers to a radical of the formula: —O-aryl.

As used herein, the term "halo" or "halogen" generally refers to a halogen atom radical, including fluoro, chloro, bromo and iodo.

As used herein, the term "halo-C₁₋₈alkoxy" refers to a radical of the formula: —O—C₁₋₈alkyl-halo, wherein C₁₋₈alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.

As used herein, the term "halo-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-halo, wherein C₁₋₈alkyl is partially or completely substituted with one or more halogen atoms where allowed by available valences.

As used herein, the term "halo-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-halo.

As used herein, the term "(halo-C₁₋₈alkyl)(C₁₋₈alkyl) amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-halo).

As used herein, the term "(halo-C₁₋₈alkyl)₂-amino" refers to a radical of the formula: —N(C₁₋₈alkyl-halo)₂.

As used herein, the term "heteroaryl-C₁₋₈alkoxy" refers to a radical of the formula: —O—C₁₋₈alkyl-heteroaryl.

126

As used herein, the term "heteroaryl-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈ alkyl-heteroaryl.

As used herein, the term "heteroaryl-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-heteroaryl.

As used herein, the term "(heteroaryl-C₁₋₈alkyl)₂-amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-heteroaryl).

As used herein, the term "heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈ alkyl-NH—C₁₋₈alkyl-heteroaryl.

As used herein, the term "(heteroaryl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-heteroaryl)₂.

As used herein, the term "(heteroaryl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-heteroaryl).

As used herein, the term "heteroaryl-C₁₋₈alkyl-amino-C₁₋₈alkyl-heteroaryl" refers to a radical of the formula: —NH-heteroaryl.

As used herein, the term "heterocyclyl-C₁₋₈alkoxy" refers to a radical of the formula: —O—C₁₋₈alkyl-heterocyclyl.

As used herein, the term "heterocyclyl-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-heterocyclyl.

As used herein, the term "heterocyclyl-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-heterocyclyl.

As used herein, the term "(heterocyclyl-C₁₋₈alkyl)amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-heterocyclyl).

As used herein, the term "heterocyclyl-C₁₋₈alkyl-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₈alkyl-NH—C₁₋₈alkyl-heterocyclyl.

As used herein, the term "(heterocyclyl-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-heterocyclyl)₂.

As used herein, the term "(heterocyclyl-C₁₋₈alkyl)(C₁₋₈alkyl)amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-heterocyclyl).

As used herein, the term "heterocyclyl-amino" refers to a radical of the formula: —NH-heterocyclyl.

As used herein, the term "(heterocyclyl)(C₁₋₈alkyl)amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(heterocyclyl).

As used herein, the term "heterocyclyl-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-NH-heterocyclyl.

As used herein, the term "heterocyclyl-carbonyl" refers to a radical of the formula: —C(O)-heterocyclyl.

As used herein, the term "heterocyclyl-carbonyl-oxy" refers to a radical of the formula: —O—C(O)-heterocyclyl.

As used herein, the term "heterocyclyl-oxy" refers to a radical of the formula: —O-heterocyclyl.

As used herein, the term "hydroxy" refers to a radical of the formula: —OH.

As used herein, the term "hydroxy-C₁₋₈alkoxy-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-O—C₁₋₈alkyl-OH.

As used herein, the term "hydroxy-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-OH, wherein C₁₋₈alkyl is partially or completely substituted with one or more hydroxy radicals where allowed by available valences.

As used herein, the term "hydroxy-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-OH.

As used herein, the term "(hydroxy-C₁₋₈alkyl)₂-amino" refers to a radical of the formula: —N(C₁₋₈alkyl-OH)₂.

As used herein, the term "(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl-amino)" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-OH).

As used herein, the term "hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-OH).

As used herein, the term "(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂.

As used herein, the term "(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl-amino-C₁₋₈alkyl)" refers to a radical of the formula: —C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-OH).

As used herein, the term "hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkoxy" refers to a radical of the formula: —O—C₁₋₈alkyl-NH—C₁₋₈alkyl-OH.

As used herein, the term "(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy" refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂.

As used herein, the term "(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl-amino-C₁₋₈alkoxy)" refers to a radical of the formula: —O—C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-OH).

As used herein, the term "hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-NH—C₁₋₈alkyl-OH.

As used herein, the term "(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino" refers to a radical of the formula: —N(C₁₋₈alkyl-NH—C₁₋₈alkyl-OH)₂.

As used herein, the term "(hydroxy-C₁₋₈alkyl)₂-amino-C₁₋₈alkyl-amino" refers to a radical of the formula: —NH—C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂.

As used herein, the term "(hydroxy-C₁₋₈alkyl-amino-C₁₋₈alkyl)(C₁₋₈alkyl)amino" refers to a radical of the formula: —N(C₁₋₈alkyl)(C₁₋₈alkyl-NH—C₁₋₈alkyl-OH).

As used herein, the term "[hydroxy-C₁₋₈alkyl]₂-amino-C₁₋₈alkyl](C₁₋₈alkyl)amino" refers to a radical of the formula: —N(C₁₋₈alkyl)[C₁₋₈alkyl-N(C₁₋₈alkyl-OH)₂].

As used herein, the term "(hydroxy-C₁₋₈alkyl)(C₁₋₈alkyl-amino-C₁₋₈alkyl-amino)" refers to a radical of the formula: —NH—C₁₋₈alkyl-N(C₁₋₈alkyl,C₁₋₈alkyl-OH).

As used herein, the term "[hydroxy-C₁₋₈alkyl](C₁₋₈alkyl)amino-C₁₋₈alkyl](C₁₋₈alkyl)amino" refers to a radical of the formula: —N(C₁₋₈alkyl) [C₁₋₈alkyl-N(C₁₋₈alkyl)(C₁₋₈alkyl-OH)].

As used herein, the term "substituent" means positional variables on the atoms of a core molecule that are substituted at a designated atom position, replacing one or more hydrogens on the designated atom, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. A person of ordinary skill in the art should note that any carbon as well as heteroatom with valences that appear to be unsatisfied as described or shown herein is assumed to have a sufficient number of hydrogen atom(s) to satisfy the valences described or shown. In certain instances one or more substituents having a double bond (e.g., "oxo" or "=O") as the point of attachment may be described, shown or listed herein within a substituent group, wherein the structure may only show a single bond as the point of attachment to the core structure of Formula (I). A person of ordinary skill in the art would understand that, while only a single bond is shown, a double bond is intended for those substituents.

As used herein, the term "and the like," with reference to the definitions of chemical terms provided herein, means that variations in chemical structures that could be expected by one skilled in the art include, without limitation, isomers (including chain, branching or positional structural isomers), hydration of ring systems (including saturation or partial unsaturation of monocyclic, bicyclic or polycyclic ring structures) and all other variations where allowed by available valences which result in a stable compound.

For the purposes of this description, where one or more substituent variables for a compound of Formula (I) or a form thereof encompass functionalities incorporated into a compound of Formula (I), each functionality appearing at any location within the disclosed compound may be independently selected, and as appropriate, independently and/or optionally substituted.

As used herein, the terms "independently selected," or "each selected" refer to functional variables in a substituent list that may occur more than once on the structure of Formula (I), the pattern of substitution at each occurrence is independent of the pattern at any other occurrence. Further, the use of a generic substituent variable on any formula or structure for a compound described herein is understood to include the replacement of the generic substituent with species substituents that are included within the particular genus, e.g., aryl may be replaced with phenyl or naphthalenyl and the like, and that the resulting compound is to be included within the scope of the compounds described herein.

As used herein, the terms "each instance of" or "in each instance, when present," when used preceding a phrase such as ". . . C₁₋₁₄cycloalkyl, C₁₋₁₄cycloalkyl-C₁₋₄alkyl, aryl, aryl-C₁₋₄alkyl, heteroaryl, heteroaryl-C₁₋₄alkyl, heterocycl and heterocycl-C₁₋₄alkyl," are intended to refer to the C₁₋₁₄cycloalkyl, aryl, heteroaryl and heterocycl ring systems when each are present either alone or as a substituent.

As used herein, the term "optionally substituted" means optional substitution with the specified substituent variables, groups, radicals or moieties.

40 Compound Forms

As used herein, the term "form" means a compound of Formula (I) having a form selected from the group consisting of a free acid, free base, prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

In certain aspects described herein, the form of the compound of Formula (I) is a free acid, free base or salt thereof.

In certain aspects described herein, the form of the compound of Formula (I) is a salt thereof.

In certain aspects described herein, the form of the compound of Formula (I) is an isotopologue thereof.

In certain aspects described herein, the form of the compound of Formula (I) is a stereoisomer, racemate, enantiomer or diastereomer thereof.

In certain aspects described herein, the form of the compound of Formula (I) is a tautomer thereof.

In certain aspects described herein, the form of the compound of Formula (I) is a pharmaceutically acceptable form.

In certain aspects described herein, the compound of Formula (I) or a form thereof is isolated for use.

As used herein, the term "isolated" means the physical state of a compound of Formula (I) or a form thereof after being isolated and/or purified from a synthetic process (e.g., from a reaction mixture) or natural source or combination thereof according to an isolation or purification process or

129

processes described herein or which are well known to the skilled artisan (e.g., chromatography, recrystallization and the like) in sufficient purity to be characterized by standard analytical techniques described herein or well known to the skilled artisan.

As used herein, the term "protected" means that a functional group in a compound of Formula (I) or a form thereof is in a form modified to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York. Such functional groups include hydroxy, phenol, amino and carboxylic acid. Suitable protecting groups for hydroxy or phenol include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, substituted benzyl, methyl, methoxymethanol, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. In certain instances, the protecting group may also be a polymer resin, such as a Wang resin or a 2-chlorotriptyl-chloride resin. Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. It will also be appreciated by those skilled in the art, although such protected derivatives of compounds described herein may not possess pharmacological activity as such, they may be administered to a subject and thereafter metabolized in the body to form compounds described herein which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds described herein are included within the scope of the use described herein.

As used herein, the term "prodrug" means a form of an instant compound (e.g., a drug precursor) that is transformed in vivo to yield an active compound of Formula (I) or a form thereof. The transformation may occur by various mechanisms (e.g., by metabolic and/or non-metabolic chemical processes), such as, for example, by hydrolysis and/or metabolism in blood, liver and/or other organs and tissues. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

In one example, when a compound of Formula (I) or a form thereof contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a functional group such as alkyl and the like. In another example, when a compound of Formula (I) or a form thereof contains a hydroxyl functional group, a prodrug form can be prepared by replacing the hydrogen atom of the hydroxyl with another functional group such as alkyl, alkylcarbonyl or a phosphonate ester and the like. In another example, when a compound of Formula (I) or a form thereof contains an amine functional group, a prodrug form can be prepared by replacing one or more amine hydrogen atoms with a functional group such as alkyl or substituted carbonyl. Pharmaceutically acceptable prodrugs of compounds of Formula (I) or a form thereof include those compounds substituted with one or more of the following groups: carboxylic acid esters, sulfonate esters, amino acid esters, phosphonate esters and

130

mono-, di- or triphosphate esters or alkyl substituents, where appropriate. As described herein, it is understood by a person of ordinary skill in the art that one or more of such substituents may be used to provide a compound of Formula (I) or a form thereof as a prodrug.

One or more compounds described herein may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and the description herein is intended to embrace both solvated and unsolvated forms.

As used herein, the term "solvate" means a physical association of a compound described herein with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. As used herein, "solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.

As used herein, the term "hydrate" means a solvate wherein the solvent molecule is water.

The compounds of Formula (I) can form salts, which are intended to be included within the scope of this description. Reference to a compound of Formula (I) or a form thereof herein is understood to include reference to salt forms thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) or a form thereof contains both a basic moiety, such as, without limitation an amine moiety, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein.

The term "pharmaceutically acceptable salt(s)", as used herein, means those salts of compounds described herein that are safe and effective (i.e., non-toxic, physiologically acceptable) for use in mammals and that possess biological activity, although other salts are also useful. Salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound of Formula (I) or a form thereof with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Pharmaceutically acceptable salts include one or more salts of acidic or basic groups present in compounds described herein. Particular aspects of acid addition salts include, and are not limited to, acetate, ascorbate, benzoate, benzenesulfonate, bisulfate, bitartrate, borate, bromide, butyrate, chloride, citrate, camphorate, camphorsulfonate, ethanesulfonate, formate, fumarate, gentisinate, gluconate, glucuronate, glutamate, iodide, isonicotinate, lactate, maleate, methanesulfonate, naphthalenesulfonate, nitrate, oxalate, pamoate, pantothenate, phosphate, propionate, saccharate, salicylate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate (also known as tosylate), trifluoroacetate salts and the like. Certain particular aspects of acid addition salts include chloride or dichloride.

Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) *Handbook of Pharmaceutical Salts. Properties, Selection and Use.* (2002) Zurich: Wiley-VCH; S. Berge et al, *Journal of Pharmaceutical Sciences* (1977) 66(1) 1-19; P. Gould, *International J.*

131

of Pharmaceutics (1986) 33, 201-217; Anderson et al, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; and in *The Orange Book* (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

Suitable basic salts include, but are not limited to, aluminum, ammonium, calcium, lithium, magnesium, potassium, sodium and zinc salts.

All such acid salts and base salts are intended to be included within the scope of pharmaceutically acceptable salts as described herein. In addition, all such acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of this description.

Compounds of Formula (I) and forms thereof, may further exist in a tautomeric form. All such tautomeric forms are contemplated and intended to be included within the scope of the compounds of Formula (I) or a form thereof as described herein.

The compounds of Formula (I) or a form thereof may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. The present description is intended to include all stereoisomeric forms of the compounds of Formula (I) as well as mixtures thereof, including racemic mixtures.

The compounds described herein may include one or more chiral centers, and as such may exist as racemic mixtures (R/S) or as substantially pure enantiomers and diastereomers. The compounds may also exist as substantially pure (R) or (S) enantiomers (when one chiral center is present). In one particular aspect, the compounds described herein are (S) isomers and may exist as enantiomerically pure compositions substantially comprising only the (S) isomer. In another particular aspect, the compounds described herein are (R) isomers and may exist as enantiomerically pure compositions substantially comprising only the (R) isomer. As one of skill in the art will recognize, when more than one chiral center is present, the compounds described herein may also exist as a (R,R), (R,S), (S,R) or (S,S) isomer, as defined by IUPAC Nomenclature Recommendations.

As used herein, the term "substantially pure" refers to compounds consisting substantially of a single isomer in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100% of the single isomer.

In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (S) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.

In one aspect of the description, a compound of Formula (I) or a form thereof is a substantially pure (R) enantiomer form present in an amount greater than or equal to 90%, in an amount greater than or equal to 92%, in an amount greater than or equal to 95%, in an amount greater than or equal to 98%, in an amount greater than or equal to 99%, or in an amount equal to 100%.

As used herein, a "racemate" is any mixture of isometric forms that are not "enantiomerically pure", including mixtures such as, without limitation, in a ratio of about 50/50, about 60/40, about 70/30, or about 80/20.

In addition, the present description embraces all geometric and positional isomers. For example, if a compound of

132

Formula (I) or a form thereof incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the description. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by use of chiral HPLC column or other chromatographic methods known to those skilled in the art. Enantiomers can also be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (I) may be atropisomers (e.g., substituted biaryls) and are considered as part of this description.

All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this description, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds described herein may, for example, be substantially free of other isomers, or may be present in a racemic mixture, as described supra.

The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or isotopologues of the instant compounds.

The term "isotopologue" refers to isotopically-enriched compounds described herein which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{35}Cl and ^{36}Cl , respectively, each of which are also within the scope of this description.

Certain isotopically-enriched compounds described herein (e.g., those labeled with ^3H and ^{14}C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., ^3H) and carbon-14 (i.e., ^{14}C) isotopes are particularly preferred for their ease of preparation and detectability.

Further, substitution with heavier isotopes such as deuterium (i.e., ^2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.

Polymorphic crystalline and amorphous forms of the compounds of Formula (I) and of the salts, solvates, hydrates, esters and prodrugs of the compounds of Formula (I) are further intended to be included in the present description.

65 Compound Uses

In accordance with the intended scope of the present description, aspects of the present description include com-

133

pounds that have been identified and have been demonstrated to be useful in selectively preventing, treating or ameliorating HD and have been provided for use for preventing, treating or ameliorating HD.

An aspect of the present description includes a method for preventing, treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

An aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

An aspect of the present description includes a method for preventing HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

An aspect of the present description includes a method for treating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

An aspect of the present description includes a method for ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound of Formula (I) or a form thereof.

Another aspect of the present description includes a method for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound salt of Formula (I) or a form thereof.

An aspect of the present description includes a method for use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form or composition thereof.

Another aspect of the present description includes a method for use of a compound salt of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or a form thereof.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof.

Another aspect of the present description includes a use for a compound salt of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or a form thereof.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.

Another aspect of the present description includes a use for a compound salt of Formula (I) or a form thereof in the manufacture of a medicament for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the medicament.

An aspect of the present description includes in vitro or in vivo use of the compound of Formula (I) or a form thereof having activity toward HD.

An aspect of the present description includes a use of the compound of Formula (I) or a form thereof in a combination

134

therapy to provide additive or synergistic activity, thus enabling the development of a combination product for treating or ameliorating HD.

Another aspect of the present description includes a combination therapy comprising compounds described herein in combination with one or more known drugs or one or more known therapies may be used to treat HD regardless of whether HD is responsive to the known drug.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof in combination with an effective amount of the one or more agents.

Another aspect of the present description includes a use for a compound salt of Formula (I) or a form thereof in a combination product with one or more therapeutic agents for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound salt of Formula (I) or a form thereof in combination with an effective amount of the one or more agents.

In an aspect of a use or method provided herein, compounds of Formula (I) or a form thereof used in combination with one or more additional agents can be administered to a subject or contacted with a subject or patient cell(s) prior to, concurrently with, or subsequent to administering to the subject or patient or contacting the cell with an additional agent(s).

A compound(s) of Formula (I) or a form thereof and an additional agent(s) can be administered to a subject or contacted with a cell in single composition or different compositions. In a specific aspect, a compound(s) of Formula (I) or a form thereof is used in combination with gene therapy to inhibit HTT expression (using, e.g., viral delivery vectors) or the administration of another small molecule HTT inhibitor. In another specific aspect, a compound(s) of Formula (I) or a form thereof are used in combination with cell replacement using differentiated non-mutant HTT stem cells. In another specific aspect, a compound(s) of Formula (I) or a form thereof are used in combination with cell replacement using differentiated HTT stem cells.

In one aspect, provided herein is the use of compounds of Formula (I) or a form thereof in combination with supportive standard of care therapies, including palliative care.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or a form thereof.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or a form thereof; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or a form thereof in a combination product with an effective amount of one or more therapeutic agents.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the compound of Formula (I) or a form thereof and instructions for administering an effective amount of the compound of Formula (I) or a form thereof;

135

and optionally, for administering to the subject an effective amount of the compound of Formula (I) or a form thereof in a combination product with an effective amount of the one or more therapeutic agents; and optionally, for administering to the subject an effective amount of the compound of Formula (I) or a form thereof in a combination product with an effective amount of the one or more therapeutic agents in a combination therapy with a standard of care supportive therapy, wherein the standard of care supportive therapy is palliative care.

In one respect, for each of such aspects, the subject is treatment naive. In another respect, for each of such aspects, the subject is not treatment naive.

As used herein, the term "preventing" refers to keeping a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having the disease, disorder and/or condition.

As used herein, the term "treating" refers to inhibiting the progression of a disease, disorder or condition in a subject already exhibiting the symptoms of the disease, disorder and/or condition, i.e., arresting the development of a disease, disorder and/or condition that has already affected the subject.

As used herein, the term "ameliorating" refers to relieving the symptoms of a disease, disorder or condition in a subject already exhibiting the symptoms of the disease, disorder and/or condition, i.e., causing regression of the disease, disorder and/or condition that has already affected the subject.

As used herein, the term "subject" refers to an animal or any living organism having sensation and the power of voluntary movement, and which requires oxygen and organic food. Nonlimiting examples include members of the human, primate, equine, porcine, bovine, murine, ratus, canine and feline specie. In certain aspects, the subject is a mammal or a warm-blooded vertebrate animal. In other aspects, the subject is a human. As used herein, the term "patient" may be used interchangeably with "subject" and "human".

As used herein, the terms "effective amount" or "therapeutically effective amount" mean an amount of compound of Formula (I) or a form, composition or medicament thereof that achieves a target plasma concentration that is effective in treating or ameliorating HD as described herein and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect in a subject in need thereof. In one aspect, the effective amount may be the amount required to treat HD in a subject or patient, more specifically, in a human.

In another aspect, the concentration-biological effect relationships observed with regard to a compound of Formula (I) or a form thereof indicate a target plasma concentration ranging from approximately 0.001 µg/mL to approximately 50 µg/mL, from approximately 0.01 µg/mL to approximately 20 µg/mL, from approximately 0.05 µg/mL to approximately 10 µg/mL, or from approximately 0.1 µg/mL to approximately 5 µg/mL. To achieve such plasma concentrations, the compounds described herein may be administered at doses that vary, such as, for example, without limitation, from 1.0 ng to 10,000 mg.

In one aspect, the dose administered to achieve an effective target plasma concentration may be administered based upon subject or patient specific factors, wherein the doses administered on a weight basis may be in the range of from about 0.001 mg/kg/day to about 3500 mg/kg/day, or about 0.001 mg/kg/day to about 3000 mg/kg/day, or about 0.001

136

mg/kg/day to about 2500 mg/kg/day, or about 0.001 mg/kg/day to about 2000 mg/kg/day, or about 0.001 mg/kg/day to about 1500 mg/kg/day, or about 0.001 mg/kg/day to about 1000 mg/kg/day, or about 0.001 mg/kg/day to about 500 mg/kg/day, or about 0.001 mg/kg/day to about 250 mg/kg/day, or about 0.001 mg/kg/day to about 200 mg/kg/day, or about 0.001 mg/kg/day to about 150 mg/kg/day, or about 0.001 mg/kg/day to about 100 mg/kg/day, or about 0.001 mg/kg/day to about 75 mg/kg/day, or about 0.001 mg/kg/day to about 50 mg/kg/day, or about 0.001 mg/kg/day to about 25 mg/kg/day, or about 0.001 mg/kg/day to about 10 mg/kg/day, or about 0.001 mg/kg/day to about 5 mg/kg/day, or about 0.001 mg/kg/day to about 1 mg/kg/day, or about 0.001 mg/kg/day to about 0.5 mg/kg/day, or about 0.001 mg/kg/day to about 0.1 mg/kg/day, or from about 0.01 mg/kg/day to about 3500 mg/kg/day, or about 0.01 mg/kg/day to about 3000 mg/kg/day, or about 0.01 mg/kg/day to about 2500 mg/kg/day, or about 0.01 mg/kg/day to about 2000 mg/kg/day, or about 0.01 mg/kg/day to about 1500 mg/kg/day, or about 0.01 mg/kg/day to about 1000 mg/kg/day, or about 0.01 mg/kg/day to about 500 mg/kg/day, or about 0.01 mg/kg/day to about 250 mg/kg/day, or about 0.01 mg/kg/day to about 200 mg/kg/day, or about 0.01 mg/kg/day to about 150 mg/kg/day, or about 0.01 mg/kg/day to about 100 mg/kg/day, or about 0.01 mg/kg/day to about 75 mg/kg/day, or about 0.01 mg/kg/day to about 50 mg/kg/day, or about 0.01 mg/kg/day to about 25 mg/kg/day, or about 0.01 mg/kg/day to about 10 mg/kg/day, or about 0.01 mg/kg/day to about 5 mg/kg/day, or about 0.01 mg/kg/day to about 1 mg/kg/day, or about 0.01 mg/kg/day to about 0.5 mg/kg/day, or about 0.01 mg/kg/day to about 0.1 mg/kg/day, or from about 0.1 mg/kg/day to about 3500 mg/kg/day, or about 0.1 mg/kg/day to about 3000 mg/kg/day, or about 0.1 mg/kg/day to about 2500 mg/kg/day, or about 0.1 mg/kg/day to about 2000 mg/kg/day, or about 0.1 mg/kg/day to about 1500 mg/kg/day, or about 0.1 mg/kg/day to about 1000 mg/kg/day, or about 0.1 mg/kg/day to about 500 mg/kg/day, or about 0.1 mg/kg/day to about 250 mg/kg/day, or about 0.1 mg/kg/day to about 200 mg/kg/day, or about 0.1 mg/kg/day to about 150 mg/kg/day, or about 0.1 mg/kg/day to about 100 mg/kg/day, or about 0.1 mg/kg/day to about 75 mg/kg/day, or about 0.1 mg/kg/day to about 50 mg/kg/day, or about 0.1 mg/kg/day to about 25 mg/kg/day, or about 0.1 mg/kg/day to about 10 mg/kg/day, or about 0.1 mg/kg/day to about 5 mg/kg/day, or about 0.1 mg/kg/day to about 1 mg/kg/day, or about 0.1 mg/kg/day to about 0.5 mg/kg/day.

Effective amounts for a given subject may be determined by routine experimentation that is within the skill and judgment of a clinician or a practitioner skilled in the art in light of factors related to the subject. Dosage and administration may be adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include genetic screening, severity of the disease state, status of disease progression, general health of the subject, ethnicity, age, weight, gender, diet, time of day and frequency of administration, drug combination(s), reaction sensitivities, experience with other therapies, and tolerance/response to therapy.

The dose administered to achieve an effective target plasma concentration may be orally administered once (once in approximately a 24 hour period; i.e., "q.d."), twice (once in approximately a 12 hour period; i.e., "b.i.d." or "q.12h"), thrice (once in approximately an 8 hour period; i.e., "t.i.d." or "q.8h"), or four times (once in approximately a 6 hour period; i.e., "q.d.s.", or "q.6h") daily.

In certain aspects, the dose administered to achieve an effective target plasma concentration may also be adminis-

137

tered in a single, divided, or continuous dose for a patient or subject having a weight in a range of between about 40 to about 200 kg (which dose may be adjusted for patients or subjects above or below this range, particularly children under 40 kg). The typical adult subject is expected to have a median weight in a range of about 70 kg. Long-acting pharmaceutical compositions may be administered every 2, 3 or 4 days, once every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

The compounds and compositions described herein may be administered to the subject via any drug delivery route known in the art. Nonlimiting examples include oral, ocular, rectal, buccal, topical, nasal, sublingual, transdermal, subcutaneous, intramuscular, intraveneous (bolus and infusion), intracerebral, and pulmonary routes of administration.

In another aspect, the dose administered may be adjusted based upon a dosage form described herein formulated for delivery at about 0.02, 0.025, 0.03, 0.05, 0.06, 0.075, 0.08, 0.09, 0.10, 0.20, 0.25, 0.30, 0.50, 0.60, 0.75, 0.80, 0.90, 1.0, 1.10, 1.20, 1.25, 1.50, 1.75, 2.0, 3.0, 5.0, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 400, 500, 1000, 1500, 2000, 2500, 3000 or 4000 mg/day.

For any compound, the effective amount can be estimated initially either in cell culture assays or in relevant animal models, such as a mouse, guinea pig, chimpanzee, marmoset or tamarin animal model. Relevant animal models may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is therapeutic index, and can be expressed as the ratio, LD₅₀/ED₅₀. In certain aspects, the effective amount is such that a large therapeutic index is achieved. In further particular aspects, the dosage is within a range of circulating concentrations that include an ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

In one aspect, provided herein are methods for modulating the amount of HTT (huntingtin protein), comprising contacting a human cell with a compound of Formula (I) or a form thereof. In a specific aspect, provided herein are methods for modulating the amount of HTT, comprising contacting a human cell with a compound of Formula (I) or a form thereof that modulates the expression of HTT. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I).

In a specific aspect, provided herein is a method for enhancing the inhibition of mutant HTT transcribed from the Htt gene, comprising contacting a human cell with a compound of Formula (I) or a form thereof. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or

138

in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of wild-type "normal" HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I).

10 In another aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or a form thereof. In a specific aspect, provided herein is a method for modulating the inhibition of mutant HTT transcribed from the Htt gene, comprising administering to a non-human animal model for HD a compound of Formula (I) or a form thereof. In a specific aspect, the compound is a form of the compound of Formula (I).

15 In another aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) or a form thereof.

20 In a specific aspect, provided herein is a method for decreasing the amount of mutant HTT, comprising contacting a human cell with a compound of Formula (I) that inhibits the transcription of mutant HTT (huntingtin mRNA) from the Htt gene. In another specific aspect, provided herein is a method for decreasing the amount of HTT, comprising contacting a human cell with a compound of

25 Formula (I) that inhibits the expression of mutant HTT transcribed from the Htt gene. The human cell can be contacted with a compound of Formula (I) or a form thereof in vitro, or in vivo, e.g., in a non-human animal or in a human. In a specific aspect, the human cell is from or in a human. In another specific aspect, the human cell is from or in a human with HD. In another specific aspect, the human cell is from or in a human with HD, caused by a CAG repeat in the Htt gene, resulting in a loss of HTT expression and/or function. In another aspect, the human cell is from a human with HD. In another aspect, the human cell is in a human with HD. In one aspect, the compound is a form of the compound of Formula (I).

30 In certain aspects, treating or ameliorating HD with a compound of Formula (I) or a form thereof (alone or in combination with an additional agent) has a therapeutic effect and/or beneficial effect. In a specific aspect, treating HD with a compound of Formula (I) or a form thereof (alone or in combination with an additional agent) results in one, two or more of the following effects: (i) reduces or ameliorates the severity of HD; (ii) delays onset of HD; (iii) inhibits the progression of HD; (iv) reduces hospitalization of a subject; (v) reduces hospitalization length for a subject; (vi) increases the survival of a subject; (vii) improves the quality of life for a subject; (viii) reduces the number of symptoms associated with HD; (ix) reduces or ameliorates the severity of a symptom(s) associated with HD; (x) reduces the duration of a symptom associated with HD; (xi) prevents the recurrence of a symptom associated with HD; (xii) inhibits the development or onset of a symptom of HD; and/or (xiii) inhibits the progression of a symptom associated with HD.

Metabolites

Another aspect included within the scope of the present description are the use of in vivo metabolic products of the compounds described herein. Such products may result, for example, from the oxidation, reduction, hydrolysis, amidation, esterification and the like of the administered com-

139

pound, primarily due to enzymatic processes. Accordingly, the description includes the use of compounds produced by a process comprising contacting a compound described herein with a mammalian tissue or a mammal for a period of time sufficient to yield a metabolic product thereof.

Such products typically are identified by preparing a radio-labeled isotopologue (e.g., ^{14}C or ^3H) of a compound described herein, administering the radio-labeled compound in a detectable dose (e.g., greater than about 0.5 mg/kg) to a mammal such as a rat, mouse, guinea pig, dog, monkey or human, allowing sufficient time for metabolism to occur (typically about 30 seconds to about 30 hours), and identifying the metabolic conversion products from urine, bile, blood or other biological samples. The conversion products are easily isolated since they are "radiolabeled" by virtue of being isotopically-enriched (others are isolated by the use of antibodies capable of binding epitopes surviving in the metabolite). The metabolite structures are determined in conventional fashion, e.g., by MS or NMR analysis. In general, analysis of metabolites may be done in the same way as conventional drug metabolism studies well-known to those skilled in the art. The conversion products, so long as they are not otherwise found *in vivo*, are useful in diagnostic assays for therapeutic dosing of the compounds described herein even if they possess no biological activity of their own.

Pharmaceutical Compositions

In accordance with the intended scope of the present description, aspects of the present description include compounds that have been identified and have been demonstrated to be useful in selectively preventing, treating or ameliorating HD and have been provided for use as one or more pharmaceutical compositions for preventing, treating or ameliorating HD.

An aspect of the present description includes a use for a compound of Formula (I) or a form thereof in the preparation of a pharmaceutical composition for treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of the compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipients.

An aspect of the present description includes a use for a pharmaceutical composition of the compound of Formula (I) or a form thereof in the preparation of a kit for treating or ameliorating HD in a subject in need thereof comprising, the pharmaceutical composition of the compound of Formula (I) or a form thereof and instructions for administering the pharmaceutical composition.

As used herein, the term "composition" means a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

The pharmaceutical composition may be formulated to achieve a physiologically compatible pH, ranging from about pH 3 to about pH 11. In certain aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 3 to about pH 7. In other aspects, the pharmaceutical composition is formulated to achieve a pH of from about pH 5 to about pH 8.

The term "pharmaceutically acceptable excipient" refers to an excipient for administration of a pharmaceutical agent, such as the compounds described herein. The term refers to any pharmaceutical excipient that may be administered without undue toxicity. Pharmaceutically acceptable excipients may be determined in part by the particular composition being administered, as well as by the particular mode of

140

administration and/or dosage form. Nonlimiting examples of pharmaceutically acceptable excipients include carriers, solvents, stabilizers, adjuvants, diluents, etc. Accordingly, there exists a wide variety of suitable formulations of pharmaceutical compositions for the instant compounds described herein (see, e.g., Remington's Pharmaceutical Sciences).

Suitable excipients may be carrier molecules that include large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive antibodies. Other exemplary excipients include antioxidants such as ascorbic acid; chelating agents such as EDTA; carbohydrates such as dextrin, hydroxyalkylcellulose, hydroxyalkylmethylcellulose (e.g., hydroxypropylmethylcellulose, also known as HPMC), stearic acid; liquids such as oils, water, saline, glycerol and ethanol; wetting or emulsifying agents; pH buffering substances; and the like. Liposomes are also included within the definition of pharmaceutically acceptable excipients.

The pharmaceutical compositions described herein may be formulated in any form suitable for the intended use described herein. Suitable formulations for oral administration include solids, liquid solutions, emulsions and suspensions, while suitable inhalable formulations for pulmonary administration include liquids and powders. Alternative formulations include syrups, creams, ointments, tablets, and lyophilized solids which can be reconstituted with a physiologically compatible solvent prior to administration.

When intended for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, non-aqueous solutions, dispersible powders or granules (including micronized particles or nanoparticles), emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide a palatable preparation.

Pharmaceutically acceptable excipients suitable for use in conjunction with tablets include, for example, inert diluents, such as celluloses, calcium or sodium carbonate, lactose, calcium or sodium phosphate; disintegrating agents, such as croscarmellose sodium, cross-linked povidone, maize starch, or alginic acid; binding agents, such as povidone, starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example celluloses, lactose, calcium phosphate, or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with non-aqueous or oil medium, such as glycerin, propylene glycol, polyethylene glycol, peanut oil, liquid paraffin, or olive oil.

In other aspects, pharmaceutical compositions described herein may be formulated as suspensions comprising a compound of Formula (I) or a form thereof in admixture with one or more pharmaceutically acceptable excipients suitable for the manufacture of a suspension. In yet other aspects, pharmaceutical compositions described herein may

141

be formulated as dispersible powders and granules suitable for preparation of a suspension by the addition of one or more excipients.

Excipients suitable for use in connection with suspensions include suspending agents, such as sodium carboxymethyl-cellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylenoxyethanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate); and thickening agents, such as carbomer, beeswax, hard paraffin, or cetyl alcohol. The suspensions may also contain one or more preservatives such as acetic acid, methyl and/or n-propyl p-hydroxy-benzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.

The pharmaceutical compositions described herein may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth; naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids; hexitol anhydrides, such as sorbitan monooleate; and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents. Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.

Additionally, the pharmaceutical compositions described herein may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous emulsion or oleaginous suspension. Such emulsion or suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,2-propanediol. The sterile injectable preparation may also be prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

The compounds described herein may be substantially insoluble in water and sparingly soluble in most pharmaceutically acceptable protic solvents and vegetable oils, but generally soluble in medium-chain fatty acids (e.g., caprylic and capric acids) or triglycerides and in propylene glycol esters of medium-chain fatty acids. Thus, contemplated in the description are compounds which have been modified by substitutions or additions of chemical or biochemical moieties which make them more suitable for delivery (e.g., increase solubility, bioactivity, palatability, decrease adverse reactions, etc.), for example by esterification, glycosylation, PEGylation, etc.

142

In certain aspects, the compound described herein is formulated for oral administration in a lipid-based composition suitable for low solubility compounds. Lipid-based formulations can generally enhance the oral bioavailability of such compounds. As such, pharmaceutical compositions described herein may comprise an effective amount of a compound of Formula (I) or a form thereof, together with at least one pharmaceutically acceptable excipient selected from medium chain fatty acids or propylene glycol esters thereof (e.g., propylene glycol esters of edible fatty acids such as caprylic and capric fatty acids) and pharmaceutically acceptable surfactants, such as polysorbate 20 or 80 (also referred to as Tween® 20 or Tween® 80, respectively) or polyoxyl 40 hydrogenated castor oil.

In other aspects, the bioavailability of low solubility compounds may be enhanced using particle size optimization techniques including the preparation of nanoparticles or nanosuspensions using techniques known to those skilled in the art. The compound forms present in such preparations include amorphous, partially amorphous, partially crystalline or crystalline forms.

In alternative aspects, the pharmaceutical composition may further comprise one or more aqueous solubility enhancer(s), such as a cyclodextrin. Nonlimiting examples of cyclodextrin include hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of α-, β-, and γ-cyclodextrin, and hydroxypropyl-β-cyclodextrin (HPBC). In certain aspects, the pharmaceutical composition further comprises HPBC in a range of from about 0.1% to about 20%, from about 1% to about 15%, or from about 2.5% to about 10%. The amount of solubility enhancer employed may depend on the amount of the compound in the composition.


Preparation of Compounds

General Synthetic Methods

As disclosed herein, general methods for preparing the compounds of Formula (I) or a form thereof as described herein are available via standard, well-known synthetic methodology. Many of the starting materials are commercially available or, when not available, can be prepared using the routes described below using techniques known to those skilled in the art. The synthetic schemes provided herein comprise multiple reaction steps, each of which is intended to stand on its own and can be carried out with or without any preceding or succeeding step(s). In other words, each of the individual reaction steps of the synthetic schemes provided herein in isolation is contemplated.

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocycl or heteroaryl ring systems, may be prepared as described in Scheme A below.



Scheme A



A1


143

-continued






Compound A1 (where X₁ and X₂ are independently bromine, chlorine and the like) is converted to Compound A2 by a nucleophilic substitution with a primary or secondary amine in the presence of a suitable base (such as K₂CO₃ and the like) in a suitable solvent (such as DMF and the like). Alternatively, Compound A1 is converted to Compound A2 via cross coupling with a primary or secondary amine (i.e., an R₁ substituent base) in the presence of a suitable catalyst (such as RuPhos Pd G2 and the like) and base (such as sodium tert-butoxide and the like) in an appropriate solvent (such as 1,4-dioxane and the like). Compound A2 is converted to Compound A3 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) (i.e., an R₂ substituted-boronic acid or ester) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) and base (such as aqueous K₂CO₃ and the like) in a suitable solvent (such as 1,4-dioxane and the like).

Compounds of Formula (I), wherein R₁ and R₂ are mono-40
cyclic or bicyclic heterocyclyl or heteroaryl ring systems,
may be prepared as described in Scheme B below.

Scheme B

Following conditions described in Scheme A, but switching the order of steps 1 and 2, compound B1 can be converted to compound A3.

Compounds of Formula (I), wherein R₁ and R₂ are mono-65
cyclic or bicyclic heterocyclyl or heteroaryl ring systems,
may be prepared as described in Scheme C below.

144Scheme C

Compound B1 (where X₁ is bromine, chlorine and the like) is converted to Compound C1 by a Suzuki coupling with an optionally substituted and appropriately protected amino-containing cycloalkyl/cycloalkenyl pinacol boronic ester (where Y is hydrogen or an optionally substituted alkyl group and P is a protecting group such as Boc and the like) (i.e., an R₁ substituted-boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) and base (such as aqueous K₂CO₃ and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound B1 is converted to Compound C1 by a Negishi coupling with an optionally substituted and appropriately protected amino-containing cycloalkyl zinc halide (i.e., an R₁ substituted-zinc halide) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) in a suitable solvent (such as 1,4-dioxane and the like).

145


like). Upon treatment with a deprotecting agent appropriate for the protecting group (such as HCl in dioxane for a Boc protecting group), Compound C1 is converted to Compound C2. Compound C2 is converted to Compound C3 by reductive amination with a suitable aldehyde and reducing agent (such as NaBH(OAc)₃ and the like) in a suitable solvent (such as 1,2-dichloroethane and the like). Alternatively, Compound C2 is converted to Compound C3 by alkylation with an alkyl halide (such as 2-iodopropane and the like) in

146

the presence of an appropriate base (such as K₂CO₃ and the like). In cases where unsaturation exists in the ring containing the basic amino group, the compound may be converted to the fully saturated analog under an atmosphere of H₂ in a suitable solvent (such as methanol and the like) and in the presence of catalyst (such as 10% Pd/C and the like).

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocycll or heteroaryl ring systems, may be prepared as described in Scheme D below.


Scheme D



147




Following the general conditions described in Scheme C, compound D1 can be converted to compound D5.

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocyclyl or heteroaryl ring systems, may be prepared as described in Scheme E below.


Scheme E

Following the general conditions described in Scheme A and/or Scheme C, compound A1 can be converted to compound E1.

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocyclyl or heteroaryl ring systems, may be prepared as described in Scheme F below.

Scheme F**148**


-continued



Compound F1 (where X is bromine, chlorine and the like) is converted to Compound F2 through a condensation with an optionally substituted N-Boc-piperidine-4-aldehyde (where Y is hydrogen or an optionally substituted alkyl group and P is a protecting group such as Boc and the like) in a suitable solvent (such as EtOH and the like). Compound F2 is converted to Compound F3 by reducing the nitro group with H₂ in the presence of a catalyst (such as PtO₂ and the like) in an appropriate solvent (such as EtOH and the like). Compound F3 is converted to Compound F4 through a cyclization/oxidation reaction with an appropriate oxidant (such as DDQ and the like) in an appropriate solvent (such as CH₃CN and the like). Compound F4 is converted to Compound F5 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid (or pinacol boronic ester) (i.e., an R₂ substituted-boronic acid or ester) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) and base (such as aqueous K₂CO₃ and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound F4 is converted to Compound F5 by treatment with pinacolato-diboron and a base (such as KOAc and the like) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) in an appropriate solvent (such as 1,4-dioxane and the like), followed by addition of an aryl- or heteroaryl-halide (i.e., an R₂ substituted-halide). Compound F5 is converted to Compound F6 upon treatment with conditions appropriate to the removal of the protecting group (such as TFA or HCl in dioxane for a Boc protecting group). Additional modification to the basic amino group can be achieved according to methods described in Scheme C.

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocyclyl or heteroaryl ring systems, may be prepared as described in Scheme G below.

149




Compound G1 (where X is bromine, chlorine and the like; Y is hydrogen or optionally substituted alkyl; and P is an appropriate protecting group) is converted to Compound G2 through a condensation/cyclization sequence in the presence of catalyst (such as CuI and the like), ligand (such as 1,10-phenanthroline and the like) and base (such as NaOt-Bu and the like) in an appropriate solvent (such as DMF and the like). Compound G2 is converted to Compound G3 by treatment with strong acid (conc. HCl and the like) in the presence of oxygen. Compound G3 is converted to Compound G4 by a Suzuki coupling with an aryl- or heteroaryl-

150

boronic acid (or pinacol boronic ester) (i.e., an R₂ substituted-boronic acid or ester) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) and base (such as aqueous K₂CO₃ and the like) in a suitable solvent (such as 1,4-dioxane and the like). Alternatively, Compound G3 is converted to Compound G4 by treatment with pinacolatodiboron and a base (such as KOAc and the like) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) in an appropriate solvent (such as 1,4-dioxane and the like), followed by addition of an aryl- or heteroaryl-halide (i.e., an R₂ substituted-halide). Compound G4 is converted to Compound G5 upon treatment with conditions appropriate to the removal of the protecting group (such as TFA or HCl in dioxane for a Boc protecting group). Additional modification to the basic amino group can be achieved according to methods described in Scheme C.

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocyclyl or heteroaryl ring systems, may be prepared as described in Scheme H below.

20




Compound H1 (where X₂ is bromine, chlorine and the like; and P is a protecting group such as tert-butyl and the like) is converted to Compound H2 by a Suzuki coupling with an aryl- or heteroaryl-boronic acid or ester (i.e., an R₂ substituted-boronic acid or ester) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) and base (such as aqueous K₂CO₃ and the like) in a suitable solvent (such as 1,4-dioxane and the like). Upon treatment with acid (such as TFA or HCl in dioxane and the like) Compound H2 is converted to Compound H3. Compound H3 is converted to Compound B1 (where X₁ is triflate and the like) by treatment with an activated triflate (such as Tf₂O or Tf₂NPh and the like) in the presence of base (such as K₂CO₃ or NaH and the like) in an appropriate solvent (such as THF or DMF and the like). Alternatively, Compound H3 can be converted to Compound B1 (where X₁ is Cl and the like) by treatment with a dehydrative halogenating agent (such as POCl₃ and

151

the like). Additional modification to the basic amino group can be achieved according to methods described in Scheme C.

Compounds of Formula (I), wherein R₁ and R₂ are monocyclic or bicyclic heterocycl or heteroaryl ring systems, may be prepared as described in Scheme I below.

Scheme I



Compound I1 (where X₁ is bromine, chlorine and the like; and P is a protecting group such as methyl and the like) is converted to Compound I2 by a Suzuki coupling with an optionally substituted and appropriately protected amino-containing cycloalkyl/cycloalkenyl pinacol boronic ester (where Y is hydrogen or an optionally substituted alkyl group and P is a protecting group such as Boc and the like) (i.e., an R₁ substituted-boronic ester) in the presence of a catalyst (such as Pd(dppf)Cl₂ and the like) and base (such as aqueous K₂CO₃ and the like) in a suitable solvent (such as 1,4-dioxane and the like). Compound I2 is converted to Compound E2 (where X₂ is triflate and the like) by treatment with an activated triflate (such as Tf₂O or Tf₂NPh and the like) in the presence of base (such as K₂CO₃ or NaH and the like) in an appropriate solvent (such as THF or DMF and the like). Additional modification to the basic amino group can be achieved according to methods described in Scheme C.

Specific Synthetic Examples

To describe in more detail and assist in understanding, the following non-limiting examples are offered to more fully

152

illustrate the scope of compounds described herein and are not to be construed as specifically limiting the scope thereof. Such variations of the compounds described herein that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the compounds as described herein and hereinafter claimed. These examples illustrate the preparation of certain compounds. Those of skill in the art will understand that the techniques described in these examples represent techniques, as described by those of ordinary skill in the art, that function well in synthetic practice, and as such constitute preferred modes for the practice thereof. However, it should be appreciated that those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific methods that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present description.

Other than in the following examples of the embodied compounds, unless indicated to the contrary, all numbers expressing quantities of ingredients, reaction conditions, experimental data, and so forth used in the specification and claims are to be understood as being modified by the term "about". Accordingly, all such numbers represent approximations that may vary depending upon the desired properties sought to be obtained by a reaction or as a result of variable experimental conditions. Therefore, within an expected range of experimental reproducibility, the term "about" in the context of the resulting data, refers to a range for data provided that may vary according to a standard deviation from the mean. As well, for experimental results provided, the resulting data may be rounded up or down to present data consistently, without loss of significant figures. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and rounding techniques used by those of skill in the art.

While the numerical ranges and parameters setting forth the broad scope of the present description are approximations, the numerical values set forth in the examples set forth below are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

COMPOUND EXAMPLES

50

As used above, and throughout the present description, the following abbreviations, unless otherwise indicated, shall be understood to have the following meanings:

Abbreviation	Meaning
Δ	heating (chemistry) or deletion (biology)
AcOH or HOAc	acetic acid
Ac ₂ O	acetic anhydride
Ag ₂ SO ₄	silver sulfate
Ar	argon
ACN or CH ₃ CN	acetonitrile
atm	atmosphere(s)
B ₂ pin ₂	bis(pinacolato)diboron
Boc	tert-butoxy-carbonyl
Boc ₂ O	di-tert-butyl dicarbonate
Br ₂	bromine

Abbreviation	Meaning
nBuLi	n-butyl lithium
iBuNO	isobutyl nitrite
BuOH	n-butanol
Bu ₃ SnCl	Tributylchlorostannane or tributyltin chloride
°C.	degrees Centigrade
Celite ® or Celite	diatomaceous earth
CO ₂ Cl ₂	oxalyl chloride
Cs ₂ CO ₃	cesium carbonate
CuI	copper (I) iodide
d/h/hr/hrs/min/s	day(d)/hour(h, hr or hrs)/minute(min)/second(s)
DCM or CH ₂ Cl ₂	dichloromethane
DDQ	2,3-dichloro-5,6-dicyano-p-benzoquinone
DIEA or DIPEA	N,N-diisopropylethylamine
DMA	dimethylacetamide
DMAP	4-(dimethylamino)pyridine or N,N-dimethylpyridin-4-amine
DMF	dimethylformamide
DMSO	dimethylsulfoxide
EtOAc	ethyl acetate
EtOH	ethanol
Et ₂ O	diethyl ether
Fe(acac) ₃	iron(III) acetylacetone
H ₂	hydrogen
HCl	hydrochloric acid
HI	hydriodic acid
H ₂ SO ₄	sulfuric acid
K ₂ CO ₃	potassium carbonate
KOAc	potassium acetate
KOtBu	Potassium t-butoxide
KOH	potassium hydroxide
K ₂ O ₈ O ₄ •2H ₂ O	potassium osmate(VI) dihydrate
LAH or LiAlH ₄	lithium aluminum hydride
Lawesson's reagent	2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide
LC/MS, LCMS or LC-MS	liquid chromatographic mass spectroscopy
LiOH	lithium hydroxide
MeOH	methanol
MeSO ₃ H	methanesulfonic acid
MgSO ₄	magnesium sulfate
MnO ₂	manganese dioxide
MS	mass spectroscopy
MsCl	methanesulfonyl chloride
NBS	N-bromosuccinimide
NEt ₃	triethylamine
NH ₄ Cl	ammonium chloride
NH ₄ OAc	ammonium acetate
NaBH ₄	sodium borohydride
NaBH(OAc) ₃	sodium triacetoxyborohydride
NaH	sodium hydride
NaHCO ₃	sodium bicarbonate
NaHMDS	sodium bis(trimethylsilyl)amide or sodium hexamethyldisilazide
NaH	sodium hydride
NaOH	sodium hydroxide
NaOMe	sodium methoxide
NaNO ₂	sodium nitrite
Na ₂ SO ₄	sodium sulfate
N ₂	nitrogen
NH ₄ Cl	ammonium chloride
NMO	4-methylmorpholine N-oxide
NMP	methylpyrrolidone
NMR	nuclear magnetic resonance
NOBF ₄	nitrosonium tetrafluoroborate or nitrosyl tetrafluoroborate
Pb(OAc) ₄	lead(IV) acetate or lead tetracetate
Pd	palladium
Pd/C	palladium on carbon
Pd(dppf)Cl ₂ or Pd(dppf)Cl ₂ —CH ₂ Cl ₂	[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane
PHBU ₃ BF ₄ or tBu ₃ PHBF ₄	tri-tert-butylphosphonium tetrafluoroborate
PhCH ₃	toluene
PhI	iodobenzene
PhI(OTFA) ₂	[bis(trifluoroacetoxy)iodo]benzene
PhMe	toluene
Ph—N(Tf) ₂ or PhN(Tf) ₂	N-phenyl triflimide, also referred to as N-phenyl-

155


-continued

156


Abbreviation	Meaning
POBr ₃	bis(trifluoromethanesulfonimide)
P ₂ O ₅	phosphoryl bromide or phosphorous(V) oxybromide
POCl ₃	phosphorous pentoxide or phosphorous(V) oxide
PhMe	phosphoryl chloride or phosphorous(V) oxychloride
Toluene	toluene
Psi	pounds per square inch pressure
Pt ₂ O	Platinum(IV) oxide
Rt or rt	room temperature
SEMCl	2-(trimethylsilyl)ethoxymethyl chloride
SnCl ₂	tin(II) chloride or stannous chloride
SOC ₂	thionyl chloride
S-Phos, SPhos or Sphos	2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
SPhos Pd G2	chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) tetrabutylammonium fluoride
TBAF	tert-butyldimethylsilyl fluoride
TBSCl	tert-butyldimethylsilyl chloride
TEA, Et ₃ N or NEt ₃	triethylamine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TIPS	triisopropylsilane
TLC	thin layer chromatography
TMEDA	tetramethylethylenediamine
TMS	trimethylsilyl
TMSCCH	trimethylsilylacetylene
t-Bu	tert-butyl
Zn(CN) ₂	zinc cyanide
ZnMe ₂	dimethyl zinc

Example 1

Preparation of Compound 11



-continued



Step A: 6-Bromo-2-chloro-quinoline (121 mg, 0.5 mmol) was combined with N,N,N',N''-pentamethylpiperidin-4-amine (170 mg, 0.95 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (2 mL) and the mixture was stirred at 100° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Cs₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-5% MeOH in CH₂Cl₂ to yield 6-bromo-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)quinolin-2-amine (480 mg, 65%). MS m/z 375.9, 377.9 [M+H]⁺.

Step B: 6-Bromo-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)quinolin-2-amine (40 mg, 0.11 mmol), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (51 mg, 0.15 mmol), and [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium(II) complex with dichloromethane (8 mg, 0.01 mmol) were combined with aqueous 1 M K₂CO₃ (0.5 mL, 0.5 mmol) and 1,4-dioxane (1 mL). The mixture was stirred at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2 N

157


NH_3) in CH_2Cl_2 to yield 6-(2,7-dimethyl-2H-indazol-5-yl)-N-methyl-N-(2,2,6,6-tetramethylpiperidin-4-yl)quinolin-2-amine (40 mg, 85%) as an off white solid.

MS m/z 442.1 [M+H]⁺; ¹H NMR (DMSO-d₆) δ : 8.35 (s, 1H), 8.11 (d, J=9.4 Hz, 1H), 8.01 (m, 1H), 7.89 (dd, J=9.0, 1.5 Hz, 1H), 7.83 (s, 1H), 7.58 (d, J=9.0 Hz, 1H), 7.46 (s, 1H), 7.13 (d, J=8.9 Hz, 1H), 5.24 (br, 1H), 4.20 (s, 3H), 2.99 (s, 3H), 2.59 (s, 3H), 1.69-1.01 (m, 16H).

Using the procedure described for Example 1, above, additional compounds described herein were prepared by substituting the appropriate boronic acid in Step B, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

158

-continued




Cpd Data

12 MS m/z 428.5 [M + H]⁺; ¹H NMR (DMSO-d₆) δ : 8.39 (s, 1H), 8.11 (d, J = 9.4 Hz, 1H), 8.00-8.05 (m, 2H), 7.91 (dd, J = 9.0, 1.5 Hz, 1H), 7.71-7.66 (m, 2H), 7.59 (d, J = 9.0 Hz, 1H), 7.13 (d, J = 8.9 Hz, 1H), 5.24 (br, 1H), 4.20 (s, 3H), 2.99 (s, 3H), 1.69-1.01 (m, 16H).

Example 2

Preparation of Compound 15



Step A: 6-Bromo-2-chloro-quinoline (242 mg, 1.0 mmol) was combined with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (45 mg, 0.05 mmol), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (350 mg, 1.0 mmol), 1,4-dioxane (5 mL) and aqueous 1 M K_2CO_3 (2.5 mL, 2.5 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in hexanes to yield 2-chloro-6-(2,7-dimethyl-2H-indazol-5-yl)quinoline (150 mg, 49%). MS m/z 308.0, 310.0 [M+H]⁺.

Step B: 2-Chloro-6-(2,7-dimethyl-2H-indazol-5-yl)quinoline (135 mg, 0.30 mmol) was combined with N-Boc-1, 2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (193 mg, 0.61 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (40 mg, 0.05 mmol), 1,4-dioxane (2.5 mL), and aqueous 1 M K_2CO_3 (1.2 mL, 1.2 mmol). The mixture was stirred at 90° C. for 2 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH in EtOAc to yield tert-butyl 4-[6-(2,7-dimethylindazol-5-yl)-2-quinolyl]-3,6-dihydro-2H-pyridine-1-carboxylate (135 mg, 61%). MS m/z 455.1 [M+H]⁺.

Step C: tert-Butyl 4-[6-(2,7-dimethylindazol-5-yl)-2-quinolyl]-3,6-dihydro-2H-pyridine-1-carboxylate (35 mg, 0.08 mmol) was combined with 10% Pd/C (10 mg) in MeOH (3 mL). The mixture was stirred under H_2 (1 atm) for 18 h. The mixture was filtered over Celite®. The filtrate was concentrated to yield tert-butyl 4-[6-(2,7-dimethylindazol-5-yl)-2-quinolyl]piperidine-1-carboxylate (35 mg, 99%). MS m/z 457.2 [M+H]⁺.

Step D: tert-Butyl 4-[6-(2,7-dimethylindazol-5-yl)-2-quinolyl]piperidine-1-carboxylate from Step C (35 mg, 0.077 mmol) was combined with TFA (1 mL). The solution stood for 20 min before the volatiles were removed with a stream of N_2 . The residue was partitioned between EtOAc and aqueous 1 M aqueous K_2CO_3 . The organic layer was collected and concentrated to yield 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline (25 mg, 91%).

MS m/z 357.1 [M+H]⁺; ¹H NMR (DMSO-d₆) δ : 8.40 (s, 1H), 8.33 (d, J=8.5 Hz, 1H), 8.23 (d, J=2.2 Hz, 1H), 8.09

159



(dd, $J=8.8, 2.2$ Hz, 1H), 7.99 (d, $J=8.8$ Hz, 1H), 7.93-7.97 (m, 1H), 7.50-7.57 (m, 1H), 7.48 (d, $J=8.5$ Hz, 1H), 4.21 (s, 3H), 3.05-3.11 (m, 2H), 2.92-2.99 (m, 1H), 2.61-2.68 (m, 2H), 2.61 (s, 3H), 1.81-1.88 (m, 2H), 1.69-1.79 (m, 2H), NH proton not observed.

Using the procedure described for Example 2, above, additional compounds described herein were prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
3	MS m/z 343.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.29 (br s, 1H), 9.19 (br s, 1H), 8.81 (br s, 1H), 8.47-8.52 (m, 2H), 8.33-8.40 (m, 2H), 8.21 (m, 1H), 7.73-7.80 (m, 3H), 4.22 (s, 3H), 3.54 (br s, 1H), 3.41-3.48 (m, 2H), 3.02-3.12 (m, 2H), 2.14-2.25 (m, 4H).

Example 3

Preparation of Compound 13



Step A: 2,2,6,6-Tetramethylpiperidin-4-one (3.1 g, 20 mmol) was dissolved in THF (100 mL) and cooled to -78°C. NaHMDS (21 mL, 21 mmol, 1.0 M in THF) was added to the solution. The mixture was stirred for 15 min at -78°C. N,N-bis(trifluoromethylsulfonyl)aniline (7.8 g, 22 mmol) was added to the mixture as a solid. The mixture was allowed to warm to room temperature before being quenched with aqueous saturated NaHCO₃. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with aqueous 2 M KOH, dried over Na₂SO₄,

160

filtered and concentrated to yield 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate (6.0 g, 100%).

¹H NMR (acetone-d₆) δ: 10.28 (br s, 1H), 6.13 (s, 1H), 2.85 (br s, 2H), 1.76 (s, 6H), 1.68 (s, 6H).



Step B: (2,2,6,6-Tetramethyl-1,3-dihydropyridin-4-yl) trifluoromethanesulfonate (100 mg, 0.35 mmol) was combined with bis(pinacolato)diboron (125 mg, 0.50 mmol), potassium acetate (100 mg, 1.0 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane

²⁰ complex (12 mg, 0.015 mmol) and 1,4-dioxane (2.4 mL). The mixture was stirred at 90°C for 2 h. The mixture was cooled to room temperature. To the mixture was added aqueous 1 M K₂CO₃ (1 mL, 1 mmol), 2-chloro-6-(2,7-dimethylindazol-5-yl)quinoline (100 mg, 0.30 mmol, prepared according to Example 2, Step A) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (12 mg, 0.015 mmol). The mixture was stirred at 80°C for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to yield 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)quinoline (90 mg, 46%).

MS m/z 411.5 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.41 (s, 1H), 8.34 (d, $J=8.5$ Hz, 1H), 8.24 (d, $J=2.2$ Hz, 1H), 8.10 (dd, $J=8.8, 2.2$ Hz, 1H), 8.02 (d, $J=8.8$ Hz, 1H), 7.93-7.97 (m, 1H), 7.88 (d, $J=8.8$ Hz, 1H), 7.54 (t, $J=1.6$ Hz, 1H), 6.78-6.82 (m, 1H), 4.21 (s, 3H), 2.61 (s, 3H), 2.50 (m, 2H), 1.49 (s, 1H), 1.26 (s, 6H), 1.17 (s, 6H).

Example 4

Preparation of Compound 14




161

6-(2,7-Dimethylindazol-5-yl)-2-(2,2,6,6-tetramethyl-1,3-dihydropyridin-4-yl)quinoline (20 mg, 0.05 mmol) was combined with 10% Pd/C (10 mg) in MeOH (2 mL). The mixture was stirred under H₂ (1 atm) at room temperature for 6 h. The mixture was then filtered over Celite. The filtrate was concentrated to yield 6-(2,7-dimethyl-2H-indazol-5-yl)-2-(2,2,6,6-tetramethylpiperidin-4-yl)quinoline (20 mg, 99%).

MS m/z 413.5 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.40 (s, 1H), 8.34 (d, J=8.5 Hz, 1H), 8.23 (d, J=2.2 Hz, 1H), 8.09 (dd, J=8.8, 2.2 Hz, 1H), 8.01 (d, J=8.8 Hz, 1H), 7.93-7.95 (m, 1H), 7.49-7.53 (m, 2H), 4.21 (s, 3H), 2.61 (s, 3H), 1.73-1.79 (m, 2H), 1.47-1.55 (m, 2H), 1.27 (s, 6H), 1.11 (s, 6H), NH proton not observed.

Example 5

Preparation of Compound 20

**162**

Step A: 6-Bromo-2-chloro-8-fluoro-quinoline (52 mg, 0.2 mmol) was combined with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (8 mg, 0.01 mmol), 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (54 mg, 0.2 mmol), 1,4-dioxane (1 mL) and aqueous 1 M K₂CO₃ (0.5 mL, 0.5 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in hexanes to yield 2-chloro-6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoroquinoline (25 mg, 38%). MS m/z 326.2, 328.2 [M+H]⁺.

Step B: Zinc powder (5 g, 76 mmol) was suspended in N,N-dimethylacetamide (10 mL) under argon. A mixture of 1,2-dibromoethane (520 μL, 6.02 mmol) and chlorotrimethylsilsilane (730 μL, 5.74 mmol) was added dropwise over 10 min. Over the course of the addition the internal temperature rose to 50° C. The reaction mixture was allowed to cool to room temperature. A solution of tert-butyl 4-iodopiperidin-1-carboxylate (16.5 g, 53.0 mmol) in N,N-dimethylacetamide (26 mL) was added dropwise over 20 min. The reaction mixture was filtered through Celite in a Schlenk filter to yield roughly 50 mL of ~1M (1-tert-butoxycarbonyl-4-piperidyl)-iodo-zinc solution. 2-Chloro-6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoroquinoline (25 mg, 0.077 mmol) was combined with the 1-Cert-butoxycarbonylpiperidin-4-ylzinc iodide solution (0.25 mL, 0.25 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (4 mg, 0.005 mmol) and 1,4-dioxane (1 mL). The mixture was stirred at 80° C. for 2 h. The mixture was cooled to room temperature. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH in EtOAc to yield tert-butyl 4-[6-(2,7-dimethylindazol-5-yl)-8-fluoro-2-quinolyl]piperidine-1-carboxylate (30 mg, 82%). MS m/z 475.4 [M+H]⁺.

Step C: tert-Butyl 4-[6-(2,7-dimethylindazol-5-yl)-8-fluoro-2-quinolyl]piperidine-1-carboxylate (30 mg, 0.06 mmol) was combined with TFA (1 mL). After 10 min, the volatiles were removed. The mixture was partitioned between CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was loaded onto silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to yield 6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoro-2-(piperidin-4-yl)quinoline (20 mg, 85%).

MS m/z 375.3 [M+H]⁺; ¹H NMR (acetone-d₆) δ: 8.22 (dd, J=8.7, 1.7 Hz, 1H), 8.14 (s, 1H), 7.88 (d, J=2.2 Hz, 1H), 7.79-7.81 (m, 1H), 7.70 (dd, J=12.5, 2.0 Hz, 1H), 7.42 (d, J=8.5 Hz, 1H), 7.36-7.40 (m, 1H), 4.12 (s, 3H), 2.99-3.06 (m, 2H), 2.87-2.93 (m, 1H), 2.58-2.65 (m, 2H), 2.52 (s, 3H), 1.67-1.81 (m, 4H), NH proton not observed.



Using the procedure described for Example 5, above, additional compounds described herein were prepared by substituting the indicated starting material in Step A, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd Starting Material and Data

- 23 Starting material: 6-bromo-2-chloroquinazoline
MS m/z 358.3 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 9.59 (s, 1H), 8.43 (s, 1H), 8.40 (s, 1H), 8.36 (dd, J = 8.5, 1.9 Hz, 1H), 7.98-8.02 (m, 2H), 7.54 (s, 1H), 4.22 (s, 3H), 3.29-3.35 (m, 2H), 2.86-2.94 (m, 1H), 3.01-3.09 (m, 2H), 2.61 (s, 3H), 1.90-1.96 (m, 2H), 1.75-1.84 (m, 2H), NH proton not observed.
- 30 Starting material: 7-bromo-3-chloroisoquinoline
MS m/z 357.3 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 9.32 (s, 1H), 8.41 (s, 1H), 8.38 (s, 1H), 8.13 (dd, J = 8.5, 1.9 Hz, 1H), 7.98 (d, J = 8.8 Hz, 1H), 7.96-7.97 (m, 1H), 7.64 (s, 1H), 7.54 (t, J = 1.6 Hz, 1H), 4.21 (s, 3H), 3.09-3.15 (m, 2H), 2.86-2.94 (m, 1H), 2.66-2.74 (m, 2H), 2.61 (s, 3H), 1.87-1.93 (m, 2H), 1.69-1.78 (m, 2H), NH proton not observed.

Example 6

Preparation of Compound 72



Step A: Methyl cyanoacetate (5.71 g, 57.6 mmol) was added to a mixture of DMSO (30 mL) and NaH (60 mass %) in mineral oil (2.3 g, 57.6 mmol) at 0°C. The mixture was stirred at 0°C. for 15 min. 5-Chloro-2,3-difluoro-benzonitrile (5.0 g, 28.8 mmol) in DMSO (5 mL) was added to the mixture. The mixture was stirred at room temperature for 30 min and then heated to 90°C. for 4 h. The mixture was cooled to room temperature and diluted with H₂O (200 mL), brine (100 mL) and

EtOAc (200 mL). A precipitate formed and was collected by vacuum filtration. The solid was washed with H₂O and dried to yield methyl 2-(4-chloro-2-cyano-6-fluoro-phenyl)-2-cyano-acetate (6 g, 82%) as a tan powder. MS m/z 251.1, 253.1 [M-H]⁻.

Step B: Methyl 2-(4-chloro-2-cyano-6-fluoro-phenyl)-2-cyano-acetate (5.5 g, 22 mmol) was combined with aqueous concentrated HCl (40 mL) and 1,4-dioxane (20 mL). The mixture was heated at 80°C. for 4 h. The mixture was cooled to room temperature and filtered. The solid was washed with H₂O and CH₃CN, and then dried to yield 7-chloro-5-fluoro-4H-isoquinoline-1,3-dione (3.0 g, 65%) as an off white solid. MS m/z 214.1, 216.1 [M+H]⁺.

Step C: 7-Chloro-5-fluoro-4H-isoquinoline-1,3-dione (3.0 g, 14.0 mmol) was combined with POCl₃ (20 mL, 212

165

mmol). The mixture was heated at 110° C. for 2 h and then 90° C. overnight. The mixture was cooled to room temperature and then poured onto ice with vigorous stirring. The solid material was collected by vacuum filtration, dried, and chromatographed on silica gel, eluting with CH₂Cl₂ to afford 1,3,7-trichloro-5-fluoro-isoquinoline (1.3 g, 37%) as a white powder. MS m/z 250.2, 252.2, 254.2 [M+H]⁺.

Step D: 1,3,7-Trichloro-5-fluoro-isoquinoline (1.3 g, 5.2 mmol) was combined with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (210 mg, 0.26 mmol), TMEDA (0.77 mL, 5.2 mmol) and THF (20 mL). To the mixture was added sodium borohydride (378 mg, 10 mmol). The mixture was stirred at room temperature for 30 min, and then was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% EtOAc in CH₂Cl₂ to yield 3,7-dichloro-5-fluoro-isoquinoline (870 mg, 78%) as a white solid.

MS m/z 216.2, 218.2, 220.2 [M+H]⁺; ¹H NMR (acetone-d₆) δ: 9.26 (m, 1H), 8.16 (m, 1H), 8.00 (s, 1H), 7.72 (dd, J=9.8, 1.9 Hz, 1H).

Step E: 3,7-Dichloro-5-fluoro-isoquinoline (432 mg, 2.0 mmol) was combined with N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (610 mg, 2.4 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (50 mg, 0.06 mmol), 1,4-dioxane (6 mL) and aqueous 1 M K₂CO₃ (4 mL, 4 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 0-30% EtOAc in hexanes to yield tert-butyl 4-(7-chloro-5-fluoro-3-isoquinolyl)-3,6-dihydro-2H-pyridine-1-carboxylate (370 mg, 51%) as an off-white solid. MS m/z 362.2, 364.2 [M-F1-1]⁺.

Step F: 6-Chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine hydrochloride (62 mg, 0.28 mmol, prepared according to the procedure in Example 11) was combined with KOAc (83 mg, 0.85 mmol), 1,1'-bis(diphenylphosphino) ferrocene-palladium(II)dichloride dichloromethane complex (23 mg, 0.03 mmol), bis(pinacolato) diboron (91 mg, 0.36 mmol) and

166

late (100 mg, 0.28 mmol). The mixture was stirred under N₂ for 1 h at 80° C. The mixture was partitioned between EtOAc and H₂O. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 5-10-100% EtOAc in CH₂Cl₂ then 5% MeOH in EtOAc to yield tert-butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-isoquinolyl]-3,6-dihydro-2H-pyridine-1-carboxylate (90 mg, 69%) as a white solid. MS m/z 474.5 [M+H]⁺.

Step G: tert-Butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-isoquinolyl]-3,6-dihydro-2H-pyridine-1-carboxylate (90 mg, 0.19 mmol) was combined with 10% Pd/C (20 mg) in MeOH (3 mL). The mixture was stirred under H₂ (1 atm) for 2 h at 40° C. The mixture was filtered through a syringe filter. The filtrate was concentrated. The residue was chromatographed on silica gel, eluting with 40-100% EtOAc in hexanes to yield tert-butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-isoquinolyl]piperidine-1-carboxylate (52 mg, 57%) as an off-white solid. MS m/z 476.3 [M+H]⁺.

Step H: tert-Butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-isoquinolyl]piperidine-1-carboxylate (52 mg, 0.11 mmol) was combined with 4 N HCl in 1,4-dioxane (2 mL, 8 mmol). The mixture was stirred and sonicated and room temperature. After 1 h, the volatiles were removed. The residue was suspended in CH₃CN, sonicated and filtered. The solid was dried to give 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(4-piperidyl)isoquinoline hydrochloride (36 mg, 46%) as a yellow solid.

MS m/z 376.5 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.58 (s, 1H), 9.14-9.22 (br, 1H), 8.96-9.05 (br, 1H), 8.89 (s, 1H), 8.48-8.53 (m, 2H), 8.34 (dd, J=11.6, 1.5 Hz, 1H), 7.84 (s, 1H), 3.39-3.45 (m, 2H), 3.25-3.31 (m, 1H), 3.02-3.12 (m, 2H), 2.79 (s, 3H), 2.60 (s, 3H), 2.07-2.17 (m, 4H).

Using the procedure described for Example 6, above, additional compounds described herein were prepared by substituting the appropriate boronic acid in Step F, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
71	MS m/z 375.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.56 (s, 1H), 9.12-9.20 (br, 1H), 8.89-8.98 (br, 1H), 8.89 (s, 1H), 8.43-8.48 (m, 2H), 8.34 (d, J = 12.2 Hz, 1H), 7.84 (s, 1H), 7.58 (s, 1H), 4.22 (s, 3H), 3.39-3.46 (m, 2H), 3.27-3.34 (m, 1H), 3.02-3.12 (m, 2H), 2.61 (s, 3H), 2.05-2.20 (m, 4H).

1,4-dioxane (1.5 mL). The mixture was stirred under N₂ at 100° C. for 2 h. To the mixture was added 1 M K₂CO₃ (aq) (0.75 mL, 0.75 mmol), followed by 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (11 mg, 0.014 mmol) and tert-butyl 4-(7-chloro-5-fluoro-3-isoquinolyl)-3,6-dihydro-2H-pyridine-1-carboxylate

Using the procedure described for Example 6, Steps E-H, above, additional compounds described herein were prepared by substituting the appropriate starting material in Step E, appropriate boronic acid in Step F, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Starting Material and Data
1	Starting material: 6-bromo-2-chloroquinoline MS m/z 343.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.75-8.80 (br, 2H), 8.64 (s, 1H), 8.54 (s, 1H), 8.47-8.50 (m, 1H), 8.22-8.26 (m, 2H), 8.07-8.10 (m, 1H), 7.83 (s, 1H), 7.70-7.76 (m, 2H), 4.22 (s, 3H), 3.42-3.48 (m, 2H), 3.05-3.14 (m, 3H), 2.07-2.12 (m, 2H), 1.87-1.95 (m, 2H).
10	Starting material: 6-bromo-2-chloroquinazoline MS m/z 344.1 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.67 (s, 1H), 9.03-9.12 (br s, 2H), 9.00 (s, 1H), 8.55 (s, 1H), 8.44-8.47 (m, 1H), 8.02-8.05 (m, 1H), 7.91-7.96 (m,

167

-continued



Cpd Starting Material and Data

2H), 7.71-7.74 (m, 1H), 4.21 (s, 3H), 3.40-3.44 (m, 2H), 3.03-3.11 (m, 3H), 1.98-2.09 (m, 4H).

168

Example 7

Preparation of Compound 74



Step A: 1,2-Difluoro-3-nitro-benzene (23 g, 145 mmol) was combined with Ag_2SO_4 (45.2 g, 145 mmol) in H_2SO_4 (150 mL). The mixture was stirred for 5 min at room temperature. To the mixture was added Br_2 (11.2 mL, 217 mmol). The mixture was stirred at room temperature for 16 h, and then was poured into ice water (800 mL). The mixture was extracted with Et_2O (3×500 mL). The combined organics were dried, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-30% CH_2Cl_2 in hexanes to yield 5-bromo-1,2-difluoro-3-nitro-benzene (18.8 g, 55%) as a white crystalline solid.

^1H NMR (acetone- d_6) δ : 8.20 (ddd, $J=5.8, 2.4, 2.2$ Hz, 1H), 8.12 (ddd, $J=9.2, 6.5, 2.2$ Hz, 1H).

Step B: 5-Bromo-1,2-difluoro-3-nitro-benzene (15 g, 63 mmol), dimethyl malonate (12.5 g, 95 mmol), Cs_2CO_3 (41.1 g, 126 mmol), and DMF (63 mL) were stirred at rt for 6 h. The reaction mixture was partitioned between aqueous 1 M HCl and EtOAc. The organic layer was washed with brine, dried over Na_2SO_4 and concentrated. The residue was combined with AcOH (30 mL) and conc. HCl (30 mL) and heated at 110°C for 16 h. The mixture was diluted with H_2O to form a precipitate. The solid was collected by vacuum filtration, washed with H_2O , washed with 1:1

169

hexane/ether and dried to afford 2-(4-bromo-2-fluoro-6-nitro-phenyl)acetic acid (14.5 g, 83%) as a white solid.

¹H NMR (acetone-d₆) δ: 11.28 (br s, 1H), 8.16 (t, J=1.5 Hz, 1H), 7.92 (dd, J=9.0, 1.5 Hz, 1H), 4.06 (s, 2H).

Step C: 2-(4-Bromo-2-fluoro-6-nitro-phenyl)acetic acid (14.5 g, 52 mmol) was suspended in CH₂Cl₂ (250 mL). Oxalyl chloride (7 mL, 79 mmol) was added to the mixture followed by DMF (0.1 mL, 1 mmol). The mixture was stirred at room temperature for 1 h, and then added dropwise to MeOH at 0° C. The volatiles were removed under vacuum to yield methyl 2-(4-bromo-2-fluoro-6-nitro-phenyl)acetate (15 g, 98%) as an off-white solid.

¹H NMR (acetone-d₆) δ: 8.16 (t, J=1.5 Hz, 1H), 7.93 (dd, J=9.0, 1.5 Hz, 1H), 4.05 (s, 2H), 3.71 (s, 3H).

Step D: Methyl 2-(4-bromo-2-fluoro-6-nitro-phenyl)acetate (15 g, 51 mmol) was suspended in a mixture of MeOH (200 mL) and NH₄Cl (55 g, 1.03 mol) at 0° C. Zinc powder (16.8 g, 257 mmol) was added in one portion. The mixture was stirred at room temperature for 4 h, and then was filtered through Celite. The filtrate was concentrated and then partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated to yield methyl 2-(2-amino-4-bromo-6-fluoro-phenyl)acetate (12.6 g, 94%) as a white solid. MS m/z 262.0, 264.0 [M+H]⁺.

Step E: Methyl 2-(2-amino-4-bromo-6-fluoro-phenyl)acetate (12.6 g, 48 mmol) was suspended in CH₂Cl₂ (150 mL) at 0° C. Nitrosonium tetrafluoroborate (8.4 g, 72 mmol) was added in one portion to the mixture. The mixture was stirred at 0° C. for 1 h. The mixture was added directly to a vigorously stirred mixture of SnCl₂ dihydrate (43.8 g, 194 mmol) in conc. HCl (200 mL) at 0° C. The mixture was allowed to slowly warm to room temperature with stirring. After 24 h, the mixture was filtered. The solid was washed with H₂O and ether, and then dried to yield 1-amino-6-bromo-4-fluoro-indolin-2-one (9.0 g, 76%) as a white solid. MS m/z 244.9, 246.9 [M]⁺.

Step F: 1-Amino-6-bromo-4-fluoro-indolin-2-one (9.0 g, 37 mmol) was suspended in CH₂Cl₂ (500 mL) at 0° C. Pb(OAc)₄ (22.8 g, 51.4 mmol) was added to the mixture in one portion. The mixture was stirred at room temperature for 16 h. MeOH (50 mL) was added to the mixture, and the mixture was eluted through a pad of silica gel. The filtrate was concentrated and chromatographed on silica gel, eluting with 0-100% EtOAc in CH₂Cl₂ to yield 7-bromo-5-fluoro-cinnolin-3-ol (3.5 g, 39%) as a yellow powder. MS m/z 241.1, 243.1 [M-H]⁻.

Step G: 7-Bromo-5-fluoro-cinnolin-3-ol (3.5 g, 14 mmol) was suspended in POCl₃ (28 mL, 300 mmol). The mixture was stirred at 100° C. for 4 h in a sealed tube. The mixture was cooled to room temperature and quenched onto ice. The ice water was extracted with CH₂Cl₂ (2×). The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% EtOAc in CH₂Cl₂ to yield 7-bromo-3-chloro-5-fluorocinnoline (2.6 g, 69%) as an off white powder. MS m/z 261.1, 263.1, 265.1 [M+H]⁺.

Step H: 7-Bromo-3-chloro-5-fluoro-cinnoline (785 mg, 3.00 mmol) was combined with (2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)boronic acid (3.6 mmol, prepared according to the procedure in Example 11), chloro(2-dicyclohex-

170

ylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (108 mg, 0.15 mmol), 1,4-dioxane and aqueous 1 M K₂CO₃ (10 mL, 10 mmol). The mixture was stirred at 50° C. for 2 h. The mixture was partitioned between EtOAc and H₂O, then filtered through Celite. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 40-100% EtOAc in hexanes followed by 5% MeOH in EtOAc to yield 3-chloro-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnoline (605 mg, 62%) as a tan solid. MS m/z 328.2, 330.2 [M+H]⁺.

Step I: 3-Chloro-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnoline (400 mg, 1.2 mmol) was combined with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (50 mg, 0.06 mmol), N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (462 mg, 1.47 mmol), 1,4-dioxane (6 mL) and aqueous 1 M K₂CO₃ (3 mL, 3.0 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 40-100% EtOAc in hexanes, then 5% MeOH in EtOAc to yield tert-butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (430 mg, 74%) as a tan solid. MS m/z 475.5 [M+H]⁺.

Step J: tert-Butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (430 mg, 0.91 mmol) was combined with 10% Pd/C (500 mg) in MeOH:EtOAc (1:1) (25 mL). The mixture was stirred under H₂ (1 atm) for 3 h at 40° C. The mixture was filtered through a syringe filter and the filtrate was concentrated. The residue was dissolved in CH₂Cl₂ (2 mL). MnO₂ (20 equiv.) was added to the solution. The mixture was stirred at room temperature for 30 min and then filtered through Celite. The filtrate was concentrated. The residue was chromatographed on silica gel, eluting with 40-100% EtOAc in hexanes to yield tert-butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (200 mg, 46%) as an off-white solid. MS m/z 477.5 [M+H]⁺.

Step K: tert-Butyl 4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (200 mg, 0.42 mmol) was combined with 4 N HCl in 1,4-dioxane (1 mL, 4 mmol). The mixture was stirred at room temperature for 1 h. The volatiles were removed with a stream of N₂. The residue was suspended in CH₃CN, sonicated and filtered. The solid was dried to give 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(4-piperidyl)cinnoline hydrochloride (190 mg, quant.) as an off white solid.

MS m/z 377.3 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.13 (s, 1H), 8.84 (br, 1H), 8.58 (br, 1H), 8.32-8.41 (m, 3H), 8.20 (s, 1H), 3.55-3.62 (m, 1H), 3.47-3.53 (m, 2H), 3.11-3.20 (m, 2H), 2.71 (s, 3H), 2.52 (s, 3H), 2.16-2.30 (m, 4H).

Using the procedure described for Example 7, above, additional compounds described herein were prepared by substituting the appropriate boronic acid or boronic acid equivalent in Step H or I, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
73	MS m/z 376.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.02-9.10 (br, 1H), 8.75-8.84 (br, 1H), 8.64 (s, 1H), 8.48 (s, 1H), 8.34 (dd, J = 11.4, 1.4 Hz, 1H), 8.16-8.19 (m, 1H), 8.10 (s, 1H), 7.68 (s, 1H), 4.23 (s, 3H), 3.51-3.59 (m, 1H), 3.43-3.50 (m, 2H), 3.08-3.18 (m, 2H), 2.62 (s, 3H), 2.18-2.28 (m, 4H).
84	MS m/z 359.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.26 (s, 1H), 8.71 (dd, J = 8.5, 1.5 Hz, 1H), 8.58 (s, 1H), 8.44 (s, 1H), 8.40 (s, 1H), 8.32 (d, J = 8.5 Hz, 1H), 3.61-3.69 (m, 3H), 2.45-2.55 (m, 2H - overlaps with residual solvent peak), 2.88 (s, 3H), 2.72 (s, 3H), 2.30-2.50 (m, 4H). NH proton not observed.
87	MS m/z 405.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.13 (s, 1H), 8.59 (s, 1H), 8.40-8.45 (m, 2H), 8.32 (s, 1H), 4.04 (m, 1H), 3.91 (t, J = 12.5 Hz, 1H), 3.79 (br s, 1H), 2.87 (s, 3H), 2.70 (s, 3H), 2.38-2.50 (m, 2H), 2.24 (d, J = 14 Hz, 1H), 2.06 (q, J = 14 Hz, 1H), 1.65 (d, J = 7 Hz, 3H), 1.45 (d, J = 6 Hz, 3H). NH and HCl protons not observed.
90	MS m/z 405.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.88 (s, 1H), 8.28 (d, J = 10 Hz, 1H), 8.14 (s, 1H), 7.98 (s, 1H), 7.85 (s, 1H), 3.48 (tt, J = 10, 3 Hz, 1H), 2.98-3.04 (m, 2H), 2.71 (s, 3H), 2.51 (s, 3H), 2.13 (d, J = 15 Hz, 2H), 1.55 (q, J = 12 Hz, 2H), 1.26 (d, J = 7 Hz, 6H). NH proton not observed.
129	MS m/z 391.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.96 (s, 1H), 8.36 (dd, J = 11 Hz, 1H), 8.23 (s, 1H), 8.02 (s, 1H), 7.90 (s, 1H), 3.60-3.71 (m, 2H), 3.37-3.52 (m, 3H), 2.74 (s, 3H), 2.42-2.55 (m, 5H), 2.30-2.40 (m, 1H), 2.05-2.30 (m, 3H), NH proton not observed.
130	MS m/z 433.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.91 (s, 1H), 8.30 (dd, J = 11, 1.5 Hz, 1H), 8.18 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 3.62-3.71 (m, 1H), 3.16-3.20 (m, 1H), 2.95-3.02 (m, 1H), 2.73 (s, 3H), 2.51 (s, 3H), 2.21 (d, J = 12.5 Hz, 1H), 2.07-2.16 (m, 2H), 1.89 (pentet, J = 7.5 Hz, 2H), 1.46-1.60 (m, 3H), 1.00-1.08 (m, 6H). NH proton not observed.
143	MS m/z 363.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.00 (s, 1H), 8.39 (d, J = 11 Hz, 1H), 8.34 (s, 1H), 8.03 (s, 1H), 7.92 (s, 1H), 4.24 (septet, J = 7.5 Hz, 1H), 3.91 (d, J = 7.5 Hz, 2H), 3.68-3.75 (m, 1H), 3.54-3.61 (m, 1H), 2.70-2.78 (m, 4H), 2.53 (s, 3H), 2.45-2.52 (m, 1H), NH proton not observed.
169	MS m/z 403.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.13 (s, 1H), 8.56 (s, 1H), 8.52 (s, 1H), 8.40 (m, 2H), 4.18 (br s, 2H), 3.87 (m, 1H), 3.12 (d, J = 15 Hz, 2H), 2.85 (s, 3H), 2.60-2.70 (m, 5H), 1.96 (m, 2H), 1.80-1.84 (m, 2H).
210	MS m/z 362.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.76 (s, 1H), 8.88 (s, 1H), 8.83-8.86 (m, 1H), 8.30 (s, 1H), 8.14 (s, 1H), 8.07 (d, J = 9.5 Hz, 1H), 7.72 (d, J = 9.5 Hz, 1H), 3.61-3.64 (m, 2H), 3.23-3.31 (m, 3H), 2.63 (s, 3H), 2.28-2.35 (m, 2H), 2.07-2.18 (m, 2H), NH and HCl protons not observed.
216	MS m/z 377.3 [M + H] ⁺ ; ¹ H NMR (methanol-d) δ 9.15 (s, 1 H), 8.55 (s, 1 H), 8.44 (br d, J = 10.8 Hz, 1 H), 8.41 (s, 1 H), 8.39 (s, 1 H), 3.83-3.45 (m, 5 H), 2.86 (s, 3 H) 2.69 (s, 3 H) 2.33-2.42 (m, 1 H) 2.02-2.19 (m, 3 H), NH and HCl protons not observed.

Boronic acid or bornic acid equivalents for use in Step H or I were prepared according to the following procedures:

Example 7-1

rac-(2R,6R)-1-Benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate and rac-(2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate

Step A: 3-Oxopentanedioic acid (20.5 g, 140 mmol) and acetaldehyde (15.7 mL, 279 mmol) were suspended in H₂O (50 mL). The mixture was stirred with a strong stir bar at room temperature for 10 min. The mixture was then cooled in an ice bath. Benzylamine (15.3 mL, 140 mmol) was added dropwise. The mixture became thick. Stirring was continued at room temperature for 5 days. Aqueous 6N HCl was added. The mixture was stirred at room temperature for 1 h. The mixture was then made basic with aqueous K₂CO₃, and washed 3 times with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. Purification by silica gel chromatography (10-20% EtOAc in hexanes) yielded 6.6 g (17% total yield) of a mixture of rac-(2R,6R)-1-benzyl-2,6-dimethylpiperidin-4-one and (2S,6R)-1-benzyl-2,6-dimethylpiperidin-4-one. These two components readily interconvert one to the other.

Step B: A roughly 2:3 ratio of rac-(2R,6R)-1-benzyl-2,6-dimethylpiperidin-4-one and (2S,6R)-1-benzyl-2,6-dimethylpiperidin-4-one (4.45 g, 18.4 mmol) was dissolved in THF (12.8 mL) at -78° C. NaHMDS (2M in THF, 13.1 mL, 26.2

mmol) was added dropwise. The mixture was stirred at -78° C. for 3 h. N,N-Bis(trifluoromethylsulfonyl)aniline (9.25 g, 20.5 mmol) was added to the mixture in one portion. The mixture was slowly warmed to room temperature over 15 h. THF was removed from the mixture under vacuum. The product mixture was diluted with CH₂Cl₂ and was filtered through a plug of silica to remove solid impurities. The filtrate was concentrated under vacuum. The residue was dissolved in EtOAc. This solution was washed with dilute aqueous NaOH (ca. 800 mL) and then with brine. The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography (50-100% CH₂Cl₂ in hexanes) yielding trans-isomer rac-(2R,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate (1.5 g, 23%) as the higher Rf component. ¹H NMR (acetone-d₄) δ: 7.37-7.40 (m, 2H), 7.30-7.35 (m, 2H), 7.22-7.27 (m, 1H), 5.87 (s, 1H), 3.76 (d, J=14.5 Hz, 1H), 3.58 (d, J=14.5 Hz, 1H), 3.30-3.42 (m, 2H), 2.41-2.50 (m, 1H), 2.24-2.30 (m, 1H), 1.20-1.25 (m, 6H). The cis-isomer rac-(2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate (2.1 g, 33%) was collected as the lower Rf component.

¹H NMR (acetone-d₄) δ: 7.37-7.40 (m, 2H), 7.30-7.35 (m, 2H), 7.20-7.25 (m, 1H), 5.85 (s, 1H), 3.87 (d, J=16 Hz, 1H), 3.82 (d, J=16 Hz, 1H), 3.50-3.57 (m, 1H), 3.16-3.22 (m, 1H), 2.49-2.57 (m, 1H), 2.24-2.30 (m, 1H), 1.22 (d, J=7 Hz, 3H), 1.17 (d, J=6.5 Hz, 3H).

173

Example 7-2

(2R,6R)-1-Benzyl-2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine

5

Potassium acetate (1.8 g, 18 mmol) was dried under Ar at 180° C. for 30 min and then cooled to room temperature. To the solid was added rac-(2S,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate (1.5 g, 4.3 mmol, prepared according to Example 36), Pd(dppf)Cl₂ (146 mg, 0.175 mmol), dppf (110 mg, 0.19 mmol), bis(pinacolato)diboron (1.2 g, 4.7 mmol), and 1,4-dioxane (14.5 mL). The mixture was heated at 80° C. for 15 h. The reaction mixture was then diluted in EtOAc and filtered through Celite. The filtrate was concentrated under vacuum. The residue was dissolved in EtOAc and washed with 800 mL of dilute aqueous NaHCO₃ and brine. The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. The residue was dissolved in ether and filtered through Celite to remove brown insoluble impurities. The filtrate was concentrated to afford (2S,6R)-1-benzyl-2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine (1.43 g, 80% pure, 81% yield) as a crude black oil.

¹H NMR (acetone-d₄) δ: 7.40-7.45 (m, 2H), 7.25-7.32 (m, 2H), 7.16-7.21 (m, 1H), 6.31 (s, 1H), 3.80 (m, 2H), 3.20-3.28 (m, 1H), 2.73-2.79 (m, 1H), 2.12-2.19 (m, 1H), 1.90-1.98 (m, 1H), 1.35 (s, 12H), 1.22 (d, J=5.5 Hz, 3H), 1.00 (d, J=6.5 Hz, 3H).

Example 7-3

(2R,6R)-1-Benzyl-2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine was prepared from rac-(2R,6R)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl trifluoromethanesulfonate according to Example 7-2

¹H NMR (acetone-d₄) δ: 7.40-7.45 (m, 2H), 7.25-7.32 (m, 2H), 7.16-7.21 (m, 1H), 6.38 (s, 1H), 3.62 (m, 2H), 3.12-3.21 (br s, 1H), 3.00-3.08 (m, 1H), 2.12-2.21 (m, 1H), 1.90-1.98 (m, 1H), 1.27 (s, 12H), 1.22 (m, 6H).


Example 7-4

(2R,6R)-1-Benzyl-2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine was prepared by substituting the appropriate acetaldehyde in Step A of Example 7-1

¹H NMR (acetone-d₄) δ: 7.40-7.45 (m, 2H), 7.25-7.32 (m, 2H), 7.16-7.21 (m, 1H), 6.38 (s, 1H), 3.62 (m, 2H), 3.12-3.21 (br s, 1H), 3.00-3.08 (m, 1H), 2.12-2.21 (m, 1H), 1.90-1.98 (m, 1H), 1.27 (s, 12H), 1.22 (m, 6H).


Example 8

Preparation of Compound 34

**174**

-continued

5



55

Step A: 2-Amino-5-bromo-3-fluoro-benzoic acid (1.0 g, 4.27 mmol) was dissolved in THF (20 mL). To the solution was added LAH (8.5 mL, 8.5 mmol, 1.0 M in THF) at 0° C. The mixture was warmed to room temperature. After 1 h, the mixture was quenched with aqueous 2 N NaOH at 0° C. After vigorous stirring for 30 min, the mixture was filtered over Celite. The filter cake was washed with THF and MeOH. The combined filtrate was concentrated to yield (2-amino-5-bromo-3-fluoro-phenyl)methanol (900 mg, 96%). MS m/z 220.2, 222.2 [M+H]⁺.

175

Step B: (2-Amino-5-bromo-3-fluoro-phenyl)methanol (900 mg, 4.09 mmol) was combined with MnO₂ (6.9 g, 79 mmol) in CH₂Cl₂ (20 mL). The mixture was stirred at room temperature for 1 h. The mixture was filtered over Celite. The filtrate was concentrated to yield 2-amino-5-bromo-3-fluoro-benzaldehyde (650 mg, 73%). MS m/z 218.1, 220.1 [M+H]⁺.

Step C: 2-Amino-5-bromo-3-fluoro-benzaldehyde (650 mg, 3.0 mmol) was combined with urea (3.6 g, 60 mmol) and DMSO (3 mL). The mixture was stirred at 180° C. for 2 h. The mixture was cooled to room temperature, upon which H₂O (10 mL) was added. The precipitate was collected, washed with H₂O and dried to yield 6-bromo-8-fluoro-quinazolin-2-ol (615 mg, 85%). MS m/z 243.1, 245.1 [M+H]⁺.

Step D: 6-Bromo-8-fluoro-quinazolin-2-ol (615 mg, 2.53 mmol) was combined with POCl₃ (5 mL, 53 mmol). The mixture was stirred at 110° C. for 2 h. The mixture was cooled to room temperature and poured over ice. After vigorously stirring for 15 min, the solid was collected, dried

176

and chromatographed on silica gel, eluting with 0-20% EtOAc in CH₂Cl₂ to yield 6-bromo-2-chloro-8-fluoroquinazoline (345 mg, 52%). MS m/z 261.1, 263.1, 265.1 [M+H]⁺.

Steps E-G: Following a procedure similar to that found in Example 5 (Steps A-C), 6-bromo-2-chloro-8-fluoroquinazoline was converted to 6-(2,7-dimethyl-2H-indazol-5-yl)-8-fluoro-2-(piperidin-4-yl)quinazoline hydrochloride.

10 MS m/z 376.3 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.70 (s, 1H), 8.86-8.93 (br, 1H), 8.54-8.63 (br, 1H), 8.46 (s, 1H), 8.34 (d, J=1.9 Hz, 1H), 8.32 (dd, J=12.10, 1.9 Hz, 1H), 8.07 (s, 1H), 7.57 (s, 1H), 4.22 (s, 3H), 3.36-3.44 (m, 3H), 3.08-3.16 (m, 2H), 2.61 (s, 3H), 2.22-2.28 (m, 2H), 2.08-2.15 (m, 2H).

Using the procedure described for Example 8, above, additional compounds described herein were prepared by substituting the appropriate boronic acid in Step E, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd Data

- 35 MS m/z 387.3 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 9.69 (d, J = 1.6 Hz, 1H), 8.79-8.85 (br, 1H), 8.78 (s, 1H), 8.67 (d, J = 1.9 Hz, 1H), 8.49-8.55 (br, 1H), 8.48 (d, J = 1.7 Hz, 1H), 8.47 (d, J = 1.8 Hz, 1H), 8.43 (dd, J = 12.2, 1.8 Hz, 1H), 4.30 (s, 3H), 3.37-3.46 (m, 3H), 3.07-3.17 (m, 2H), 2.22-2.28 (m, 2H), 2.07-2.16 (m, 2H).
- 36 MS m/z 380.3 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 9.69 (s, 1H), 8.73-8.79 (br, 1H), 8.63 (d, J = 1.9 Hz, 1H), 8.43-8.52 (br, 1H), 8.40 (d, J = 1.8 Hz, 1H), 8.37 (dd, J = 12.3, 1.8 Hz, 1H), 8.13 (d, J = 1.8 Hz, 1H), 7.65 (dd, J = 12.2, 1.9 Hz, 1H), 4.25 (s, 3H), 3.37-3.46 (m, 3H), 3.08-3.18 (m, 2H), 2.22-2.28 (m, 2H), 2.05-2.14 (m, 2H).
- 37 MS m/z 377.3 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 9.83 (s, 1H), 8.85-8.91 (br, 1H), 8.83 (d, J = 1.9 Hz, 1H), 8.59-8.64 (br, 1H), 8.56 (dd, J = 12.3, 1.8 Hz, 1H), 8.42 (s, 1H), 8.31 (s, 1H), 3.58 (s, 3H), 3.39-3.47 (m, 3H), 3.08-3.18 (m, 2H), 2.74 (s, 3H), 2.23-2.30 (m, 2H), 2.07-2.15 (m, 2H).

Using the procedure described for Example 8, above, 45 additional compounds described herein were prepared by substituting the indicated starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:


Cpd Starting Material and Data

- 38 Starting material: 6-amino-3-bromo-2-fluorobenzoic acid
MS m/z 376.4 [M + H]⁺; ¹H NMR (methanol-d₄) δ: 8.70 (s, 1H), 7.94 (s, 1H), 7.81-7.86 (m, 1H), 7.58-7.61 (m, 1H), 7.47 (d, J = 8.5 Hz, 1H), 6.37 (s, 1H), 4.40 (s, 3H), 3.63-3.70 (m, 3H), 3.21-3.29 (m, 2H), 2.69 (s, 3H), 2.29-2.40 (m, 4H) NH proton not observed.
- 39 Starting material: 2-amino-5-bromo-4-fluorobenzoic acid
MS m/z 376.3 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 8.77 (s, 1H), 7.98 (s, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.63-7.68 (m, 1H), 7.43 (d, J = 10.4 Hz, 1H), 6.27 (s, 1H), 4.42 (s, 3H), 3.63-3.70 (m, 3H), 3.24-3.31 (m, 2H), 2.69 (s, 3H), 2.28-2.45 (m, 4H), NH proton not observed.

177

Example 9

Preparation of Compound 17



Step A: 4-Bromo-2-nitroaniline (3.7 g, 17 mmol), cyanoamide (5.72 g, 135 mmol) and Et₂O (3 mL) were combined in a 75 mL tube. The mixture was stirred at 100° C. for 30 min. The mixture was cooled to 50° C. To the mixture was slowly added aqueous concentrated HCl (7.2 mL). The resulting mixture was stirred for 1 h at 110° C. The reaction

178

mixture was again cooled to 50° C., before adding aqueous 7.5 M NaOH (16 mL). The mixture was again heated to 110° C. for 1 h. After cooling to room temperature, 20 mL of H₂O was added to the mixture. The solid material was collected, washed with H₂O and dried to yield 7-bromo-1-oxido-1,2,4-benzotriazin-1-iium-3-amine (3.2 g, 79%). MS m/z 240.8, 242.8 [M+H]⁺.

Step B: To a solution of 7-bromo-1-oxido-1,2,4-benzotriazin-1-iium-3-amine (3.2 g, 13 mmol) and TFA (25 mL) was added NaNO₂ (2.76 g, 40.0 mmol) in small portions at room temperature. The mixture stirred at room temperature for 30 min. To the mixture was added H₂O (75 mL) to form a white precipitate. The solid was collected, washed with H₂O and dried. The solid was combined with POCl₃ (30 mL, 318.6 mmol). The mixture was stirred at 110° C. for 2 h. After cooling to room temperature, the mixture was poured onto ice with vigorous stirring. After stirring for 10 min, CH₂Cl₂ (400 mL) was added. The organic phase was collected and dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% EtOAc in CH₂Cl₂ to yield 7-bromo-3-chloro-1-oxido-1,2,4-benzotriazin-1-iium (2.37 g, 54%). MS m/z 259.9, 261.9, 264.0 [M+H]⁺.

Step C: 7-Bromo-3-chloro-1-oxido-1,2,4-benzotriazin-1-iium (520 mg, 2.0 mmol) was combined with N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (773 mg, 2.45 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (80 mg, 0.10 mmol), 1,4-dioxane (10 mL), and aqueous 1 M K₂CO₃ (5 mL, 5.0 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in hexanes to yield tert-butyl 4-(3-chloro-1-oxido-1,2,4-benzotriazin-1-iium-7-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (540 mg, 75%). MS m/z 307.1, 309.1 [M+H-tBu]⁺ (molecule ionizes as M+H minus tBu).

Step D: tert-Butyl 4-(3-chloro-1-oxido-1,2,4-benzotriazin-1-iium-7-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (72 mg, 0.20 mmol) was combined with 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (80 mg, 0.30 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (8 mg, 0.01 mmol), 1,4-dioxane (1 mL), and aqueous 1 M K₂CO₃ (0.5 mL, 0.5 mmol). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 5% MeOH in EtOAc to yield tert-butyl 4-[3-(2,7-dimethylindazol-5-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (72 mg, 77%). MS m/z 473.4 [M+H]⁺.

Step E: tert-Butyl 4-[3-(2,7-dimethylindazol-5-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (60 mg, 0.13 mmol) was combined with 10% Pd/C (10 mg) and MeOH (3 mL). The mixture was stirred under H₂ (1 atm) for 2 h at 30° C. The mixture was filtered through a 0.2 μm syringe filter to yield tert-butyl 4-[3-(2,7-dimethylindazol-5-yl)-1,2,4-benzotriazin-7-yl]piperidine-1-carboxylate (58 mg, 99%). MS m/z 459.4 [M+H]⁺.

Step F: tert-Butyl 4-[3-(2,7-dimethylindazol-5-yl)-1,2,4-benzotriazin-7-yl]piperidine-1-carboxylate (58 mg, 0.13 mmol) was dissolved in TFA (1 mL). After 20 min, the volatiles were removed from the mixture. The residue was partitioned between EtOAc and aqueous 1 M K₂CO₃. The

179

organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2 N NH_3) in CH_2Cl_2 to yield 3-(2,7-dimethyl-2H-indazol-5-yl)-7-(piperidin-4-yl)benzo[e][1,2,4]triazine (20 mg, 44%).

MS m/z 359.3 [M+H] $^+$; ^1H NMR (DMSO-d₆) δ : 9.01 (s, 1H), 8.59 (s, 1H), 8.31 (s, 1H), 8.26 (s, 1H), 8.06-8.12 (m, 2H), 4.24 (s, 3H), 3.11-3.19 (m, 2H), 2.94-3.01 (m, 1H), 2.68-2.76 (m, 2H), 2.64 (s, 3H), 1.88-1.94 (m, 2H), 1.66-1.76 (m, 2H), NH proton not observed.

5


Using the procedure described for Example 9, above, additional compounds described herein were prepared by substituting the appropriate boronic acid in Steps B and/or C, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

10

Cpd	Data
25	MS m/z 363.3 [M + H] $^+$; ^1H NMR (DMSO-d ₆) δ : 9.03 (s, 1H), 8.76 (d, J = 2.7 Hz, 1H), 8.31 (s, 1H), 8.16 (dd, J = 13.0, 1.2 Hz, 1H), 8.10-8.14 (m, 2H), 4.24 (s, 3H), 3.14-3.20 (m, 2H), 2.97-3.05 (m, 1H), 2.71-2.79 (m, 2H), 1.90-1.97 (m, 2H), 1.69-1.79 (m, 2H), NH proton not observed.
26	MS m/z 370.3 [M + H] $^+$; ^1H NMR (methanol-d ₄) δ : 9.48 (d, J = 1.6 Hz, 1H), 9.05 (d, J = 1.6 Hz, 1H), 8.68 (s, 1H), 8.36 (s, 1H), 8.09-8.17 (m, 2H), 4.36 (s, 3H), 3.35-3.42 (m, 2H), 3.11-3.20 (m, 1H), 2.97-3.05 (m, 2H), 2.11-2.19 (m, 2H), 1.89-1.99 (m, 2H), NH proton not observed.
27	MS m/z 359.3 [M + H] $^+$; ^1H NMR (methanol-d ₄) δ : 9.52 (s, 1H), 8.29 (s, 1H), 8.18 (s, 1H), 8.01-8.07 (m, 2H), 7.73 (s, 1H), 3.27-3.32 (m, 2H), 3.03-3.10 (m, 1H), 2.88-2.94 (m, 2H), 2.63 (s, 3H), 2.45 (s, 3H), 2.04-2.09 (m, 2H), 1.81-1.91 (m, 2H), NH proton not observed.
43	MS m/z 363.3 [M + H] $^+$; ^1H NMR (DMSO-d ₆) δ : 9.78 (s, 1H), 8.36 (s, 1H), 8.10-8.17 (m, 3H), 8.04 (dd, J = 12.2, 1.3 Hz, 1H), 3.09-3.15 (m, 2H), 2.94-3.01 (m, 1H), 2.66-2.72 (m, 2H), 2.42 (s, 3H), 1.87-1.93 (m, 2H), 1.64-1.74 (m, 2H), NH proton not observed.
52	MS m/z 375.4 [M + H] $^+$; ^1H NMR (DMSO-d ₆) δ : 8.78 (s, 1H), 8.57 (s, 1H), 8.31 (s, 1H), 8.07-8.12 (m, 2H), 7.82 (s, 1H), 4.21 (s, 3H), 4.07 (s, 3H), 3.10-3.17 (m, 2H), 2.93-2.99 (m, 1H), 2.66-2.73 (m, 2H), 1.87-1.93 (m, 2H), 1.65-1.75 (m, 2H), NH proton not observed.
56	MS m/z 389.2 [M + H] $^+$; ^1H NMR (methanol-d ₄) δ : 10.01 (s, 1H), 8.88-8.92 (m, 1H), 8.75 (s, 1H), 8.36 (dd, J = 9.0, 2.2 Hz, 1H), 8.30-8.33 (m, 1H), 8.24-8.27 (m, 1H), 4.18-4.28 (m, 2H), 3.61-3.69 (m, 1H), 2.58-2.74 (m, 5H), 2.20-2.33 (m, 4H), 2.08-2.13 (m, 2H), NH proton not observed.


180

-continued




Example 10

Preparation of Compound 28



181

-continued



Step A: 1-(1H-Pyrrol-2-yl)ethanone (1.09 g, 10.0 mmol) was dissolved in 50 mL CH₂Cl₂ and cooled to -78° C. A solution of Br₂ (620 μL, 12.1 mmol) in 12 mL of CH₂Cl₂ was added dropwise to the solution. The reaction mixture was poured onto ice. The organic layer was washed with aqueous 1M NaOH, dried over MgSO₄, filtered and concentrated to yield 1-(4-bromo-1H-pyrrol-2-yl)ethanone (1.42 g, 76%).

¹H NMR (acetone-d₆) δ: 11.08 (br s, 1H), 7.19 (m, 1H), 7.02 (m, 1H), 2.34 (s, 3H).

Step B: 1-(4-Bromo-1H-pyrrol-2-yl)ethanone (1.36 g, 7.2 mmol) was dissolved in DMF (15 mL) and cooled to 0° C. To the solution was added NaH (60 mass % in mineral oil) (316 mg, 7.9 mmol). The mixture was warmed to room temperature for 30 min. Chloroacetone (0.6 mL, 7 mmol) was added dropwise. The mixture was stirred at room temperature for 16 h. The mixture was partitioned between H₂O and EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 30% EtOAc in hexanes to yield 1-(2-acetyl-4-bromo-pyrrol-1-yl)propan-2-one (1.2 g, 68%) as a white solid.

¹H NMR (acetone-d₆) δ: 7.13 (d, J=2 Hz, 1H), 7.10 (d, J=2 Hz, 1H), 5.17 (s, 2H), 2.36 (s, 3H), 2.18 (s, 3H).

Step C: 1-(2-Acetyl-4-bromo-pyrrol-1-yl)propan-2-one (1.15 g, 4.7 mmol), acetic acid (40 mL) and ammonium acetate (7.2 g, 93 mmol) were heated at 120° C. for 16 h. The volatiles were removed under reduced pressure. The residue was partitioned between aqueous 1 M NaOH and EtOAc. The organic layer was dried over MgSO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-50% EtOAc in CH₂Cl₂ to yield 7-bromo-1,3-dimethyl-pyrrolo[1,2-a]pyrazine (975 mg, 92%).

¹H NMR (acetone-d₆) δ: 7.86 (s, 1H), 7.63 (s, 1H), 6.84 (s, 1H), 2.56 (s, 3H), 2.31 (s, 3H).

Step D: 7-Bromo-1,3-dimethylpyrrolo[1,2-a]pyrazine (2.0 g, 8.9 mmol) was dissolved in THF (90 mL). The solution was cooled to -78° C., upon which n-butyllithium was added (6.7 mL, 13.3 mmol, 2 M solution in cyclohexane). The mixture was stirred at -78° C. for 30 min. To the mixture was added tributylchlorostannane. The mixture was allowed to slowly warm to 0° C. The excess reagent was quenched with saturated aqueous NH₄Cl. The mixture was partitioned between EtOAc and H₂O. The organic layer was dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tributyl-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)stannane (1.3 g, 30%).

¹H NMR (chloroform-d) δ: 7.53 (s, 1H), 7.20 (s, 1H), 6.72 (s, 1H), 2.65 (s, 3H), 2.37 (s, 3H), 1.52-1.58 (m, 6H), 1.30-1.38 (m, 6H), 1.04-1.08 (m, 6H), 0.88-0.94 (m, 9H).

Step E: tert-Butyl 4-(3-chloro-1-oxido-1,2,4-benzotriazin-4-iium-7-yl)-3,6-dihydro-2H-pyridine-1-carboxylate

182

(72 mg, 0.20 mmol, prepared according to the procedure in Example 9, Step C) was combined with tributyl-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)stannane (140 mg, 0.32 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (12 mg, 0.015 mmol), 1,4-dioxane (1.5 mL) and aqueous 1 M K₂CO₃ (0.75 mL, 0.75 mmol). The mixture was stirred at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 50-100% EtOAc in CH₂Cl₂, then EtOAc containing 5% MeOH to yield tert-butyl 4-[3-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (50 mg, 53%). MS m/z 473.5 [M+M]⁺.


Step F: tert-Butyl 4-[3-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (30 mg, 0.06 mmol) was combined with 10% Pd/C (10 mg) in EtOAc:MeOH (1:1, 2 mL). The mixture was stirred under H₂ (1 atm) for 2 h at 40° C. The mixture was filtered through a 2 μm syringe filter. The filtrate was concentrated to yield tert-butyl 4-(3-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)benzo[e][1,2,4]triazin-7-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (25 mg, 86%). MS m/z 457.5 [M+H]⁺.

Step G: tert-Butyl 4-[3-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-1-oxido-1,2,4-benzotriazin-7-yl]piperidine-1-carboxylate (25 mg, 0.05 mmol) was dissolved in TFA (1 mL). After 15 min, the volatiles were removed. The residue was partitioned between CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was loaded on silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to yield 3-(1,3-dimethylpyrrolo[1,2-a]pyrazin-7-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)benzo[e][1,2,4]triazine (8 mg, 43%).

¹H NMR (DMSO-d₆) δ: 8.34 (s, 1H), 8.25 (s, 1H), 8.23 (dd, T=9.0, 2.0 Hz, 1H), 7.90 (d, T=8.8 Hz, 1H), 7.86 (s, 1H), 7.57 (s, 1H), 6.62 (s, 1H), 3.58-3.62 (m, 2H), 3.15-3.19 (m, 2H), 2.64-2.70 (m, 5H), 2.35 (s, 3H), NH proton not observed.


Example 11

Preparation of Compound 44



183

-continued



Step A: 4-Bromo-6-chloro-pyridazin-3-amine (5.2 g, 25 mmol) was combined with tetrakis(triphenylphosphine)palladium(0) (700 mg, 0.61 mmol) and DMF (50 mL). To the mixture was added dimethylzinc in heptane (50 mL, 50 mmol, 1.0 M) at room temperature. The mixture was heated at 50°C for 2 h then 70°C for 1 h. The mixture was cooled to 0°C, and excess reagent was quenched by the addition of H₂O. The mixture was filtered over Celite and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH in CH₂Cl₂. MS m/z 144.2, 146.2 [M+H]⁺.

Step B: 6-Chloro-4-methyl-pyridazin-3-amine (3.5 g, 24 mmol) was combined with ethanol (40 mL), triethylamine (8.7 mL, 62 mmol) and chloroacetone (4 mL, 49 mmol) in a 100 mL high pressure flask. The flask was sealed and heated behind a blast shield at 150°C for 45 min. The mixture was concentrated and chromatographed on silica gel, eluting with 30-80% EtOAc in CH₂Cl₂ to yield 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine (2.2 g, 49%). MS m/z 182.3, 184.3 [M+H]⁺.

Step C: 6-Chloro-2,8-dimethyl-imidazo[1,2-b]pyridazine (54 mg, 0.30 mmol) was combined with potassium acetate (87 mg, 0.89 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (12 mg, 0.015 mmol), and bis(pinacolato)diboron (94 mg, 0.37 mmol) in 1,4-dioxane (1 mL). The mixture was stirred under N₂ at 95°C for 2 h to yield (2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)boronic acid. MS m/z 192.4 [M+H]⁺. The crude mixture was used directly in the next step.

184

Step D: To the crude mixture from Step C was added aqueous 1 M K₂CO₃ (0.75 mL, 0.75 mmol), tert-butyl 4-(3-chloro-1-oxido-1,2,4-benzotriazin-1-iium-7-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (72 mg, 0.20 mmol, prepared according to the procedure in Example 9, Step C), and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (8 mg, 0.01 mmol). The mixture was stirred at 80°C for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-80% EtOAc in CH₂Cl₂ to yield tert-butyl 4-[3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (69 mg, 73%). MS m/z 474.4 [M+H]⁺.


Step E: tert-Butyl 4-[3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (69 mg, 0.15 mmol) was combined with 10% Pd/C (20 mg) in MeOH (2 mL). The mixture was stirred under H₂ (1 atm) for 2 h at 40°C. The mixture was filtered. The filtrate was concentrated and chromatographed on silica gel, eluting with 20-100% EtOAc in hexanes to yield tert-butyl 4-[3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (69 mg, 97%). MS m/z 460.4 [M+H]⁺.


Step F: tert-Butyl 4-[3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-1-oxido-1,2,4-benzotriazin-1-iium-7-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (69 mg, 0.15 mmol) was suspended in 4 N HCl in 1,4-dioxane (1 mL, 4 mmol). The volatiles were removed after 30 min. The residue was partitioned between CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to yield 3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(piperidin-4-yl)benzo[e][1,2,4]triazine.

MS m/z 360.4 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.47 (s, 1H), 8.32 (s, 1H), 8.18-8.25 (m, 2H), 8.10 (s, 1H), 3.35-3.40 (m, 2H), 3.15-3.22 (m, 1H), 2.96-3.04 (m, 2H), 2.78 (s, 3H), 2.56 (s, 3H), 2.12-2.18 (m, 2H), 1.89-1.99 (m, 2H), NH proton not observed.

Example 12

Preparation of Compound 16



185**186**


7-dimethylindazol-5-yl)-1,2,4-benzotriazin-3-yl]piperidine-1-carboxylate (100 mg, 50%). MS m/z 459.1 [M+H]⁺.

Step D: tert-Butyl 4-[7-(2,7-dimethylindazol-5-yl)-1,2,4-benzotriazin-3-yl]piperidine-1-carboxylate (50 mg, 0.11 mmol) was dissolved in TFA (1 mL). After 20 min, the volatiles were removed from the reaction mixture. The residue was partitioned between CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was loaded directly to silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to yield 7-(2,7-dimethyl-2H-indazol-5-yl)-3-(piperidin-4-yl)benzo[e][1,2,4]triazine (30 mg, 77%).

MS m/z 359.1 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.77 (d, J=2.5 Hz, 1H), 8.56 (dd, J=9.0, 1.9 Hz, 1H), 8.47 (s, 1H), 8.12-8.18 (m, 2H), 7.66 (s, 1H), 4.23 (s, 3H), 3.40-3.47 (m, 1H), 3.08-3.15 (m, 2H), 2.69-2.76 (m, 2H), 2.63 (s, 3H), 2.00-2.07 (m, 2H), 1.83-1.92 (m, 2H), NH proton not observed.

Example 13

Preparation of Compound 46




Step A: 7-Bromo-3-chloro-1-oxido-1,2,4-benzotriazin-1-ium (260 mg, 1.0 mmol, prepared in Example 9 Step B) was combined with 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-indazole (360 mg, 1.06 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (45 mg, 0.05 mmol), 1,4-dioxane (5 mL) and aqueous 1 M K₂CO₃ (2.5 mL). The mixture was stirred at 70° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-90% EtOAc in hexanes to yield 3-chloro-7-(2,7-dimethyl-2H-indazol-5-yl)benzo[e][1,2,4]triazine-1-oxide (200 mg, 54%). MS m/z 326.0, 328.0 [M+H]⁺.

Step B: 3-Chloro-7-(2,7-dimethyl-2H-indazol-5-yl)benzo[e][1,2,4]triazine-1-oxide (200 mg, 0.54 mmol) was combined with N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (250 mg, 0.80 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (40 mg, 0.05 mmol), 1,4-dioxane (3 mL) and aqueous 1 M K₂CO₃ (1.5 mL, 1.5 mmol). The mixture was stirred at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in hexanes to yield tert-butyl 4-[7-(2,7-dimethylindazol-5-yl)-1-oxido-1,2,4-benzotriazin-1-ium-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (200 mg, 78%). MS m/z 473.1 [M+H]⁺.

Step C: tert-Butyl 4-[7-(2,7-dimethylindazol-5-yl)-1-oxido-1,2,4-benzotriazin-1-ium-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (200 mg, 0.085 mmol) was combined with 10% Pd/C (40 mg) in MeOH (5 mL). The mixture was stirred under H₂ (1 atm) for 2 h at 40° C. The mixture was filtered through a 2 μm syringe filter. The filtrate was concentrated and chromatographed on silica gel, eluting with 10-100% EtOAc in CH₂Cl₂ to yield tert-butyl 4-[7-(2,

187

-continued



Step A: 5-Bromo-1,3-difluoro-2-nitro-benzene (9.52 g, 40.0 mmol) was dissolved in EtOH (50 mL). To the solution was added hydrazine monohydrate (16.6 mL, 160 mmol). The solution was stirred at room temperature for 24 h. The mixture was concentrated under reduced pressure. The residue was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-30% EtOAc in hexanes to yield (5-bromo-3-fluoro-2-nitrophenyl)hydrazine (8.5 g, 85%). MS m/z 250.2, 252.2 [M+H]⁺.

Step B: (5-Bromo-3-fluoro-2-nitrophenyl)hydrazine (1.25 g, 5.0 mmol) and tert-butyl 4-formylpiperidine-1-carboxylate (3.2 g, 15 mmol) were combined in EtOH (25 mL). The mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in CH₂Cl₂ to yield tert-butyl (E)-4-((2-(5-bromo-3-fluoro-2-nitrophenyl)hydrazono)methyl)piperidine-1-carboxylate (2.2 g, 99%) MS m/z 443.1, 445.4 [M-H]⁻.

Step C: tert-Butyl (E)-4-((2-(5-bromo-3-fluoro-2-nitrophenyl)hydrazono)methyl)piperidine-1-carboxylate (2.2 g, 4.9 mmol) was suspended in EtOH (50 mL) with PtO₂ (100 mg, 0.4402 mmol). The mixture was stirred under H₂ (1 atm, balloon) at room temperature for 3 h. The reaction mixture was filtered over Celite. The filtrate was concentrated under reduced pressure to yield tert-butyl (E)-4-((2-(2-amino-5-bromo-3-fluorophenyl)hydrazono)methyl)piperidine-1-carboxylate (2.03 g, 98%). MS m/z 413.3, 415.3 [M-H]⁻.

Step D: tert-Butyl 4-(7-bromo-5-fluoro-1,2,3,4-tetrahydro-1,2,4-benzotriazin-3-yl)piperidine-1-carboxylate (2.03 g, 4.9 mmol) was dissolved in CH₃CN (40 mL, 765 mmol). To the mixture was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (3.41 g, 15.0 mmol). The mixture was

188

stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The residue was suspended in CH₂Cl₂ and filtered. The filtrate was concentrated and chromatographed on silica gel, eluting with 0-30% EtOAc in hexanes to yield tert-butyl 4-(7-bromo-5-fluorobenzo[e][1,2,4]triazin-3-yl)piperidine-1-carboxylate (805 mg, 39%). MS m/z 411.2, 413.2 [M+H]⁺.

Step E: tert-Butyl 4-(7-bromo-5-fluorobenzo[e][1,2,4]triazin-3-yl)piperidine-1-carboxylate (500 mg, 1.22 mmol) was combined with KOAc (358 mg, 3.65 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (100 mg, 0.12 mmol), bis(pinacolato)diboron (386 mg, 1.52 mmol) and 1,4-dioxane (3 mL). The mixture was stirred at 100° C. for 2 h. After cooling the mixture to room temperature, aqueous 1 M K₂CO₃ (1.5 mL, 1.5 mmol), 6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine (270 mg, 1.22 mmol, prepared according the procedure in Example 11), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (100 mg, 0.12 mmol) were added. The mixture was stirred at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 20-80% EtOAc in hexanes to yield tert-butyl 4-(7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorobenzo[e][1,2,4]triazin-3-yl)piperidine-1-carboxylate (550 mg, 94%). MS m/z 478.6 [M+H]⁺.

Step F: tert-Butyl 4-(7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorobenzo[e][1,2,4]triazin-3-yl)piperidine-1-carboxylate (67 mg, 0.14 mmol) was suspended in 4 N HCl in 1,4-dioxane (2 mL, 8 mmol). The mixture was stirred vigorously for 1 h. The solid was collected, washed with CH₃CN, and dried to afford 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)benzo[c][1,2,4]triazine hydrochloride (46 mg, 73%).

MS m/z 378.3 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.24 (s, 1H), 8.68 (d, J=10.6 Hz, 1H), 8.60 (s, 1H), 8.44 (s, 1H), 3.91 (m, 1H), 3.59-3.67 (m, 2H), 3.34-3.42 (m, 2H), 2.87 (s, 3H), 2.70 (s, 3H), 2.53-2.61 (m, 2H), 2.32-2.43 (m, 2H), NH proton not observed.


Using the procedure described for Example 13, above, additional compounds described herein were prepared by substituting the appropriate aryl halide in Step E, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
32	MS m/z 381.1 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.67-8.69 (m, 1H), 8.49 (d, J = 2.8 Hz, 1H), 8.34 (dd, J = 11.0, 1.9 Hz, 1H), 8.12 (d, J = 1.6 Hz, 1H), 7.63 (dd, J = 12.6, 1.6 Hz, 1H), 4.31 (s, 3H), 3.83-3.90 (m, 1H), 3.60-3.67 (m, 2H), 3.32-3.38 (m, 2H), 2.52-2.59 (m, 2H), 2.32-2.42 (m, 2H), NH proton not observed.
33	MS m/z 377.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.69 (d, J = 1.9 Hz, 1H), 8.47-8.52 (m, 2H), 8.20-8.23 (m, 1H), 7.69-7.71 (m, 1H), 4.23 (s, 3H), 3.44-3.51 (m, 1H), 3.10-3.15 (m, 2H), 2.69-2.77 (m, 2H), 2.62 (s, 3H), 2.03-2.08 (m, 2H), 1.83-1.92 (m, 2H), NH proton not observed.
58	MS m/z 381.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.42 (s, 1H), 9.02-9.09 (br, 1H), 8.95 (s, 1H), 8.74-8.82 (br, 1H), 8.58 (dd, J = 13.0, 1.2 Hz, 1H), 8.30-8.37 (m, 1H), 8.07 (s, 1H), 3.77-3.84 (m, 1H), 3.43-3.49 (m, 2H), 3.14-3.24 (m, 2H), 2.51 (s, 3H), 2.33-2.39 (m, 2H), 2.17-2.27 (m, 2H).
59	MS m/z 408.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.35 (s, 1H), 8.94-9.01 (br, 1H), 8.65-8.75 (m, 2H), 8.26 (s, 1H), 7.82 (s, 1H), 4.64 (q, J = 7.3 Hz, 2H), 3.78-3.86 (m, 1H), 3.43-3.50 (m, 2H), 3.15-3.25 (m, 2H), 2.46 (s, 3H), 2.34-2.41 (m, 2H), 2.18-2.27 (m, 2H), 1.54 (t, J = 6.9 Hz, 3H).
60	MS m/z 377.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.23 (s, 1H), 8.86 (d, J = 1.7 Hz, 1H), 8.37 (dd, J = 10.5, 1.5 Hz, 1H), 8.31 (s, 1H), 8.08 (s, 1H), 3.88-3.93 (m, 1H), 3.68-3.61 (m, 2H), 3.32-3.39 (m, 2H), 2.78 (s, 3H), 2.65 (s, 3H), 2.54-2.60 (m, 2H), 2.34-2.43 (m, 2H), NH proton not observed.

Cpd	Data
61	MS m/z 431.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.61 (s, 1H), 9.02 (br, 1H), 8.98 (s, 1H), 8.72 (br, 1H), 8.63 (dd, J = 11.8, 2.0 Hz, 1H), 8.40 (s, 1H), 8.00 (s, 1H), 3.77-3.83 (m, 1H), 3.42-3.49 (m, 2H), 3.15-3.24 (m, 2H), 2.47 (s, 3H), 2.33-2.39 (m, 2H), 2.16-2.27 (m, 2H).
62	MS m/z 378.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.84 (s, 1H), 8.56 (dd, J = 11.6, 1.9 Hz, 1H), 8.20 (s, 1H), 7.89 (s, 1H), 3.75-3.82 (m, 1H), 3.44-3.49 (m, 2H), 3.16-3.23 (m, 2H), 2.68 (s, 3H), 2.62 (s, 3H), 2.32-2.38 (m, 2H), 2.15-2.25 (m, 2H), NH proton not observed.
63	MS m/z 377.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 14.98 (br, 1H), 9.05 (br, 1H), 8.87 (s, 1H), 8.77 (br, 1H), 8.60 (dd, J = 11.5, 1.9 Hz, 1H), 8.17 (s, 1H), 8.02 (s, 1H), 3.77-3.83 (m, 1H), 3.44-3.49 (m, 2H), 3.16-3.23 (m, 2H), 2.85 (s, 3H), 2.70 (s, 3H), 2.32-2.38 (m, 2H), 2.15-2.25 (m, 2H).
64	MS m/z 377.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.89-8.92 (m, 1H), 8.86 (d, J = 1.6 Hz, 1H), 8.46 (dd, J = 10.7, 1.9 Hz, 1H), 8.37-8.42 (m, 2H), 3.85-3.91 (m, 1H), 3.61-3.67 (m, 2H), 3.35-3.39 (m, 2H), 3.05 (s, 3H), 2.53-2.60 (m, 5H), 2.33-2.44 (m, 2H), NH proton not observed.
65	MS m/z 377.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.95 (br, 1H), 8.90 (s, 1H), 8.59-8.66 (m, 2H), 8.26 (s, 1H), 7.53 (s, 1H), 6.60 (s, 1H), 3.77-3.83 (m, 1H), 3.44-3.49 (m, 2H), 3.16-3.23 (m, 2H), 2.77 (s, 3H), 2.48 (s, 3H), 2.32-2.38 (m, 2H), 2.15-2.25 (m, 2H).
66	MS m/z 378.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.17 (s, 1H), 9.08 (br, 1H), 8.82 (dd, J = 11.5, 1.9 Hz, 1H), 8.78 (s, 1H), 8.76 (br, 1H), 8.21 (s, 1H), 4.28 (s, 3H), 3.75-3.83 (m, 1H), 3.43-3.49 (m, 2H), 3.15-3.23 (m, 2H), 2.69 (s, 3H), 2.32-2.38 (m, 2H), 2.15-2.25 (m, 2H).
67	MS m/z 378.1 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.17 (s, 1H), 8.79-8.86 (m, 2H), 8.64 (s, 1H), 8.58 (s, 1H), 8.52 (br, 1H), 4.31 (s, 3H), 3.77-3.83 (m, 1H), 3.44-3.51 (m, 2H), 3.15-3.23 (m, 2H), 2.89 (s, 3H), 2.32-2.38 (m, 2H), 2.15-2.25 (m, 2H).
68	MS m/z 382.0 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.68 (s, 1H), 8.27 (d, J = 13.0, 1H), 8.01 (s, 1H), 7.72 (d, J = 13.0, 1H), 3.58-3.67 (m, 1H), 3.26-3.30 (m, 2H), 2.87-2.96 (m, 2H), 2.72 (s, 3H), 2.20-2.28 (m, 2H), 2.05-2.16 (m, 2H), NH proton not observed.

Example 14

Preparation of Compound 57



191

Step A: 5-Bromo-1,2-difluoro-3-nitro-benzene (11.7 g, 49 mmol, prepared according to the procedure in Example 7, Step A) was combined with guanidine hydrochloride (23.5 g, 246 mmol), K₂CO₃ (34 g, 246 mmol) and DMSO (75 mL). The mixture was vigorously stirred at 120° C. for 30 min. The mixture was cooled to room temperature. To the mixture was added aqueous 7.5 N NaOH (100 mL). The mixture was stirred at 60° C. for 30 min. To the mixture was added AcOH (75 mL) and H₂O (400 mL). The mixture was filtered. The collected solid was dried to yield 7-bromo-5-fluoro-1-oxido-1,2,4-benzotriazin-1-i¹⁰um-3-amine (9.6 g, 76%). MS m/z 259.1, 261.1 [M+H]⁺.

Step B: 7-Bromo-5-fluoro-1-oxido-1,2,4-benzotriazin-1-i¹⁵um-3-amine (9.6 g, 37 mmol) was dissolved in TFA (66 mL). To the mixture was added NaNO₂ (13.1 g, 190 mmol) in small portions at 0° C. The mixture was stirred at room temperature for 20 min, and then cooled to 0° C. Ice water was slowly added to the mixture (20 mL). A solid formed and was collected, washed with H₂O and dried. The solid was suspended in CH₃CN, collected by filtration and dried to yield 7-bromo-5-fluoro-1-oxido-1,2,4-benzotriazin-1-i²⁰um-3-ol (5.3 g, 55%). MS m/z 260.1, 262.1 [M+H]⁺.

Step C: 7-Bromo-5-fluoro-1-oxido-1,2,4-benzotriazin-1-i²⁵um-3-ol (2.9 g, 11 mmol) was combined with POCl₃ (30 mL, 320 mmol). The mixture was stirred at 110° C. for 2 h. The mixture was cooled to room temperature and then added to ice. The mixture was partitioned in CH₂Cl₂ and H₂O. The organic layer was collected and loaded onto silica gel, eluting with 0-10% EtOAc in CH₂Cl₂ to yield 7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-N-methyl-N-(piperidin-4-yl)benzo[e][1,2,4]triazin-3-amine (490 mg, 16%). MS m/z 277.9, 279.9, 281.9 [M+H]⁺.

Step D: 7-Bromo-3-chloro-5-fluoro-1-oxido-1,2,4-benzotriazin-1-i³⁰um (78 mg, 0.28 mmol) was combined with (2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)boronic acid (53 mg, 0.28 mmol, prepared according to the procedure in Example 11), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (11 mg, 0.014 mmol), 1,4-dioxane (1.5 mL) and aqueous 1 M K₂CO₃ (0.75 mL). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in CH₂Cl₂ to yield 7-bromo-3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-1-(λ1-oxidanyl)-1λ4-benzo[e][1,2,4]triazine (69 mg, 63%). MS m/z 389.0, 391.0 [M+H]⁺.

192

Step E: 7-Bromo-3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-1-(λ1-oxidanyl)-1λ4-benzo[e][1,2,4]triazine (20 mg, 0.051 mmol) was combined with N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester (19 mg, 0.062 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (4 mg, 0.005 mmol), 1,4-dioxane (1 mL) and aqueous 1 M K₂CO₃ (0.5 mL). The mixture was heated at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in CH₂Cl₂ to yield tert-butyl 4-(3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-1-(λ1-oxidanyl)-1λ4-benzo[e][1,2,4]triazin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (20 mg, 79%). MS m/z 492.3 [M+H]⁺.

Step F: tert-Butyl 4-(3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-1-(λ1-oxidanyl)-1λ4-benzo[e][1,2,4]triazin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (20 mg, 0.04 mmol) was combined with 10% Pd/C (5 mg) in MeOH (2 mL). The mixture was stirred under H₂ (1 atm) for 2 h at 40° C. The mixture was filtered over Celite. The filtrate was concentrated and chromatographed on a reversed phase C18 column, eluting with 40-100% CH₃CN in H₂O to yield tert-butyl 4-(3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorobenzo[e][1,2,4]triazin-7-yl)piperidine-1-carboxylate (17 mg, 87%). MS m/z 478.5 [M+H]⁺.

Step G: tert-Butyl 4-(3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorobenzo[e][1,2,4]triazin-7-yl)piperidine-1-carboxylate (17 mg, 0.036 mmol) was suspended in 4 N HCl in 1,4-dioxane (1 mL, 4 mmol HCl). The volatiles were removed from the mixture after 30 min. The residue was suspended in CH₃CN. The solid was collected and dried to yield 3-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-7-(piperidin-4-yl)benzo[e][1,2,4]triazine hydrochloride (8 mg, 54%).

¹H NMR (methanol-d₄) δ: 8.89 (d, J=1.6 Hz, 1H), 8.48 (d, J=1.9 Hz, 1H), 8.51 (d, J=1.3 Hz, 1H), 8.08 (dd, J=10.6, 1.7 Hz, 1H), 3.61-3.67 (m, 2H), 3.35-3.43 (m, 1H), 3.25-3.33 (m, 2H), 2.92 (s, 3H), 2.73 (s, 3H), 2.32-2.38 (m, 2H), 2.09-2.19 (m, 2H), NH protons not observed.


Using the procedure described for Example 14, above, additional compounds described herein were prepared by substituting the appropriate aryl boronic acid in Step D, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
40	MS m/z 377.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.84-8.86 (m, 1H), 8.64-8.67 (m, 1H), 8.25 (dd, J = 11.0, 1.9 Hz, 1H), 7.71 (s, 1H), 7.64 (s, 1H), 3.63-3.70 (m, 1H), 3.32-3.38 (m, 2H), 2.94-3.02 (m, 2H), 2.66 (s, 3H), 2.48 (s, 3H), 2.25-2.32 (m, 2H), 2.10-2.19 (m, 2H), NH proton not observed.
41	Starting material: 2-amino-5-bromo-4-fluorobenzoic acid MS m/z 381.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.89 (d, J = 1.6 Hz, 1H), 8.65-8.68 (m, 1H), 8.25 (dd, J = 10.8, 1.9 Hz, 1H), 7.83 (dd, J = 2.8, 0.6 Hz, 1H), 7.70 (dd, J = 12.0, 1.6 Hz, 1H), 3.60-3.68 (m, 1H), 3.27-3.32 (m, 2H), 2.89-2.97 (m, 2H), 2.48 (s, 3H), 2.21-2.29 (m, 2H), 2.06-2.16 (m, 2H), NH proton not observed.

193

Example 15

Preparation of Compound 4



Step A: 7-Bromo-3-chloro-5-fluoro-1-oxido-1,2,4-benzotriazin-1-ium (60 mg, 0.22 mmol, prepared according to the procedure in Example 14, Step C) was combined with Cs₂CO₃ (104 mg, 0.32 mmol) and 1-Boc-4-methylaminopiperidine (56 mg, 0.26 mmol) in DMF (2 mL). The mixture was stirred at 60° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-80% EtOAc in CH₂Cl₂ to 7-bromo-3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-5-fluorobenzo[e][1,2,4]triazine 1-oxide (64 mg, 65%). MS m/z 356.2, 358.2 [M-FH-Boc]⁺.

Step B: 7-bromo-3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-5-fluorobenzo[e][1,2,4]triazine 1-oxide (64 mg, 0.14 mmol) and 2,7-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole (46 mg, 0.17 mmol)

194

were combined with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.05 equiv., 0.007 mmol) and 1,4-dioxane (1 mL). To the mixture was added aqueous 1 M K₂CO₃ (0.5 mL).

5 The mixture was stirred at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 10-90% EtOAc in CH₂Cl₂ to yield 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluorobenzo[e][1,2,4]triazine 1-oxide (74 mg, 100%). MS m/z 522.4 [M+H]⁺.


10 Step C: 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)-7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluorobenzo[e][1,2,4]triazine 1-oxide (74 mg, 0.14 mmol) was combined with 10% Pd/C (20 mg) in MeOH (2 mL). The mixture was stirred under H₂ (1 atm) at rt for 1 h. The mixture was filtered over Celite. The filtrate was concentrated to yield tert-butyl 4-[[7-(2,7-dimethylindazol-5-yl)-5-fluoro-1,2,4-benzotriazin-3-yl]-methyl-amino]piperidine-1-carboxylate (70 mg, 97%). MS m/z 506.3 [M+H]⁺.


15 Step D: tert-Butyl 4-[[7-(2,7-dimethylindazol-5-yl)-5-fluoro-1,2,4-benzotriazin-3-yl]-methyl-amino]piperidine-1-carboxylate (70 mg, 0.14 mmol) was suspended in 4 N HCl in 1,4-dioxane (1 mL, 4 mmol HCl). The mixture was stirred at room temperature for 1 h. The volatiles were removed from the reaction mixture with a stream of N₂. The residue was partitioned in CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to yield 7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-N-methyl-N-(piperidin-4-yl)benzo[e][1,2,4]triazin-3-amine (43 mg, 77%).

20 35 40 MS m/z 406.4 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.42 (s, 1H), 8.37 (s, 1H), 8.15-8.19 (m, 1H), 8.04-8.07 (m, 1H), 7.60 (s, 1H), 4.24-4.30 (m, 1H), 4.21 (s, 3H), 3.22 (br s, 3H), 3.06-3.11 (m, 2H), 2.61-2.66 (m, 2H), 2.60 (s, 3H), 1.72-1.81 (m, 2H), 1.64-1.70 (m, 2H), NH proton not observed.

Example 17

Preparation of Compound 50



195**196**

Step B: tert-Butyl 4-(6-bromo-8-fluoro-2-quinolyl)piperidine-1-carboxylate (40 mg, 0.10 mmol) was combined with (8-fluoro-2-methyl-imidazo[1,2-a]pyridin-6-yl)boronic acid (40 mg, 0.21 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (4 mg, 0.005 mmol), 1,4-dioxane (1.5 mL) and aqueous 1 M K_2CO_3 (0.75 mL). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-80% EtOAc in CH_2Cl_2 to yield tert-butyl 4-[8-fluoro-6-(8-fluoro-2-methyl-imidazo[1,2-a]pyridin-6-yl)-2-quinolyl]piperidine-1-carboxylate (45 mg, 96%). MS m/z 479.4 [M+H]⁺.

Step C: tert-Butyl 4-[8-fluoro-6-(8-fluoro-2-methyl-imidazo[1,2-a]pyridin-6-yl)-2-quinolyl]piperidine-1-carboxylate (45 mg, 0.09 mmol) was suspended in 4 N HCl in 1,4-dioxane (1 mL, 4 mmol HCl). The volatiles were removed from the reaction mixture after 30 min. The residue was partitioned between CH_2Cl_2 and aqueous 1 M K_2CO_3 . The organic layer was concentrated and chromatographed on silica gel, eluting with 0-10% MeOH (2 N NH_3) in CH_2Cl_2 . The collected material was dissolved in 1.25 M HCl in MeOH. The volatiles were removed to yield 8-fluoro-6-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-2-(piperidin-4-yl)quinoline hydrochloride (35 mg, 90%).

MS m/z 379.3 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.36-9.39 (m, 1H), 9.16 (br, 1H), 8.88 (br, 1H), 8.46-8.50 (m, 1H), 8.41 (d, J=11.8 Hz, 1H), 8.34 (d, J=2.2 Hz, 1H), 8.17 (s, 1H), 8.13 (dd, J=12.1, 1.9 Hz, 1H), 7.69 (d, J=8.5 Hz, 1H), 3.39-3.46 (m, 2H), 3.27-3.35 (m, 1H), 3.03-3.12 (m, 2H), 2.54 (s, 3H), 2.04-2.18 (m, 4H).


Using the procedure described for Example 17, above, additional compounds described herein were prepared by substituting the indicated starting material in Step A, the appropriate boronic acid Step B, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Starting Material and Data
29	Starting material: 7-bromo-3-chloroquinoline MS m/z 357.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.26 (d, J = 2.5 Hz, 1H), 8.59 (d, J = 2.5 Hz, 1H), 8.43 (s, 1H), 8.01-8.03 (m, 1H), 7.98 (d, J = 8.5 Hz, 1H), 7.81-7.83 (m, 1H), 7.53-7.58 (m, 2H), 4.22 (s, 3H), 3.06-3.11 (m, 2H), 2.79-2.86 (m, 1H), 2.63-2.69 (m, 2H), 2.61 (s, 3H), 1.80-1.86 (m, 2H), 1.59-1.69 (m, 2H), NH proton not observed.
45	Starting material: 6-bromo-2-chloro-8-fluoro-quinoline MS m/z 376.1 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.63-8.68 (m, 2H), 8.48 (s, 1H), 8.38 (s, 1H), 8.35 (d, J = 11.5 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 3.60-3.65 (m, 2H), 3.46-3.50 (m, 1H), 3.25-3.33 (m, 2H), 2.86 (s, 3H), 2.70 (s, 3H), 2.27-2.33 (m, 4H), NH proton not observed.
49	Starting material: 6-bromo-2-chloro-8-fluoro-quinoline MS m/z 391.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.11 (br, 1H), 8.77 (br, 1H), 8.46 (d, J = 8.5 Hz, 1H), 8.41 (s, 1H), 8.17-8.20 (m, 1H), 8.05 (dd, J = 12.7, 2.1, 1H), 7.73 (d, J = 1.3 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.06-7.08 (m, 1H), 4.18 (s, 3H), 4.05 (s, 3H), 3.39-3.45 (m, 2H), 3.24-3.31 (m, 1H), 3.02-3.12 (m, 2H), 2.04-2.18 (m, 4H).

197

Example 18

Preparation of Compound 51

**198**

Step A: 8-Bromo-6-chloro-2-methyl-imidazo[1,2-b]pyridazine (250 mg, 1.01 mmol) was combined with Cs₂CO₃ (700 mg, 2.15 mmol) in CH₃CN (5 mL). To the mixture was added MeOH (0.2 mL). The mixture was stirred at room temperature for 4 h. The volatiles were removed from the reaction mixture. The residue was partitioned between EtOAc and H₂O. The organic layer was collected, concentrated and chromatographed on silica gel, eluting with 20-100% EtOAc in hexanes to yield 6-chloro-8-methoxy-2-methyl-imidazo[1,2-b]pyridazine (180 mg, 90%). MS m/z 198.2, 202.2 [M+H]⁺.

Step B: 6-Chloro-8-methoxy-2-methyl-imidazo[1,2-b]pyridazine (39 mg, 0.20 mmol) was combined with KOAc (59 mg, 0.60 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (8 mg, 0.01 mmol), and bis(pinacolato)diboron (63 mg, 0.25 mmol) in 1,4-dioxane (1 mL). The mixture was stirred under N₂ at 95°C for 1 h. To the mixture was added aqueous 1 M K₂CO₃ (0.75 mL), tert-butyl 4-(6-bromo-8-fluoro-2-quinolyl)piperidine-1-carboxylate (40 mg, 0.10 mmol, obtained in Example 17, Step A) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (4 mg, 0.005 mmol). The mixture was stirred at 80°C for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-80% EtOAc in CH₂Cl₂ to yield tert-butyl 4-[8-fluoro-6-(8-methoxy-2-methyl-imidazo[1,2-b]pyridazin-6-yl)-2-quinolyl]piperidine-1-carboxylate (38 mg, 79%). MS m/z 492.4 [M+H]⁺.

Step C: tert-Butyl 4-[8-fluoro-6-(8-methoxy-2-methyl-imidazo[1,2-b]pyridazin-6-yl)-2-quinolyl]piperidine-1-carboxylate (38 mg, 0.08 mmol) was suspended in 4 N HCl in 1,4-dioxane (1 mL, 4 mmol HCl). The volatiles were removed from the reaction mixture with a stream of N₂ after 30 min. The residue was suspended in CH₃CN, collected by filtration and dried to yield 8-fluoro-6-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-2-(piperidin-4-yl)quinoline hydrochloride (26 mg, 79%).

MS m/z 392.4 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.22 (br, 1H), 8.95 (br, 1H), 8.77-8.80 (m, 1H), 8.60 (d, J=8.6 Hz, 1H), 8.47 (s, 1H), 8.37 (dd, J=12.0, 2.0 Hz, 1H), 7.99 (s, 1H), 7.73 (d, J=8.5 Hz, 1H), 4.35 (s, 3H), 3.39-3.45 (m, 2H), 3.29-3.37 (m, 1H), 3.02-3.12 (m, 2H), 2.53 (s, 3H), 2.06-2.20 (m, 4H).


Using the procedure described for Example 18, above, additional compounds described herein were prepared by substituting the appropriate reagent in Step A, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
53	MS m/z 436.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.97 (br, 1H), 8.71 (br, 1H), 8.68 (s, 1H), 8.57 (d, J = 8.6 Hz, 1H), 8.28-8.35 (m, 2H), 7.76 (br s, 1H), 7.71 (d, J = 8.5 Hz, 1H), 4.70-4.74 (m, 2H), 3.84-3.88 (m, 2H), 3.42-3.47 (m, 2H), 3.39 (s, 3H), 3.29-3.37 (m, 1H), 3.05-3.14 (m, 2H), 2.48 (s, 3H), 2.06-2.20 (m, 4H).
54	MS m/z 435.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.59-8.64 (m, 2H), 8.30 (dd, J = 12.0, 1.7 Hz, 1H), 8.18 (d, J = 1.3 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.41 (s, 1H), 3.78-3.84 (m, 4H), 3.60-3.65 (m, 2H), 3.49 (s, 3H), 3.43-3.49 (m, 1H), 3.24-3.31 (m, 2H), 2.64 (s, 3H), 2.24-2.36 (m, 4H), NH protons not observed.

199

Example 19

Preparation of Compound 70

**200**

7-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(4-piperidyl)-1,2,4-benzotriazine dihydrochloride (36 mg, 0.08 mmol, prepared according to the procedure in Example 13) was combined with 1,2-dichloroethane (1 mL), EtOH (0.2 mL) and triethylamine (22 μ L, 0.16 mmol). To the mixture was added acetaldehyde (18 μ L, 0.32 mmol). The mixture became homogeneous. The mixture was stirred for 5 min. To the mixture was added sodium triacetoxyborohydride (36 mg, 0.16 mmol). After 20 min of stirring at room temperature, the mixture was loaded directly to silica gel and chromatographed, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂, to afford 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorobenzo[e][1,2,4]triazine (32 mg, 84%) as a yellow powder.

15 MS m/z 406.3 [M+H]⁺; ¹H NMR (methanol-d₄) δ : 9.06 (s, 1H), 8.62 (dd, J=10.9 Hz, 1H), 8.04 (s, 1H), 7.94 (s, 1H), 3.69-3.77 (m, 1H), 3.48-3.56 (m, 2H), 2.98 (q, J=7.2 Hz, 2H), 2.84-2.92 (m, 2H), 2.75 (s, 3H), 2.54 (s, 3H), 2.45-2.52 (in, 2H), 2.32-2.42 (m, 2H), 1.34 (t, J=7.3 Hz, 3H).

20 Using the reductive amination procedure described for Example 19, above, additional compounds described herein were prepared by substituting the indicated starting materials, aldehyde, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Starting Material and Data
2	Starting material: 2-(2-methyl-2H-indazol-5-yl)-6-(piperidin-4-yl)quinoline (prepared according to the procedure in Example 6) and acetaldehyde MS m/z 371.1 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 8.99 (br s, 1H), 8.66 (s, 1H), 8.57 (s, 1H), 8.34-8.40 (m, 2H), 8.15-8.20 (m, 1H), 8.04-8.10 (m, 2H), 7.19 (d, J = 9.5 Hz, 1H), 4.33 (s, 3H), 3.76-3.82 (m, 2H), 3.49-3.56 (m, 1H), 3.26 (q, J = 7.5 Hz, 2H), 3.19-3.24 (m, 2H), 2.31-2.36 (m, 2H), 2.18-2.23 (m, 2H), 1.44 (t, J = 7.5 Hz, 3H).
6	Starting material: 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoline (prepared according to the procedure in Example 17) and formaldehyde MS m/z 357.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ : 8.95 (br s, 1H), 8.57 (s, 1H), 8.51 (s, 1H), 8.44-8.50 (m, 2H), 8.24 (s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.76-7.78 (m, 2H), 4.22 (s, 3H), 4.00-4.07 (m, 2H), 3.22-3.28 (m, 1H), 3.14-3.20 (m, 2H), 2.81 (s, 3H), 2.27-2.33 (m, 4H).
9	Starting material: 6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline (prepared according to the procedure in Example 2) and acetaldehyde MS m/z 371.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ : 9.11 (d, J = 8.5 Hz, 1H), 8.58-8.64 (m, 2H), 8.48-8.54 (m, 2H), 8.23 (s, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.74-7.78 (m, 2H), 4.23 (s, 3H), 3.75-3.80 (m, 1H), 3.63-3.67 (m, 2H), 3.08-3.18 (m, 4H), 2.32-2.46 (m, 4H), 1.32 (t, J = 7.5 Hz, 3H).
47	Starting material: 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoline (prepared according to the procedure in Example 17) and formaldehyde MS m/z 390.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ : 8.67 (s, 1H), 8.57 (d, J = 8.0 Hz, 1H), 8.47 (s, 1H), 8.42 (s, 1H), 8.27 (d, J = 12.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 3.54-3.57 (m, 1H), 3.14-3.25 (m, 4H), 2.80 (s, 3H), 2.76 (s, 3H), 2.58 (s, 3H), 2.20-2.25 (m, 4H).
48	Starting material: 6-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoline (prepared according to the procedure in Example 17) and acetaldehyde MS m/z 404.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ : 8.67 (s, 1H), 8.57 (d, J = 8.0 Hz, 1H), 8.47 (s, 1H), 8.42 (s, 1H), 8.27 (d, J = 12.0 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 3.60-3.64 (m, 1H), 3.27-3.32 (m, 2H), 3.07-3.16 (m, 4H), 2.77 (s, 3H), 2.59 (s, 3H), 2.22-2.26 (m, 4H), 1.30 (t, J = 7.5 Hz, 3H).
69	Starting material: 7-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(4-piperidyl)-1,2,4-benzotriazine (prepared according to the procedure in Example 13) and formaldehyde MS m/z 392.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ : 9.27 (s, 1H), 8.70 (dd, J = 11.0, 1.7 Hz, 1H), 8.54 (s, 1H), 8.45 (s, 1H), 3.70-3.77 (m, 1H), 3.59-3.65 (m, 2H), 3.21-3.30 (m, 2H), 2.84 (d, J = 4.7 Hz, 3H), 2.76 (s, 3H), 2.56 (s, 3H), 2.41-2.47 (m, 2H), 2.25-2.35 (m, 2H).
75	Starting material: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 7) and 1,4-dioxane-2,5-diol MS m/z 421.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 9.17 (s, 1H), 8.61 (d, J = 1.0 Hz, 1H), 8.42-8.47 (m, 2H), 8.35 (s, 1H), 3.98-4.01 (m, 2H), 3.88-3.94 (m, 2H), 3.63-3.70 (m, 1H), 3.35-3.42 (m, 4H), 2.88 (s, 3H), 2.71 (s, 3H), 2.44-2.52 (m, 4H), OH proton not observed.

Cpd	Starting Material and Data
76	Starting material: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline and acetaldehyde (prepared according to the procedure in Example 7) MS m/z 405.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.17 (s, 1H), 8.60 (d, J = 1.0 Hz, 1H), 8.42-8.47 (m, 2H), 8.35 (s, 1H), 3.81-3.87 (m, 2H), 3.63-3.70 (m, 1H), 3.25-3.38 (m, 4H), 2.88 (s, 3H), 2.71 (s, 3H), 2.38-2.52 (m, 4H), 1.47 (t, J = 7.4 Hz, 3H). protons not observed.
77	Starting material: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 7) MS m/z 419.5 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.02 (s, 1H), 8.32 (dd, J = 11.0, 1.3 Hz, 1H), 8.15 (s, 1H), 8.14 (d, J = 0.6 Hz, 1H), 8.05 (d, J = 0.9 Hz, 1H), 3.10-3.22 (m, 3H), 2.94-3.07 (m, 2H), 2.65 (d, J = 0.9 Hz, 3H), 2.43 (d, J = 0.6 Hz, 3H), 2.02-2.14 (m, 4H), 1.52-1.61 (m, 2H), 1.12-1.18 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H), HCl protons not observed.
79	Starting material: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 7) MS m/z 391.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.05 (s, 1H), 8.36 (dd, J = 10.9, 1.4 Hz, 1H), 8.19 (s, 1H), 8.15 (d, J = 0.6 Hz, 1H), 8.07 (d, J = 0.9 Hz, 1H), 3.36-3.48 (m, 3H), 2.80-2.94 (m, 2H), 2.67 (s, 3H), 2.65 (s, 3H), 2.44 (d, J = 0.6 Hz, 3H), 2.18-2.28 (m, 4H), HCl protons not observed.
85	Starting material: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 7) MS m/z 387.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.01 (s, 1H), 8.57 (dd, J = 9, 1.5 Hz, 1H), 8.13 (m, 2H), 8.00 (s, 1H), 7.85 (s, 1H), 3.26-3.33 (m, 3H), 2.74 (s, 3H), 2.65 (q, J = 7.5 Hz, 2H), 2.52 (s, 3H), 2.35-2.41 (m, 2H), 2.20-2.24 (m, 2H), 2.06-2.18 (m, 2H), 1.23 (t, J = 7.5 Hz, 3H).
100	Starting material: 5-fluoro-7-(2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 391.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.14 (s, 1H), 8.58 (d, J = 9.5 Hz, 1H), 8.43-8.48 (m, 2H), 8.40 (s, 1H), 8.32 (s, 1H), 3.82-3.86 (m, 2H), 3.61-3.68 (m, 1H), 3.24-3.33 (m, 4H), 2.67 (s, 3H), 2.38-2.52 (m, 4H), 1.46 (t, J = 7.6 Hz, 3H), HCl protons not observed.
102	Starting material: 5-fluoro-7-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-3-(piperidin-4-yl)cinnoline hydrochloride (prepared according to the procedure in Example 29) MS m/z 408.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.28 (d, J = 1.2 Hz, 1H), 8.78 (s, 1H), 8.47 (dd, J = 11.0, 1.2 Hz, 1H), 8.33 (s, 1H), 8.21 (d, J = 1.2 Hz, 1H), 8.12 (dd, J = 10.5, 1.7 Hz, 1H), 3.84 (br d, J = 12.5 Hz, 2H), 3.61-3.69 (m, 1H), 3.24-3.35 (m, 4H), 2.66 (d, J = 0.9 Hz, 3H), 2.38-2.51 (m, 4H), 1.46 (t, J = 7.3 Hz, 3H), HCl protons not observed.
110	Starting material: 6-(2,8-dimethylimidazo[1,2-a]pyridin-6-yl)-8-fluoro-2-(piperidin-4-yl)quinoxaline hydrochloride (prepared according to the procedure in Example 38) MS m/z 405.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.88 (s, 1H), 8.26 (d, J = 0.9 Hz, 1H), 8.03 (dd, J = 11.3, 1.8 Hz, 1H), 7.81 (s, 1H), 7.57 (d, J = 1.2 Hz, 1H), 3.17 (d, J = 11.3 Hz, 2H), 3.06 (spt, J = 4.9 Hz, 1H), 2.59-2.61 (m, 1H), 2.60 (s, 2H), 2.54 (q, J = 7.3 Hz, 2H), 2.60 (s, 3H), 2.21 (td, J = 11.3, 3.7 Hz, 2H), 2.03-2.12 (m, 4H), 1.18 (t, J = 7.3 Hz, 3H).
111	Starting material: 5-fluoro-7-(8-methoxy-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 421.0 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.80 (s, 1H), 8.21 (d, J = 12 Hz, 1H), 7.94 (s, 1H), 7.75 (s, 1H), 7.00 (s, 1H), 4.23 (s, 3H), 3.37-3.42 (m, 1H), 3.21 (d, J = 11.3 Hz, 2H), 2.52-2.55 (m, 5H), 2.19-2.25 (m, 4H), 2.01-2.09 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H).
113	Starting material: (6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol dihydrochloride (prepared according to the procedure in Example 29) MS m/z 421.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.13 (s, 1H), 8.61 (s, 1H), 8.46 (d, J = 0.9 Hz, 1H), 8.43 (dd, J = 10.6, 1.3 Hz, 1H), 8.33 (s, 1H), 5.17 (d, J = 1.1 Hz, 2H), 3.82 (br d, J = 12.2 Hz, 2H), 3.61-3.70 (m, 1H), 3.23-3.30 (m, 4H), 2.69 (s, 3H), 2.39-2.50 (m, 4H), 1.45 (t, J = 7.3 Hz, 3H), HCl and OH protons not observed.
114	Starting material: 6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile dihydrochloride (prepared according to the procedure in Example 29) MS m/z 416.0 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.53 (s, 1H), 8.23 (dd, J = 10.8, 1.5 Hz, 1H), 8.02 (s, 1H), 7.99 (d, J = 0.4 Hz, 1H), 7.95 (s, 1H), 3.36-3.43 (m, 1H), 3.19 (br d, J = 11 Hz, 2H), 2.64 (s, 3H), 2.52-2.54 (m, 2H), 2.21-2.23 (m, 4H), 1.98-2.08 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H).
115	Starting material: 7-(8-cyclopropyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 29) MS m/z 431.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.78 (s, 1H), 8.19 (d, J = 12 Hz, 1H), 7.94 (s, 1H), 7.81 (s, 1H), 7.10 (s, 1H), 3.28-3.42 (m, 1H), 3.29 (br d, J = 12 Hz, 2H), 2.60-2.72 (m, 3H), 2.56 (s, 3H), 2.24-2.27 (m, 2H), 2.09-2.13 (m, 4H), 1.33-1.37 (m, 2H), 1.19-1.25 (m, 5H).
119	Starting material: 7-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 41) MS m/z 405.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.86 (s, 1H), 8.56 (s, 1H), 8.21 (m, 3H), 4.59 (s, 1H), 3.28 (s, 2H), 2.90 (s, 3H), 2.65 (dd, J = 14.4, 7.1 Hz, 2H), 2.48 (s, 3H), 2.39 (t, J = 11.8 Hz, 2H), 2.27-2.06 (m, 4H), 1.23 (t, J = 7.2 Hz, 3H).

Cpd	Starting Material and Data
120	Starting material: 6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2,4-dimethylbenzo[d]thiazole (prepared according to the procedure in Example 29) MS m/z 421.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.58 (s, 1H), 8.03 (d, J = 1.6 Hz, 1H), 7.90 (s, 1H), 7.71 (dd, J = 10.6, 1.2 Hz, 1H), 7.63 (d, J = 0.8 Hz, 1H), 3.34-3.40 (m, 1H), 3.20 (d, J = 11.2 Hz, 2H), 2.89 (s, 3H), 2.83 (s, 3H), 2.51-2.56 (m, 2H), 2.08-2.24 (m, 4H), 2.01-2.05 (m, 2H), 1.23 (t, J = 7.2 Hz, 3H).
121	Starting material: 7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 419.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.18 (s, 1H), 8.54 (s, 1H), 8.40-8.50 (m, 2H), 8.33 (s, 1H), 3.84 (br d, J = 12.5 Hz, 2H), 3.61-3.70 (m, 1H), 3.16-3.31 (m, 6H), 2.71 (s, 3H), 2.38-2.52 (m, 4H), 1.58 (t, J = 7.6 Hz, 3H), 1.46 (t, J = 7.6 Hz, 3H), HCl protons not observed.
122	Starting material: 7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 405.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.16 (s, 1H), 8.47 (s, 1H), 8.45 (d, J = 10.4 Hz, 1H), 8.40 (s, 1H), 8.33 (s, 1H), 3.75-3.80 (m, 2H), 3.59-3.69 (m, 1H), 3.32-3.38 (m, 2H), 3.23 (q, J = 7.5 Hz, 2H), 3.02 (s, 3H), 2.69 (s, 3H), 2.37-2.49 (m, 4H), 1.57 (t, J = 7.5 Hz, 3H), HCl protons not observed.
123	Starting material: 7-(8-ethyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 435.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.17 (s, 1H), 8.50 (s, 1H), 8.45 (d, J = 10.7 Hz, 1H), 8.42 (s, 1H), 8.33 (s, 1H), 3.98-4.02 (m, 2H), 3.88-3.94 (m, 2H), 3.62-3.68 (m, 1H), 3.35-3.42 (m, 4H), 3.23 (q, J = 7.5 Hz, 2H), 2.70 (s, 3H), 2.44-2.51 (m, 4H), 1.58 (t, J = 7.5 Hz, 3H), HCl and OH protons not observed.
124	Starting material: rac-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-((2R,6R)-2,6-dimethylpiperidin-4-yl)-5-fluorocinnoline dihydrochloride (prepared according to the procedure in Example 7) MS m/z 419.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.92 (s, 1H), 8.32 (d, J = 10 Hz, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 3.76 (tt, J = 12.5, 3.5 Hz, 1H), 3.43 (m, 1H), 3.00 (m, 1H), 2.73 (s, 3H), 2.52 (s, 3H), 2.47 (s, 3H), 2.30-2.36 (dd, J = 13, 5 Hz, 1H), 2.05-2.15 (m, 2H), 1.8 (q, J = 12.5 Hz, 1H), 1.32 (d, J = 7 Hz, 3H), 1.23 (d, J = 6 Hz, 3H).
125	Starting material: rac-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-((2R,6R)-2,6-dimethylpiperidin-4-yl)-5-fluorocinnoline hydrochloride (prepared according to the procedure in Example 7) MS m/z 433.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.91 (s, 1H), 8.31 (d, J = 11 Hz, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 7.87 (s, 1H), 3.65-3.80 (m, 2H), 3.13-3.27 (m, 2H), 2.73 (s, 3H), 2.64 (m, 1H), 2.51 (s, 3H), 2.31 (m, 1H), 2.13 (t, J = 13.5 Hz, 2H), 1.90 (q, J = 12.5 Hz, 1H), 1.34 (d, J = 6.5 Hz, 3H), 1.21-1.30 (m, 6H).
131	Starting material: rac-3-(2R,6R)-2,6-diethylpiperidin-4-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline (prepared according to the procedure in Example 7) MS m/z 447.6 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.94 (s, 1H), 8.33 (d, J = 11 Hz, 1H), 8.23 (s, 1H), 8.00 (s, 1H), 7.89 (s, 1H), 3.71 (m, 1H), 3.32 (m, 1H), 3.18 (br s, 1H), 2.73 (s, 3H), 2.66 (s, 3H), 2.52 (s, 3H), 2.28-2.35 (m, 1H), 2.16-2.23 (m, 2H), 1.80-2.00 (m, 4H), 1.51 (m, 1H), 1.08 (t, J = 7.5 Hz, 3H), 1.02 (t, J = 7.5 Hz, 3H), proton not observed.
132	Starting material: 7-(2,7-dimethyl-3H-imidazo[4,5-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 405.2 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 9.30 (s, 1H), 8.50 (d, J = 12 Hz, 1H), 7.99 (s, 1H), 7.37 (s, 1H), 3.37 (t, J = 13.2, 1H), 3.20 (d, J = 11.2, 2H), 2.93 (s, 3H), 2.69 (s, 3H), 2.56-2.51 (m, 2H), 2.22-2.04 (m, 6H), 1.17 (t, J = 8 Hz, 3H), NH proton not observed.
135	Starting material: 5-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2,7-dimethylthiazolo[5,4-b]pyridine dihydrochloride (prepared according to the procedure in Example 29) MS m/z 422.3 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.90 (s, 1H), 8.34 (dd, J = 11, 1.2 Hz, 1H), 7.93 (s, 2H), 3.42 (m, 1H), 3.33 (d, J = 12.4 Hz, 2H), 2.90 (s, 3H), 2.84 (s, 3H), 2.65-2.71 (m, 2H), 2.37-2.39 (m, 2H), 2.24-2.29 (m, 2H), 2.13-2.20 (m, 2H), 1.23 (t, J = 7.4 Hz, 3H).
136	Starting material: 2-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-4,6-dimethyloxazolo[4,5-c]pyridine dihydrochloride (prepared according to the procedure in Example 29) MS m/z 406.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.11 (s, 1H), 8.35 (dd, J = 9.9, 1.2 Hz, 1H), 8.25 (s, 1H), 7.57 (s, 1H), 3.41-3.56 (m, 1H), 3.28-3.25 (m, 2H), 2.86 (s, 3H), 2.69 (s, 3H), 2.61 (q, J = 7.2 Hz, 2H), 2.34 (td, J = 11.6, 2.1 Hz, 2H), 2.24-2.10 (m, 4H), 1.22 (t, J = 7.3 Hz, 3H).
147	Starting material: 2-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-4,6-dimethyloxazolo[4,5-c]pyridine dihydrochloride (prepared according to the procedure in Example 29) MS m/z 422.3 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.89 (s, 1H), 8.32 (dd, J = 10, 1.2 Hz, 1H), 7.94 (s, 1H), 7.59 (s, 1H), 3.40 (m, 1H), 3.22 (d, J = 12.4 Hz, 2H), 3.04 (s, 3H), 2.68 (s, 3H), 2.54-2.57 (m, 2H), 2.21-2.25 (br s, 4H), 2.04-2.11 (m, 2H), 1.18 (t, J = 14.4 Hz, 3H).


Cpd	Starting Material and Data
152	Starting material: 5-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2,7-dimethyloxazolo[5,4-b]pyridine dihydrochloride (prepared according to the procedure in Example 29) MS m/z 406.2 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.89 (s, 1H), 8.29 (dd, J = 10.6, 1.6 Hz, 1H), 7.92 (s, 1H), 7.86 (s, 1H), 3.35-3.39 (m, 1H), 3.21 (d, J = 10.4 Hz, 2H), 2.70 (s, 6H), 2.55 (d, J = 6.8 Hz, 2H), 2.18-2.21 (m, 4H), 2.03-2.07 (m, 2H), 1.18 (t, J = 7.2 Hz, 3H).
155	Starting material: rac-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-((2R,6R)-2,6-dimethylpiperidin-4-yl)-5-fluorocinnoline hydrochloride (prepared according to the procedure in Example 7) MS m/z 449.5 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.96 (s, 1H), 8.26 (d, J = 11.5 Hz, 1H), 8.06 (m, 2H), 7.88 (s, 1H), 3.68 (m, 1H), 3.52 (t, J = 6.5 Hz, 2H), 3.43 (m, 1H), 3.09 (br s, 1H), 2.83 (m, 1H), 2.60-2.70 (m, 4H), 2.47 (s, 3H), 2.22 (td, J = 12.5, 5.5 Hz, 1H), 1.98 (d, J = 12 Hz, 1H), 1.90 (d, J = 11.5 Hz, 1H), 1.70 (q, J = 12.5 Hz, 1H), 1.26 (d, J = 6.5 Hz, 3H), 1.13 (d, J = 6.5 Hz, 3H), OH proton not observed.
161	Starting material: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-3-((2S,4R,6R)-2,6-dimethylpiperidin-4-yl)-5-fluorocinnoline dihydrochloride (prepared according to the procedure in Example 7) MS m/z 419.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.92 (s, 1H), 8.32 (d, J = 11 Hz, 1H), 8.18 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 3.51 (m, 1H), 2.8 (br s, 2H), 2.73 (s, 3H), 2.56 (s, 3H), 2.52 (s, 3H), 2.20 (d, J = 11.5 Hz, 2H), 1.96 (q, J = 12.5 Hz, 2H), 1.37 (d, J = 6.5 Hz, 6H).
164	Starting material: 7-(2,7-dimethyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 405.2 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.88 (s, 1H), 8.38 (dd, J = 10.8, 1.2 Hz, 1H), 8.24 (s, 1H), 7.95 (s, 1H), 7.78 (d, J = 0.8 Hz, 1H), 4.32 (s, 3H), 3.32-3.44 (m, 3H), 2.86 (s, 3H), 2.66-2.71 (m, 2H), 2.25-2.29 (m, 4H), 2.20 (s, 3H), 1.25-1.29 (m, 2H).
173	Starting material: 5-fluoro-7-(7-methoxy-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 421.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.84 (s, 1H), 8.37 (dd, J = 10.8, 1.2 Hz, 1H), 8.20 (s, 1H), 7.93 (s, 1H), 7.29 (s, 1H), 4.29 (s, 3H), 4.22 (s, 3H), 3.34-3.41 (m, 1H), 3.20 (br d, J = 12 Hz, 2H), 2.50-2.55 (m, 2H), 2.17-2.23 (m, 4H), 1.98-2.08 (m, 2H), 1.21 (t, J = 6.4 Hz, 3H).
174	Starting material: 7-(7-ethyl-2-methyl-2H-pyrazolo[4,3-b]pyridin-5-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 29) MS m/z 419.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.89 (s, 1H), 8.38 (dd, J = 10.9, 1.3 Hz, 1H), 8.24 (s, 1H), 7.93 (s, 1H), 7.79 (s, 1H), 4.31 (s, 3H), 3.39 (t, J = 11.9 Hz, 1H), 3.27-3.13 (m, 4H), 2.56 (dd, J = 14.0, 7.5 Hz, 2H), 2.24 (d, J = 10.5 Hz, 4H), 2.07 (dd, J = 24.6, 12.5 Hz, 2H), 1.52 (t, J = 7.6 Hz, 3H), 1.19 (t, J = 7.2 Hz, 3H).
176	Starting material: 6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile dihydrochloride (prepared according to the procedure in Example 29) MS m/z 402.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.22 (s, 1H), 9.17 (s, 1H), 8.58 (s, 1H), 8.43 (dd, J = 10.8, 0.9 Hz, 1H), 8.37 (s, 1H), 3.76 (br d, J = 12.5 Hz, 2H), 3.64 (tt, J = 10.6, 6.2 Hz, 1H), 3.35 (dd, J = 12.0, 4.4 Hz, 2H), 3.00 (s, 3H), 2.71 (s, 3H), 2.49-2.34 (m, 4H), HCl protons not observed.
178	Starting material: 6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile dihydrochloride (prepared according to the procedure in Example 29) MS m/z 432.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.16 (s, 2H), 8.55 (s, 1H), 8.43 (br d, J = 10.22 Hz, 1H), 8.34 (s, 1H), 3.96-4.02 (m, 2H), 3.89 (br d, J = 12.51 Hz, 2H), 3.58-3.71 (m, 2H), 3.35-3.40 (m, 3H), 2.69 (s, 3H), 2.41-2.51 (m, 4H), OH and HCl protons not observed.
179	Starting material: 6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile (prepared according to the procedure in Example 29) MS m/z 434.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.16 (s, 1H), 9.14 (s, 1H), 8.54 (s, 1H), 8.42 (d, J = 10.0 Hz, 1H), 8.35 (s, 1H), 4.98-5.02 (m, 1H), 4.89-4.93 (m, 1H), 3.90 (br d, J = 12.5 Hz, 2H), 3.62-3.71 (m, 3H), 3.39-3.50 (m, 2H), 2.69 (s, 3H), 2.44-2.52 (m, 4H), HCl protons not observed.
180	Starting material: (6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol (prepared according to the procedure in Example 29) MS m/z 407.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.94 (s, 1H), 8.33-8.39 (m, 1H), 8.25 (s, 1H), 8.04 (d, J = 1.98 Hz, 2H), 5.10 (s, 2H), 3.48-3.63 (m, 3H), 3.11 (br s, 2H), 2.87 (s, 3H), 2.50 (s, 3H), 2.31-2.40 (m, 4H), OH proton not observed.
181	Starting material: (6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol dihydrochloride (prepared according to the procedure in Example 29) MS m/z 437.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.14 (s, 1H), 8.62 (s, 1H), 8.46 (s, 1H), 8.44 (d, J = 10.1 Hz, 1H), 8.36 (s, 1H), 5.17 (s, 2H), 3.96-4.01 (m, 2H), 3.89 (br d, J = 12.7 Hz, 2H), 3.35-3.40 (m, 3H), 3.20-3.27 (m, 2H), 2.69 (s, 3H), 2.43-2.50 (m, 4H), OH and HCl protons not observed.
182	Starting material: (6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol dihydrochloride MS m/z 439.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.14 (s, 1H), 8.62 (s, 1H), 8.45-

Cpd	Starting Material and Data
188	8.49 (m, 1H), 8.43 (d, $J = 10$ Hz, 1H), 8.33-8.37 (m, 1H), 5.17 (s, 2H), 4.91-5.06 (m, 2H), 3.90 (br d, $J = 12.21$ Hz, 2H), 3.61-3.72 (m, 3H), 3.37-3.47 (m, 2H), 2.69 (s, 3H), 2.43-2.54 (m, 4H), OH and HCl protons not observed.
189	Starting material: 3-(azepan-4-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline dihydrochloride (prepared according to the procedure in Example 7) MS m/z 405.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.92 (s, 1H), 8.32 (d, $J = 11.5$ Hz, 1H), 8.18 (s, 1H), 8.01 (s, 1H), 7.89 (s, 1H), 3.62 (septet, $J = 5$ Hz, 1H), 3.03-3.09 (m, 1H), 2.85-2.92 (m, 3H), 2.73 (s, 3H), 2.52 (s, 3H), 2.51 (s, 3H), 2.28-2.40 (m, 1H), 2.20-2.28 (m, 2H), 2.03-2.20 (m, 2H), 1.90-1.99 (m, 1H).
190	Starting material: rac-3-(azepan-4-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline (prepared according to the procedure in Example 7) MS m/z 419.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.87 (s, 1H), 8.27 (d, $J = 11$ Hz, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 7.85 (s, 1H), 3.60 (septet, $J = 5$ Hz, 1H), 3.09-3.15 (m, 1H), 2.83-3.00 (m, 3H), 2.75 (q, $J = 7$ Hz, 2H), 2.71 (s, 3H), 2.51 (s, 3H), 2.20-2.35 (m, 3H), 2.00-2.20 (m, 2H), 1.90-1.98 (m, 1H), 1.20 (t, $J = 7$ Hz, 3H).
191	Starting material: rac-3-(azepan-4-yl)-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnoline (prepared according to the procedure in Example 7) MS m/z 435.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.91 (s, 1H), 8.31 (d, $J = 11$ Hz, 1H), 8.18 (s, 1H), 8.00 (s, 1H), 7.87 (s, 1H), 3.76 (t, $J = 6$ Hz, 2H), 3.60 (m, 1H), 3.17-3.21 (m, 1H), 2.99-3.07 (m, 3H), 2.88 (t, $J = 6$ Hz, 2H), 2.73 (s, 3H), 2.51 (s, 3H), 2.00-2.34 (m, 5H), 1.91-1.98 (m, 1H), OH proton not observed.
192	Starting material: 2-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-4,6-dimethylthiazolo[5,4-c]pyridine (prepared according to the procedure in Example 29) MS m/z 422.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.93 (s, 1H), 8.21 (dd, $J = 9.9, 1.4$ Hz, 1H), 7.88 (s, 1H), 7.62 (s, 1H), 3.38-3.29 (m, 1H), 3.16 (d, $J = 11.2$ Hz, 2H), 2.79 (s, 3H), 2.64 (s, 3H), 2.49 (q, $J = 7.2$ Hz, 2H), 2.25-2.09 (m, 4H), 2.06-1.93 (m, 2H), 1.12 (t, $J = 7.2$ Hz, 3H).
193	Starting material: 5-fluoro-7-(2-methyl-8-phenoxyimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 29) MS m/z 483.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.59 (s, 1H), 8.25 (dd, $J = 10.8, 1.2$ Hz, 1H), 8.21 (s, 1H), 8.09 (s, 1H), 7.61-7.65 (m, 2H), 7.42-7.49 (m, 3H), 6.95 (s, 1H), 3.33-3.34 (m, 1H), 3.23-3.32 (m, 2H), 2.54-2.62 (m, 2H), 2.54 (s, 3H), 2.28-2.34 (m, 2H), 2.07-2.19 (m, 4H), 1.20 (t, $J = 7.2$ Hz, 3H).
194	Starting material: 2-(6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazin-8-yl)acetonitrile dihydrochloride (prepared according to the procedure in Example 29) MS m/z 430.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.00 (s, 1H), 8.39 (dd, $J = 11, 1.6$ Hz, 1H), 8.26 (s, 1H), 8.15 (s, 1H), 8.09 (s, 1H), 3.49-3.52 (m, 3H), 2.91-2.94 (m, 2H), 2.70-2.79 (br s, 2H), 2.56 (s, 3H), 2.22-2.35 (m, 6H), 1.32 (t, $J = 7.2$ Hz, 3H).
195	Starting material: 2-(6-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-2-methylimidazo[1,2-b]pyridazin-8-yl)ethanol-1-ol dihydrochloride (prepared according to the procedure in Example 29) MS m/z 435.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.96 (s, 1H), 8.36 (dd, $J = 11.6, 1.2$ Hz, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.93 (s, 1H), 4.09 (t, $J = 6.2$ Hz, 2H), 3.34-3.37 (br s, 3H), 3.25-3.28 (m, 2H), 2.61-2.63 (m, 2H), 2.53 (s, 3H), 2.34 (m, 2H), 2.14-2.20 (m, 4H), 1.22 (t, $J = 7.2$ Hz, 3H), OH proton not observed.
196	Starting material: 5-fluoro-7-(2-methyl-8-propylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline dihydrochloride (prepared according to the procedure in Example 29) MS m/z 435.2 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.84 (s, 1H), 8.22 (dd, $J = 10.4$ Hz, 1.2 Hz, 1H), 7.95 (s, 1H), 7.81 (s, 1H), 7.51 (s, 1H), 3.43 (t, $J = 12$ Hz, 1H), 3.26 (d, $J = 10.8$ Hz, 2H), 3.12 (t, $J = 7.6, 2H$), 2.60 (d, $J = 7.2$ Hz, 2H), 2.56 (s, 3H), 2.27-1.91 (m, 8H), 1.21 (t, $J = 7.2$ Hz, 3H), 1.11 (t, $J = 7.2$ Hz, 3H).
197	Starting material: 2-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-4,6-dimethyloxazolo[4,5-c]pyridine dihydrochloride (prepared according to the procedure in Example 29) MS m/z 422.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 9.11 (s, 1H), 8.22 (dd, $J = 9.6, 1.2$ Hz, 1H), 7.90 (s, 1H), 7.25 (s, 1H), 3.80-3.66 (m, 2H), 3.46-3.27 (m, 3H), 2.87-2.70 (m, 5H), 2.64-2.50 (m, 5H), 2.30-2.18 (m, 4H), OH proton not observed.
198	Starting material: 2-(5-fluoro-3-(piperidin-4-yl)cinnolin-7-yl)-4,6-dimethyloxazolo[4,5-c]pyridine (prepared according to the procedure in Example 29) MS m/z 392.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 9.17 (s, 1H), 8.26 (dd, $J = 9.7, 1.3$ Hz, 1H), 7.93 (s, 1H), 7.32 (s, 1H), 3.40-3.29 (m, 1H), 3.10 (d, $J = 11.7$ Hz, 2H), 2.89 (s, 3H), 2.71 (s, 3H), 2.39 (s, 3H), 2.30-2.15 (m, 4H), 2.11-1.98 (m, 2H).
199	Starting material: 5-fluoro-7-(8-isopropyl-2-methylimidazo[1,2-b]pyridazin-6-yl)-3-(piperidin-4-yl)cinnoline (prepared according to the procedure in Example 29) MS m/z 433.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.97 (s, 1H), 8.36 (dd, $J = 10.9, 1.3$ Hz, 1H), 8.22 (s, 1H), 8.04 (s, 1H), 7.84 (s, 1H), 3.76-3.69 (m, 1H), 3.39 (d, $J = 11.7$ Hz, 2H), 3.28 (s, 1H), 2.65 (dd, $J = 14.4, 7.2$ Hz, 2H), 2.54 (s, 3H), 2.38 (t, $J = 11.0$ Hz, 2H), 2.27-2.10 (m, 4H), 1.54 (d, $J = 6.9$ Hz, 6H), 1.23 (t, $J = 7.3$ Hz, 3H).

209

Example 20

Preparation of Compound 18



Step A: 6-Bromo-2-chloro-quinoline (300 mg, 1.2 mmol) was dissolved in THF (7.5 mL). To the solution was added a solution of KOtBu in THF (2.5 mL, 2.5 mmol, 1.0 M). The mixture was heated at 40° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in hexanes to yield 6-bromo-2-tert-butoxy-quinoline (310 mg, 89%). MS m/z 224.2, 226.2 [M+H-tBu]⁺.

Step B: 6-Bromo-2-tert-butoxy-quinoline (310 mg, 1.11 mmol) was combined with bis(pinacolato)diboron (375 mg, 1.46 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (40 mg, 0.048

210

mmol), KOAc (300 mg, 3.03 mmol) and 1,4-dioxane (4 mL). The mixture was stirred at 90° C. for 2 h to yield 2-tert-butoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline as a crude mixture that was used without purification. MS m/z 272.3 [M-FH-tBu]⁺.

6-Bromo-2,8-dimethyl-imidazo[1,2-a]pyrazine (100 mg, 0.44 mmol) and 2-tert-butoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline (164 mg, 0.50 mmol, prepared above) were combined with 1,1'-bis(diphenylphosphino)

10 ferrocene-palladium(II)dichloride dichloromethane complex (20 mg, 0.024 mmol), 1,4-dioxane (2.5 mL) and aqueous 1 M K₂CO₃ (1.5 mL). The mixture was heated at 80° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in hexanes to yield 2-tert-butoxy-6-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)quinoline (140 mg, 73%). MS m/z 347.3 [M+H]⁺.

20 Step C: 2-tert-Butoxy-6-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)quinoline (130 mg, 0.38 mmol) was suspended in 4 N HCl in 1,4-dioxane (1 mL, 4 mmol). The mixture was stirred at room temperature for 1 h. The volatiles were removed. The residue was suspended in DMF (1 mL) with

25 Cs₂CO₃ (325 mg, 1.0 mmol). To the mixture was added N,N-bis(trifluoromethylsulfonyl)aniline (107 mg, 0.30 mmol). The mixture was stirred at room temperature for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in hexanes to yield [6-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-2-quinolyl]trifluoromethanesulfonate (90 mg, 56%). MS m/z 423.3 [M+H]⁺.

Step D: [6-(2,8-Dimethylimidazo[1,2-a]pyrazin-6-yl)-2-

35 quinolyl]trifluoromethanesulfonate (90 mg, 0.21 mmol) was combined with 1-tert-butoxycarbonylpiperidin-4-ylzinc iodide (0.25 mL, 0.25 mmol, prepared according to the procedure in Example 5, Step B), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (8 mg, 0.01 mmol), 1,4-dioxane (2 mL). The mixture was heated at 80° C. for 20 min. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-100% EtOAc in hexanes, followed by 5% MeOH in EtOAc to yield tert-butyl 4-[6-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-2-quinolyl]piperidine-1-carboxylate (60 mg, 62%). MS m/z 458.4 [M+H]⁺.

Step E: tert-Butyl 4-[6-(2,8-dimethylimidazo[1,2-a]

50 pyrazin-6-yl)-2-quinolyl]piperidine-1-carboxylate (60 mg, 0.1311 mmol) was dissolved in TFA (1 mL). After 20 min, the volatiles were removed. The residue was partitioned between CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was loaded directly onto silica gel, eluting with 0-20% MeOH (2 M NH₃) in CH₂Cl₂ to yield 6-(2,8-dimethylimidazo[1,2-a]pyrazin-6-yl)-2-(piperidin-4-yl)quinoline as white powder (15 mg, 32%).

MS m/z 358.4 [M+H]⁺. ¹H NMR (DMSO-d₆) δ: 9.17 (s, 1H), 8.61 (d, J=2.2 Hz, 1H), 8.39 (d, J=8.5 Hz, 1H), 8.36 (dd, J=8.8, 2.2 Hz, 1H), 8.04 (d, J=8.8 Hz, 1H), 7.88 (s, 1H), 7.51 (d, J=8.5 Hz, 1H), 3.11-3.17 (m, 2H), 2.98-3.05 (m, 1H), 2.83 (s, 3H), 2.69-2.77 (m, 2H), 2.44 (s, 3H), 1.87-1.95 (m, 2H), 1.75-1.85 (m, 2H).


Using the procedure described for Example 20, above, additional compounds described herein were prepared by substituting the appropriate aryl boronic acid in Step B, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd Data

19 MS m/z 358.4 [M + H]⁺; ¹H NMR (DMSO-d₆) δ: 8.67 (d, J = 2.2 Hz, 1H), 8.45 (d, J = 8.5 Hz, 1H), 8.42 (dd, J = 8.8, 2.0 Hz, 1H), 8.11 (s, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.82 (d, J = 1.3 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 3.24-3.30 (m, 2H), 3.09-3.15 (m, 1H), 2.84-2.91 (m, 2H), 2.65 (s, 3H), 2.43 (s, 3H), 1.87-1.95 (m, 2H), 1.75-1.85 (m, 2H).

Example 21

Preparation of Compound 55



tert-Butyl 4-(7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluorocinnolin-3-yl)-3,6-dihydropyridine-1(2H)-carboxylate (25 mg, 0.053 mmol, prepared according to Example 7, Step I) was stirred in the presence of HCl in dioxane (4M, 1 mL, 4 mmol) for 1 h. The reaction mixture was filtered, and the solids were washed with ether, then 9:1 CH₂Cl₂:MeOH to yield 7-(2,7-dimethyl-2H-indazol-5-yl)-5-fluoro-3-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride (19 mg, 88%).

MS m/z 374.4 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.30-9.40 (br s, 2H), 8.66 (s, 1H), 8.48 (s, 1H), 8.32 (s, 1H), 8.24 (dd, J=11.5, 1 Hz, 1H), 8.20 (s, 1H), 7.69 (s, 1H), 7.21 (br s, 1H), 4.23 (s, 3H), 3.94 (br s, 2H), 3.40-3.50 (m, 2H), 3.05 (br s, 2H), 2.64 (s, 3H).

Using the procedure described for Example 2, above, additional compounds described herein were prepared by substituting the appropriate starting material, suitable reagents and reaction conditions, obtaining compounds such as those selected from:


Cpd Data

- 225 MS m/z 375.3 [M + H]⁺; ¹H NMR (chloroform-d) δ: 8.70 (s, 1H), 8.08 (dd, J = 10.7, 1.0 Hz, 1H), 7.86 (s, 1H), 7.73-7.67 (m, 1H), 7.40 (s, 1H), 7.11 (br s, 1H), 4.23 (dd, J = 6.8, 2.2 Hz, 2H), 3.73 (dd, J = 5.2 Hz, 2H), 2.79 (br s, 2H), 2.69 (s, 3H), 2.48 (s, 3H), NH and HCl protons not observed.
- 208 MS m/z 431.5 [M + H]⁺; ¹H NMR (chloroform-d) δ: 8.81-8.89 (m, 1H), 8.21 (d, J = 10.1 Hz, 1H), 8.00 (s, 1H), 7.82 (s, 1H), 7.54 (d, J = 0.9 Hz, 1H), 7.13 (br s, 1H), 2.78 (s, 3H), 2.59-2.73 (br m, 2H), 2.53-2.57 (m, 3H), 1.43 (br s, 12H).

213

Example 22

Preparation of Compound 4



Step A: 7-Bromocinnolin-3-ol (100 mg, 0.44 mmol, prepared according to the procedure used for 7-Bromo-5-fluoro-cinnolin-3-ol in Example 7), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (200 mg, 0.65 mmol), Pd(dppf)Cl₂—CH₂Cl₂ (50 mg, 0.061 mmol), DMF (2.5 mL), and aqueous K₂CO₃ (2M, 0.825 mL, 0.825 mmol) were heated at 80° C. for 1 hour. The mixture was then partitioned between H₂O and EtOAc. The organic layer was washed with H₂O and then brine. The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. Purification by silica gel chromatography (5% MeOH in CH₂Cl₂), followed by ether trituration, yielded tert-butyl 4-(3-hydroxycinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (110 mg) as a yellow solid. MS m/z 328.0 [M+H]⁺.

Step B: tert-Butyl 4-(3-hydroxycinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (108 mg, 0.33 mmol), 1,1,1-trifluoro-N-phenyl-N-((trifluoromethyl)sulfonyl)methanesulfonamide (143 mg, 0.4 mmol), Cs₂CO₃ (175 mg, 0.54 mmol) and DMF (1 mL) were stirred at room temperature for 30 min. The mixture was partitioned between H₂O and EtOAc. The organic layer was washed with H₂O and brine. The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. Purification by silica gel chro-


214


matography (0-5% EtOAc in CH₂Cl₂) yielded tert-butyl 4-((trifluoromethyl)sulfonyloxy)cinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (109 mg, 54% over two steps) as a white solid.

- 5 ¹H NMR (acetone-d₆) δ: 8.53 (s, 1H), 8.43 (s, 1H), 8.28 (dd, J=9 Hz, 2 Hz, 1H), 8.23 (d, J=9 Hz, 1H), 6.69 (br s, 1H), 4.22 (s, 2H), 3.75 (in, 2H), 2.79 (m, 2H), 1.51 (s, 9H).
- 10 Step C: A mixture of tert-butyl 4-((trifluoromethyl)sulfonyloxy)cinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (85 mg, 0.18 mmol), (2-methyl-2H-indazol-5-yl) boronic acid (51 mg, 0.29 mmol), Pd(dppf)Cl₂—CH₂Cl₂ (40 mg, 0.05 mmol), dioxane (1.05 mL), and aqueous K₂CO₃ (2M, 220 μL, 0.44 mmol) were heated at 80° C. for 90 min.
- 15 The mixture was partitioned between H₂O and CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (20% acetone in CH₂Cl₂, followed by 5% MeOH in CH₂Cl₂). The material obtained was triturated with 2:1 hexanes:CH₂Cl₂. The solid material was collected and dried yielding tert-butyl 4-(3-(2-methyl-2H-indazol-5-yl)cinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (51 mg, 64%) as a yellow solid.
- 20 ¹H NMR (DMSO-d₆) δ: 8.72 (s, 1H), 8.71 (s, 1H), 8.55 (s, 1H), 8.39 (s, 1H), 8.21 (dd, J=9 Hz, 2 Hz, 1H), 8.11 (dd, J=9 Hz, 2 Hz, 1H), 8.06 (d, J=9 Hz, 1H), 7.80 (d, J=9 Hz, 1H), 6.61 (br s, 1H), 4.23 (s, 3H), 4.13 (s, 2H), 3.64 (t, J=5.5 Hz, 2H), 2.72 (s, 2H), 1.46 (s, 9H).
- 25 Step D: A solution of tert-butyl 4-(3-(2-methyl-2H-indazol-5-yl)cinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (51 mg, 0.12 mmol) in CH₂Cl₂ (1 mL) and TFA (0.3 mL) was stirred at room temperature for 1 h. The volatiles were removed by a N₂ stream. The solid material was triturated with 1 N HCl in ether for 1 h and the volatiles were removed by a N₂ stream. The residue was washed with 4:1 CH₂Cl₂:MeOH and dried to yield 3-(2-methyl-2H-indazol-5-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride (42 mg, 100%) as a light tan solid.
- 30 40 MS m/z 342.0 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.25 (br s, 1H), 8.75 (s, 1H), 8.73 (s, 1H), 8.56 (s, 1H), 8.47 (s, 1H), 8.22 (dd, J=9 Hz, 1.5 Hz, 1H), 8.14 (dd, J=9 Hz, 2 Hz, 1H), 8.10 (d, J=9 Hz, 1H), 7.81 (d, J=9 Hz, 1H), 6.65 (br s, 1H), 4.24 (s, 3H), 3.88 (s, 2H), 3.41 (m, 2H), 2.95 (s, 2H).

Example 23

Preparation of Compound 24



215

Step A: Quinoxalin-2-ol (2.0 g, 13.7 mmol), concentrated H_2SO_4 (14 mL), Ag_2SO_4 (2.12 g, 6.8 mmol), and Br_2 (0.7 mL, 13.6 mmol) were stirred at room temperature for 15 h. The mixture was filtered to remove AgBr . The solid was washed with sulfuric acid. The combined filtrate was poured onto ice. A white solid was collected by filtration, washed with H_2O , EtOH, and ether, and then dried to yield 6-bromoquinoxalin-2-ol (2.7 g, 87%) as a light tan solid containing 10% unreacted starting material.

$^1\text{H NMR}$ (DMSO-d_6) δ : 12.54 (br s, 1H), 8.21 (s, 1H), 7.99 (d, $J=2$ Hz, 1H), 7.73 (dd, $J=9$ Hz, 2 Hz, 1H), 7.27 (d, $J=9$ Hz, 1H).

Step B: 6-Bromoquinoxalin-2-ol (200 mg, 0.88 mmol), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-(trifluoromethyl)-2H-indazole (300 mg, 1.09 mmol), $\text{Pd}(\text{dpf})\text{Cl}_2-\text{CH}_2\text{Cl}_2$ (50 mg, 0.061 mmol), DMF (5 mL), and aqueous K_2CO_3 (2M, 1.65 mL, 3.3 mmol) were heated at 90°C . for 2 h. To the mixture was added dilute aqueous HCl. The solid material was collected by filtration, washed with H_2O , EtOH and ether, and then dried to yield crude

216

6-(2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl)quinoxalin-2-ol (231 mg). MS m/z 345.2 [M+H] $^+$.

Step C: 6-(2-Methyl-7-(trifluoromethyl)-2H-indazol-5-yl)quinoxalin-2-ol (231 mg, 0.67 mmol), CH_3CN (3 mL) and POBr_3 (1.2 g, 4.18 mmol) were heated at 90°C . for 15 h. The mixture was diluted in ether and filtered. The solid material was washed with CH_2Cl_2 . The mixture was dissolved in $\text{CH}_2\text{Cl}_2:\text{MeOH}$ and was filtered through a silica plug to remove baseline impurities. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (30% EtOAc in CH_2Cl_2). The product was triturated with CH_2Cl_2 . The solid was collected and dried to yield 2-bromo-6-(2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl)quinoxaline (117 mg, 32% over two steps) as an off-white solid.

15 $^1\text{H NMR}$ (acetone- d_6) δ : 9.02 (s, 1H), 8.61 (s, 1H), 8.55 (s, 1H), 8.46 (d, $J=2$ Hz, 1H), 8.37 (dd, $J=8.5$ Hz, 2 Hz, 1H), 8.14-8.17 (m, 2H), 4.36 (s, 3H).

Step D: 2-Bromo-6-(2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl)quinoxaline (85 mg, 0.21 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (10 mg, 0.013 mmol), 1,4-dioxane (0.5 mL), and (1-(tert-butoxycarbonyl)piperidin-4-yl)zinc(II) iodide (1M in DMA, 0.5 mL, 0.5 mmol, prepared according to Example 5) were heated at 80°C . for 2 h. The mixture was partitioned between EtOAc and aqueous saturated NH_4Cl . The organic layer was dried over MgSO_4 , filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (1:1 CH_2Cl_2 :EtOAc, followed by 20% acetone in CH_2Cl_2). The collected material was triturated with 1:1 hexanes:ether. The solid material was collected by vacuum filtration and dried to yield tert-butyl 4-(2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl)quinoxalin-2-yl)piperidine-1-carboxylate (41 mg, 38%) as a pink solid.

35 $^1\text{H NMR}$ (acetone- d_6) δ : 8.97 (s, 1H), 8.59 (s, 1H), 8.51 (s, 1H), 8.39 (d, $J=2$ Hz, 1H), 8.26 (dd, $J=8.5$ Hz, 2 Hz, 1H), 8.14-8.17 (m, 2H), 4.36 (s, 3H), 4.25-4.34 (m, 2H), 3.42 (m, 1H), 2.90-3.15 (br s, 2H), 2.05-2.10 (m, 2H), 1.91 (qd, $J=12.5$ Hz, 4 Hz, 2H), 1.50 (s, 9H).

40 Step E: tert-Butyl 4-(6-(2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl)quinoxalin-2-yl)piperidine1-carboxylate (25 mg, 0.049 mmol) and 4 N HCl in dioxane (1 mL, 4 mmol) were heated at 80°C . for 1 h. The mixture was diluted in ether. The solid material was collected by vacuum filtration and dried to yield 6-(2-methyl-7-(trifluoromethyl)-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoxaline hydrochloride as a yellow solid (20 mg, 91%).

45 MS m/z 412.1 [M+H] $^+$; $^1\text{H NMR}$ (methanol- d_4) δ : 8.97 (s, 1H), 8.55 (s, 1H), 8.47 (s, 1H), 8.37 (d, $J=2$ Hz, 1H), 8.27 (dd, $J=9$ Hz, 2 Hz, 1H), 8.21 (d, $J=8.5$ Hz, 1H), 8.12 (s, 1H), 4.34 (s, 3H), 3.59-3.66 (m, 2H), 3.45-3.54 (m, 1H), 3.24-3.33 (m, 2H), 2.33-2.40 (m, 2H), 2.22-2.33 (m, 2H), NH proton not observed.



50 Using the procedure described for Example 23, above, additional compounds described herein were prepared by substituting the appropriate boronic acid in Step B, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
31	MS m/z 358.2 [M + H] $^+$; $^1\text{H NMR}$ (methanol- d_4) δ : 8.98 (s, 1H), 8.86 (s, 1H), 8.39 (d, $J = 2$ Hz, 1H), 8.27 (dd, $J = 9$ Hz, 2 Hz, 1H), 8.23 (s, 1H), 8.21 (d, $J = 8.5$ Hz, 1H), 8.00 (s, 1H), 4.46 (s, 3H), 3.60-3.69 (m, 2H), 3.46-3.54 (m, 1H), 3.24-3.33 (m, 2H), 2.75 (s, 3H), 2.33-2.40 (m, 2H), 2.21-2.31 (m, 2H), NH proton not observed.

217

Example 24

Preparation of Compound 5



Step A: 4-Bromoaniline (5.0 g, 29.1 mmol) was dissolved in EtOAc (60 mL) and Et₃N (5.25 mL, 37.5 mmol) at 0°C. Methyl 3-chloro-3-oxopropanoate (3.95 mL, 31.5 mmol) was added dropwise to the solution. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was partitioned between EtOAc and dilute aqueous HCl. The organic layer was washed with aqueous NaHCO₃ and brine. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was triturated with 2:1 hexane:ether. The solid material was collected by vacuum filtration and dried to yield ethyl 3-((4-bromophenyl)amino)-3-oxopropanoate (6.23 g, 75%) as a white solid.

¹H NMR (acetone-d₆) δ: 9.50 (br s, 1H), 7.64 (m, 2H), 7.49 (m, 2H), 4.19 (q, J=7 Hz, 2H), 3.48 (s, 2H), 1.26 (t, J=7 Hz, 3H).

Step B: Ethyl 3-((4-bromophenyl)amino)-3-oxopropanoate (6.23 g, 22.1 mmol) was dissolved in THF (60 mL) and MeOH (15 mL) at 0°C. Aqueous 2 N NaOH (15 mL, 30 mmol) was added dropwise to the mixture. The mixture was stirred at 0°C for 1 h, upon which excess reagent was quenched with aqueous 6 N HCl (7.5 mL). The mixture was concentrated under vacuum. The residue was suspended in H₂O. The solid material was collected by vacuum filtration and dried to yield 3-((4-bromophenyl)amino)-3-oxopropanoic acid (5.7 g, 100%) as a white solid.

¹H NMR (acetone-d₆) δ: 9.63 (br s, 1H), 7.64 (m, 2H), 7.49 (m, 2H), 3.50 (s, 2H), CO₂H proton not observed.

Step C: Methanesulfonic acid (28 mL), 3-((4-bromophenyl)amino)-3-oxopropanoic acid (5.7 g, 22.1 mmol), and P₂O₅ (9 g, 63.4 mmol) were combined and heated at 80°C for 6 h. The mixture was poured onto ice, and the resulting solid material was collected by vacuum filtration. The solid material was washed with EtOH and ether, and dried to yield 6-bromo-2-hydroxyquinolin-4(1H)-one (3.48 g, 65%) as a tan solid. MS m/z 240.0, 242.0 [M-al]⁺.

Step D: 6-Bromo-2-hydroxyquinolin-4(1H)-one (3.48 g, 14.5 mmol) and POCl₃ (25 mL) were heated at 100°C for 15 h. The mixture was poured into ice-water. The resulting mixture was extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (30%

219

hexanes in CH_2Cl_2) to yield 6-bromo-2,4-dichloroquinoline (2.9 g, 72%) as a white solid.

¹H NMR (acetone-d₆) δ: 8.42 (d, J=2 Hz, 1H), 8.06 (dd, J=9 Hz, 2 Hz, 1H), 7.98 (d, J=9 Hz, 1H), 7.85 (s, 1H).

Step E: 6-Bromo-2,4-dichloroquinoline (2.82 g, 10.2 mmol) and 0.5 M NaOMe in MeOH (21.2 mL, 10.6 mmol) were combined and heated at reflux for 2 h. The mixture was partitioned between H₂O and CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (50-70% CH₂Cl₂ in hexanes) to yield 6-bromo-4-chloro-2-methoxyquinoline (1.02 g, 37%).

¹H NMR (acetone-d₆) δ: 8.25 (d, J=2 Hz, 1H), 7.88 (dd, J=9, 2 Hz, 1H), 7.80 (d, J=9 Hz, 1H), 7.22 (s, 1H), 4.06 (s, 3H).

Step F: 6-Bromo-4-chloro-2-methoxyquinoline (210 mg, 0.77 mmol), (2-methyl-2H-indazol-5-yl)boronic acid (161 mg, 0.91 mmol), Pd(PPh₃)₄ (90 mg, 0.078 mmol), 2 M aqueous K₂CO₃ (1.4 mL, 2.8 mmol) and 1,4-dioxane (4.2 mL) were combined and heated at 80° C. for 1 h. The reaction mixture was partitioned between CH₂Cl₂ and H₂O. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (30% EtOAc in CH₂Cl₂). The collected product was triturated in ether. The solid material was collected by vacuum filtration and dried to yield 4-chloro-2-methoxy-6-(2-methyl-2H-indazol-5-yl)quinoline (182 mg, 73%) as a white solid.

¹H NMR (acetone-d₆) δ: 8.37 (d, J=2 Hz, 1H), 8.32 (s, 1H), 8.14 (dd, J=9 Hz, 2 Hz, 1H), 8.11 (m, 1H), 7.96 (d, J=8.5 Hz, 1H), 7.76-7.80 (m, 1H), 7.72 (dd, J=8.5 Hz, 1.5 Hz, 1H), 7.20 (s, 1H), 4.27 (s, 3H), 4.08 (s, 3H).

Step G: 4-Chloro-2-methoxy-6-(2-methyl-2H-indazol-5-yl)quinoline (120 mg, 0.37 mmol) was combined with Pd(dppf)Cl₂-CH₂Cl₂ (35 mg, 0.043 mmol) in 1,4-dioxane (0.5 mL). To the mixture was added dimethylzinc (1.2 M in toluene, 1 mL, 1.2 mmol). The mixture was heated at 80° C. for 4 h. The reaction mixture was cooled to room temperature, upon which excess reagent was carefully quenched with MeOH. The mixture was partitioned between NH₄OH and CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. Purification by silica gel chromatography (30% EtOAc in CH₂Cl₂), followed by ether trituration, yielded 2-methoxy-4-methyl-6-(2-methyl-2H-indazol-5-yl)quinoline (102 mg, 91%) as a white solid.

¹H NMR (acetone-d₆) δ: 8.31 (s, 1H), 8.23 (d, J=2 Hz, 1H), 8.08 (t, J=1.5 Hz, 1H), 8.02 (dd, J=8.5 Hz, 2.5 Hz, 1H), 7.89 (d, J=9 Hz, 1H), 7.74 (m, 2H), 6.88 (s, 1H), 4.27 (s, 3H), 4.03 (s, 3H), 2.76 (s, 3H).

Step H: 2-Methoxy-4-methyl-6-(2-methyl-2H-indazol-5-yl)quinoline (100 mg, 0.33 mmol) and 4 N HCl in 1,4-dioxane (1.5 mL, 6 mmol) were heated at 110° C. for 3 h. The mixture was diluted in ether and was filtered. The solid was dried, yielding 4-methyl-6-(2-methyl-2H-indazol-5-yl)quinolin-2-ol (82 mg, 84%) as a light tan solid. MS m/z 289.9 [M+H]⁺.

Step I: 4-Methyl-6-(2-methyl-2H-indazol-5-yl)quinolin-2-ol (82 mg, 0.28 mmol) and POCl₃ (1.5 mL) were heated at 120° C. for 2 h. The mixture was poured onto ice. Aqueous saturated NaHCO₃ was added to the ice to neu-

220

tralize the mixture. The aqueous mixture was washed with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (5% MeOH in CH₂Cl₂). The collected product was triturated with 1:1 acetone:CH₂Cl₂. The solid was collected and dried to yield 2-chloro-4-methyl-6-(2-methyl-2H-indazol-5-yl)quinoline (84 mg, 100%) as an orange solid.

¹H NMR (DMSO-d₆) δ: 8.46 (s, 1H), 8.32 (d, J=2 Hz, 1H), 8.17-8.23 (m, 2H), 8.01 (d, J=9 Hz, 1H), 7.79 (dd, J=9 Hz, 1.5 Hz, 1H), 7.75 (d, J=9 Hz, 1H), 7.52 (s, 1H), 4.22 (s, 3H), 2.80 (s, 3H).

Step J: 2-Chloro-4-methyl-6-(2-methyl-2H-indazol-5-yl)quinoline (75 mg, 0.24 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (93 mg, 0.3 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-

(2'-amino-1,1'-biphenyl)]palladium(II) (10 mg, 0.014 mmol), aqueous 2 M K₂CO₃ (0.45 mL, 0.9 mmol) and DMF (1.35 mL) were combined and heated at 80° C. for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (30-50% EtOAc in CH₂Cl₂). The collected product was triturated with ether. The solid was collected and dried to yield tert-butyl 4-(4-methyl-6-(2-methyl-2H-indazol-5-yl)quinolin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (73 mg, 67%) as a white solid.

¹H NMR (acetone-d₆) δ: 8.32 (s, 1H), 8.31 (s, 1H), 8.14 (t, J=1.5 Hz, 1H), 8.06-8.12 (m, 2H), 7.75-7.80 (m, 2H), 7.73 (s, 1H), 6.86 (br s, 1H), 4.27 (s, 3H), 4.20 (s, 2H), 3.69 (t, J=5.5 Hz, 2H), 2.88 (m, 2H), 2.83 (s, 3H), 1.51 (s, 9H).

Step K: tert-Butyl 4-(4-methyl-6-(2-methyl-2H-indazol-5-yl)quinolin-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (70 mg, 0.15 mmol) was combined with 4:1 CH₂Cl₂:MeOH (1.5 mL) and 10% Pd/C (35 mg). The mixture was stirred at room temperature under H₂ (1 atm) for 4 h. The mixture was filtered through Celite. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (1:1 CH₂Cl₂:EtOAc, followed by 20% acetone in CH₂Cl₂). The collected material was triturated in ether. The solid was collected and dried to yield tert-butyl 4-(4-methyl-6-(2-methyl-2H-indazol-5-yl)quinolin-2-yl)piperidine-1-carboxylate (55 mg, 79%) as a white solid.

¹H NMR (acetone-d₆) δ: 8.32 (s, 1H), 8.30 (s, 1H), 8.12 (t, J=1.5 Hz, 1H), 8.04-8.11 (m, 2H), 7.73-7.78 (m, 2H), 7.37 (s, 1H), 4.27 (m, 5H), 3.03-3.14 (m, 1H), 2.85-3.01 (m, 2H), 2.82 (s, 3H), 1.95-2.03 (m, 2H), 1.82-1.92 (m, 2H), 1.49 (s, 9H).


Step L: tert-Butyl 4-(4-methyl-6-(2-methyl-2H-indazol-5-yl)quinolin-2-yl)piperidine-1-carboxylate (53 mg, 0.12 mmol) and 4 N HCl in 1,4-dioxane (1 mL, 4 mmol) were combined and heated at 50° C. for 1 h. The mixture was diluted with ether. The solid material was collected by vacuum filtration, washed with 9:1 CH₂Cl₂:MeOH and dried to yield 4-methyl-6-(2-methyl-2H-indazol-5-yl)-2-(piperidin-4-yl)quinoline hydrochloride (46 mg, 100%) as a yellow solid.

MS m/z 357.0 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.11-9.23 (br s, 1H), 8.95-9.10 (br s, 1H), 8.38-8.53 (m, 4H), 8.28 (s, 1H), 7.83 (dd, J=9 Hz, 1.5 Hz, 1H), 7.72-7.80 (m, 2H), 4.23 (s, 3H), 3.50-3.60 (m, 1H), 3.41-3.49 (m, 2H), 3.09 (m, 2H), 3.00 (s, 3H), 2.20-2.38 (m, 4H).

221

Example 25

Preparation of Compound 7



Step A: 6-Bromoquinolin-2-ol (670 mg, 3.0 mmol) was combined with piperazine (504 mg, 6.0 mmol), potassium tert-butoxide (840 mg, 7.5 mmol), 2-dicyclohexylphosphino-2',6'-disopropoxybiphenyl (280 mg, 0.6 mmol) and tris(dibenzylideneacetone)dipalladium(0) (275 mg, 0.3 mmol) in 1,4-dioxane (10 mL). The mixture was heated at 100° C. for 16 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% MeOH in CH₂Cl₂ to yield 6-(piperazin-1-yl)quinolin-2-ol (575 mg, 84%). MS m/z 230.1 [M+H]⁺.

Step B: 6-(Piperazin-1-yl)quinolin-2-ol (575 mg, 2.5 mmol) was suspended in POCl₃ (4.6 mL, 50 mmol). The mixture was heated at 100° C. for 16 h. The mixture was slowly added to a vigorously stirred mixture of CH₂Cl₂ (100 mL), H₂O (100 mL), and 10 g of (NaHCO₃). The organic layer was collected and concentrated. The residue was chromatographed on silica gel, eluting with 0-15% MeOH in CH₂Cl₂ to yield 2-chloro-6-(piperazin-1-yl)quinoline (280 mg, 45%). MS m/z 248.1, 250.1 [M+H]⁺.

Step C: 2-Chloro-6-(piperazin-1-yl)quinoline (280 mg, 1.1 mmol) was combined with 2-methylindazole-5-boronic acid (387 mg, 1.5 mmol), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloromethane complex (80 mg, 0.10 mmol), 1,4-dioxane (10 mL), and aqueous 1 M


222

K₂CO₃ (5 mL, 5 mmol). The mixture was stirred at 100° C. for 16 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-15% MeOH in CH₂Cl₂ to yield 2-(2-methyl-2H-indazol-5-yl)-6-(piperazin-1-yl)quinoline (51 mg, 20%).

MS m/z 344.1 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.52 (s, 1H), 8.46 (s, 1H), 8.18-8.22 (m, 2H), 8.05 (d, J=8.5 Hz), 7.88 (d, J=9.0 Hz), 7.69 (d, J=9.0 Hz), 7.60 (d, J=8.5 Hz), 7.18 (s, 1H), 4.20 (s, 3H), 3.19-3.22 (m, 4H), 2.88-2.91 (m, 4H), NH proton not observed.

Example 26

Preparation of Compound 117



223

Step A: A mixture of 7-bromo-3-chloro-5-fluorocinnoline (120 mg, 0.46 mmol, prepared according to Example 7), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (153 mg, 0.49 mmol), and chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (25 mg, 0.034 mmol) in 1,4-dioxane (3.5 mL) and aqueous 2 M K₂CO₃ (0.7 mL, 1.4 mmol) was heated to 80° C. for 2 h.

The crude reaction mixture was cooled to room temperature, filtered over celite, and concentrated. The residue was chromatographed on silica gel, eluting with 10-50% EtOAc in hexanes to yield tert-butyl 4-(3-chloro-5-fluorocinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (120 mg, 72%) as a tan solid. MS m/z 364.4, 366.4 [M+H]⁺.

Step B: A mixture of 8-fluoro-2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine (69 mg, 0.25 mmol), tert-butyl 4-(3-chloro-5-fluorocinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (60 mg, 0.16 mmol), and chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (12 mg, 0.016 mmol) in 1,4-dioxane (1.5 mL) and aqueous 2 M K₂CO₃ (0.25 mL, 0.5 mmol) was heated to 90° C. for 2 h. The mixture was cooled to room temperature, filtered over celite, and concentrated. The residue was chro-

224

matographed on silica gel, eluting with 5-10% MeOH in CH₂Cl₂ to yield tert-butyl 4-(5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)cinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (54 mg, 69%) as a brown solid. MS m/z 478.5 [M+H]⁺.

Step C: To a solution of tert-butyl 4-(5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)cinnolin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (54 mg, 0.11 mmol) in CH₂Cl₂ (1.5 mL) was added trifluoroacetic acid (1.5 mL). The reaction was stirred at room temperature for 15 minutes, then concentrated. The residue was dissolved in HCl in MeOH (1.25 M) and concentrated. This procedure was repeated once more to afford 5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride (26 mg, 56%) as a yellow solid.

MS m/z 378.4 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 9.82 (s, 1H), 9.35-9.42 (br s, 2H), 8.92 (s, 1H), 8.64 (d, J=11.9 Hz, 1H), 8.43 (s, 1H), 8.21-8.25 (br s, 1H), 8.13 (d, J=11.6 Hz, 1H), 7.64-7.77 (br s, 1H), 3.87-3.92 (br s, 2H), 3.39-3.44 (m, 2H), 2.92-2.97 (m, 2H), 2.53 (s, 3H).


Using the procedure described for Example 26, above, additional compounds described herein were prepared by substituting the appropriate boronic acid in Step B, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
134	MS m/z 378.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.21-9.26 (br s, 2H), 8.77 (s, 1H), 8.65-8.74 (m, 2H), 8.38 (s, 1H), 8.12 (d, J = 13.4 Hz, 1H), 8.06 (d, J = 11.9 Hz, 1H), 6.70-6.74 (br s, 1H), 4.27 (s, 3H), 3.85-3.90 (m, 2H), 3.35-3.44 (m, 2H), 2.90-2.95 (m, 2H).
156	MS m/z 374.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.65 (s, 1H), 8.89 (d, J = 1.0 Hz, 1H), 8.69 (t, J = 1.2 Hz, 1H), 8.46 (s, 1H), 8.14 (d, J = 0.9 Hz, 1H), 8.00 (dd, J = 11.1, 1.4 Hz, 1H), 6.67 (dt, J = 3.4, 1.8 Hz, 1H), 4.02 (d, J = 3.1 Hz, 2H), 3.61 (t, J = 6.1 Hz, 2H), 3.01-3.11 (m, 2H), 2.81 (s, 3H), 2.65 (s, 3H), NH and HCl protons not observed.
157	MS m/z 374.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.82 (s, 1H), 8.58-8.61 (m, 2H), 8.38 (s, 1H), 8.14 (s, 1H), 7.97 (d, J = 10.4 Hz, 1H), 6.64-6.67 (m, 1H), 4.36 (s, 3H), 4.01-4.03 (m, 2H), 3.60 (t, J = 6.1 Hz, 2H), 3.04-3.08 (m, 2H), 2.75 (s, 3H), NH and HCl protons not observed.
165	MS m/z 378.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.73 (d, J = 2.4 Hz, 1H), 8.37 (s, 1H), 7.66-7.72 (m, 1H), 7.62 (s, 1H), 7.50 (d, J = 11.4 Hz, 1H), 6.37-6.43 (m, 1H), 6.24-6.28 (m, 1H), 4.34-4.39 (s, 3H), 3.92-3.97 (m, 2H), 3.51-3.55 (m, 2H), 2.84-2.93 (m, 2H), NH and HCl protons not observed.
166	MS m/z 377.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.70 (d, J = 9.8 Hz, 1H), 8.57 (dd, J = 2.4, 1.4 Hz, 1H), 8.44 (s, 1H), 8.31 (d, J = 8.9 Hz, 1H), 7.99 (s, 1H), 7.94 (m, 2H), 6.52 (br s, 1H), 4.29-4.36 (m, 3H), 3.98 (d, J = 2.1 Hz, 2H), 3.58 (dd, J = 7.8, 6.1 Hz, 2H), 2.96-3.04 (m, 2H), NH and HCl protons not observed.
167	MS m/z 375.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.08 (s, 1H), 8.86 (s, 1H), 8.39 (s, 1H), 8.32 (s, 1H), 7.91 (d, J = 11.0 Hz, 1H), 6.57-6.59 (br s, 1H), 3.87-3.95 (m, 2H), 3.49 (t, J = 6.1 Hz, 2H), 2.94-2.98 (m, 2H), 2.78 (s, 3H), 2.59 (s, 3H), NH protons not observed.
171	MS m/z 379.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.20-9.25 (br s, 2H), 8.96 (s, 1H), 8.88 (s, 1H), 8.41 (s, 1H), 8.36 (d, J = 12.5 Hz, 1H), 8.11 (d, J = 11.6 Hz, 1H), 6.73-6.76 (br s, 1H), 4.62 (s, 3H), 3.87-3.91 (m, 2H), 3.39-3.44 (m, 2H), 2.92-2.97 (m, 2H).
175	MS m/z 385.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.25 (s, 1H), 9.05-9.10 (br s, 2H), 8.90 (s, 1H), 8.94 (s, 1H), 8.84 (s, 1H), 8.41 (s, 1H), 8.09 (d, J = 11.0 Hz, 1H), 6.72-6.75 (m, 1H), 4.32 (s, 3H), 3.88-3.92 (m, 2H), 3.40-3.45 (m, 2H), 2.91-2.96 (m, 2H).
198	MS m/z 388.3 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.67 (s, 1H), 8.65 (s, 1H), 8.52 (s, 1H), 8.37 (s, 1H), 8.08 (s, 1H), 7.86-7.88 (d, J = 11 Hz, 1H), 6.45 (t, J = 6.5 Hz, 1H), 4.34 (s, 3H), 3.97 (m, 2H), 3.00 (m, 2H), 2.65 (s, 3H), 2.37 (m, 2H), 2.02, (m, 2H), NH proton not observed.

225

Example 27

Preparation of Compound 128



A suspension of 5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(1,2,3,6-tetrahydropyridin-4-yl)cinnoline hydrochloride (22 mg, 0.05 mmol) and Pd/C (20 mg) in MeOH (2 mL) was stirred under H₂ (1 atm) at room temperature for 12 h. The mixture was filtered over celite and concentrated. The residue was dissolved in DMF (1 mL). To the solution was added MnO₂ (45 mg, 0.5 mmol). The reaction was stirred at room temperature for 1 h, then filtered over celite. The filtrate was concentrated. The residue was dissolved in 1.25 M HCl in MeOH. Concentration afforded 5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)cinnoline hydrochloride (15 mg, 62%) as a yellow solid.


MS m/z 380.4 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.69 (s, 1H), 8.93 (s, 1H), 8.79 (d, J=11.0 Hz, 1H), 8.33 (s, 1H), 8.25 (s, 1H), 7.74 (d, J=10.7 Hz, 1H), 3.61 (d, J=12.5 Hz, 2H), 3.21-3.35 (m, 3H), 2.65 (s, 3H), 2.31 (d, J=14.0 Hz, 2H), 2.00-2.18 (m, 2H), NH and HCl protons not observed.

Using the procedure described for Example 27, above, additional compounds described herein were prepared by substituting suitable reagents and reaction conditions, obtaining compounds such as those selected from:

226

Example 28

Preparation of Compound 144



To a suspension of 5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)-7-(piperidin-4-yl)cinnoline hydrochloride (175 mg, 0.42 mmol) and sodium triacetoxyborohydride (900 mg, 4.2 mmol) in CH₂Cl₂ (4 mL) and EtOH (1 mL) was added a solution of acetaldehyde (0.25 mL, 4.4 mmol) in EtOH (1 mL). The reaction was stirred at room temperature for 1 h, then quenched with saturated aqueous K₂CO₃. The mixture was partitioned between CH₂Cl₂ and H₂O. The aqueous layer was extracted once with CH₂Cl₂. The combined organics were dried over Na₂SO₄ filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% 1.4 N NH₃/MeOH in CH₂Cl₂ to yield 7-(1-ethylpiperidin-4-yl)-5-fluoro-3-(8-fluoro-2-methylimidazo[1,2-a]pyridin-6-yl)cinnoline (120 mg, 70%) as a light orange solid.

MS m/z 408.5 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.29 (d, J=1.2 Hz, 1H), 8.70 (s, 1H), 8.22 (s, 1H), 8.01 (dd, J=12.2, 1.2 Hz, 1H), 7.88 (d, J=2.1 Hz, 1H), 7.65 (d, J=10.7 Hz, 1H), 3.36-3.39 (m, 2H), 2.98-3.09 (m, 1H), 2.76 (q, J=7.2 Hz, 2H), 2.44-2.55 (m, 5H), 2.16 (d, J=13.1 Hz, 2H), 1.95-2.03 (m, 2H), 1.27 (t, J=7.2 Hz, 3H).

Cpd Data


151	MS m/z 380.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.71 (s, 1H), 8.47-8.57 (m, 2H), 8.23 (s, 1H), 8.02 (d, J = 12.2 Hz, 1H), 7.64 (d, J = 10.1 Hz, 1H), 4.31 (s, 3H), 3.62 (d, J = 11.6 Hz, 2H), 3.21-3.29 (m, 3H), 2.32 (d, J = 13.4 Hz, 2H), 1.97-2.15 (m, 2H), NH and HCl protons not observed.
177	MS m/z 376.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.00-9.07 (br s, 1H), 8.87-8.95 (br s, 1H), 8.60-8.66 (m, 2H), 8.51 (s, 1H), 8.17 (s, 1H), 8.06 (s, 1H), 7.68 (d, J = 10.5 Hz, 1H), 4.23 (s, 3H), 3.46-3.55 (m, 1H), 3.15-3.22 (m, 2H), 3.01-3.10 (br s, 2H), 2.64 (s, 3H), 2.12-2.19 (m, 2H), 1.98-2.07 (m, 2H).
185	MS m/z 377.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.21 (s, 1H), 9.01 (s, 1H), 8.45 (s, 1H), 8.38 (s, 1H), 7.78 (d, J = 9.5 Hz, 1H), 3.63 (d, J = 12.5 Hz, 2H), 3.23-3.40 (m, 3H), 2.90 (s, 3H), 2.71 (s, 3H), 2.34 (d, J = 14.0 Hz, 2H), 2.06-2.17 (m, 2H), NH and HCl protons not observed.
192	MS m/z 379.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.46 (d, J = 2.4 Hz, 1H), 8.35-8.40 (m, 2H), 8.16 (d, J = 8.9 Hz, 1H), 8.03 (dd, J = 13.2, 1.1 Hz, 1H), 7.61 (s, 1H), 7.48 (dd, J = 11.9, 1.5 Hz, 1H), 4.29 (s, 3H), 3.30 (br s, 2H), 2.88-3.01 (m, 3H), 2.04 (d, J = 12.5 Hz, 2H), 1.80-1.90 (m, 2H), NH proton not observed.


Using the procedure described for Example 28 above, additional compounds described herein were prepared by substituting suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
153	MS m/z 406.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.83 (s, 1H), 8.55 (d, J = 1.5 Hz, 2H), 8.38 (s, 1H), 8.01 (dd, J = 12.8, 1.2 Hz, 1H), 7.97 (dd, J = 11.3, 1.2 Hz, 1H), 6.63-6.67 (br s, 1H), 4.32 (s, 3H), 4.25 (d, J = 13.1 Hz, 1H), 3.88-4.01 (m, 2H), 3.38-3.50 (m, 3H), 3.10-3.18 (m, 2H), 1.49 (t, J = 7.3 Hz, 3H), HCl proton not observed.
154	MS m/z 408.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.66-8.71 (m, 1H), 8.48-8.54 (m, 2H), 8.21 (s, 1H), 8.01 (dd, J = 12.8, 1.2 Hz, 1H), 7.63 (d, J = 10.7 Hz, 1H), 4.31 (s, 3H), 3.42-3.55 (m, 2H), 3.12 (t, J = 12.4 Hz, 1H), 2.91-2.97 (m, 2H), 2.70-2.78 (m, 2H), 2.23 (d, J = 13.1 Hz, 2H), 1.98-2.14 (m, 2H), 1.33 (t, J = 7.3 Hz, 3H).
183	MS m/z 404.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.63 (d, J = 6.4 Hz, 2H), 8.51 (s, 1H), 8.18 (s, 1H), 8.06 (s, 1H), 7.74 (d, J = 10.4 Hz, 1H), 4.23 (s, 3H), 3.12-3.25 (m, 3H), 2.86-2.96 (m, 2H), 2.64 (s, 3H), 2.45-2.55 (m, 2H), 1.97-2.05 (m, 2H), 1.84-1.91 (m, 2H), 1.06-1.17 (m, 3H).
184	MS m/z 405.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.83 (d, J = 9.5 Hz, 1H), 8.61 (d, J = 2.3 Hz, 1H), 8.45 (s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 8.07 (s, 1H), 8.02 (d, J = 11.7 Hz, 1H), 7.91 (d, J = 12.4 Hz, 1H), 6.54 (br s, 1H), 4.33 (s, 3H), 4.22 (d, J = 15.4 Hz, 1H), 3.81-3.99 (m, 2H), 3.37-3.49 (m, 3H), 3.04-3.15 (m, 2H), 1.48 (t, J = 7.2 Hz, 3H).
186	MS m/z 405.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.04 (d, J = 0.9 Hz, 1H), 8.39 (d, J = 1.2 Hz, 1H), 8.27 (s, 1H), 8.05 (d, J = 0.9 Hz, 1H), 7.66-7.73 (m, 1H), 3.47 (d, J = 11.9 Hz, 2H), 3.07-3.17 (m, 1H), 2.90 (q, J = 7.2 Hz, 2H), 2.76 (d, J = 0.9 Hz, 3H), 2.69 (t, J = 11.6 Hz, 2H), 2.54 (s, 3H), 2.23 (d, J = 13.7 Hz, 2H), 2.04 (qd, J = 12.9, 3.5 Hz, 2H), 1.32 (t, J = 7.3 Hz, 3H).
193	MS m/z 407.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.47 (d, J = 2.4 Hz, 1H), 8.37-8.41 (m, 2H), 8.18 (d, J = 8.7 Hz, 1H), 8.04 (d, J = 13.3 Hz, 1H), 7.63 (s, 1H), 7.49 (d, J = 12.2 Hz, 1H), 4.30 (s, 3H), 3.42-3.52 (m, 2H), 2.87-3.01 (m, 3H), 2.59-2.76 (m, 2H), 2.15 (d, J = 16.6 Hz, 2H), 2.00 (m, 2H), 1.32 (t, J = 7.3 Hz, 3H).
201	MS m/z 406.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.58 (s, 1H), 8.89 (s, 1H), 8.50 (d, J = 2.6 Hz, 1H), 8.24 (d, J = 14.3 Hz, 1H), 7.97 (d, J = 11.6 Hz, 1H), 7.91 (s, 1H), 6.50 (br s, 1H), 4.29 (s, 3H), 2.92 (t, J = 6.7 Hz, 2H), 2.77-2.83 (m, 2H), 2.70 (d, J = 7.3 Hz, 2H), 1.31 (br s, 2H), 1.25 (t, J = 7.2 Hz, 3H).
202	MS m/z 408.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.59 (br s, 1H), 8.91 (br s, 1H), 8.51 (br s, 1H), 8.25 (d, J = 13.1 Hz, 1H), 7.82 (br s, 1H), 7.74 (d, J = 12.4 Hz, 1H), 4.30 (br s, 3H), 3.68 (d, J = 9.3 Hz, 2H), 3.20 (br s, 3H), 3.08 (br s, 2H), 2.28 (d, J = 14.8 Hz, 2H), 1.99-2.12 (m, 2H), 1.35-1.44 (t, J = 7.2 Hz, 3H).

Example 29

Preparation of Compound 108



229

Step A: 1-Bromo-2,3-difluoro-5-nitrobenzene (10.0 g, 42.0 mmol, prepared in Example 7, Step A) was combined with tert-butyl 4-(3-ethoxy-3-oxo-propanoyl)piperidine-1-carboxylate (13.8 g, 46.2 mmol) in DMF (100 mL). To the solution was added Cs₂CO₃ (27.4 g, 84.0 mmol). The mixture turned dark red upon addition. The mixture was stirred at 60° C. for 4 h. The mixture was partitioned between EtOAc and aqueous 0.5 M HCl. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated to yield tert-butyl 4-[2-(2-bromo-6-fluoro-4-nitro-phenyl)-3-ethoxy-3-oxo-propanoyl]piperidine-1-carboxylate (21.5 g) as a crude oil. MS m/z 515.5, 517.5 [M-H]⁻.

Step B: The crude material from Step A was suspended in AcOH (40 mL) and conc. aqueous HCl (37 mass %, 40 mL). The mixture was heated at 120° C. for 4 h, then 100° C. for 16 h. Volatiles were removed under reduced pressure. The residue was dissolved in MeOH (100 mL) and triethylamine (23.4 mL, 168.0 mmol). To the mixture was added di-tert-butyl dicarbonate (13.7 g, 63.0 mmol). The mixture was stirred at room temperature for 30 min. The volatile material

230

was removed from the mixture under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in CH₂Cl₂ to yield tert-butyl 4-[2-(2-bromo-6-fluoro-4-nitro-phenyl)acetyl]piperidine-1-carboxylate (10.2 g, 55%). MS m/z 443.5, 445.5 [M-H]⁻.
Step C: tert-Butyl 4-[2-(2-bromo-6-fluoro-4-nitro-phenyl)acetyl]piperidine-1-carboxylate (10 g, 22.5 mmol) was combined with Zn (73.2, 112 mmol), NH₄Cl (24.1 g, 450 mmol) and MeOH (100 mL). The mixture was stirred at 40° C. for 3 h. The mixture was diluted with EtOAc and filtered through celite. The filtrate was concentrated to yield tert-butyl 4-[2-(4-amino-2-bromo-6-fluoro-phenyl)acetyl]piperidine-1-carboxylate (9.5 g, 100%). MS m/z 315.2, 317.2 [M-Boc+H]⁺.
Step D: tert-Butyl 4-[2-(4-amino-2-bromo-6-fluoro-phenyl)acetyl]piperidine-1-carboxylate (9.5 g, 23 mmol) was combined with CuCl (4.6 g, 46 mmol), CuCl₂ (9.3 g, 69 mmol) and CH₃CN (100 mL). To the mixture was added isoamyl nitrite (9.3 mL, 69 mmol) dropwise at 0° C. The mixture was stirred at 60° C. for 2 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-40% EtOAc in hexanes to yield tert-butyl 4-[2-(2-bromo-4-chloro-6-fluoro-phenyl)acetyl]piperidine-1-carboxylate (7.5 g, 75% Yield). ¹H NMR (acetone-d₆) δ: 7.56 (t, J=1.7 Hz, 1H), 7.34 (dd, J=9.1, 1.9 Hz, 1H), 4.15 (d, J=1.9 Hz, 2H), 4.11 (br d, J=12.0 Hz, 2H), 2.78-2.96 (m, 3H), 1.98 (br d, J=12.3 Hz, 2H), 1.48-1.58 (m, 2H), 1.46 (s, 9H).
Step E: tert-Butyl 4-[2-(2-bromo-4-chloro-6-fluoro-phenyl)acetyl]piperidine-1-carboxylate (7.5 g, 17 mmol) was combined benzoyl hydrazide (3.6 g, 26 mmol), CuI (0.32 g, 1.7 mmol), 1,10-phenanthroline (0.31 g, 1.7 mmol) and sodium tert-butoxide (3.36 g, 35 mmol) in DMF (50 mL). The mixture was stirred under N₂ at 70° C. for 1 h. The mixture was partitioned between EtOAc and 0.25 M HCl (aq). The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-40% EtOAc in hexanes to yield tert-butyl 4-(1-benzoyl-7-chloro-5-fluoro-2H-cinnolin-3-yl)piperidine-1-carboxylate (6.4 g, 79%). MS m/z 470.6, 472.6 [M-H]⁻.
Step F: tert-Butyl 4-(1-benzoyl-7-chloro-5-fluoro-2H-cinnolin-3-yl)piperidine-1-carboxylate (6.2 g, 13 mmol) was suspended in conc. aqueous HCl (37 mass %, 30 mL) and EtOH (20 mL). The mixture was heated at 100° C. for 24 h. The mixture was cooled to 60° C. Air was bubbled through the mixture for 5 h. The volatile material was removed with a stream of N₂. To the crude residue was added MeOH (50 mL), triethylamine (7.4 mL, 53 mmol) and then di-tert-butyl dicarbonate (5.7 g, 26 mmol). The mixture was stirred at room temperature for 30 min. The volatiles were removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-60% EtOAc in hexanes to yield tert-butyl 4-(7-chloro-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (3.0 g, 62%).

MS m/z 310.2, 312.2 [M-tBu+H]⁺. ¹H NMR (acetone-d₆) δ: 8.38 (s, 1H), 8.09 (s, 1H), 7.71 (dd, J=9.5, 1.9 Hz, 1H), 4.26-4.38 (m, 2H), 3.49 (tt, J=12.0, 3.7 Hz, 1H), 3.00 (br s, 2H), 2.10-2.15 (m, 2H), 1.95 (qd, J=12.6, 4.4 Hz, 2H), 1.49 (s, 9H).
Step G: Powdered tert-butyl 4-(7-chloro-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (1.00 g, 2.73 mmol) was weighed into a 50-mL screw-cap tube, followed by anhydrous 1,4-dioxane (27 mL), followed by (Bpin)₂ (0.76 g, 3.0 mmol), SPhos Pd G2 pre-catalyst (0.20 g, 0.27 mmol), and

231

powdered potassium acetate (1.02 g, 10.4 mmol) last. The yellow mixture was then sparged for 2 minutes with argon, the headspace was purged, and the vial was capped and sealed tightly. The vial was placed in an aluminum heating block and stirred vigorously at 90° C. for 3 h. After this time, the reaction mixture was cooled to room temperature. The dark-brown reaction mixture was filtered through Celite. The Celite was washed with EtOAc (60 mL). The brown filtrate was then washed with water (60 mL), 50% aq. NaHCO₃ (2×60 mL), and brine (60 mL), then dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford tert-butyl 4-[5-fluoro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cinnolin-3-yl]piperidine-1-carboxylate as a crude, dark brown powder without further purification.

MS m/z 490.5 [M+MeOH+H]⁺; ¹H NMR (chloroform-d) δ: ppm 8.84 (s, 1H), 7.87 (s, 1H), 7.72 (d, J=9.5 Hz, 1H), 4.37 (br s, 2H), 3.45 (t, 1H), 2.98 (br s, 2H), 2.16 (br d, J=13.6 Hz, 2H), 1.93 (qd, J=12.6, 4.0, 2H), 1.52 (s, 12H), 1.42 (s, 9H).

Step H: A screw-top vial was charged with solid 6-chloro-2-methyl-imidazo[1,2-b]pyridazine-8-carbonitrile (0.14 g, 0.72 mmol) and anhydrous 1,4-dioxane (6.56 mL), followed by tert-butyl 4-[5-fluoro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cinnolin-3-yl]piperidine-1-carboxylate (0.30 g, 0.66 mmol), SPhos Pd G2 pre-catalyst (0.047 g, 0.065 mmol), granular K₂CO₃ (0.27 g, 1.96 mmol), and water (0.33 mL). The brown mixture was sparged with argon for 5 minutes, then sealed with a screw cap. The reaction mixture was stirred vigorously at 90° C. for 3 h. The reaction mixture was cooled to room temperature, diluted with EtOAc (100 mL), washed with water (2×100 mL) and brine

232

(100 mL), then dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The dark-brown, crude material was purified by silica gel column chromatography (hexanes/EtOAc gradient elution) to afford tert-butyl 4-[7-(8-cyano-2-methyl-imidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]piperidine-1-carboxylate (0.182 g, 57%) as a yellow powder.

MS m/z 488.5 [M+H]⁺; ¹H NMR (chloroform-d) δ: 8.87 (s, 1H), 8.18 (d, J=10.2 Hz, 1H), 8.03 (s, 1H), 8.00 (s, 1H), 7.91 (s, 1H), 4.37 (br d, J=5.6 Hz, 2H), 3.49 (tt, J=12.0, 3.4 Hz, 1H), 2.98 (br t, J=12.2 Hz, 2H), 2.63 (s, 3H), 2.16 (br d, J=12.5 Hz, 2H), 1.93 (qd, J=12.6, 4.0 Hz, 2H), 1.50 (s, 9H).

Step I: tert-Butyl 4-[7-(8-cyano-2-methyl-imidazo[1,2-b]pyridazin-6-yl)-5-fluorocinnolin-3-yl]piperidine-1-carboxylate (0.060 g, 0.12 mmol) was dissolved in anhydrous 1,4-dioxane (4 mL), and a 4.0 M solution of HCl in 1,4-dioxane (0.15 mL, 0.60 mmol) was added. The reaction mixture was stirred at room temperature for 4 h, after which time the reaction mixture was concentrated on a rotovap. The crude product was triturated in Et₂O (5 mL), then dried under high vacuum to afford 6-[5-fluoro-3-(4-piperidyl)cinnolin-7-yl]-2-methyl-imidazo[1,2-b]pyridazine-8-carbonitrile hydrochloride (0.060 g, 100%) as a tan solid.

MS m/z 388.4 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.11 (s, 1H), 8.81 (s, 1H), 8.42 (d, J=11.3 Hz, 1H), 8.37 (s, 1H), 8.30 (s, 1H), 3.58-3.77 (m, 5H), 2.63 (s, 3H), 2.21-2.47 (m, 4H).

Using the procedure described for Example 29, above, additional compounds described herein were prepared by substituting the appropriate aryl halide in Step H, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
91	MS m/z 363.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.77 (d, J = 2.4 Hz, 1H), 9.54 (d, J = 2.1 Hz, 1H), 8.84 (s, 1H), 8.35 (s, 1H), 8.16 (d, J = 9.2 Hz, 1H), 8.08 (s, 1H), 3.61-3.70 (m, 3H), 3.28-3.37 (m, 2H), 2.67 (s, 3H), 2.31-2.44 (m, 4H), NH and HCl protons not observed.
92	MS m/z 380.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.27 (d, J = 1.2 Hz, 1H), 8.78 (s, 1H), 8.46 (dd, J = 11.0, 1.2 Hz, 1H), 8.31 (s, 1H), 8.21 (s, 1H), 8.12 (dd, J = 10.4, 1.5 Hz, 1H), 3.59-3.69 (m, 3H), 3.27-3.37 (m, 2H), 2.66 (d, J = 0.9 Hz, 3H), 2.32-2.45 (m, 4H), NH and HCl protons not observed.
93	MS m/z 387.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.61 (d, J = 1.5 Hz, 1H), 9.01 (d, J = 1.5 Hz, 1H), 8.80 (s, 1H), 8.31 (s, 1H), 8.21 (d, J = 1.2 Hz, 1H), 8.13 (dd, J = 10.5, 1.7 Hz, 1H), 3.60-3.70 (m, 3H), 3.28-3.36 (m, 2H), 2.66 (d, J = 0.9 Hz, 3H), 2.31-2.45 (m, 4H), NH and HCl protons not observed.
94	MS m/z 363.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.47 (s, 1H), 8.75 (s, 1H), 8.44 (br d, J = 9.5 Hz, 1H), 8.29 (s, 1H), 8.15 (dd, J = 10.7, 1.5 Hz, 1H), 7.99 (d, J = 9.5 Hz, 1H), 3.60-3.69 (m, 3H), 3.25-3.37 (m, 2H), 2.69 (s, 3H), 2.30-2.44 (m, 4H), NH and HCl protons not observed.
95	MS m/z 362.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.61 (s, 2H), 8.47 (s, 1H), 8.40 (s, 1H), 8.19 (dd, J = 10.7, 1.2 Hz, 1H), 8.03 (dd, J = 9.0, 1.7 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 4.36 (s, 3H), 3.62-3.70 (m, 3H), 2.39-2.46 (m, 2H), 2.28-2.39 (m, 2H), NH and HCl protons not observed; CH ₂ obscured by solvent peak.
96	MS m/z 380.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.99 (s, 1H), 8.51 (d, J = 17.4 Hz, 2H), 8.32 (d, J = 10.7 Hz, 1H), 8.18 (s, 1H), 7.59 (d, J = 12.2 Hz, 1H), 4.25 (s, 3H), 3.72 (t, J = 10.1 Hz, 1H), 3.61 (d, J = 12.2 Hz, 2H), 3.28-3.32 (m, 2H), 2.22-2.47 (m, 4H), NH and HCl protons not observed.
97	MS m/z 380.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.06 (s, 1H), 8.84 (s, 1H), 8.60 (s, 1H), 8.41 (br d, J = 7.0 Hz, 1H), 8.22 (br d, J = 10.1 Hz, 1H), 7.66 (d, J = 11.3 Hz, 1H), 4.40 (s, 3H), 3.82 (t, J = 10.4 Hz, 1H), 3.68 (d, J = 12.5 Hz, 2H), 3.35-3.42 (m, 2H), 2.47 (d, J = 11.9 Hz, 2H), 2.33-2.44 (m, 2H), NH and HCl protons not observed.
99	MS m/z 363.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.14 (s, 1H), 8.59 (d, J = 9.8 Hz, 1H), 8.47 (d, J = 10.1 Hz, 1H), 8.44 (dd, J = 10.7, 1.5 Hz, 1H), 8.41 (s, 1H), 8.31 (s, 1H), 3.60-3.70 (m, 3H), 3.30-3.35 (m, 2H), 2.67 (d, J = 0.9 Hz, 3H), 2.31-2.43 (m, 4H), NH and HCl protons not observed.
101	MS m/z 376.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.84 (d, J = 1.2 Hz, 1H), 8.81 (s, 1H), 8.39 (s, 2H), 8.29 (s, 1H), 8.21 (dd, J = 10.4, 1.2 Hz, 1H), 3.62-3.67 (m, 3H), 3.28-3.33 (m, 2H), 3.04 (s, 3H), 2.55 (s, 3H), 2.30-2.43 (m, 4H), NH and HCl protons not observed.

Cpd	Data
103	MS m/z 376.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.21 (s, 1H), 8.75 (s, 1H), 8.27-8.39 (m, 2H), 8.12 (d, J = 10.6 Hz, 1H), 8.08 (s, 1H), 3.62-3.69 (m, 3H), 3.29-3.36 (m, 2H), 2.78 (s, 3H), 2.65 (s, 3H), 2.30-2.45 (m, 4H), NH and HCl protons not observed.
104	MS m/z 387.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.67 (d, J = 1.5 Hz, 1H), 8.64 (s, 1H), 8.64 (br s, 1H), 8.63 (br s, 1H), 8.42 (d, J = 1.5 Hz, 1H), 8.25 (br d, J = 10.1 Hz, 1H), 4.36 (s, 3H), 3.69-3.75 (m, 1H), 3.66 (d, J = 12.8 Hz, 2H), 2.42 (d, J = 12.5 Hz, 2H), 2.35 (qd, J = 12.8, 3.4 Hz, 2H), NH and HCl protons not observed, CH ₂ obscured by solvent peak.
105	MS m/z 391.2 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.86 (s, 1H), 8.23 (dd, J = 10.8, 1.5 Hz, 1H), 7.92 (s, 1H), 7.81 (d, J = 0.7 Hz, 1H), 7.53 (s, 1H), 3.42-3.52 (m, 1H), 3.33 (br d, J = 12.2 Hz, 2H), 3.20 (q, J = 7.6 Hz, 2H), 2.87-2.96 (m, 2H), 2.56 (s, 3H), 2.14-2.22 (m, 2H), 1.92 (dq, J = 11.2, 4.2 Hz, 2H), 1.51 (t, J = 7.6 Hz, 3H), NH proton not observed.
106	MS m/z 393.1 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.18 (s, 1H), 8.39 (dd, J = 11, 1.5 Hz, 1H), 8.16 (s, 1H), 8.09 (d, J = 0.7 Hz, 1H), 7.56 (s, 1H), 4.22 (s, 3H), 3.47-3.56 (m, 3H), 3.01-3.09 (m, 2H), 2.39 (s, 3H), 2.07-2.24 (m, 4H), NH proton not observed.
107	MS m/z 393.1 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 8.93 (s, 1H), 8.32 (d, J = 11 Hz, 1H), 8.19 (s, 1H), 8.13 (s, 1H), 7.99 (s, 1H), 5.77 (br s, 1H), 4.99 (s, 2H), 3.12-3.20 (m, 3H), 2.71-2.80 (m, 2H), 2.43 (s, 3H), 1.96-2.03 (m, 2H), 1.82-1.96 (m, 2H), NH proton not observed.
109	MS m/z 380.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.22 (s, 1H), 8.75 (s, 1H), 8.60 (s, 1H), 8.31 (d, J = 10.4 Hz, 1H), 7.82 (t, J = 8.2 Hz, 1H), 7.68 (d, J = 8.9 Hz, 1H), 4.37 (s, 3H), 3.85 (t, J = 11.3 Hz, 1H), 3.68 (d, J = 12.2 Hz, 2H), 3.34-3.42 (m, 2H), 2.48 (d, J = 12.8 Hz, 2H), 2.39 (q, J = 11.8 Hz, 2H), NH and HCl protons not observed.
112	MS m/z 403.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.78 (s, 1H), 8.22 (d, J = 12 Hz, 1H), 7.90 (s, 1H), 7.80 (s, 1H), 7.10 (s, 1H), 3.33-3.49 (m, 1H), 3.31 (d, J = 12.4 Hz, 2H), 2.90 (t, J = 12.2 Hz, 2H), 2.70-2.74 (m, 1H), 2.56 (s, 3H), 2.17 (d, J = 12.4 Hz, 2H), 1.85-1.92 (m, 2H), 1.25-1.38 (m, 2H), 1.22-1.25 (m, 2H), NH proton not observed.
118	MS m/z 393.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.59 (s, 1H), 8.03 (d, J = 1.2 Hz, 1H), 7.91 (s, 1H), 7.74 (dd, J = 10.4, 1.2 Hz, 1H), 7.63 (s, 1H), 3.43-3.50 (m, 3H), 3.01 (t, J = 12 Hz, 2H), 2.90 (s, 3H), 2.83 (s, 3H), 2.25 (d, J = 13.2 Hz, 2H), 2.03-2.06 (m, 2H), NH proton not observed.
126	MS m/z 377.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.13 (s, 1H), 8.41 (d, J = 10.5 Hz, 1H), 8.11 (s, 1H), 7.33 (s, 1H), 3.43 (s, 2H), 3.24 (s, 1H), 3.16 (d, J = 12.0 Hz, 2H), 2.78 (s, 3H), 2.55 (s, 3H), 2.05-1.82 (m, 4H), NH protons not observed.
133	MS m/z 394.1 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.03 (s, 1H), 8.47 (dd, J = 11.2, 1.6 Hz, 1H), 8.24 (s, 1H), 8.22 (s, 1H), 3.59-3.63 (m, 3H), 3.24-3.28 (m, 2H), 2.92 (s, 3H), 2.85 (s, 3H), 2.29-2.37 (m, 4H), NH proton observed.
137	MS m/z 378.0 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.00 (s, 1H), 8.29 (d, J = 9.8 Hz, 1H), 8.16 (s, 1H), 7.63 (s, 1H), 3.22-3.31 (m, 1H), 3.14 (d, J = 11.9 Hz, 2H), 2.76 (s, 3H), 2.71 (d, J = 11.0 Hz, 2H), 2.60 (s, 3H), 1.97-2.00 (m, 2H), 1.82-1.93 (m, 2H).
148	MS m/z 378.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.91 (s, 1H), 8.54 (dd, J = 11, 1.6 Hz, 1H), 7.89 (s, 2H), 3.42-3.48 (m, 1H), 3.33 (br d, J = 12 Hz, 2H), 2.89-2.95 (m, 2H), 2.73 (s, 6H), 2.16-2.19 (m, 2H), 1.92-1.96 (m, 2H), NH proton not observed.
148	MS m/z 394.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.89 (s, 1H), 8.33 (dd, J = 10, 1.2 Hz, 1H), 7.91 (s, 1H), 7.59 (s, 1H), 3.44-3.50 (m, 1H), 3.33 (d, J = 12.4 Hz, 2H), 3.04 (s, 3H), 2.89-2.95 (m, 2H), 2.68 (s, 3H), 2.18 (d, J = 12.4 Hz, 2H), 1.90-1.94 (m, 2H), NH proton not observed.
162	MS m/z 377.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.89 (s, 1H), 8.38 (dd, J = 9.6, 1.2 Hz, 1H), 8.24 (s, 1H), 7.91 (s, 1H), 7.79 (s, 1H), 4.32 (s, 3H), 3.38-3.51 (m, 3H), 2.94-3.00 (m, 2H), 2.78 (s, 3H), 2.21-2.24 (m, 2H), 1.97-2.07 (m, 2H), NH proton not observed.
163	MS m/z 393.1 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.88 (s, 1H), 8.42 (dd, J = 10.8, 1.2 Hz, 1H), 8.20 (s, 1H), 7.97 (s, 1H), 7.31 (s, 1H), 4.29 (s, 3H), 4.23 (s, 3H), 3.57-3.62 (m, 3H), 3.05-3.15 (m, 4H), 2.31-2.36 (m, 2H), NH proton not observed.
172	MS m/z 391.2 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.06 (s, 1H), 8.74 (s, 1H), 8.44-8.57 (m, 1H), 8.08 (d, J = 12.9 Hz, 2H), 4.26 (s, 3H), 3.03-3.20 (m, 4H), 2.95 (d, J = 7.9 Hz, 1H), 2.71 (t, J = 11.6 Hz, 2H), 1.97 (d, J = 11.9 Hz, 2H), 1.85 (qd, J = 12.3, 3.9 Hz, 2H), 1.44 (t, J = 7.6 Hz, 3H).
187	MS m/z 402.2 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.94 (s, 1H), 8.62 (br s, 1H); 8.23 (dd, J = 10.4, 1.2 Hz, 1H), 7.99 (s, 1H), 7.90 (s, 1H), 7.86 (s, 1H), 4.32 (s, 2H), 3.56-3.60 (m, 3H), 3.11 (br s, 2H), 2.56 (s, 3H), 2.26-2.35 (m, 4H).
194	MS m/z 429.1 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.29 (s, 1H), 9.15 (s, 1H), 8.55 (br s, 2H), 8.27-8.28 (m, 2H), 8.19 (s, 1H), 7.33 (s, 1H), 3.60-3.64 (m, 3H), 3.25-3.29 (m, 2H), 2.58 (s, 3H), 2.30-2.41 (m, 4H), NH proton not observed.
195	MS m/z 455.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.59 (s, 1H), 8.25 (dd, J = 10.8, 1.2 Hz, 1H), 8.21 (s, 1H), 8.09 (s, 1H), 7.61-7.65 (m, 2H), 7.42-7.49 (m, 3H), 6.96 (s, 1H), 3.59-3.63 (m, 3H), 3.25-3.28 (m, 2H), 2.55 (s, 3H), 2.27-2.38 (m, 4H), NH proton not observed.
196	MS m/z 394.0 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.00 (s, 1H), 8.30-8.48 (m, 2H), 8.17 (s, 1H), 7.80 (s, 1H), 3.44-3.51 (m, 1H), 3.33 (d, J = 10.2 Hz, 2H), 2.89-3.00 (m, 2H), 2.75 (s, 3H), 2.60 (s, 3H), 2.00-2.17 (m, 4H).

Cpd	Data
204	MS m/z 405.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.93 (s, 1H), 8.33 (dd, J = 10.9, 1.3 Hz, 1H), 8.20 (s, 1H), 8.01 (d, J = 0.6 Hz, 1H), 7.86 (s, 1H), 3.43-3.50 (m, 2H), 3.26-3.31 (m, 1H), 3.09 (t, J = 8 Hz, 2H), 2.91-2.98 (m, 2H), 2.53 (s, 3H), 2.17 (d, J = 12.2 Hz, 2H), 1.90-2.08 (m, 4H), 1.12 (t, J = 7.4 Hz, 3H), NH proton not observed.
207	MS m/z 407.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.05 (s, 1H), 8.42 (dd, J = 10.8, 1.2 Hz, 1H), 8.28 (s, 1H), 8.15 (s, 1H), 8.10 (s, 1H), 4.10 (t, J = 6 Hz, 2H), 3.63-3.66 (br s, 3H), 3.35-3.36 (m, 2H), 3.28-3.32 (m, 2H), 2.58 (s, 3H), 2.32-2.42 (m, 4H), NH and OH protons not observed.
211	MS m/z 405.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.94 (s, 1H), 8.33 (dd, J = 10.9, 1.3 Hz, 1H), 8.19 (s, 1H), 8.01 (d, J = 0.7 Hz, 1H), 7.82 (s, 1H), 3.74-3.67 (m, 1H), 3.48-3.44 (m, 1H), 3.36 (s, 2H), 2.97 (td, J = 12.5, 2.6 Hz, 2H), 2.53 (s, 3H), 2.19 (d, J = 12.7 Hz, 2H), 3.01-2.94 (m, 2H), 1.53 (d, J = 6.9 Hz, 6H). NH proton not observed.

Halides for use in Step H were prepared according to the following procedures:

Example 29-1

8-(((tert-Butyldimethylsilyl)oxy)methyl)-6-chloro-2-methylimidazo[1,2-b]pyridazine

Step A: To ethyl 3-amino-6-chloropyridazine-4-carboxylate (4.0 g, 19.9 mmol) in dry THF (1 mL) was slowly added LiAlH₄ (2.42 g, 64 mmol) at 0° C. The mixture was stirred at 0° C. for 30 min. Excess reagent was quenched carefully with water (1 mL), then 15% aqueous NaOH (1 mL) was added. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield (3-amino-6-chloropyridazin-4-yl)methanol (1.0 g, 32%). MS m/z 160.1, 162.1 [M+H]⁺.

Step B: (3-Amino-6-chloropyridazin-4-yl)methanol (1.0 g, 6.3 mmol) was combined with DIEA (2.44 g, 18.8 mmol) and 1-bromopropan-2-one (860 mg, 6.3 mmol) in isopropyl alcohol (10 mL). The reaction vessel was degassed and then charged with nitrogen three times. The mixture was stirred at 80° C. for 16 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-50% EtOAc in petroleum ether to yield (6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol (0.9 g, 73%). MS m/z 198.2, 200.2 [M+H]⁺.

Step C: (6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)methanol (900 mg, 4.5 mmol) was combined with TBS-Cl (1.72 g, 9.1 mmol) and imidazole (1.24 g, 14.6 mmol) in CH₂Cl₂ (15 mL). The mixture was stirred at room temperature for 16 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in petroleum ether to yield 8-(((tert-butyldimethylsilyl)oxy)methyl)-6-chloro-2-methylimidazo[1,2-b]pyridazine (500 mg, 35.2% yield). MS m/z 312.1, 314.1 [M+H]⁺.

Example 29-2

6-Chloro-8-ethyl-2-methylimidazo[1,2-b]pyridazine

Step A: 6-Chloropyridazin-3-amine (50 g, 388 mmol) and NaHCO₃ (65 g, 775 mmol) were combined in MeOH (500 mL). To the mixture was added Br₂ (30 mL, 580 mmol) dropwise at 0° C. The mixture was stirred at room tempera-

ture for 16 h. One half of the volume of solvent was removed under reduced pressure. The remaining was poured into ice water. The solid formed was collected and dried to yield 4-bromo-6-chloropyridazin-3-amine (80 g, 99%). MS m/z 207.9 [M+H]⁺.

Step B: 4-Bromo-6-chloropyridazin-3-amine (20 g, 97 mmol), Na₂CO₃ (10.2 g, 97 mmol) and 1-bromopropan-2-one (9.7 mL, 116 mmol) were added into isopropyl alcohol (200 mL). The reaction vessel was degassed and then charged with nitrogen three times. The mixture was stirred at 90° C. for 16 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in petroleum ether to yield 8-bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (8.1 g, 34%). MS m/z 245.9, 247.9 [M+H]⁺.

Step C: 8-Bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (200 mg, 0.82 mmol) was combined with triethylborane (1M in THF, 2 mL, 2 mmol), K₂CO₃ (283 mg, 2.05 mmol) and Pd(PPh₃)₄ (92 mg, 0.08 mmol) in DMF (3 mL). The reaction vessel was degassed and then charged with nitrogen three times. The mixture was stirred at 100° C. for 5 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 6-chloro-8-ethyl-2-methylimidazo[1,2-b]pyridazine (80 mg, 50%). MS m/z 196.0, 198.0 [M+H]⁺.

Example 29-3

6-Chloro-8-cyclopropyl-2-methylimidazo[1,2-b]pyridazine

A mixture of 8-bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (1.2 g, 4.9 mmol), cyclopropylboronic acid (843 mg, 9.8 mmol), Pd(dppf)Cl₂ (359 mg, 0.49 mmol) and Na₂CO₃ (1.56 g, 14.7 mmol) in 1,4-dioxane (12 mL) and water (3 mL) was stirred at 90° C. under N₂ for 48 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 6-chloro-8-cyclopropyl-2-methylimidazo[1,2-b]pyridazine (405 mg, 40%). MS m/z 208.0, 210.0 [M+H]⁺.

Example 29-4

6-Chloro-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile

8-Bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (1.2 g, 4.9 mmol) was combined with Zn(CN)₂ (850 mg, 7.3

237

mmol) and $\text{Pd}(\text{PPh}_3)_4$ (570 mg, 0.49 mmol) in DMF (20 mL). The reaction vessel was degassed and then charged with nitrogen three times. The mixture was stirred at 100° C. for 1 h under μ wave irradiation. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 6-chloro-2-methylimidazo[1,2-b]pyridazine-8-carbonitrile (0.5 g, 53%). MS m/z 193.0, 195.0 [M+H]⁺.

Example 29-5

6-bromo-2,4-dimethylbenzo[d]thiazole

Step A: 2,4-Dibromo-6-methylaniline (3.8 g, 14.5 mmol) was combined with KOAc (1.56 g, 15.9 mmol) and acetic anhydride (5.5 mL, 58 mmol) in toluene (40 mL). The mixture was stirred at room temperature for 16 h. The solvent was removed in vacuo. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield N-(2,4-dibromo-6-methylphenyl)acetamide (3.9 g, 82%). MS m/z 305.9, 308.0 [M+H]⁺.

Step B: N-(2,4-Dibromo-6-methylphenyl)acetamide (4.0 g, 13 mmol) was combined with Lawesson's reagent (10.6 g, 26 mmol) in toluene (40 mL). The mixture was stirred at 110° C. for 16 h. The solvent was removed in vacuo. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield N-(2,4-dibromo-6-methylphenyl)ethanethioamide (3.9 g, 93%). MS m/z, 322.9, 324.9 [M+H]⁺.

Step C: N-(2,4-Dibromo-6-methylphenyl)ethanethioamide (3.8 g, 11.8 mmol) was dissolved in NMP (40 mL). To the solution was added NaH (94.7 mg, 2.4 mmol) in portions at room temperature. The reaction vessel was degassed and then charged with nitrogen three times. The mixture was stirred at 120° C. for 2 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-25% EtOAc in petroleum ether to yield 6-bromo-2,4-dimethylbenzo[d]thiazole (369 mg, 12%). MS m/z 241.9, 243.9 [M+H]⁺.

Example 29-6

5-Chloro-2,7-dimethyl-3-((2-(trimethylsilyl)ethoxy)methyl)-3H-imidazo[4,5-b]pyridine

Step A: 6-Chloro-4-methyl-3-nitropyridin-2-amine (187 mg, 1 mmol), iron powder (56 mg, 10 mmol) in AcOH (3 mL) was stirred at 100° C. for 16 h. The mixture was concentrated. To the residue was added aqueous NaOH (2 N) until pH>9. The mixture was filtered through Celite. The filtrate was extracted with EtOAc (50 mL×3). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated to afford 5-chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridine, which was used without further purification (154 mg crude, 85% crude). MS m/z 182.0, 184.0 [M+H]⁺.

Step B: 5-Chloro-2,7-dimethyl-3H-imidazo[4,5-b]pyridine (1.1 g, 6.07 mmol) was dissolved in THF (30 mL). To the mixture was added NaH (310 mg, 7.9 mmol) in portions at 0° C. After stirring the mixture at 0° C. for 10 min, 2-(trimethylsilyl)ethoxymethyl chloride (1.2 mL, 6.69 mmol) was added. The resulting mixture was stirred at room temperature for 2 h. MeOH (10 mL) was added to the solution, after which all volatile material was removed under

238

reduced pressure. The residue was chromatographed on silica gel, eluting with 25% EtOAc in petroleum ether to afford a mixture of N-alkylated products, which was used without separation (900 mg, 76%). MS m/z 312.0, 314.0 [M+H]⁺.

Example 29-7

5-Chloro-2,7-dimethyloxazolo[5,4-b]pyridine

Step A: A solution of 2,6-dichloro-4-methylnicotinonitrile (3 g, 16 mmol) in H_2SO_4 (15 mL) was stirred at 80° C. for 4 h. The mixture was cooled to room temperature, and then poured into ice water (100 mL). The suspension was filtered. The filter cake was washed with water to afford 2,6-dichloro-4-methylnicotinamide (3.2 g, 91%) as a yellow solid. MS m/z 204.9, 206.9 [M+H]⁺.

Step B: To a solution of NaOH (3.7 g, 93 mmol) in H_2O (100 mL) was added Br_2 (4.7 g, 29.4 mmol) dropwise at 0° C. The mixture was stirred at 0° C. for 1 h before adding 2,6-dichloro-4-methylnicotinamide (5 g, 24.5 mmol). The mixture was allowed to warm to room temperature gradually over 1 h. The mixture was then heated to 75° C. for 1 h. The resulting suspension was cooled to room temperature with stirring overnight. The suspension was filtered. The collected solid material was washed with water to afford 2,6-dichloro-4-methylpyridin-3-amine (3.3 g, 76%). MS m/z 176.9, 178.9 [M+H]⁺.

Step C: To a solution of 2,6-dichloro-4-methylpyridin-3-amine (3 g, 17 mmol) in toluene (50 mL) was added KOAc (2 g, 20.4 mmol) and Ac_2O (6.9 g, 68 mmol). The mixture was stirred at 70° C. for 48 h. The mixture was cooled to room temperature, and then poured into ice water (100 mL). The water was extracted with EtOAc (60 mL×3). The combined organic phases were concentrated under reduced pressure. The residue was chromatographed on silica gel eluting with 25% EtOAc in petroleum ether to afford N-(2,6-dichloro-4-methylpyridin-3-yl) acetamide (842 mg, 22%) as a yellow solid. MS m/z 219.0, 221.0 [M+H]⁺.

Step D: To a solution of N-(2,6-dichloro-4-methylpyridin-3-yl)acetamide (700 mg, 3.2 mmol) in NMP (10 mL) was added NaH (128 mg, 3.2 mmol) in portions at room temperature. The reaction vessel was degassed and then charged with nitrogen three times. The mixture was stirred at 120° C. for 2 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-25% EtOAc in petroleum ether to yield 5-chloro-2,7-dimethyloxazolo[5,4-b]pyridine (400 mg, 68%). MS m/z 183.1, 185.1 [M+H]⁺.

Example 29-8

5-Chloro-2,7-dimethylthiazolo[5,4-b]pyridine

N-(2,6-dichloro-4-methylpyridin-3-yl)acetamide (1.6 g, 7.3 mmol) was combined with Lawesson's reagent (5.93 g, 14.7 mmol) in toluene (20 mL). The mixture was stirred at 110° C. for 16 h. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 5-chloro-2,7-dimethylthiazolo[5,4-b]pyridine (500 mg, 34.4% yield). MS m/z 199.0, 201.0 [M+H]⁺.

Example 29-9

2-Bromo-4,6-dimethyloxazolo[4,5-c]pyridine

Step A: 2,6-Dimethylpyridin-4-ol (3 g, 24.3 mmol) was added in portions to conc. HNO_3 (11 mL). Conc. H_2SO_4 (16

239

5 mL) was then added slowly while keeping the temperature below 20° C. The mixture was stirred at room temperature for 3 h. The mixture was then slowly poured onto ice and neutralized with K₂CO₃. The mixture was extracted with CH₂Cl₂. The organic phases were concentrated under reduced pressure. The residue was chromatographed on silica gel, eluting with 10-20% MeOH in CH₂Cl₂ to afford 2,6-dimethyl-3-nitropyridin-4-ol as a white solid (3.69 g, 90%). MS m/z 169.1 [M+H]⁺.

Step B: A mixture of 2,6-dimethyl-3-nitropyridin-4-ol (1.68 g, 10 mmol) and 10% Pd/C (106 mg, 0.1 mmol) in MeOH (16 mL) was stirred under H₂ for 16 h. The mixture was filtered over Celite to afford 3-amino-2,6-dimethylpyridin-4-ol as a white solid (1.3 g, 95%). MS m/z 139.0 [M+H]⁺.

Step C: To a solution of 3-amino-2,6-dimethylpyridin-4-ol (1.38 g, 10 mmol) in EtOH (10 mL) was added cyanogen bromide (1.16 g, 11 mmol) at room temperature. The mixture was stirred at room temperature for 16 h. A precipitate was formed and collected by filtration. The solid material was dried to afford 4,6-dimethyloxazolo[4,5-c]pyridin-2-amine as a white solid (1.2 g, 75%). MS m/z 164.1 [M+H]⁺.

Step D: To a mixture of 4,6-dimethyloxazolo[4,5-c]pyridin-2-amine (600 mg, 3.7 mmol) and CuBr₂ (2.5 g, 11.1 mmol) in CH₃CN (6 mL) was added t-butyl nitrite (1.3 mL, 11.1 mmol) at 0° C. The mixture was stirred at 0° C. for 10 min and then stirred at 55° C. for 2 h. The reaction mixture was made basic with sat. NaHCO₃ and then extracted with EtOAc (200 mL). The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The residue was chromatographed on silica gel, eluting 10-20% EtOAc in petroleum ether to afford 2-bromo-4,6-dimethyloxazolo[4,5-c]pyridine as a white solid (416 mg, 50% yield). MS m/z 227.0, 229.0 [M+H]⁺.

Example 29-10

2-Bromo-4,6-dimethylthiazolo[4,5-c]pyridine

Step A: 4-Chloro-2,6-dimethyl-3-nitropyridine (4.7 g, 25 mmol) was combined with Fe powder (4.24 mg, 75 mmol) in AcOH (40 mL). The mixture was stirred at 70° C. for 2 h. The volatile material was removed under reduced pressure. The residue was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-80% EtOAc in petroleum ether to yield 4-chloro-2,6-dimethylpyridin-3-amine (4.0 g, 99%). MS m/z 157.2, 159.2 [M+H]⁺.

Step B: 4-Chloro-2,6-dimethylpyridin-3-amine (3.8 g, 24 mmol) was combined with benzoyl isothiocyanate (4.77 g, 29 mmol) in acetone (40 mL) and the mixture was stirred at 56° C. for 2 h. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-50% EtOAc in petroleum ether to yield N-(4,6-dimethylthiazolo[4,5-c]pyridin-2-yl)benzamide (6.5 g, 95%). MS m/z 284.2 [M+H]⁺.

Step C: N-(4,6-Dimethylthiazolo[4,5-c]pyridin-2-yl)benzamide (4.5 g, 16 mmol) was combined with NaOH (1.27 g, 32 mmol) in H₂O (10 mL) and MeOH (30 mL). The mixture was stirred at 100° C. for 1 h under μ wave irradiation. The volatile material was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-60% EtOAc in petroleum ether to yield 4,6-dimethylthiazolo[4,5-c]pyridin-2-amine (2.7 g, 95%). MS m/z 180.0 [M+H]⁺.

240

Step D: 4,6-Dimethylthiazolo[4,5-c]pyridin-2-amine (2.7 g, 15 mmol) was combined with isobutyl nitrite (4.67 g, 45 mmol) and CuBr₂ (16.8 g, 75 mmol) in CH₃CN (30 mL). The mixture was stirred at 50° C. for 0.5 h. The volatile material was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 0-50% EtOAc in petroleum ether to yield 2-bromo-4,6-dimethylthiazolo[4,5-c]pyridine (1.0 g, 27%). MS m/z 242.9, 245 [M+H]⁺.

Example 29-11

5-Chloro-2,7-dimethyl-2H-pyrazolo[4,3-b]pyridine

Step A: 6-Chloro-2-methylpyridin-3-amine (40 g, 282 mmol) was combined with AcOH (32 mL) in MeOH (400 mL). To the solution was added Br₂ (26 mL, 507 mmol) dropwise at 0° C. The mixture was stirred at room temperature for 16 h. The volatile material was removed under reduced pressure. The residual reagent was quenched by the addition of aqueous NaHSO₃. The aqueous solution was neutralized with aqueous sat'd NaHCO₃ and extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in petroleum ether to yield 4-bromo-6-chloro-2-methylpyridin-3-amine (60 g, 97%). MS m/z 220.9, 222.9 [M+H]⁺.

Step B: 4-Bromo-6-chloro-2-methylpyridin-3-amine (13 g, 59 mmol) was combined with isobutyl nitrite (9.13 g, 89 mmol), KOAc (13.3 g, 136 mmol) and AcOH (34 mL, 590 mmol) in toluene (130 mL). The mixture was stirred at 60° C. for 10 h. The volatile material was removed under reduced pressure. The residue was treated with aqueous sat'd NaHCO₃. The mixture was diluted with H₂O and extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-30% EtOAc in petroleum ether to yield 7-bromo-5-chloro-2H-pyrazolo[4,3-b]pyridine (3.7 g, 27%). MS m/z 232.0, 234.0 [M+H]⁺.

Step C: 7-Bromo-5-chloro-2H-pyrazolo[4,3-b]pyridine (3.7 g, 16 mmol) was combined with K₂CO₃ (4.4 g, 32 mmol) and iodomethane (2.7 g, 19 mmol) in DMF (40 mL). The mixture was stirred at room temperature for 1 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-20% EtOAc in petroleum ether to yield 7-bromo-5-chloro-2-methyl-2H-pyrazolo[4,3-b]pyridine (1.5 g, 38%). MS m/z 245.9, 247.9 [M+H]⁺.

Step D: 7-Bromo-5-chloro-2-methyl-2H-pyrazolo[4,3-b]pyridine (3.0 g, 12 mmol) was combined with 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (5.2 mL, 18 mmol), K₂CO₃ (6.7 g, 49 mmol) and Pd(PPh₃)₄ (707 mg, 0.6 mmol) in DMF (30 mL). The reaction mixture was degassed and then charged with nitrogen three times. The mixture was stirred at 100° C. for 5 h. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 5-chloro-2,7-dimethyl-2H-pyrazolo[4,3-b]pyridine (1.2 g, 54%). MS m/z 182.0, 184.0 [M+H]⁺.

Example 29-12

5-Chloro-7-methoxy-2-methyl-2H-pyrazolo[4,3-b]pyridine

7-Bromo-5-chloro-2-methyl-2H-pyrazolo[4,3-b]pyridine (250 mg, 1.0 mmol) was combined with MeOH (0.2 mL, 5

241

mmol) and K_2CO_3 (296.7 mg, 2.15 mmol) in CH_3CN (5 mL). The mixture was stirred at room temperature for 16 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-25% EtOAc in petroleum ether to yield (190 mg, 80%). MS m/z 198.0, 200.0 [M+H]⁺.

Example 29-13

5-Chloro-7-ethyl-2-methyl-2H-pyrazolo[4,3-b]pyridine

7-Bromo-5-chloro-2-methyl-2H-pyrazolo[4,3-b]pyridine (200 mg, 0.8 mmol) was combined with triethylborane (1 M in THF, 1.95 mL, 1.95 mmol), K_2CO_3 (441.6 g, 3.2 mmol) and $Pd(PPh_3)_4$ (30 mg, 0.04 mmol) in DMF (3 mL). The reaction mixture was degassed and then charged with nitrogen three times. The mixture was stirred at 100° C. for 5 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 5-chloro-7-ethyl-2-methyl-2H-pyrazolo[4,3-b]pyridine (72 mg, 45%). MS m/z 196.0, 198.0 [M+H]⁺.

Example 29-14

2-Bromo-4,6-dimethylthiazolo[5,4-c]pyridine

Step A: A mixture of 2,6-dimethylpyridin-4-amine (0.5 g, 4.07 mmol) and bromine (0.21 mL, 4.07 mmol) in acetic acid (1 mL) was stirred at room temperature for 2 h. The mixture was treated with aqueous 20% sodium hydroxide (10 mL) and extracted with 30 mL CH_2Cl_2 . The combined organics were washed with brine, dried over Na_2SO_4 and concentrated. The residue was suspended in hot heptanes. The solid material was collected and dried to yield 3-bromo-2,6-dimethylpyridin-4-amine (0.43 g, 52%). MS m/z 201.1, 203.1 [M+H]⁺.

Step B: A mixture of 3-bromo-2,6-dimethylpyridin-4-amine (400 mg, 2 mmol) and benzoyl isothiocyanate (296 μ L, 2.2 mmol) in THF (4 mL) was stirred at 45° C. for 2 h. The mixture was concentrated and the residue was chromatographed on silica gel, eluting with 17% EtOAc in petroleum ether to afford N-((3-bromo-2,6-dimethylpyridin-4-yl)carbamothioyl)benzamide as a light-yellow solid (363 mg, 50%). MS m/z 364.0, 366.0 [M+H]⁺.

Step C: A mixture of N-((3-bromo-2,6-dimethylpyridin-4-yl)carbamothioyl)benzamide (181 mg, 0.5 mmol), $Pd(PPh_3)_4$ (58 mg, 0.05 mmol) and Cs_2CO_3 (326 mg, 1 mmol) in DME (5 mL) was stirred at 100° C. under N_2 for 3 h. After completion, the reaction mixture was cooled to room temperature and partitioned between EtOAc (50 mL) and water (50 mL). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated. The residue was chromatographed on silica gel, eluting 30-100% EtOAc in petroleum ether to afford N-(4,6-dimethylthiazolo[5,4-c]pyridin-2-yl)benzamide as a light-yellow solid (92 mg, 65%). MS m/z 284.1 [M+H]⁺.

Step D: A mixture of N-(4,6-dimethylthiazolo[5,4-c]pyridin-2-yl)benzamide (2 g, 7.1 mmol) and NaOH (1.42 g, 36 mmol) in MeOH (45 mL) and water (15 mL) was stirred in a sealed tube at 85° C. for 24 h. The mixture was extracted with EtOAc (150 mL×2). The combined organic phases were washed with brine, dried over Na_2SO_4 and concentrated. The residue was chromatographed on silica gel, eluting

242

50-100% EtOAc in CH_2Cl_2 to afford 4,6-dimethylthiazolo[5,4-c]pyridin-2-amine as a light-yellow solid (0.88 g, 70%). MS m/z 180.1 [M+H]⁺.

Step E: To a mixture of 4,6-dimethylthiazolo[5,4-c]pyridin-2-amine (880 mg, 4.9 mmol) and $CuBr_2$ (3.25 g, 14.7 mmol) in MeCN (10 mL) was added tert-butyl nitrite (1.74 mL, 14.7 mmol) at 0° C. The mixture was stirred at 0° C. for 2 h and then 55° C. for 1 h. To the reaction mixture was added aqueous sat'd $NaHCO_3$. The mixture was extracted with EtOAc (200 mL). The organic layer was washed with brine, dried over Na_2SO_4 and concentrated. The residue was chromatographed on silica gel, eluting 20% EtOAc in petroleum ether to afford 2-bromo-4,6-dimethylthiazolo[5,4-c]pyridine as a white solid (595 mg, 50%). MS m/z 242.9, 245.0 [M+H]⁺.

Example 29-15

2-(6-Chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)ethan-1-ol

Step A: A dry three-necked round-bottomed flask at -78° C. under inert atmosphere was charged with anhydrous THF (20 mL). A solution of n-butyllithium (2.5 M in hexane, 26.1 mL, 65.3 mmol) was added dropwise, followed by addition of anhydrous acetonitrile (4 mL, 65.3 mmol). The internal temperature was maintained below -70° C. during the entire addition process. After stirring 30 min at -78° C., a solution of 8-bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (2.0 g, 8.2 mmol, prepared according to Example 43) in anhydrous THF (20 mL) was added drop-wise. The mixture was stirred for 2 h at -78° C. The excess reagent was quenched carefully with sat'd aqueous NH_4Cl . The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 2-(6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)acetonitrile (1.2 g, 71%). MS m/z 207.1, 209.1 [M+H]⁺.

Step B: 2-(6-Chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)acetonitrile (500 mg, 2.4 mmol) was combined with MeOH (0.97 mL, 24 mmol) in conc. H_2SO_4 (2 mL). The mixture was stirred at 60° C. for 16 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-30% EtOAc in petroleum ether to yield methyl 2-(6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)acetate (500 mg, 86%). MS m/z 240.1, 242.1 [M+H]⁺.

Step C: To methyl 2-(6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)acetate (500 mg, 2.1 mmol) in dry THF (5 mL) was added $LiAlH_4$ (183 mg, 5.2 mmol) in small portions at 0° C. The mixture was stirred at 0° C. for 20 min. The reaction was quenched carefully with water (1 mL), followed by aqueous 15% NaOH (1 mL). The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-35% EtOAc in petroleum ether to yield 2-(6-chloro-2-methylimidazo[1,2-b]pyridazin-8-yl)ethan-1-ol (144 mg, 33%). MS m/z 212.1, 214.1 [M+H]⁺.

Example 29-16

6-Chloro-8-(1H-imidazol-1-yl)-2-methylimidazo[1,2-b]pyridazine

8-Bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (500 mg, 2.0 mmol, prepared according to Example 43) was

243

combined with K_2CO_3 (550 mg, 4.0 mmol) and 1H-imidazole (250 mg, 0.36 mmol) in NMP (5 mL). The mixture was stirred at 120° C. for 16 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-30% EtOAc in petroleum ether to yield 6-chloro-8-(1H-imidazol-1-yl)-2-methylimidazo[1,2-b]pyridazine (228 mg, 48%). MS m/z 234.0, 236.0 [M+H]⁺.


Example 29-17

6-Chloro-2-methyl-8-phenoxyimidazo[1,2-b]pyridazine

8-Bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (1.0 g, 4.0 mmol) was combined with K_2CO_3 (1.1 g, 8 mmol) and phenol (0.6 g, 6.0 mmol) in NMP (10 mL). The mixture was stirred at 60° C. for 16 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-30% EtOAc in petroleum ether to yield 6-chloro-2-methyl-8-phenoxyimidazo[1,2-b]pyridazine (560 mg, 53%). MS m/z 260.0, 262.0 [M+H]⁺.

5 [M+H]⁺.

10 Preparation of Compound 78



Example 29-18

6-Chloro-8-isopropyl-2-methylimidazo[1,2-b]pyridazine

Step A: 8-Bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (500 mg, 2.05 mmol, prepared according to example 43) was combined with vinylboronic acid pinacol ester (0.43 mL, 2.3 mmol), Pd(dppf)Cl₂ (150 mg, 0.21 mmol) and K_2CO_3 (850 mg, 6.15 mmol) in 1,4-dioxane (10 mL) and H_2O (2 mL). The mixture was stirred at 90° C. for 2 h under N_2 . The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-20% EtOAc in petroleum ether to yield 6-chloro-2-methyl-8-(prop-1-en-2-yl)imidazo[1,2-b]pyridazine (300 mg, 77%). MS m/z 208.0, 210.0 [M+H]⁺.

Step B: 6-Chloro-2-methyl-8-(prop-1-en-2-yl)imidazo[1,2-b]pyridazine (250 mg, 1.21 mmol) was combined with PtO₂ (30 mg, 0.13 mmol) in EtOAc (10 mL). The mixture was stirred at room temperature for 3 h under an atmosphere of H_2 . The mixture was filtered over Celite, and the filtrate was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 20-35% EtOAc in petroleum ether to yield 6-chloro-8-isopropyl-2-methylimidazo[1,2-b]pyridazine (200 mg, 80%). MS m/z 210.0, 212.0 [M+H]⁺.

Example 29-19


6-Chloro-2-methyl-8-propylimidazo[1,2-b]pyridazine

8-Bromo-6-chloro-2-methylimidazo[1,2-b]pyridazine (1 g, 4.1 mmol, prepared according to Example 43) was combined with propylmagnesiumbromide (660 mg, 4.5 mmol) and iron(III) 2,4-pentanedionate (140 mg, 0.4 mmol) in dry THF (30 mL). The mixture was stirred at 50° C. for 1 h under N_2 . The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried

over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 20-30% EtOAc in petroleum ether to yield 6-chloro-2-methyl-8-propylimidazo[1,2-b]pyridazine (230 mg, 27%). MS m/z 210.0, 212.0 [M+H]⁺.

Example 30

10 Preparation of Compound 78



7-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(4-piperidyl)cinnoline dihydrochloride (55 mg, 0.13 mmol, prepared in Example 7) was combined with Cs_2CO_3 (85 mg, 0.26 mmol), 2-iodopropane (26 μ L, 0.26 mmol) and DMF (1 mL). The mixture was stirred at 60° C. for 4 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH_2Cl_2 to yield 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(1-isopropyl-4-piperidyl)cinnoline (6 mg, 11%).


MS m/z 419.4 [M+H]⁺; ¹H NMR (methanol-d₄) δ : 8.92 (s, 1H), 8.32 (dd, J=11.0, 1.5 Hz, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 3.91-4.02 (m, 2H), 3.61-3.68 (m, 1H), 3.24-3.33 (m, 2H), 2.73 (s, 3H), 2.56-2.62 (m, 1H), 2.52 (s, 3H), 2.20-2.26 (m, 2H), 2.06-2.16 (m, 2H), 1.21 (d, J=7.2 Hz, 6H).

Using the procedure described for Example 30, above, additional compounds described herein were prepared by substituting the appropriate aryl halide, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
83	MS m/z 423.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.17 (s, 1H), 8.60 (d, J = 1.3 Hz, 1H), 8.43-8.47 (m, 2H), 8.35 (s, 1H), 4.98 (ddd, J = 47, 5.1, 3.7 Hz, 2H), 3.89-3.95 (m, 2H), 3.63-3.73 (m, 3H), 3.40-3.49 (m, 2H), 2.88 (d, J = 0.9 Hz, 3H), 2.71 (d, J = 0.9 Hz, 3H), 2.46-2.53 (m, 4H), HCl protons not observed.
98	MS m/z 441.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 9.15 (s, 1H), 8.54 (d, J = 1.2 Hz, 1H), 8.44 (dd, J = 10.7, 1.5 Hz, 1H), 8.41 (d, J = 0.9 Hz, 1H), 8.34 (s, 1H), 6.53 (tt, J = 53.7, 3.5 Hz, 1H), 3.82-3.96 (m, 4H), 3.64-3.71 (m, 1H), 3.49-3.59 (m, 2H), 2.87 (d, J = 1.2 Hz, 3H), 2.69 (d, J = 0.9 Hz, 3H), 2.46-2.57 (m, 4H), HCl protons not observed.
168	MS m/z 433.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.92 (s, 1H), 8.32 (d, J = 11 Hz, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 7.88 (s, 1H), 3.60 (m, 1H), 3.30 (br s, 4H), 2.73 (s, 3H), 2.52 (s, 3H), 2.26-2.32 (m, 2H), 2.01 (m, 2H), 1.41 (d, J = 6 Hz, 6H), 1.21 (m, 3H).
170	MS m/z 451.6 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.90 (s, 1H), 8.30 (d, J = 10.5 Hz, 1H), 8.15 (s, 1H), 8.00 (s, 1H), 7.87 (s, 1H), 4.64 (dd, J = 50, 5.0 Hz, 2H), 3.51 (m, 1H), 3.15-3.32 (m, 2H), 3.07 (br s, 2H), 2.73 (s, 3H), 2.52 (s, 3H), 2.13 (d, J = 12.5 Hz, 2H), 1.85 (q, J = 12 Hz, 2H), 1.32 (d, J = 6 Hz, 6H).
199	MS m/z 437.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.90 (s, 1H), 8.29 (d, J = 10 Hz, 1H), 8.16 (s, 1H), 7.99 (s, 1H), 7.87 (s, 1H), 4.64 (dd, J = 50, 5.0 Hz, 2H), 3.60 (m, 1H), 3.13-3.19 (m, 1H), 2.95-3.08 (m, 5H), 2.72 (s, 3H), 2.52 (s, 3H), 2.00-2.30 (m, 5H), 1.90-2.00 (m, 1H).

Example 31

Preparation of Compound 158



Step A: A solution of oxaly chloride (105 μ L, 1.2 mmol) in CH₂Cl₂ (1.4 mL) was cooled to -78° C. To the solution was added DMSO (150 μ L, 2.1 mmol) in CH₂Cl₂ (0.5 mL). The solution was stirred at -78° C. for 30 min. To the solution was added 3-(dimethylamino)propan-1-ol (55 mg, 0.53 mmol) in CH₂Cl₂ (1 mL). The solution was stirred for 30 min at -78° C. Triethylamine (42 μ L, 0.30 mmol) was

added to the solution. The mixture was allowed to slowly warm to 0° C. over ~30 min. The excess reagent was quenched by the addition of aqueous saturated NaHCO₃. The organic layer was removed and dried over Na₂SO₄, filtered and concentrated. The crude product was used directly in the next step without additional purification.

Step B: 7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-3-(4-piperidyl)cinnoline dihydrochloride (45 mg, 0.10 mmol, prepared in Example 7) was combined with CH₂Cl₂ (2 mL), triethylamine (42 μ L, 0.30 mmol), and EtOH (0.2 mL). To the mixture was added 3-(dimethylamino)propanal (53 mg, 0.52 mmol, from Step A) in CH₂Cl₂ (0.5 mL). The mixture was stirred at room temperature until homogeneous, and then sodium triacetoxyborohydride (64, 0.30 mmol) was added. After stirring for 20 min at room temperature, the mixture was concentrated. The residue was dissolved in TFA and CH₂Cl₂ and was dried onto Celite. The dry material was chromatographed on a reverse phase C18 column, eluting with 5-60% CH₃CN (0.1% TFA) in H₂O (0.1% TFA). The collected fractions were concentrated. The residue was partitioned in CH₂Cl₂ and aqueous 1 M K₂CO₃. The organic layer was loaded onto silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to afford 3-[4-(7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl)-1-piperidyl]-N,N-dimethyl-propan-1-amine (7 mg, 15%).

MS m/z 462.5 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 8.96 (s, 1H), 8.36 (dd, J=11.0, 1.5 Hz, 1H), 8.25 (s, 1H), 8.02 (s, 1H), 7.90 (d, J=0.9 Hz, 1H), 3.54-3.60 (m, 2H), 3.46-3.53 (m, 1H), 3.20-3.26 (m, 2H), 2.99-3.08 (m, 2H), 2.92 (s, 6H), 2.81-2.90 (m, 2H), 2.74 (d, J=0.9 Hz, 3H), 2.53 (s, 3H), 2.26-2.37 (m, 4H), 2.14 (quin, J=7.2 Hz, 2H).


Using the procedure described for Example 31, above, additional compounds described herein were prepared by substituting the appropriate alcohol in Step A, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
145	MS m/z 535.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.91 (s, 1H), 8.31 (dd, J = 10.8, 1.4 Hz, 1H), 8.25 (s, 1H), 8.15 (s, 1H), 8.00 (s, 1H), 7.87 (s, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.67 (d, J = 7.9 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.31 (t, J = 7.7 Hz, 1H), 4.45 (t, J = 6.6 Hz, 2H), 3.23-3.31 (m, 1H), 3.12 (br d, J = 11.3 Hz, 2H), 2.73 (s, 3H), 2.52 (s, 3H), 2.47 (t, J = 6.6 Hz, 2H), 2.16-2.28 (m, 4H), 2.01-2.15 (m, 4H), HCl protons not observed.

Cpd	Data
159	MS m/z 521.2 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.94 (s, 1H), 8.34 (dd, J = 10.7, 1.3 Hz, 1H), 8.29 (s, 1H), 8.17 (s, 1H), 8.02 (s, 1H), 7.90 (d, J = 0.9 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.66 (d, J = 8.2 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 4.51 (t, J = 6.4 Hz, 2H), 3.24-3.31 (m, 1H), 3.18 (br d, J = 11.3 Hz, 2H), 2.94 (t, J = 6.4 Hz, 2H), 2.75 (s, 3H), 2.53 (s, 3H), 2.39-2.46 (m, 2H), 2.02-2.20 (m, 4H).
160	MS m/z 485.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.89 (s, 1H), 8.29 (dd, J = 11.0, 1.2 Hz, 1H), 8.16 (s, 1H), 7.98 (s, 1H), 7.85 (d, J = 1.2 Hz, 1H), 7.70 (d, J = 2.1 Hz, 1H), 7.53 (d, J = 1.8 Hz, 1H), 6.32 (t, J = 2.1 Hz, 1H), 4.29 (m, 2H), 3.26-3.31 (m, 1H), 3.20 (br d, J = 11.6 Hz, 2H), 2.72 (d, J = 0.9 Hz, 3H), 2.51 (s, 3H), 2.46-2.50 (m, 2H), 2.28-2.36 (m, 2H), 2.07-2.21 (m, 6H).

Example 32

Preparation of Compound 127





Step A: 2-[4-[7-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-1-piperidyl]ethanol dihydrochloride (200 mg, 0.41 mmol, prepared in Example 19) was combined with CH₂Cl₂ (4 mL) and triethylamine (0.22 mL, 1.6 mmol). To the mixture was added methanesulfonyl chloride (137 μL, 0.81 mmol) at room temperature. The mixture was stirred at room temperature for 30 min. The mixture was washed with aqueous 1 M K₂CO₃. The organic layer was loaded onto silica gel, eluting with 0-10% MeOH (2 N NH₃) in CH₂Cl₂ to provide 2-[4-[7-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-1-piperidyl]ethyl methanesulfonate. MS m/z 499.4 [M+H]⁺.

15 Step B: 2-[4-[7-(2,8-Dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-1-piperidyl]ethyl methanesulfonate (30 mg, 0.06 mmol) was combined with N,N-diisopropylethylamine (105 μL, 0.60 mmol), DMF (1 mL) and dimethylamine hydrochloride (55 mg, 0.60 mmol). The mixture was heated at 40°C for 18 h. The volatile material was removed. The residue was dissolved in TFA and CH₂Cl₂ and was dried onto Celite. The dry material was chromatographed on a reverse phase C18 column, eluting with 5-65% CH₃CN (0.1% TFA) in H₂O (0.1% TFA). The collected material was concentrated. The residue was dissolved in 1.25 M HCl in MeOH. The volatiles were removed. The residue was suspended in CH₃CN, sonicated, collected by filtration and dried yielding 2-[4-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-1-piperidyl]-N,N-dimethyl-ethanamine trihydrochloride (13 mg, 39%). MS m/z 448.5 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.15 (s, 1H), 8.56 (m, 1H), 8.43 (d, J=9.5 Hz, 1H), 8.42 (s, 1H), 8.35 (s, 1H), 3.93 (br s, 2H), 3.68-3.83 (m, 5H), 3.46 (br d, J=10.4 Hz, 2H), 3.07 (s, 6H), 2.87 (s, 3H), 2.70 (s, 3H), 2.48-2.63 (m, 4H), HCl protons not observed.

Example 33

Preparation of Compound 141



249

Step A: 8-Bromo-6-chloro-2-methyl-imidazo[1,2-b]pyridazine (124 mg, 0.50 mmol) was combined with 3-(1H-pyrazol-1-yl)propan-1-ol (252 mg, 2.0 mmol) and cesium carbonate (650 mg, 2.0 mmol) in CH_3CN (4 mL). The mixture was stirred at 40° C. for 16 h. To the mixture was added EtOAc (10 mL). The mixture was filtered over Celite. The filtrate was concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH in EtOAc to yield 6-chloro-2-methyl-8-(3-pyrazol-1-ylpropoxy)imidazo[1,2-b]pyridazine (70 mg, 48%). MS m/z 292.3 [M+H]⁺.

Step B: tert-Butyl 4-(7-chloro-5-fluoro-cinnolin-3-yl)pyridine-1-carboxylate (73 mg, 0.20 mmol, prepared in Example 29) was combined with bis(pinacolato)diboron (64 mg, 0.25 mmol), KOAc (59 mg, 0.60 mmol), chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (14 mg, 0.02 mmol) and 1,4-dioxane (3 mL). The mixture was stirred at 90° C.

250

for 1 h. To the mixture was added aqueous 1 M K_2CO_3 (1 mL), followed by another portion of chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (14 mg, 0.02 mmol) and 6-chloro-2-methyl-8-(3-pyrazol-1-ylpropoxy)imidazo[1,2-b]pyridazine (70 mg, 0.24 mmol) (in 1 mL of 1,4-dioxane). The mixture was stirred at 80° C. for 1 h. The mixture was partitioned between EtOAc and H_2O . The organic layer was concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH in EtOAc to yield tert-butyl 4-[5-fluoro-7-[2-methyl-8-(3-pyrazol-1-ylpropoxy)imidazo[1,2-b]pyridazin-6-yl]cinnolin-3-yl]piperidine-1-carboxylate (110 mg, 94%). MS m/z 587.3 [M+H]⁺.

Step C: tert-Butyl 4-[5-fluoro-7-[2-methyl-8-(3-pyrazol-1-ylpropoxy)imidazo[1,2-b]pyridazin-6-yl]cinnolin-3-yl]piperidine-1-carboxylate (110 mg, 0.18 mmol) was dissolved in trifluoroacetic acid (1 mL) and 1 mL CH_2Cl_2 . The solution was dried over Celite. The dry material was chromatographed on a reverse phase C18 column, eluting with 5-65% CH_3CN (0.1% TFA) in H_2O (0.1% TFA). The desired fractions were concentrated. The residue was dissolved in 1.25 M HCl in MeOH. The volatiles were removed. The residue was suspended in CH_3CN , sonicated, filtered and dried to yield 5-fluoro-7-[2-methyl-8-(3-pyrazol-1-ylpropoxy)imidazo[1,2-b]pyridazin-6-yl]-3-(4-piperidyl)cinnoline dihydrochloride (66 mg, 63%) as a pale yellow solid.

MS m/z 487.4 [M+H]⁺; ¹H NMR (methanol-d₄) δ : 9.18 (s, 1H), 8.44 (d, J=10.7 Hz, 1H), 8.40 (d, J=0.6 Hz, 1H), 8.33 (s, 1H), 8.08 (s, 1H), 7.84 (d, J=2.1 Hz, 1H), 7.66 (d, J=1.8 Hz, 1H), 6.41 (t, J=2.3 Hz, 1H), 4.67 (t, J=6.7 Hz, 2H), 4.58 (t, J=6.7 Hz, 2H), 3.63-3.70 (m, 3H), 3.29-3.35 (m, 2H), 2.70 (s, 3H), 2.59 (quin, J=6.3 Hz, 2H), 2.33-2.45 (m, 4H), NH and HCl protons not observed.


Using the procedure described for Example 33, above, additional compounds described herein were prepared by substituting the appropriate alcohol in Step A, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
138	MS m/z 450.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 9.20 (s, 1H), 8.46 (dd, J = 10.7, 1.2 Hz, 1H), 8.38 (s, 1H), 8.32 (s, 1H), 8.14 (s, 1H), 5.06 (t, J = 5.0 Hz, 2H), 3.90 (t, J = 5.0 Hz, 2H), 3.63-3.71 (m, 3H), 3.29-3.37 (m, 2H), 3.12 (s, 6H), 2.69 (s, 3H), 2.32-2.46 (m, 4H), NH and HCl protons not observed.
139	MS m/z 464.5 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 9.19 (s, 1H), 8.45 (dd, J = 10.5, 1.4 Hz, 1H), 8.39 (s, 1H), 8.32 (s, 1H), 8.10 (s, 1H), 4.82 (t, J = 6.1 Hz, 2H), 3.63-3.70 (m, 3H), 3.55-3.60 (m, 2H), 3.28-3.37 (m, 2H), 3.03 (s, 6H), 2.70 (s, 3H), 2.49-2.56 (m, 2H), 2.31-2.45 (m, 4H), NH and HCl protons not observed.
140	MS m/z 473.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 9.16 (s, 1H), 8.42 (d, J = 10.4 Hz, 1H), 8.38 (s, 1H), 8.35 (s, 1H), 8.04 (s, 1H), 7.92 (d, J = 1.8 Hz, 1H), 7.63 (s, 1H), 6.40 (t, J = 2.1 Hz, 1H), 5.01-5.06 (m, 2H), 4.85-4.90 (m, 2H), 3.63-3.71 (m, 3H), 3.29-3.37 (m, 2H), 2.69 (s, 3H), 2.32-2.46 (m, 4H), NH and HCl protons not observed.
142	MS m/z 487.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 9.19 (s, 2H), 8.45 (dd, J = 10.5, 1.4 Hz, 1H), 8.41 (d, J = 0.9 Hz, 1H), 8.33 (s, 1H), 8.11 (s, 1H), 7.84 (t, J = 1.7 Hz, 1H), 7.67 (t, J = 1.7 Hz, 1H), 4.77 (t, J = 5.8 Hz, 2H), 4.71 (t, J = 7.3 Hz, 2H), 3.62-3.71 (m, 3H), 3.29-3.37 (m, 2H), 2.71 (s, 3H), 2.65-2.70 (m, 2H), 2.32-2.45 (m, 4H), NH and HCl protons not observed.
150	MS m/z 537.4 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ : 9.72 (s, 1H), 9.16 (s, 1H), 8.44 (d, J = 10.6 Hz, 1H), 8.40 (s, 1H), 8.32 (s, 1H), 8.11-8.16 (m, 1H), 8.08 (s, 1H), 7.89-7.95 (m, 1H), 7.68-7.77 (m, 2H), 5.00 (t, J = x Hz, 2H), 4.83 (t, J = x Hz, 2H), 3.63-3.70 (m, 3H), 3.28-3.37 (m, 2H), 2.80 (dt, J = 13.4, 6.4 Hz, 2H), 2.72 (d, J = 0.9 Hz, 3H), 2.31-2.45 (m, 4H), NH proton not observed.

251

Example 34

Preparation of Compound 223



Step A: A screw-cap tube was charged with 3-chloro-7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnoline (0.037 g, 0.11 mmol), tert-butyl N-[1S*,5R*]-3-azabicyclo[3.1.0]hexan-6-yl]carbamate (0.034 g, 0.17 mmol), granular cesium carbonate (0.110 g, 0.338 mmol), and RuPhos Pd G4 pre-catalyst (0.0011 g, 0.0013 mmol). Anhydrous 1,4-dioxane (5 mL) was added last, and the mixture was sparged with argon for 10 minutes. The vial was tightly capped with a screw-cap, placed on a pre-heated aluminum block, and stirred vigorously at 100° C. for 2 h. After this time, the reaction mixture was cooled to room temperature. The brown, heterogeneous reaction mixture was diluted with sat. aq. Na₂CO₃ (20 mL) and extracted with CH₂Cl₂ (2×30 mL). The combined CH₂Cl₂ extracts were diluted with more CH₂Cl₂ (30 mL) and washed with brine (30 mL), dried over

252

anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. The brown, crude product was purified by silica gel column chromatography (CH₂Cl₂/methanolic ammonia (1.0 M) gradient elution) to afford the desired tert-butyl N-[1S*,5R*]-3-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-3-azabicyclo[3.1.0]hexan-6-yl]carbamate (0.048 g, 87%) as a yellow solid.

MS m/z 490.3 [M+H]⁺; ¹H NMR (chloroform-d) δ: 8.54 (s, 1H), 7.97 (dd, J=11.3, 1.2 Hz, 1H), 7.97 (d, J=1.3 Hz, 1H), 7.47 (s, 1H), 6.76 (s, 1H), 4.83 (br s, 1H), 4.07 (br d, J=9.6 Hz, 2H), 3.72 (br d, J=9.9 Hz, 2H), 2.76 (s, 3H), 2.55 (s, 3H), 2.46 (br s, 1H), 2.00 (br s, 2H), 1.47 (m, 9H).

Step B: tert-Butyl N-[1S*,5R*]-3-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-3-azabicyclo[3.1.0]hexan-6-yl]carbamate (0.048 g, 0.098 mmol) was dissolved in CH₂Cl₂ (5 mL), and trifluoroacetic acid (0.10 mL, 1.3 mmol) was added dropwise to the yellow solution, resulting in instantaneous color change to a wine red. The reaction mixture was capped and allowed to sit at room temperature for 17 h. After this time, the wine-red solution was concentrated on a rotovap. The red, crude oil was purified by C18 reverse-phase column chromatography (H₂O:MeCN (0.1% TFA) gradient elution) to afford (1S*,5R*)-3-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-3-azabicyclo[3.1.0]hexan-6-amine tetra(trifluoroacetic acid) (0.054 g, 65%) as a dark red oil. MS m/z 390.3 [M+H]⁺.

Step C: (1S*,5R*)-3-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-3-azabicyclo[3.1.0]hexan-6-amine tetra(trifluoroacetic acid) (0.050 g, 0.059 mmol), was dissolved in CH₂Cl₂ (3 mL) in a screw-top vial. A 37% aqueous solution of formaldehyde (0.018 mL, 0.24 mmol) was added, followed by anhydrous MgSO₄ (0.021 g, 0.17 mmol), triethylamine (0.025 mL, 0.18 mmol), and NaBH(OAc)₃ (0.031 g, 0.15 mmol). The vial was sealed with a screw-cap, and the reaction mixture was stirred vigorously at room temperature for 5 days. After this time, the reaction mixture was diluted with CH₂Cl₂ (30 mL), washed with sat. aq. Rochelle's salt (20 mL) and brine (20 mL), then dried over anhydrous Na₂SO₄, decanted, and concentrated on a rotovap to afford a dark yellow solid/oil mixture. The crude product was purified by silica gel column chromatography (CH₂Cl₂/methanolic ammonia (1.0 M) gradient) to afford the desired (1S*,5R*)-3-[7-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-5-fluoro-cinnolin-3-yl]-N,N-dimethyl-3-azabicyclo[3.1.0]hexan-6-amine (0.021 g, 85%) as a yellow solid.

MS m/z 418.3 [M+H]⁺; ¹H NMR (chloroform-d) δ: 8.54 (s, 1H), 7.98 (dd, J=11.3, 1.3 Hz, 1H), 7.76 (s, 1H), 7.45 (s, 1H), 6.76 (s, 1H), 3.83 (ABq, J=126.7, 9.6 Hz, 4H), 2.74 (s, 3H), 2.54 (s, 3H), 2.40 (s, 6H), 1.93 (s, 2H), 1.57 (s, 1H).

Using the procedure described for Example 34, above, additional compounds described herein were prepared by substituting the appropriate amine in Step A, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
80	MS m/z 378.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.29 (br s, 2H), 8.94 (s, 1H), 8.44 (br s, 1H), 8.39 (br s, 1H), 8.19 (dd, J = 11.3, 1.3 Hz, 1H), 7.60 (s, 1H), 4.06-4.20 (m, 4H), 3.26-3.35 (m, 4H), 2.73 (s, 3H), 2.54 (s, 3H).
81	MS m/z 406.4 [M + H] ⁺ ; ¹ H NMR (DMSO-d ₆) δ: 9.53 (br s, 1H), 9.11 (br s, 1H), 8.93 (s, 1H), 8.45 (br s, 1H), 8.39 (br s, 1H), 8.19 (d, J = 11.3 Hz, 1H), 7.67 (s, 1H), 4.87 (br d, J = 12.0 Hz, 2H), 3.45 (br s, 2H), 3.12 (dd, J = 14.2, 11.7 Hz, 2H), 2.73 (s, 3H), 2.54 (m, 3H), 1.39 (d, J = 6.3 Hz, 6H).


253

-continued

Cpd	Data
86	MS m/z 406.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.44 (s, 1H), 7.84-7.94 (m, 2H), 7.66 (s, 1H), 6.90 (s, 1H), 3.92-4.00 (m, 1H), 3.83-3.90 (m, 1H), 3.54-3.62 (m, 1H), 3.35-3.46 (m, 2H), 2.99-3.08 (m, 1H), 2.66 (s, 3H), 2.47 (s, 3H), 2.42 (s, 6H), 1.99-2.09 (m, 1H).
88	MS m/z 420.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.50 (s, 1H), 7.96 (dd, J = 11.4, 1.4 Hz, 1H), 7.88 (s, 1H), 7.69 (s, 1H), 7.29 (s, 1H), 4.64-4.73 (m, 2H), 3.02-3.13 (m, 2H), 2.67 (s, 3H), 2.57 (tt, J = 11.3, 3.8 Hz, 1H), 2.48 (s, 3H), 2.37 (s, 6H), 2.10 (br d, J = 12.2 Hz, 2H), 1.60 (qd, J = 12.2, 4.0 Hz, 2H).
89	MS m/z 406.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.49 (s, 1H), 7.95 (dd, J = 11.6, 1.5 Hz, 1H), 7.89 (d, J = 0.6 Hz, 1H), 7.70 (d, J = 0.9 Hz, 1H), 6.94 (s, 1H), 3.95-4.02 (m, 1H), 3.85-3.92 (m, 1H), 3.60 (td, J = 10.1, 7.0 Hz, 1H), 3.40-3.47 (m, 1H), 2.99-3.07 (m, 1H), 2.68 (d, J = 0.9 Hz, 3H), 2.48 (s, 3H), 2.38-2.45 (m, 7H), 1.99-2.08 (m, 1H).
209	MS m/z 404.3 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.55 (s, 1H), 7.99 (dd, J = 11.3, 1.4 Hz, 1H), 7.77 (s, 1H), 7.46 (s, 1H), 6.81 (s, 1H), 5.13 (bs, 1H), 3.74 (d, J = 9.3 Hz, 1H), 3.69 (s, 1H), 3.57 (dd, J = 9.7, 1.7 Hz, 1H), 3.09 (dd, J = 9.9, 1.4 Hz, 1H), 2.80 (d, J = 8.0 Hz, 1H), 2.75 (s, 3H), 2.54 (s, 3H), 2.48 (s, 3H), 2.15 (d, J = 9.6 Hz, 1H), 1.99 (d, J = 9.7 Hz, 1H).
215	MS m/z 404.3 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.55 (s, 1H), 7.99 (dd, J = 11.3, 1.3 Hz, 1H), 7.77 (s, 1H), 7.46 (s, 1H), 6.81 (s, 1H), 5.13 (bs, 1H), 3.74 (d, J = 9.3 Hz, 1H), 3.69 (s, 1H), 3.57 (d, J = 9.0 Hz, 1H), 3.09 (d, J = 9.3 Hz, 1H), 2.80 (bs, 1H), 2.75 (s, 3H), 2.54 (s, 3H), 2.48 (s, 3H), 2.15 (d, J = 9.5 Hz, 1H), 2.00 (d, J = 9.5 Hz, 1H).
217	MS m/z 404.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.77 (s, 1H), 8.50 (s, 1H), 8.39 (s, 1H), 8.22 (d, J = 10.7 Hz, 1H), 7.58 (s, 1H), 4.48 (ABq, J = 36.1, 9.0 Hz, 4H), 3.68 (s, 2H), 3.47 (dd, J = 7.4 Hz, 2H), 2.84 (s, 3H), 2.68 (s, 3H), 2.50 (dd, J = 7.3 Hz, 2H), NH and HCl protons not observed.
218	MS m/z 418.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.82 (s, 1H), 8.49 (s, 1H), 8.37 (s, 1H), 8.18 (d, J = 10.8 Hz, 1H), 7.28 (s, 1H), 4.21 (ABq, J = 59.7, 8.7 Hz, 4H), 3.53 (s, 2H), 3.23-3.18 (m, 2H), 2.83 (s, 3H), 2.68 (s, 3H), 2.14-2.06 (m, 2H), 1.97-1.90 (m, 2H), NH and HCl protons not observed.
219	MS m/z 418.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.43 (s, 1H), 7.90 (dd, J = 11.5, 1.3 Hz, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.25 (s, 1H), 3.98 (s, 4H), 3.81 (ddd, J = 7.5, 3.7, 1.9 Hz, 4H), 2.61 (s, 3H), 2.45 (s, 3H), 2.04 (ddd, J = 7.4, 3.7, 1.9 Hz, 4H), NH and TFA protons not observed.
220	MS m/z 404.3 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.63 (s, 1H), 8.21 (s, 1H), 8.18 (s, 1H), 8.00 (dd, J = 11.2, 1.0 Hz, 1H), 6.99 (s, 1H), 4.23 (ABq, J = 51.2, 11.5 Hz, 4H), 4.00 (s, 2H), 3.74 (dd, J = 6.9 Hz, 2H), 2.74 (s, 3H), 2.59 (s, 3H), 2.51 (dd, J = 7.0 Hz, 2H), NH and TFA protons not observed.
221	MS m/z 418.3 [M + H] ⁺ ; ¹ H NMR (methanol-d ₄) δ: 8.73 (s, 1H), 8.29 (s, 1H), 8.24 (s, 1H), 8.08 (d, J = 11.2 Hz, 1H), 7.04 (s, 1H), 4.13 (s, 4H), 3.28 (dd, J = 7.3, 5.7 Hz, 4H), 2.77 (s, 3H), 2.62 (s, 3H), 2.18 (dd, J = 7.3, 5.6 Hz, 4H), NH and TFA protons not observed.
224	MS m/z 434.3 [M + H] ⁺ ; ¹ H NMR (chloroform-d) δ: 8.56 (s, 1H), 7.98 (dd, J = 11.3, 1.3 Hz, 1H), 7.77 (s, 1H), 7.46 (s, 1H), 7.09 (s, 1H), 3.92-3.79 (m, 4H), 2.74 (s, 3H), 2.54 (s, 3H), 2.29 (s, 6H), 2.00 (dd, J = 13.7, 5.9 Hz, 2H), 1.67 (dt, J = 12.9, 5.9 Hz, 2H), 1.03 (s, 3H).

Example 35

Preparation of Compound 203



255


5-fluoro-cinnolin-7-yl]-3,4-dihydroxy-piperidine-1-carboxylate (cis-diol, racemate) (14.0 mg, 0.0276 mmol, 65.3% yield) as a yellow solid. MS m/z 508.2 [M+H]⁺.

Step B: A vial was charged with tert-butyl 4-[3-(2,7-dimethylindazol-5-yl)-5-fluoro-cinnolin-7-yl]-3,4-dihydroxy-piperidine-1-carboxylate (7.00 mg, 0.0138 mmol), trifluoroacetic acid (0.22 mL, 2.9 mmol) and dichloromethane (0.5 mL). The mixture was stirred at room temperature for 1 h. The mixture was concentrated. To the mixture was added 1.25 N HCl in methanol (1 mL). The mixture concentrated (this step was repeated three times). The solid was washed with ethyl acetate, ether and hexanes in a fritted funnel and then freeze dried to give 4-(3-(2,7-dimethyl-2H-indazol-5-yl)-5-fluorocinnolin-7-yl)piperidine-3,4-diol hydrogen chloride (cis-diol, racemate) (7.3 mg, 0.018 mmol, 100% yield).


MS m/z 408.3 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 8.69 (s, 1H), 8.53 (s, 1H), 8.50 (s, 1H), 8.42 (s, 1H), 8.03 (s, 1H), 7.85 (d, J=11 Hz, 1H), 4.35 (dd, J=5, 1.5 Hz, 1H), 4.30 (s, 3H), 3.40 (m, 6H), 2.70 (s, 3H). NH and OH protons not observed.

Example 36

Preparation of Compound 146

**256**

-continued



Step A: 2,6-Dimethylpyridin-3-ol (996 mg, 8.1 mmol) was dissolved in aqueous sodium hydroxide (2.0 M, 4.1 mL) while stirring at room temperature. To this stirred solution was added iodine (2.65 g, 10.4 mmol). The mixture was warmed to 50° C. and stirred for 3 h. The mixture was neutralized with aqueous hydrochloric acid (6 M), then quenched with saturated aqueous sodium thiosulfate solution. MeOH (5 mL) was added to the mixture, and then the reaction mixture was concentrated. CH₂Cl₂ (90 mL) and MeOH (10 mL) were added, the reaction was stirred for 10 min, then filtered. The filtrate was concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield 4-iodo-2,6-dimethyl-pyridin-3-ol (564.6 mg, 28%).

MS m/z 250.1 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 7.61 (s, 1H), 2.47 (s, 3H), 2.39 (s, 3H), OH proton not observed.

Step B: tert-Butyl 4-(7-chloro-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (500 mg, 1.37 mmol), sodium tert-butoxide (198 mg, 2.06 mmol), and chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl)[2-2'-amino-1,1'-biphenyl]palladium(II) (103 mg, 0.14 mmol), 1,4-dioxane (10 mL), and diphenylmethanimine (260 uL, 1.55 mmol) were combined, argon degassed, and heated to 100° C. for 16 h. After cooling the reaction mixture to room temperature, hydroxylamine hydrochloride (445 mg, 6.4 mmol), potassium acetate (815 mg, 8.3 mmol) and methanol (30 mL) were added. The reaction mixture was stirred at room temperature for 7 h. The mixture was concentrated, and the residue was partitioned between EtOAc and H₂O. The layers were separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-10% MeOH in CH₂Cl₂ to yield tert-butyl 4-(7-amino-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (337 mg, 71%).

257

MS m/z 347.3 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 7.87 (s, 1H), 7.14 (s, 1H), 7.06 (dd, J=11.6, 1.8 Hz, 1H), 4.30 (d, J=13.7 Hz, 2H), 3.29 (tt, J=12.2, 3.7 Hz, 1H), 2.92-3.11 (m, 2H), 2.04 (d, J=12.2 Hz, 2H), 1.87 (qd, J=12.6, 4.3 Hz, 2H), 1.51 (s, 9H), NH₂ protons not observed.

Step C: tert-Butyl 4-(7-amino-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (187 mg, 0.54 mmol) was dissolved in trifluoroacetic acid (4.0 mL) and stirred at room temperature for 5 min. Sodium nitrite (43 mg, 0.63 mmol) was added to the mixture, which was stirred at room temperature for 10 min. The mixture was concentrated under reduced pressure. The residue was dissolved in acetonitrile (4.0 mL) and water (1.0 mL). To this stirred solution at room temperature was added potassium iodide (394 mg, 2.37 mmol) portion wise. The mixture was stirred for 20 min at room temperature. Diisopropylethylamine (1.4 mL, 8.0 mmol) and di-tert-butyl dicarbonate (800 uL, 3.35 mmol) were added to the mixture. The mixture was stirred at room temperature for 18 h. The mixture was concentrated, and the residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tert-butyl 4-(5-fluoro-7-iodocinnolin-3-yl)piperidine-1-carboxylate (119 mg, 48%).

MS m/z 402.3 [M+H-tBu]⁺; ¹H NMR (CDCl₃) δ: 8.82 (s, 1H), 7.84 (s, 1H), 7.69 (d, J=8.2 Hz, 1H), 4.36 (br s, 2H), 3.45 (tt, J=12.2, 3.7 Hz, 1H), 2.97 (t, J=11.0 Hz, 2H), 2.15 (br d, J=13.1 Hz, 2H), 1.91 (qd, J=12.5, 4.3 Hz, 2H), 1.50-1.54 (m, 9H).

Step D: tert-butyl 4-(5-fluoro-7-iodocinnolin-3-yl)piperidine-1-carboxylate, cuprous iodide (1.0 mg, 0.0053 mmol), and bis(triphenylphosphine)palladium(II) dichloride (6.2 mg, 0.0088 mmol) were combined under a nitrogen atmosphere, followed by the addition of CH₃CN (2.0 mL). The solution was argon degassed for 30 s, followed by the addition of trimethylamine (40 uL, 0.29 mmol). The solution was argon degassed for 3 min, followed by the addition of trimethylsilylacetylene (20 uL, 0.14 mmol). This mixture was stirred at room temperature under a nitrogen atmosphere for 16 h. The mixture was concentrated, and the residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tert-butyl 4-(5-fluoro-7-((trimethylsilyl)ethynyl)cinnolin-3-yl)piperidine-1-carboxylate (24.5 mg, 72%). MS m/z 372.5 [M+H-tBu]⁺.

Step E: tert-Butyl 4-(5-fluoro-7-((trimethylsilyl)ethynyl)cinnolin-3-yl)piperidine-1-carboxylate (25 mg, 0.057 mmol) was dissolved in MeOH (2.0 mL). The stirred solution was cooled to 0° C. Potassium carbonate (17.9 mg, 0.130 mmol) was added and the reaction mixture continued stirring at 0° C. for 1 h. The reaction was quenched with sat'd aqueous NH₄Cl (8.0 mL). The mixture was partitioned between CH₂Cl₂ and H₂O. The aqueous layer was extracted twice with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, filtered and concentrated to yield tert-butyl 4-(7-ethynyl-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate as a crude mixture that was used without purification. MS m/z 300.0 [M-FH-t-Bu]⁺. tert-Butyl 4-(7-ethynyl-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (20 mg, 0.057 mmol), cuprous iodide (0.3 mg, 0.002 mmol), bis(triphenylphosphine)palladium(II) dichloride (4.4 mg, 0.0063 mmol), and 4-iodo-2,6-dimethyl-pyridin-3-ol (15.8 mg, 0.063 mmol) were combined under a nitrogen atmosphere, followed by the addition of N,N-dimethylformamide (1.0 mL). The solution was argon degassed for 30 s, followed by the addition of trimethylamine (50.0 uL, 0.36 mmol). This solution was argon degassed for 5 min, then stirred at 45° C. under an argon atmosphere for 20 h. The mixture was concentrated, and the residue was chromatographed on silica gel, eluting with 0-30% MeOH in CH₂Cl₂ to yield tert-butyl

258


4-[7-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (10.3 mg, 38%). MS m/z 477.5 [M+H]⁺.



Step F: tert-Butyl 4-[7-(5,7-dimethylfuro[2,3-c]pyridin-2-yl)-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (10.3 mg, 0.022 mmol) was dissolved in trifluoroacetic acid (2 mL). After 15 minutes, the volatile material was removed. The residue was chromatographed on a reversed phase C18 column, eluting with 0-100% CH₃CN in H₂O (0.1% v/v TFA additive). The collected fractions were concentrated. The residue was dissolved in 1.25 M HCl in MeOH. The volatile material was removed to yield 2-[5-fluoro-3-(4-piperidyl)cinnolin-7-yl]-5,7-dimethyl-furo[2,3-c]pyridine hydrochloride (8.3 mg, 93%).

MS m/z 377.5 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.11 (s, 1H), 8.48 (s, 1H), 8.40 (br d, J=10.1 Hz, 1H), 8.04 (s, 1H), 7.99 (s, 1H), 3.69-3.77 (m, 1H), 3.66 (br d, J=12.8 Hz, 2H), 3.34-3.39 (m, 2H), 3.12 (s, 3H), 2.84 (s, 3H), 2.27-2.50 (m, 4H), NH and HCl protons not observed.

Example 37

Preparation of Compound 191



259

Step A: 4-Chloro-2,6-dimethyl-3-nitro-pyridine (1.1054 g, 5.9239 mmol), acetonitrile (4.0 mL), and aqueous hydroiodic acid (concentrated, 57%, 4.0 mL) were combined and heated to 70° C. for 20 h. The mixture was partitioned between CH₂Cl₂, aqueous sat'd Na₂C₃, and aqueous NaOH (1 M). The aqueous layer was extracted with CH₂Cl₂. The combined organic phases were dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield 4-iodo-2,6-dimethyl-3-nitro-pyridine (1.48 g, 90%). MS m/z 279.1 [M+H]⁺.

Step B: 4-Iodo-2,6-dimethyl-3-nitro-pyridine (1.004 g, 3.611 mmol), stannous chloride dihydrate (3.32 g, 14.7 mmol) and EtOAc (5.0 mL) were combined and heated to 60° C. for 10 min. The mixture was partitioned between EtOAc, aqueous sat'd Na₂CO₃ and aqueous NaOH (1 M). The aqueous layer was extracted with EtOAc. The combined organic phases were dried over Na₂SO₄, filtered and concentrated to yield 4-iodo-2,6-dimethyl-pyridin-3-amine (723.7 mg, 81%). MS m/z 249.1 [M+H]⁺.

Step C: 4-Iodo-2,6-dimethyl-pyridin-3-amine (724 mg, 2.92 mmol), di-tert-butyl dicarbonate (2.2 mL, 9.2 mmol), 4-dimethylaminopyridine (42 mg, 0.34 mmol) and CH₂Cl₂ (5.0 mL) were combined and stirred at 40° C. for 17 h. The mixture was concentrated, and the residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tert-Butyl N-tert-butoxycarbonyl-N-(4-iodo-2,6-dimethyl-3-pyridyl)carbamate (489 mg, 37%). MS m/z 449.4 [M+H]⁺.

Step D: tert-Butyl N-tert-butoxycarbonyl-N-(4-iodo-2,6-dimethyl-3-pyridyl)carbamate (489 mg, 1.1 mmol), aqueous NaOH (1 M, 4.0 mL), and MeOH (4.0 mL) were combined and stirred at 70° C. for 7 h. The mixture was partitioned between CH₂Cl₂ and H₂O. The aqueous layer was extracted twice with MeOH/CH₂Cl₂ (1:9) and the combined organic

phases were dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tert-butyl N-(4-iodo-2,6-dimethyl-3-pyridyl)carbamate (278 mg, 73%). MS m/z 349.1 [M+H]⁺; ¹H NMR (CDCl₃) δ: 7.54 (s, 1H), 6.00 (br d, J=2.7 Hz, 1H), 2.57 (s, 3H), 2.48 (s, 3H), 1.53 (s, 9H).

Step E: tert-Butyl 4-(5-fluoro-7-((trimethylsilyl)ethynyl)cinnolin-3-yl)piperidine-1-carboxylate (from Example 38, 104 mg, 0.24 mmol) was dissolved in methanol (2.0 mL).

The stirred solution was cooled to 0° C. Potassium carbonate (50.6 mg, 0.366 mmol) was added and the mixture was stirred at 0° C. for 1 h. The reaction mixture was quenched with sat'd aqueous NH₄Cl (8.0 mL). The mixture was partitioned between CH₂Cl₂ and H₂O. The aqueous layer was extracted twice with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, filtered and concentrated to yield tert-butyl 4-(7-ethynyl-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate as a crude mixture that was used without purification. MS m/z 300.0 [M+H-tBu]⁺. tert-Butyl 4-(7-ethynyl-5-fluoro-cinnolin-3-yl)piperidine-1-carboxylate (86 mg, 0.24 mmol) was dissolved in DMF (1.0 mL). The vessel was purged with argon. Triethylamine (135 uL, 0.97 mmol) was added. The vessel was again purged with argon. This solution was added to a mixture of cuprous iodide (1.4 mg, 0.0073 mmol), bis(triphenylphosphine) palladium(II) dichloride (10.2 mg, 0.0146 mmol), and tert-butyl N-(4-iodo-2,6-dimethyl-3-pyridyl)carbamate (93 mg, 0.27 mmol) under an argon atmosphere. The solution was stirred at 50° C. for 17 h. The mixture was concentrated, and the residue partitioned between CH₂Cl₂ and brine. The aqueous layer was extracted with CH₂Cl₂. The combined organic phases were dried over Na₂SO₄, filtered and concentrated to yield tert-butyl 4-[7-[2-[3-(tert-butoxycarbonylamino)-2,6-dimethyl-4-pyridyl]ethynyl]-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate as a crude mixture that was used without purification. MS m/z 576.5 [M+H]⁺.

Step F: tert-Butyl 4-[7-[2-[3-(tert-butoxycarbonylamino)-2,6-dimethyl-4-pyridyl]ethynyl]-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (140 mg, 0.24 mmol), tetrahydrofuran (4.0 mL), and tetrabutylammonium fluoride (1.0 M in THF, 730 uL, 0.73 mmol) were combined and stirred at 65° C. for 2 h. The reaction was concentrated and the residue was chromatographed on silica gel, eluting with 0-30% MeOH in CH₂Cl₂ to yield tert-butyl 4-[7-(5,7-dimethyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (34.2 mg, 30%). MS m/z 476.5 [M+H]⁺.


Step G: tert-Butyl 4-[7-(5,7-dimethyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-fluoro-cinnolin-3-yl]piperidine-1-carboxylate (34.2 mg, 0.0719 mmol) was dissolved in trifluoroacetic acid (1 mL). After 1 min, the volatile material was removed. The residue was chromatographed on a reversed phase C18 column, eluting with 0-100% CH₃CN in H₂O (0.1% v/v TFA additive), and subsequently chromatographed on silica gel, eluting with 0-100% MeOH (2.5% v/v NH₄OH additive) in CH₂Cl₂, to yield 7-(5,7-dimethyl-1H-pyrrolo[2,3-c]pyridin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline hydrochloride.

MS m/z 376.3 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 8.95 (s, 1H), 8.23 (s, 1H), 8.22 (dd, J=10.7, 1.2 Hz, 1H), 7.67 (s, 1H), 7.41 (s, 1H), 3.50-3.61 (m, 3H), 3.17-3.26 (m, 2H), 2.99 (s, 3H), 2.64 (s, 3H), 2.18-2.34 (m, 4H), NH and HCl protons not observed.

261

Example 38

Preparation of Compound 82



Step A: 5-Bromo-3-fluoro-benzene-1,2-diamine (1.07 g, 5.2 mmol), tert-butyl 4-(2-bromoacetyl)piperidine-1-carboxylate (1.60 g, 5.2 mmol), and DMF (80 mL) were combined and stirred at room temperature for 16 h, 50°C. for 24 h, and 70°C. for 24 h. After cooling to room temperature, potassium carbonate (1.08 g, 7.84 mmol) and di-tert-butyl dicarbonate (1.4 mL, 6.3 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The mixture was partitioned between EtOAc and brine. The organic layer was washed twice with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tert-butyl 4-(6-bromo-8-fluoro-quinoxalin-2-yl)piperidine-1-carboxylate and tert-butyl 4-(7-bromo-5-fluoroquinoxalin-2-yl)piperidine-1-carboxylate as an

MS m/z 310.2 [M+H—CO₂-t-Bu]⁺; ¹H NMR (CDCl₃) δ: 8.84 (s, 1H, A), 8.82 (s, 1H, B), 8.12 (t, J=1.7 Hz, 1H, A), 8.09 (t, J=1.7 Hz, 1H, B), 7.61 (dd, J=9.2, 2.1 Hz, 1H, A), 7.58 (dd, J=9.0, 2.0 Hz, 1H, B), 4.34 (apt d, J=12.2 Hz, 4H), 3.17 (apt qt, J=11.9, 3.7 Hz, 2H), 2.94 (apt br tt, J=13.1, 2.8 Hz, 4H), 1.99-2.06 (m, 4H), 1.93 (apt quint J=11.6, 4.0 Hz, 4H), 1.51 (apt d, J=1.8 Hz, 18H).

Step B: A 1:1 mixture of tert-butyl 4-(6-bromo-8-fluoro-quinoxalin-2-yl)piperidine-1-carboxylate and tert-butyl 4-(7-bromo-5-fluoroquinoxalin-2-yl)piperidine-1-carboxylate was combined with sodium tert-butoxide (760 mg, 7.9 mmol), tris(dibenzylideneacetone) dipalladium(0) (74 mg, 0.08 mmol), racemic 2,2'-bis(diphenylphosphino)-1,1-binaphthyl (144 mg, 0.23 g), toluene (13.0 mL) and benzophenone imine (500 uL, 3.6 mmol) were combined under a nitrogen atmosphere. The vessel was argon purged for 6

263

min, then warmed to 80° C. for 20 h. Hydroxylamine hydrochloride (1.37 g, 19.6 mmol), potassium acetate (2.47 g, 25.2 mmol), and MeOH (65 mL) were added to the mixture. The mixture was stirred at room temperature for 24 h and then was concentrated. The residue was partitioned between sat'd aqueous Na₂CO₃, brine, and CH₂Cl₂. The aqueous layer was extracted twice with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100% EtOAc in hexanes to yield tert-butyl 4-(6-amino-8-fluoro-quinoxalin-2-yl)piperidine-1-carboxylate (340.0 mg, 38%).

MS m/z 291.3 [M+H-t-Bu]⁺; ¹H NMR (DMSO-d₆) δ: 8.69 (s, 1H), 7.01 (dd, J=12.5, 2.1 Hz, 1H), 6.77 (d, J=2.1 Hz, 1H), 6.11 (s, 2H), 4.03-4.21 (m, 2H), 3.06 (tt, J=11.5, 3.4 Hz, 1H), 2.89 (br s, 2H), 1.86-1.93 (m, 2H), 1.66 (qd, J=12.6, 4.4 Hz, 2H), 1.43 (s, 9H).

Step C: Sodium nitrite (23.9 mg, 0.346 mmol) was added to a stirred solution of tert-butyl 4-(6-amino-8-fluoro-quinoxalin-2-yl)piperidine-1-carboxylate in trifluoroacetic acid (1.5 mL). The mixture was stirred at room temperature for 1 min. The mixture was concentrated and azeotroped twice with MeCN. The residue was dissolved in acetonitrile (1.4 mL) and cooled to 0° C. This solution was added dropwise to a solution of copper(I) chloride (47 mg, 0.47 mmol) and copper(II) chloride (95 mg, 0.71 mmol) in acetonitrile (1.2 mL) at 0° C. After stirring for 1 min at 0° C., the reaction mixture was partitioned between EtOAc, aqueous sat'd Na₂CO₃, and aqueous NaOH (1 M). The aqueous layer was extracted with EtOAc. The combined organic phases were dried over Na₂SO₄, filtered and concentrated to yield 6-chloro-8-fluoro-2-(4-piperidyl)quinoxaline (130.0 mg) as a crude mixture that was used without purification. MS m/z 266.3 [M+H]⁺. 6-Chloro-8-fluoro-2-(4-piperidyl)quinoxaline (61 mg, 0.23 mmol), CH₂Cl₂ (3.0 mL), N,N-diisopropylethylamine (400 uL, 2.3 mmol), and di-tert-butyl dicarbonate (230 uL, 0.96 mmol) were combined and stirred at room temperature for 18 h. The mixture was partitioned between CH₂Cl₂ and H₂O. The aqueous layer was extracted twice with CH₂Cl₂. The combined organic phases were dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-40% EtOAc in hexanes to yield tert-butyl 4-(6-chloro-8-fluoro-quinoxalin-2-yl)piperidine-1-carboxylate (52.7 mg, 50%).

MS m/z 310.3 [M+H-t-Bu]⁺; ¹H NMR (CDCl₃) δ: 8.84 (s, 1H), 7.93 (t, J=1.8 Hz, 1H), 7.48 (dd, J=9.5, 2.1 Hz, 1H), 4.26-4.44 (m, 2H), 3.19 (tt, J=11.7, 3.8 Hz, 1H), 2.94 (br t, J=12.2 Hz, 2H), 2.04 (d, J=11.9 Hz, 2H), 1.94 (qd, J=12.2, 4.3 Hz, 2H), 1.52 (s, 9H).

Step D: 6-Chloro-2,8-dimethyl-imidazol[1,2-b]pyridazine (50.0 mg, 0.275 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium(II) dichloride (15 mg, 0.019 mmol), bis(pinacolato)diboron (96 mg, 0.37 mmol), and potassium acetate (dried at 250° C. under vacuum immediately prior to using, 89 mg, 0.89 mmol), and 1,4-dioxane (1.5 mL) were combined. The mixture stirred under argon at 95° C. for 2 h. tert-Butyl 4-(6-chloro-8-fluoro-quinoxalin-2-yl)piperidine-1-carboxylate (65.8 mg, 0.180 mmol), chloro(2-dicyclohexylphosphino-2'6'-dimethoxy-1,1'-bi-phenyl)(2'-amino-1,1'-biphenyl-2-yl) palladium(II) (6.6 mg, 0.0091 mmol), and aqueous K₂CO₃ (1 M, 750 uL) were added to the mixture. The mixture was argon flushed, and then was stirred at 80° C. for 16 h. The reaction was partitioned between EtOAc and H₂O. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 0-100%

264


EtOAc in hexanes to yield tert-butyl 4-[6-(2,8-dimethylimidazol[1,2-b]pyridazin-6-yl)-8-fluoro-quinoxalin-2-yl]piperidine-1-carboxylate (44 mg, 52%). MS m/z 477.6 [M+H]⁺.

Step E: tert-Butyl 4-[6-(2,8-dimethylimidazol[1,2-b]pyridazin-6-yl)-8-fluoro-quinoxalin-2-yl]piperidine-1-carboxylate (45 mg, 0.094 mmol) was dissolved in CH₂Cl₂ (2 mL) and TFA (2 mL). After 10 min, the volatile material was removed. The residue was dissolved in methanolic hydrogen chloride (1.25 M) and concentrated to yield 6-(2,8-dimethylimidazol[1,2-b]pyridazin-6-yl)-8-fluoro-2-(4-piperidyl)quinoxaline hydrochloride (47 mg, quant.).

MS m/z 377.3 [M+H]⁺; ¹H NMR (methanol-d₄) δ: 9.11 (s, 1H), 8.75 (s, 1H), 8.51 (d, J=0.9 Hz, 1H), 8.35-8.46 (m, 2H), 3.64 (dt, J=12.9, 3.2 Hz, 2H), 3.58 (tt, J=11.0, 3.8 Hz, 1H), 3.24-3.32 (m, 2H), 2.87 (s, 3H), 2.71 (s, 3H), 2.35-2.42 (m, 2H), 2.26-2.34 (m, 2H), NH and HCl protons not observed.

Example 39

Preparation of Compound 116



265

Step A: tert-Butyl 4-(7-chloro-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (500 mg, 1.4 mmol) was combined with tri-butyl(1-ethoxyvinyl)tin (0.52 mL, 1.54 mmol) and CsF (470 mg, 3.08 mmol) in 1,4-dioxane (16 mL). The mixture was stirred at 90° C. for 2 h under N₂. The mixture was partitioned between EtOAc and H₂O. The organic layer was washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was chromatographed on silica gel, eluting with 10-20% EtOAc in petroleum ether to yield tert-butyl 4-(7-(1-ethoxyvinyl)-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (500 mg, 90%). MS m/z 402.7 [M+H]⁺.

Step B: tert-Butyl 4-(7-(1-ethoxyvinyl)-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (480 mg, 1.2 mmol) was combined with NBS (235 mg, 1.32 mmol) in THF (20 mL) and H₂O (10 mL). The mixture was stirred at room temperature for 10 min. The THF was removed under reduced pressure. The solution was filtered. The solid was dried to yield tert-butyl 4-(7-(2-bromoacetyl)-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (500 mg, 92%). MS m/z 474.0, 476.0 [M+Na]⁺.

Step C: tert-Butyl 4-(7-(2-bromoacetyl)-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (477 mg, 1.06 mmol) was combined with 3,5-dimethylpyrazin-2-amine (234 mg, 1.9

266


mmol) in EtOH (20 mL). The mixture was stirred at 90° C. for 4 h. Then the mixture was cooled to room temperature, and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel, eluting with 30-50% EtOAc in CH₂Cl₂ to yield tert-butyl 4-(7-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (270 mg, 53%). MS m/z 477.2 [M+H]⁺.

Step D: tert-Butyl 4-(7-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-5-fluorocinnolin-3-yl)piperidine-1-carboxylate (230 mg, 0.48 mmol) was added to TFA (2 mL). The mixture was stirred at room temperature for 1 h. The volatile material was removed under reduced pressure. The residue was purified by prep-HPLC to yield 7-(6,8-dimethylimidazo[1,2-a]pyrazin-2-yl)-5-fluoro-3-(piperidin-4-yl)cinnoline hydrochloride (86 mg, 45% Yield).

MS m/z 377.2 [M+H]⁺; ¹H NMR (DMSO-d₆) δ: 8.93 (s, 1H), 8.83 (s, 1H), 8.29-8.38 (m, 2H), 8.11 (s, 1H), 3.82 (s, 1H), 3.12 (dd, J=12.5, 9.5 Hz, 4H), 2.82 (d, J=13.2 Hz, 3H), 2.41 (s, 3H), 2.10-2.28 (m, 4H), NH proton not observed

Example 40


Preparation of Compound 226



267

268

-continued



Step A: KOAc (6.6 g, 67 mmol) was dried under sweeping argon at 180° C. for 30 min. The mixture was cooled to room temperature. 7-Bromo-3-chloro-5-fluorocinnoline (90% purity, 3 g, 10.3 mmol) was added, along with bis(pinacolato)diboron (3 g, 11.8 mmol), SPhos Pd G2 (300 mg, 0.41 mmol) and 1,4-dioxane (40 mL). The mixture was heated at 80° C. for 15 h. The mixture was diluted in EtOAc and was filtered through Celite. The filtrate was concentrated under vacuum. The residue was chromatographed on silica gel, eluting with 20-50% EtOAc in CH₂Cl₂ to yield crude boronic acid. This material was suspended in 100 mL of 1:1 acetone:H₂O at 0° C. Oxone (20 g, 32.3 mmol) was added. The mixture was stirred at 0° C. for 15 min. The reaction mixture was diluted in 600 mL H₂O and then filtered. The collected material was dried to yield 3-chloro-5-fluorocinnolin-7-ol (1.92 g, 84%) as a dark yellow solid.

¹H NMR (DMSO-d₆) δ: 11.34 (s, 1H), 8.39 (s, 1H), 7.49 (s, 1H), 7.40 (dd, J=11, 2 Hz, 1H).

Step B: 3-Chloro-5-fluorocinnolin-7-ol (1.9 g, 8.6 mmol, 90% purity) was dissolved in DMF (37 mL). K₂CO₃ (3.8 g, 27 mmol) was added to the solution. The mixture was stirred at room temperature for 30 min. Iodomethane (1.9 mL, 31 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 2 h. The mixture was partitioned between H₂O and EtOAc. The organic layer was washed with H₂O and brine, dried over MgSO₄, filtered, and concentrated under vacuum. The residue was chromatographed on silica gel, eluting with 20% EtOAc in hexanes to yield 3-chloro-5-fluoro-7-methoxycinnoline (1.04 g, 57%) as a white solid.

¹H NMR (acetone-d₄) δ: 8.26 (s, 1H), 7.69 (s, 1H), 7.37 (dd, J=10.5, 2 Hz, 1H), 4.13 (s, 3H).

Step C: 3-Chloro-5-fluoro-7-methoxycinnoline (990 mg, 4.65 mmol), (2R,6S)-1-benzyl-2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine (80% purity, 2.14 g, 5.24 mmol), Pd(dppf)Cl₂—CH₂Cl₂ (190 mg, 0.23 mmol), 1,4-dioxane (26 mL), and aqueous K₂CO₃ (2.0 M, 13 mL, 26 mmol) were heated at 90° C. for 4 h. The mixture was partitioned between CH₂Cl₂ and H₂O. The organic layer was dried over MgSO₄, filtered,

and concentrated under vacuum. The residue was chromatographed on silica gel, eluting with 10-20% acetone in CH₂Cl₂ to yield 3-(2R,6S)-1-benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5-fluoro-7-methoxycinnoline (1.28 g, 73%) as an off-white solid.

¹H NMR (acetone-d₄) δ: 8.07 (s, 1H), 7.67 (s, 1H), 7.47-7.51 (m, 2H), 7.30-7.36 (m, 2H), 7.20-7.27 (m, 2H), 7.00 (s, 1H), 4.11 (s, 3H), 3.97 (d, J=16 Hz, 1H), 3.91 (d, J=16 Hz, 1H), 3.53-3.60 (m, 1H), 3.10-3.15 (m, 1H), 2.86-2.92 (m, 1H), 2.54-2.62 (m, 1H), 1.32 (d, J=6.5 Hz, 3H), 1.21 (d, J=6.5 Hz, 3H).

Step D: 3-(2R,6S)-1-Benzyl-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5-fluoro-7-methoxycinnoline (1.28 g, 3.39 mmol) was dissolved in 140 mL of 1:1 CH₂Cl₂:MeOH. 10% Pd/C (300 mg) and 20% Pd(OH)₂/C (300 mg) were added. The mixture was stirred under H₂ (50 psi) for 2 d. The reaction mixture was filtered over Celite, washing with CH₂Cl₂:MeOH. The filtrate was concentrated under vacuum. The residue was partitioned between aqueous NaOH and CH₂Cl₂. The organic layer was dried over MgSO₄, filtered, and concentrated under vacuum. The residue was dissolved in CH₂Cl₂ (20 mL). To the solution was added MnO₂ (5 g, 57.5 mmol). The mixture was stirred at room temperature for 2 h. The reaction mixture was filtered over Celite, washing with CH₂Cl₂:MeOH. The filtrate was concentrated and the residue was chromatographed on silica gel, eluting with CH₂Cl₂:MeOH:NH₄OH (9:1:0.1) to yield 3-((2S,4R,6R)-2,6-dimethylpiperidin-4-yl)-5-fluoro-7-methoxycinnoline (568 mg, 53%) as yellow solid. This compound is the higher R_f component of the product mixture.

¹H NMR (methanol-d₄) δ: 8.06 (s, 1H), 7.59 (s, 1H), 7.27 (dd, J=10.5, 1.5 Hz, 1H), 4.06 (s, 3H), 3.43 (tt, J=12.5, 3.5 Hz, 1H), 3.00-3.05 (m, 2H), 2.09 (d, J=12.5 Hz, 2H), 1.54 (q, J=12.5 Hz, 2H), 1.25 (d, J=6.5 Hz, 6H), NH proton not observed.

Step E: A solution of 3-(2S,4R,6R)-2,6-Dimethylpiperidin-4-yl)-5-fluoro-7-methoxycinnoline (565 mg, 1.95 mmol) in MeOH (2 mL) and CH₂Cl₂ (8 mL) was treated with 37% formaldehyde in water (4 mL, 54 mmol). Sodium

269

triacetoxylborohydride (3.3 g, 16 mmol) was added in three portions over 3 h. The reaction mixture was partitioned between aqueous NaOH and CH_2Cl_2 . The organic layer was dried over MgSO_4 , filtered, and concentrated under vacuum to yield 5-fluoro-7-methoxy-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnoline (566 mg, 95%) as a yellow solid.

^1H NMR (methanol-d₄) δ : 8.06 (s, 1H), 7.59 (s, 1H), 7.27 (dd, $J=10.5, 1.5$ Hz, 1H), 4.06 (s, 3H), 3.43 (m, 1H), 2.50 (m, 2H), 2.41 (s, 3H), 2.08 (d, $J=11$ Hz, 2H), 1.82 (q, $J=12$ Hz, 2H), 1.29 (d, $J=6.5$ Hz, 6H).

Step F: 5-Fluoro-7-methoxy-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnoline (485 mg, 1.6 mmol) was dissolved in CH_2Cl_2 (4 mL) at 0° C. BBr_3 (2 mL, 21.2 mmol) was added dropwise. The mixture became difficult to stir after 10 min. The mixture was warmed to room temperature. The sticky clumps were broken up with a spatula until the mixture could be stirred. The mixture was stirred at room temperature for 16 h. The mixture was added slowly to ice. NaOH pellets were added until the solution was basic. The volatile material was removed under vacuum. The crude product was re-dissolved in 20 mL H_2O . Reverse-phase chromatography was used to desalt the product. Aqueous HCl was added to the purest fractions. The fractions were concentrated under reduced pressure to afford crude 5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnolin-7-ol hydrochloride (70% purity, 687 mg, 92%). This material appears as a crude 2:1 tautomeric mixture by ^1H NMR in CD_3OD . MS m/z 290.2 [M+H]⁺.

Step G: Crude 5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnolin-7-ol hydrochloride (70% purity, 685 mg, 1.47 mmol), N,N-bis(trifluoromethylsulfonyl)aniline (2.7 g, 7.6 mmol), K_2CO_3 (2.7 g, 20 mmol), and DMF (7 mL) were stirred at room temperature for 15 h. The volatile material was removed under vacuum. The crude product was dissolved in CH_2Cl_2 and was filtered to remove solid impurities. The filtrate was concentrated under vacuum. The residue was chromatographed on silica gel, eluting with 5-20% MeOH in CH_2Cl_2 to yield 5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnolin-7-yl trifluoromethanesulfonate (535 mg, 79% over 2 steps) as a yellow solid.

270

^1H NMR (methanol-d₄) δ : 8.39 (s, 1H), 8.24 (s, 1H), 7.81 (dd, $J=9.5, 2$ Hz, 1H), 3.60 (m, 1H), 2.95 (br s, 2H), 2.63 (br s, 3H), 2.23 (d, $J=12.5$ Hz, 2H), 2.01 (q, $J=12.5$ Hz, 2H), 1.43 (d, $J=6.5$ Hz, 6H).

Step H: A mixture of 5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnolin-7-yl trifluoromethanesulfonate (36 mg, 0.085 mmol), KOAc (30 mg, 0.30 mmol), bis(pinacolato)diboron (26 mg, 0.1 mmol), Pd(dppf)Cl₂ (7 mg, 0.0084 mmol), and 1,4-dioxane (0.35 mL) were heated at 90° C. for 15 h. The reaction mixture was diluted in EtOAc and was filtered over Celite. The filtrate was concentrated under vacuum. The crude boronic acid was dissolved in Et_2O and filtered over Celite to remove black insoluble impurities. The filtrate was concentrated by nitrogen stream to afford 51 mg of crude boronic acid as a black oil. 5-Chloro-2,7-dimethyloxazolo[5,4-b]pyridine (11 mg, 0.06 mmol), Pd(dppf)Cl₂ (7 mg, 0.0084 mmol), 1,4-dioxane (0.3 mL), and aqueous K_2CO_3 (2.0 M, 0.15 mL, 0.3 mmol) were added to the crude boronic acid. The mixture was stirred at 90° C. for 1 h. The mixture was partitioned between CH_2Cl_2 and H_2O . The organic layer was dried over MgSO_4 , filtered, and concentrated under vacuum. The residue chromatographed on silica gel, eluting with $\text{CH}_2\text{Cl}_2:\text{MeOH}:\text{NH}_4\text{OH}$ (95:5:0.5) to $\text{CH}_2\text{Cl}_2:\text{MeOH}:\text{NH}_4\text{OH}$ (90:10:1). Recrystallization from 1.5 mL methanol yielded 5-(5-fluoro-3-((2S,4R,6R)-1,2,6-trimethylpiperidin-4-yl)cinnolin-7-yl)-2,7-dimethyloxazolo[5,4-b]pyridine (17 mg, 47%) as a white solid.

MS m/z 420.3 [M+H]⁺; ^1H NMR (methanol-d₄) δ : 8.95 (s, 1H), 8.36 (d, $J=11$ Hz, 1H), 8.16 (s, 1H), 8.10 (s, 1H), 3.46-3.53 (in, 1H), 2.74 (s, 3H), 2.73 (s, 3H), 2.53 (m, 2H), 2.43 (s, 3H), 2.13 (d, $J=12$ Hz, 2H), 1.88 (q, $J=12$ Hz, 2H), 1.31 (d, $J=6$ Hz, 6H).

Using the procedure described for Example 40, above, additional compounds described herein were prepared by substituting the appropriate heteroaryl halide in Step H, suitable reagents and reaction conditions, obtaining compounds such as those selected from:

Cpd	Data
227	MS m/z 419.3 [M + H] ⁺ ; ^1H NMR (methanol-d ₄) δ : 8.89 (s, 1H), 8.53 (s, 1H), 8.39 (dd, $J = 11, 1.5$ Hz, 1H), 8.16 (s, 1H), 7.95 (s, 1H), 4.33 (s, 3H), 3.45-3.51 (m, 1H), 2.76 (s, 3H), 2.50-2.55 (m, 2H), 2.43 (s, 3H), 2.13 (d, $J = 13.5$ Hz, 2H), 1.87 (q, $J = 12.5$ Hz, 2H), 1.31 (d, $J = 6.5$ Hz, 6H).
228	MS m/z 420.3 [M + H] ⁺ ; ^1H NMR (methanol-d ₄) δ : 9.08 (s, 1H), 8.32 (dd, $J = 10, 1$ Hz, 1H), 8.20 (s, 1H), 7.55 (s, 1H), 3.48-3.55 (m, 1H), 2.84 (s, 3H), 2.68 (s, 3H), 2.50-2.55 (m, 2H), 2.43 (s, 3H), 2.14 (d, $J = 13.5$ Hz, 2H), 1.89 (q, $J = 13$ Hz, 2H), 1.31 (d, $J = 6.5$ Hz, 6H).

271

Biological Examples

The following in vitro biological examples demonstrate the usefulness of the compounds of the present description for treating Huntington's disease.

To describe in more detail and assist in understanding the present description, the following non-limiting biological examples are offered to more fully illustrate the scope of the description and are not to be construed as specifically limiting the scope thereof. Such variations of the present description that may be now known or later developed, which would be within the purview of one skilled in the art to ascertain, are considered to fall within the scope of the present description and as hereinafter claimed.

Compounds of Formula (I) were tested using the Meso Scale Discovery (MSD) Assay provided in International Application No. PCT/US2016/066042, filed on Dec. 11, 2016 and claiming priority to United States Provisional Application U.S. 62/265,652 filed on Dec. 10, 2015, the entire contents of which are incorporated herein by reference.

The Endogenous Huntingtin Protein assay used in Example 1 was developed using the ELISA-based MSD electrochemiluminescence assay platform.

Example 1

Endogenous Huntingtin Protein Assay

Meso Scale Discovery (MSD) 96-well or 384-well plates were coated overnight at 4° C. with MW1 (expanded poly-glutamine) or MAB2166 monoclonal antibody (for capture) at a concentration of 1 µg/mL in PBS (30 µL per well). Plates were then washed three times with 300 µL wash buffer (0.05% Tween-20 in PBS) and blocked (100 µL blocking buffer; 5% BSA in PBS) for 4-5 hours at room temperature with rotational shaking and then washed three times with wash buffer.

Samples (25 µL) were transferred to the antibody-coated MSD plate and incubated overnight at 4° C. After removal of the lysates, the plate was washed three times with wash buffer, and 25 µL of #5656S (Cell signaling; rabbit monoclonal) secondary antibody (diluted to 0.25 µg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 Hour at room temperature. Following incubation with the secondary antibody, the wells were rinsed with wash buffer after which 25 µL of goat anti-rabbit SULFO TAG secondary detection antibody (required aspect of the MSD system) (diluted to 0.25 µg/mL in 0.05% Tween-20 in blocking buffer) was added to each well and incubated with shaking for 1 hour at room temperature. After rinsing three times with wash buffer, 150 µL of read buffer T with surfactant (MSD) were added to each empty well, and the plate was imaged on a SI 6000 imager (MSD) according to manufacturers' instructions provided for 96- or 384-well plates. The resulting IC₅₀ values (µM) for compounds tested are shown in Table 1.

As shown in Table 1, test compounds described herein had the following IC₅₀ values, an IC₅₀ value between >3 µM and <9 µM is indicated by a single star (*), an IC₅₀ value between >1 µM and ≤3 µM is indicated by two stars (**), an IC₅₀ value between >0.5 µM and ≤1 µM is indicated by three stars (***)¹⁰, an IC₅₀ value between >0.1 µM and ≤0.5 µM is indicated by four stars (****) and an IC₅₀ value of ≤0.1 µM is indicated by five stars (*****).

272

TABLE 1

Cpd	IC ₅₀
1	**
2	**
3	*****
4	***
5	**
6	*****
7	**
9	**
10	*****
11	**
12	***
13	**
14	*****
15	*****
16	****
17	*****
18	****
19	*****
20	*****
23	****
24	****
25	*****
26	*****
27	****
28	**
29	**
30	*****
31	****
32	****
33	*****
34	*****
35	*****
36	*****
37	**
38	**
39	*****
40	*****
41	*****
42	*****
43	*****
44	*****
45	*****
46	*****
47	*****
48	*****
49	*****
50	*****
51	*****
52	*****
53	***
54	***
55	*****
56	*****
57	*****
58	*****
59	*****
60	****
61	***
62	*****
63	*****
64	*****
65	***
66	*****
67	***
68	*****
69	*****
70	*****
71	*****
72	*****
73	*****
74	*****
75	*****
76	*****
77	*****
78	*****
79	*****
80	*****
81	*****

US 12,384,789 B2

273

TABLE 1-continued

Cpd	IC ₅₀
82	*****
83	*****
84	*****
85	****
86	*****
87	*****
88	*****
89	*****
90	*****
91	**
92	*****
93	*****
94	****
95	*****
96	*****
97	***
98	****
99	*****
100	*****
101	*****
102	*****
103	*****
104	*****
105	*****
106	*****
107	*****
108	*****
109	***
110	*****
111	*****
112	*****
113	*****
114	*****
115	****
116	***
117	****
118	***
119	**
120	**
121	*****
122	*****
123	*****
124	*****
125	*****
126	*****
127	*****
128	*****
129	*****
130	*****
131	*****
132	*****
133	*****
134	****
135	*****
136	*****
137	*****
138	***
139	*****
140	*****
141	*****
142	***
143	*****
144	*****
145	*****
146	*****
147	***
148	*****
149	***
150	*****
151	*****
152	***
153	*****
154	*****
155	*****
156	*****
157	*****
158	*****
159	*****

274

TABLE 1-continued


Cpd	IC ₅₀
5	160
5	161
5	162
10	163
10	164
10	165
10	166
15	167
15	168
15	169
15	170
15	171
15	172
15	173
15	174
20	175
20	176
20	177
20	178
20	179
20	180
20	181
20	182
25	183
25	184
25	185
25	186
30	187
30	188
30	189
30	190
30	191
30	192
35	193
35	194
35	195
35	196
35	197
35	198
35	199
35	200
35	201
35	202
35	203
40	204
40	205
40	206
40	207
40	208
40	209
40	210
45	211
45	212
45	213
45	214
45	215
45	216
45	217
45	218
45	219
45	220
45	221
45	222
45	223
45	224
45	225
45	226
45	227
45	228
50	60

Without regard to whether a document cited herein was specifically and individually indicated as being incorporated by reference, all documents referred to herein are incorporated by reference into the present application for any and all purposes to the same extent as if each individual reference was fully set forth herein.

Having now fully described the subject matter of the claims, it will be understood by those having ordinary skill in the art that the same can be performed within a wide range of equivalents without affecting the scope of the subject matter or particular aspects described herein. It is intended that the appended claims be interpreted to include all such equivalents.

What is claimed is:

1. A compound of Formula (Ig1), Formula (Ii1), or Formula (Im1);



or a form thereof, wherein:

R_1 is heterocycl or heterocycl-amino, wherein heterocycl is selected from the group consisting of azetidinyl, tetrahydrofuranlyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydrodipyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydrodipyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydrodipyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydrodipyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydrodipyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydrodipyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydrodipyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydrodipyrrolo[1,2-a]pyrazin-(2H)-one, hexahydrodipyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydrodipyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydrodipyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydrodipyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydro-1H-cyclobutal[1,2-c:1,4-c']dipyrrrol-(3H)-yl, (8aS)-octahydrodipyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydrodipyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo

[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 1,4-diazabicyclo[3.1.1]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 1,4-diazabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]octanyl, 2,6-diazaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octanyl, 1,7-diazaspiro[4.4]nonyl, 2,6-diazaspiro[3.5]nonyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]nonyl, 2,7-diazaspiro[4.4]nonyl, 2,7-diazaspiro[4.5]decanyl and 6,9-diazaspiro[4.5]decyl,

wherein, each instance of heterocyclyl is optionally substituted with one, two or three R_3 substituents and optionally, with one additional R_4 substituent, or, wherein, alternatively, each instance of heterocyclyl is optionally substituted with one, two, three or four R_3 substituents;

R₂ is heteroaryl, selected from the group consisting of thiienyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, 2H-pyrazolo[3,4-c]pyridinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[2,1-b][1,3,2]thiadiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,3]oxazolo[4,5-c]pyridinyl, [1,3]thiazolo[4,5-c]pyridinyl, [1,3]thiazolo[5,4-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl and quinoxalinyl, wherein each instance of heteroaryl is optionally substituted.

wherein, each instance of heteroaryl is optionally substituted with one, two or three R_6 substituents and optionally, with one additional R_7 substituent;

R_α is, in each instance, independently selected from the group consisting of hydrogen and C_{1-8} -alkyl;

R_b , is, in each instance, independently selected from the group consisting of hydrogen and halogen;

R_3 is, in each instance, independently selected from the group consisting of cyano, halogen, hydroxy, C_{1-8} alkyl, halo- C_{1-8} alkyl, C_{1-8} alkyl-carbonyl, C_{1-8} alkoxy, halo- C_{1-8} alkoxy, C_{1-8} alkoxy- C_{1-8} alkyl, C_{1-8} salkoxy-carbo-nyl, amino, C_{1-8} alkyl-amino, $(C_{1-8}$ alkyl)₂-amino, amino- C_{1-8} alkyl, C_{1-8} alkyl-amino- C_{1-8} alkyl, $(C_{1-8}$ alkyl)₂-amino- C_{1-8} alkyl, amino- C_{1-8} alkyl-amino, C_{1-8} alkyl-amino- C_{1-8} alkyl-amino, $(C_{1-8}$ alkyl-amino- C_{1-8} alkyl)₂-amino, $(C_{1-8}$ alkyl)₂-amino- C_{1-8} alkyl-amino, $[(C_{1-8}$ alkyl)₂-amino- C_{1-8} alkyl]₂-amino, $(C_{1-8}$ alkyl-amino- C_{1-8} alkyl)(C_{1-8} alkyl)amino, $[(C_{1-8}$ alkyl)₂-amino- C_{1-8} alkyl](C_{1-8} alkyl)amino, C_{1-8} alkoxy- C_{1-8} alkyl-amino, $(C_{1-8}$ alkoxy- C_{1-8} alkyl)₂-amino, $(C_{1-8}$ alkoxy- C_{1-8} alkyl)(C_{1-8} alkyl)amino, C_{1-8} alkyl-carbonyl-amino, C_{1-8} alkoxy-carbonyl-amino, hydroxy- C_{1-8} alkyl, hydroxy- C_{1-8} alkoxy- C_{1-8} alkyl, hydroxy- C_{1-8} alkyl-amino, (hydroxy- C_{1-8} alkyl)₂-amino and (hydroxy- C_{1-8} alkyl)(C_{1-8} alkyl)amino.

nyl, aryl-sulfonyloxy-C₁₋₈alkyl, heterocyclyl, hetero-cyclyl-C₁₋₈alkyl, heteroaryl or heteroaryl-C₁₋₈alkyl; wherein, each instance of C₃₋₁₄cycloalkyl, aryl, hetero-cyclyl and heteroaryl is optionally substituted with one, two or three R₅ substituents;

5

R₅ is, in each instance, independently selected from the group consisting of halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, halo-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, hydroxy-C₁₋₈alkyl, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, (C₁₋₈alkyl)₂-amino-C₁₋₈alkyl, C₁₋₈alkyl-¹⁰thio and heteroaryl-C₁₋₈alkyl;

R₆ is, in each instance, independently selected from the group consisting of halogen, hydroxy, cyano, nitro, C₁₋₈alkyl, C₂₋₈alkenyl, cyano-C₁₋₈alkyl, halo-C₁₋₈alkyl, hydroxy-C₁₋₈alkyl, C₁₋₈alkoxy, halo-C₁₋₈alkoxy, (C₁₋₈alkyl)₂-amino-C₁₋₈alkoxy, C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkoxy-C₁₋₈alkoxy, amino, C₁₋₈alkyl-amino, (C₁₋₈alkyl)₂-amino, C₁₋₈alkoxy-C₁₋₈alkyl-amino, (C₁₋₈alkoxy-C₁₋₈alkyl, C₁₋₈alkyl)amino and C₁₋₈alkyl-²⁰thio; and,

R₇ is C₃₋₁₄cycloalkyl, C₃₋₁₄cycloalkyl-oxy, aryl, hetero-cyclyl, heteroaryl or heteroaryl-C₁₋₈alkoxy, wherein the form of the compound is selected from the group consisting of a salt, hydrate, solvate, clathrate, isotope, 25 isologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.

2. A compound of claim 1, wherein the form of the compound is a compound salt selected from the group consisting of hydrochloride, hydrobromide, trifluoroacetate, formate, dihydrochloride, dihydrobromide, ditrifluoracetate, 30 diformate, trihydrochloride, trihydrobromide, tritrifluoracetate and triformate.

* * * * *